Human single nucleotide polymorphisms

Abstract

The invention provides nucleic acid segments of the human genome, particularly nucleic acid segments from genes including polymorphic sites. Allele-specific primers and probes hybridizing to regions flanking or containing these sites are also provided. The nucleic acids, primers and probes are used in applications such as phenotype correlations, forensics, paternity testing, medicine and genetic analysis.

Description

BACKGROUND OF THE INVENTION

[0002] The genomes of all organisms undergo spontaneous mutation in the course of their continuing evolution, generating variant forms of progenitor nucleic acid sequences (Gusella, Ann. Rev. Biochem. 55, 831-854 (1986)). The variant form may confer an evolutionary advantage or disadvantage relative to a progenitor form, or may be neutral. In some instances, a variant form confers a lethal disadvantage and is not transmitted to subsequent generations of the organism. In other instances, a variant form confers an evolutionary advantage to the species and is eventually incorporated into the DNA of many or most members of the species and effectively becomes the progenitor form. In many instances, both progenitor and variant form(s) survive and coexist in a species population. The coexistence of multiple forms of a sequence gives rise to polymorphisms.

[0003] Several different types of polymorphism have been reported. A restriction fragment length polymorphism (RFLP) is a variation in DNA sequence that alters the length of a restriction fragment (Botstein et al., Am. J. Hum. Genet. 32, 314-331 (1980)). The restriction fragment length polymorphism may create or delete a restriction site, thus changing the length of the restriction fragment. RFLPs have been widely used in human and animal genetic analyses (see WO 90/13668; W)90/11369; Donis-Keller, Cell 51, 319-337 (1987); Lander et al., Genetics 121, 85-99 (1989)). When a heritable trait can be linked to a particular RFLP, the presence of the RFLP in an individual can be used to predict the likelihood that the animal will also exhibit the trait.

[0004] Other polymorphisms take the form of short tandem repeats (STRs) that include tandem di-, tri- and tetra-nucleotide repeated motifs. These tandem repeats are also referred to as variable number tandem repeat (VNTR) polymorphisms. VNTRs have been used in identity and paternity analysis (U.S. Pat. No. 5,075,217; Armour et al., FEBS Lett. 307, 113-115 (1992); Horn et al., WO 91/14003; Jeffreys, EP 370,719), and in a large number of genetic mapping studies.

[0005] Other polymorphisms take the form of single nucleotide variations between individuals of the same species. Such polymorphisms are far more frequent than RFLPs, STRs and VNTRs. Some single nucleotide polymorphisms (SNP) occur in protein-coding nucleic acid sequences (coding sequence SNP (cSNP)), in which case, one of the polymorphic forms may give rise to the expression of a defective or otherwise variant protein and, potentially, a genetic disease. Examples of genes in which polymorphisms within coding sequences give rise to genetic disease include β-globin (sickle cell anemia), apoE4 (Alzheimer's Disease), Factor V Leiden (thrombosis), and CFTR (cystic fibrosis). cSNPs can alter the codon sequence of the gene and therefore specify an alternative amino acid. Such changes are called “missense” when another amino acid is substituted, and “nonsense” when the alternative codon specifies a stop signal in protein translation. When the cSNP does not alter the amino acid specified the cSNP is called “silent”.

[0006] Other single nucleotide polymorphisms occur in noncoding regions. Some of these polymorphisms may also result in defective protein expression (e.g., as a result of defective splicing). Other single nucleotide polymorphisms have no phenotypic effects.

[0007] Single nucleotide polymorphisms can be used in the same manner as RFLPs and VNTRs, but offer several advantages. Single nucleotide polymorphisms occur with greater frequency and are spaced more uniformly throughout the genome than other forms of polymorphism. The greater frequency and uniformity of single nucleotide polymorphisms means that there is a greater probability that such a polymorphism will be found in close proximity to a genetic locus of interest than would be the case for other polymorphisms. The different forms of characterized single nucleotide polymorphisms are often easier to distinguish than other types of polymorphism (e.g., by use of assays employing allele-specific hybridization probes or primers).

[0008] Only a small percentage of the total repository of polymorphisms in humans and other organisms has been identified. The limited number of polymorphisms identified to date is due to the large amount of work required for their detection by conventional methods. For example, a conventional approach to identifying polymorphisms might be to sequence the same stretch of DNA in a population of individuals by dideoxy sequencing. In this type of approach, the amount of work increases in proportion to both the length of sequence and the number of individuals in a population and becomes impractical for large stretches of DNA or large numbers of persons.

SUMMARY OF THE INVENTION

[0009] Work described herein pertains to the identification of polymorphisms which can predispose individuals to disease, by resequencing large numbers of genes in a large number of individuals. Various genes from a number of individuals have been resequenced as described herein, and SNPs in these genes have been discovered (see the Table). Some of these SNPs are cSNPs which specify a different amino acid sequence (shown as mutation type “M” in the Table), some of the SNPs are silent cSNPs (shown as mutation type “S” in the Table), and some of these cSNPs specify a stop signal in protein translation (shown as an “N” in the “Mutation Type” column and an asterisk in the “Alt AA” column in the Table). Some of the identified SNPs were located in non-coding regions (indicated with a dash in the “Mutation Type” column in the Table).

[0010] The invention relates to a nucleic acid molecule which comprises a single nucleotide polymorphism at a specific location. In a particular embodiment the invention relates to the variant allele of a gene having a single nucleotide polymorphism, which variant allele differs from a reference allele by one nucleotide at the site(s) identified in the Table. Complements of these nucleic acid segments are also included. The segments can be DNA or RNA, and can be double- or single-stranded. Segments can be, for example, 5-10, 5-15, 10-20, 5-25, 10-30, 10-50 or 10-100 bases long.

[0011] The invention further provides allele-specific oligonucleotides that hybridize to a nucleic acid molecule comprising a single nucleotide polymorphism or to the complement of the nucleic acid molecule. These oligonucleotides can be probes or primers.

[0012] The invention further provides a method of analyzing a nucleic acid from an individual. The method allows the determination of whether the reference or variant base is present at any one of the polymorphic sites shown in the Table. Optionally, a set of bases occupying a set of the polymorphic sites shown in the Table is determined. This type of analysis can be performed on a number of individuals, who are also tested (previously, concurrently or subsequently) for the presence of a disease phenotype. The presence or absence of disease phenotype is then correlated with a base or set of bases present at the polymorphic site or sites in the individuals tested.

[0013] Thus, the invention further relates to a method of predicting the presence, absence, likelihood of the presence or absence, or severity of a particular phenotype or disorder associated with a particular genotype. The method comprises obtaining a nucleic acid sample from an individual and determining the identity of one or more bases (nucleotides) at specific (e.g., polymorphic) sites of nucleic acid molecules described herein, wherein the presence of a particular base at that site is correlated with a specified phenotype or disorder, thereby predicting the presence, absence, likelihood of the presence or absence, or severity of the phenotype or disorder in the individual.

DETAILED DESCRIPTION OF THE INVENTION

[0014] The present invention relates to a nucleic acid molecule which comprises a single nucleotide polymorphism (SNP) at a specific location. The nucleic acid molecule, e.g., a gene, which includes the SNP has at least two alleles, referred to herein as the reference allele and the variant allele. The reference allele (prototypical or wild type allele) has been designated arbitrarily and typically corresponds to the nucleotide sequence of the nucleic acid molecule which has been deposited with GenBank or TIGR under a given Accession number. The variant allele differs from the reference allele by one nucleotide at the site(s) identified in the Table. The present invention also relates to variant alleles of the described genes and to complements of the variant alleles. The invention further relates to portions of the variant alleles and portions of complements of the variant alleles which comprise (encompass) the site of the SNP and are at least 5 nucleotides in length. Portions can be, for example, 5-10, 5-15, 10-20, 5-25, 10-30, 10-50 or 10-100 bases long. For example, a portion of a variant allele which is 21 nucleotides in length includes the single nucleotide polymorphism (the nucleotide which differs from the reference allele at that site) and twenty additional nucleotides which flank the site in the variant allele. These additional nucleotides can be on one or both sides of the polymorphism. Polymorphisms which are the subject of this invention are defined in the Table with respect to the reference sequence deposited in GenBank or TIGR under the Accession number indicated.

[0015] For example, the invention relates to a portion of a gene (e.g., diacylglycerol kinase, gamma (DGKG)) having a nucleotide sequence as deposited in GenBank or TIGR (e.g., under Accession No. D26135) comprising a single nucleotide polymorphism at a specific position (e.g., nucleotide 824). The reference nucleotide for this polymorphic form of DGKG is shown in column 8 of the Table, and the variant nucleotide is shown in column 9 of the Table. In a preferred embodiment, the nucleic acid molecule of the invention comprises the variant (alternate) nucleotide at the polymorphic position. For example, the invention relates to a nucleic acid molecule which comprises the nucleic acid sequence shown in row 1, column 6, of the Table having a “G” at nucleotide position 824. The nucleotide sequences of the invention can be double- or single-stranded.

[0016] The invention further provides allele-specific oligonucleotides that hybridize to a gene comprising a single nucleotide polymorphism or to the complement of the gene. Such oligonucleotides will hybridize to one polymorphic form of the nucleic acid molecules described herein but not to the other polymorphic form(s) of the sequence. Thus, such oligonucleotides can be used to determine the presence or absence of particular alleles of the polymorphic sequences described herein. These oligonucleotides can be probes or primers.

[0017] The invention further provides a method of analyzing a nucleic acid from an individual. The method determines which base is present at any one of the polymorphic sites shown in the Table. Optionally, a set of bases occupying a set of the polymorphic sites shown in the Table is determined. This type of analysis can be performed on a number of individuals, who are also tested (previously, concurrently or subsequently) for the presence of a disease phenotype. The presence or absence of disease phenotype is then correlated with a base or set of bases present at the polymorphic site or sites in the individuals tested.

[0018] Thus, the invention further relates to a method of predicting the presence, absence, likelihood of the presence or absence, or severity of a particular phenotype or disorder associated with a particular genotype. The method comprises obtaining a nucleic acid sample from an individual and determining the identity of one or more bases (nucleotides) at polymorphic sites of nucleic acid molecules described herein, wherein the presence of a particular base is correlated with a specified phenotype or disorder, thereby predicting the presence, absence, likelihood of the presence or absence, or severity of the phenotype or disorder in the individual. The correlation between a particular polymorphic form of a gene and a phenotype can thus be used in methods of diagnosis of that phenotype, as well as in the development of treatments for the phenotype.

DEFINITIONS

[0019] An oligonucleotide can be DNA or RNA, and single- or double-stranded. Oligonucleotides can be naturally occurring or synthetic, but are typically prepared by synthetic means. Preferred oligonucleotides of the invention include segments of DNA, or their complements, which include any one of the polymorphic sites shown in the Table. The segments can be between 5 and 250 bases, and, in specific embodiments, are between 5-10, 5-20, 10-20, 10-50, 20-50 or 10-100 bases. For example, the segment can be 21 bases. The polymorphic site can occur within any position of the segment. The segments can be from any of the allelic forms of DNA shown in the Table.

[0020] As used herein, the terms “nucleotide”, “base” and “nucleic acid” are intended to be equivalent. The terms “nucleotide sequence”, “nucleic acid sequence”, “nucleic acid molecule” and “segment” are intended to be equivalent.

[0021] Hybridization probes are oligonucleotides which bind in a base-specific manner to a complementary strand of nucleic acid. Such probes include peptide nucleic acids, as described in Nielsen et al., Science 254, 1497-1500 (1991). Probes can be any length suitable for specific hybridization to the target nucleic acid sequence. The most appropriate length of the probe may vary depending upon the hybridization method in which it is being used; for example, particular lengths may be more appropriate for use in microfabricated arrays, while other lengths may be more suitable for use in classical hybridization methods. Such optimizations are known to the skilled artisan. Suitable probes and primers can range from about 5 nucleotides to about 30 nucleotides in length. For example, probes and primers can be 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 25, 26, 28 or 30 nucleotides in length. The probe or primer preferably overlaps at least one polymorphic site occupied by any of the possible variant nucleotides. The nucleotide sequence can correspond to the coding sequence of the allele or to the complement of the coding sequence of the allele.

[0022] As used herein, the term “primer” refers to a single-stranded oligonucleotide which acts as a point of initiation of template-directed DNA synthesis under appropriate conditions (e.g., in the presence of four different nucleoside triphosphates and an agent for polymerization, such as DNA or RNA polymerase or reverse transcriptase) in an appropriate buffer and at a suitable temperature. The appropriate length of a primer depends on the intended use of the primer, but typically ranges from 15 to 30 nucleotides. Short primer molecules generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. A primer need not reflect the exact sequence of the template, but must be sufficiently complementary to hybridize with a template. The term primer site refers to the area of the target DNA to which a primer hybridizes. The term primer pair refers to a set of primers including a 5′ (upstream) primer that hybridizes with the 5′ end of the DNA sequence to be amplified and a 3′ (downstream) primer that hybridizes with the complement of the 3′ end of the sequence to be amplified.

[0023] As used herein, linkage describes the tendency of genes, alleles, loci or genetic markers to be inherited together as a result of their location on the same chromosome. It can be measured by percent recombination between the two genes, alleles, loci or genetic markers.

[0024] As used herein, polymorphism refers to the occurrence of two or more genetically determined alternative sequences or alleles in a population. A polymorphic marker or site is the locus at which divergence occurs. Preferred markers have at least two alleles, each occurring at frequency of greater than 1%, and more preferably greater than 10% or 20% of a selected population. A polymorphic locus may be as small as one base pair. Polymorphic markers include restriction fragment length polymorphisms, variable number of tandem repeats (VNTR's), hypervariable regions, minisatellites, dinucleotide repeats, trinucleotide repeats, tetranucleotide repeats, simple sequence repeats, and insertion elements such as Alu. The first identified allelic form is arbitrarily designated as the reference form and other allelic forms are designated as alternative or variant alleles. The allelic form occurring most frequently in a selected population is sometimes referred to as the wildtype form. Diploid organisms may be homozygous or heterozygous for allelic forms. A diallelic or biallelic polymorphism has two forms. A triallelic polymorphism has three forms.

[0025] Work described herein pertains to the resequencing of large numbers of genes in a large number of individuals to identify polymorphisms which can predispose individuals to disease. For example, polymorphisms in genes which are expressed in liver may predispose individuals to disorders of the liver.

[0026] By altering amino acid sequence, SNPs may alter the function of the encoded proteins. The discovery of the SNP facilitates biochemical analysis of the variants and the development of assays to characterize the variants and to screen for pharmaceutical that would interact directly with on or another form of the protein. SNPs (including silent SNPs) may also alter the regulation of the gene at the transcriptional or post-transcriptional level. SNPs (including silent SNPs) also enable the development of specific DNA, RNA, or protein-based diagnostics that detect the presence or absence of the polymorphism in particular conditions.

[0027] A single nucleotide polymorphism occurs at a polymorphic site occupied by a single nucleotide, which is the site of variation between allelic sequences. The site is usually preceded by and followed by highly conserved sequences of the allele (e.g., sequences that vary in less than {fraction (1/100)} or {fraction (1/1000)} members of the populations).

[0028] A single nucleotide polymorphism usually arises due to substitution of one nucleotide for another at the polymorphic site. A transition is the replacement of one purine by another purine or one pyrimidine by another pyrimidine. A transversion is the replacement of a purine by a pyrimidine or vice versa. Single nucleotide polymorphisms can also arise from a deletion of a nucleotide or an insertion of a nucleotide relative to a reference allele. Typically the polymorphic site is occupied by a base other than the reference base. For example, where the reference allele contains the base “T” at the polymorphic site, the altered allele can contain a “C”, “G” or “A” at the polymorphic site.

[0029] Hybridizations are usually performed under stringent conditions, for example, at a salt concentration of no more than 1 M and a temperature of at least 25° C. For example, conditions of 5×SSPE (750 mM NaCl, 50 mM NaPhosphate, 5 mM EDTA, pH 7.4) and a temperature of 25-30° C., or equivalent conditions, are suitable for allele-specific probe hybridizations. Equivalent conditions can be determined by varying one or more of the parameters given as an example, as known in the art, while maintaining a similar degree of identity or similarity between the target nucleotide sequence and the primer or probe used.

[0030] The term “isolated” is used herein to indicate that the material in question exists in a physical milieu distinct from that in which it occurs in nature. For example, an isolated nucleic acid of the invention may be substantially isolated with respect to the complex cellular milieu in which it naturally occurs. In some instances, the isolated material will form part of a composition (for example, a crude extract containing other substances), buffer system or reagent mix. In other circumstance, the material may be purified to essential homogeneity, for example as determined by PAGE or column chromatography such as HPLC. Preferably, an isolated nucleic acid comprises at least about 50, 80 or 90 percent (on a molar basis) of all macromolecular species present.

I. Novel Polymorphisms of the Invention

[0031] The novel polymorphisms of the invention are shown in the Table. Columns one and two show designations for the indicated polymorphism. Column three shows the Genbank or TIGR Accession number for the wild type (or reference) allele. Column four shows the location (nucleotide position) of the polymorphic site in the nucleic acid sequence with reference to the Genbank or TIGR sequence shown in column three. Column five shows common names for the gene in which the polymorphism is located. Column six shows the polymorphism and a portion of the 3′ and 5′ flanking sequence of the gene. Column seven shows the type of mutation; N, non-sense; S, silent; and M, missense. Columns eight and nine show the reference and alternate nucleotides, respectively, at the polymorphic site. Columns ten and eleven show the reference and alternate amino acids, respectively, encoded by the reference and variant, respectively, alleles.

II. Analysis of Polymorphisms

[0032] A. Preparation of Samples

[0033] Polymorphisms are detected in a target nucleic acid from an individual being analyzed. For assay of genomic DNA, virtually any biological sample (other than pure red blood cells) is suitable. For example, convenient tissue samples include whole blood, semen, saliva, tears, urine, fecal material, sweat, buccal, skin and hair. For assay of cDNA or mRNA, the tissue sample must be obtained from an organ in which the target nucleic acid is expressed. For example, if the target nucleic acid is a cytochrome P450, the liver is a suitable source.

[0034] Many of the methods described below require amplification of DNA from target samples. This can be accomplished by e.g., PCR. See generally PCR Technology: Principles and Applications for DNA Amplification (ed. H. A. Erlich, Freeman Press, NY, N.Y., 1992); PCR Protocols: A Guide to Methods and Applications (eds. Innis, et al., Academic Press, San Diego, Calif., 1990); Mattila et al., Nucleic Acids Res. 19, 4967 (1991); Eckert et al., PCR Methods and Applications 1, 17 (1991); PCR (eds. McPherson et al., IRL Press, Oxford); and U.S. Pat. No. 4,683,202.

[0035] Other suitable amplification methods include the ligase chain reaction (LCR) (see Wu and Wallace, Genomics 4, 560 (1989), Landegren et al., Science 241, 1077 (1988), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA 86, 1173 (1989)), and self-sustained sequence replication (Guatelli et al., Proc. Nat. Acad. Sci. USA, 87, 1874 (1990)) and nucleic acid based sequence amplification (NASBA). The latter two amplification methods involve isothermal reactions based on isothermal transcription, which produce both single stranded RNA (ssRNA) and double stranded DNA (dsDNA) as the amplification products in a ratio of about 30 or 100 to 1, respectively.

[0036] B. Detection of Polymorphisms in Target DNA

[0037] There are two distinct types of analysis of target DNA for detecting polymorphisms. The first type of analysis, sometimes referred to as de novo characterization, is carried out to identify polymorphic sites not previously characterized (i.e., to identify new polymorphisms). This analysis compares target sequences in different individuals to identify points of variation, i.e., polymorphic sites. By analyzing groups of individuals representing the greatest ethnic diversity among humans and greatest breed and species variety in plants and animals, patterns characteristic of the most common alleles/haplotypes of the locus can be identified, and the frequencies of such alleles/haplotypes in the population can be determined. Additional allelic frequencies can be determined for subpopulations characterized by criteria such as geography, race, or gender. The de novo identification of polymorphisms of the invention is described in the Examples section.

[0038] The second type of analysis determines which form(s) of a characterized (known) polymorphism are present in individuals under test. There are a variety of suitable procedures, which are discussed in turn.

[0039] 1. Allele-Specific Probes

[0040] The design and use of allele-specific probes for analyzing polymorphisms is described by e.g., Saiki et al., Nature 324, 163-166 (1986); Dattagupta, EP 235,726, Saiki, WO 89/11548. Allele-specific probes can be designed that hybridize to a segment of target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms in the respective segments from the two individuals. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Some probes are designed to hybridize to a segment of target DNA such that the polymorphic site aligns with a central position (e.g., in a 15-mer at the 7 position; in a 16-mer, at either the 8 or 9 position) of the probe. This design of probe achieves good discrimination in hybridization between different allelic forms.

[0041] Allele-specific probes are often used in pairs, one member of a pair showing a perfect match to a reference form of a target sequence and the other member showing a perfect match to a variant form. Several pairs of probes can then be immobilized on the same support for simultaneous analysis of multiple polymorphisms within the same target sequence.

[0042] 2. Tiling Arrays

[0043] The polymorphisms can also be identified by hybridization to nucleic acid arrays, some examples of which are described in WO 95/11995. The same arrays or different arrays can be used for analysis of characterized polymorphisms. WO 95/11995 also describes subarrays that are optimized for detection of a variant form of a precharacterized polymorphism. Such a subarray contains probes designed to be complementary to a second reference sequence, which is an allelic variant of the first reference sequence. The second group of probes is designed by the same principles as described, except that the probes exhibit complementarity to the second reference sequence. The inclusion of a second group (or further groups) can be particularly useful for analyzing short subsequences of the primary reference sequence in which multiple mutations are expected to occur within a short distance commensurate with the length of the probes (e.g., two or more mutations within 9 to 21 bases).

[0044] 3. Allele-Specific Primers

[0045] An allele-specific primer hybridizes to a site on target DNA overlapping a polymorphism and only primes amplification of an allelic form to which the primer exhibits perfect complementarity, See Gibbs, Nucleic Acid Res. 17, 2427-2448 (1989). This primer is used in conjunction with a second primer which hybridizes at a distal site. Amplification proceeds from the two primers, resulting in a detectable product which indicates the particular allelic form is present. A control is usually performed with a second pair of primers, one of which shows a single base mismatch at the polymorphic site and the other of which exhibits perfect complementarity to a distal site. The single-base mismatch prevents amplification and no detectable product is formed. The method works best when the mismatch is included in the 3′-most position of the oligonucleotide aligned with the polymorphism because this position is most destabilizing to elongation from the primer (see, e.g., WO 93/22456).

[0046] 4. Direct-Sequencing

[0047] The direct analysis of the sequence of polymorphisms of the present invention can be accomplished using either the dideoxy chain termination method or the Maxam-Gilbert method (see Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd Ed., CSHP, New York 1989); Zyskind et al., Recombinant DNA Laboratory Manual, (Acad. Press, 1988)).

[0048] 5. Denaturing Gradient Gel Electrophoresis

[0049] Amplification products generated using the polymerase chain reaction can be analyzed by the use of denaturing gradient gel electrophoresis. Different alleles can be identified based on the different sequence-dependent melting properties and electrophoretic migration of DNA in solution. Erlich, ed., PCR Technology, Principles and Applications for DNA Amplification, (W. H. Freeman and Co, New York, 1992), Chapter 7.

[0050] 6. Single-Strand Conformation Polymorphism Analysis

[0051] Alleles of target sequences can be differentiated using single-strand conformation polymorphism analysis, which identifies base differences by alteration in electrophoretic migration of single stranded PCR products, as described in Orita et al., Proc. Nat. Acad. Sci. 86, 2766-2770 (1989). Amplified PCR products can be generated as described above, and heated or otherwise denatured, to form single stranded amplification products. Single-stranded nucleic acids may refold or form secondary structures which are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification products can be related to base-sequence differences between alleles of target sequences.

[0052] 7. Single Base Extension

[0053] An alternative method for identifying and analyzing polymorphisms is based on single-base extension (SBE) of a fluorescently-labeled primer coupled with fluorescence resonance energy transfer (FRET) between the label of the added base and the label of the primer. Typically, the method, such as that described by Chen et al., (PNAS 94:10756-61 (1997)), uses a locus-specific oligonucleotide primer labeled on the 5′ terminus with 5-carboxyfluorescein (FAM). This labeled primer is designed so that the 3′ end is immediately adjacent to the polymorphic site of interest. The labeled primer is hybridized to the locus, and single base extension of the labeled primer is performed with fluorescently-labeled dideoxyribonucleotides (ddNTPs) in dye-terminator sequencing fashion. An increase in fluorescence of the added ddNTP in response to excitation at the wavelength of the labeled primer is used to infer the identity of the added nucleotide.

III. Methods of Use

[0054] The determination of the polymorphic form(s) present in an individual at one or more polymorphic sites defined herein can be used in a number of methods.

[0055] A. Forensics

[0056] Determination of which polymorphic forms occupy a set of polymorphic sites in an individual identifies a set of polymorphic forms that distinguishes the individual. See generally National Research Council, The Evaluation of Forensic DNA Evidence (Eds. Pollard et al., National Academy Press, D.C., 1996). The more sites that are analyzed, the lower the probability that the set of polymorphic forms in one individual is the same as that in an unrelated individual. Preferably, if multiple sites are analyzed, the sites are unlinked. Thus, polymorphisms of the invention are often used in conjunction with polymorphisms in distal genes. Preferred polymorphisms for use in forensics are biallelic because the population frequencies of two polymorphic forms can usually be determined with greater accuracy than those of multiple polymorphic forms at multi-allelic loci.

[0057] The capacity to identify a distinguishing or unique set of forensic markers in an individual is useful for forensic analysis. For example, one can determine whether a blood sample from a suspect matches a blood or other tissue sample from a crime scene by determining whether the set of polymorphic forms occupying selected polymorphic sites is the same in the suspect and the sample. If the set of polymorphic markers does not match between a suspect and a sample, it can be concluded (barring experimental error) that the suspect was not the source of the sample. If the set of markers does match, one can conclude that the DNA from the suspect is consistent with that found at the crime scene. If frequencies of the polymorphic forms at the loci tested have been determined (e.g., by analysis of a suitable population of individuals), one can perform a statistical analysis to determine the probability that a match of suspect and crime scene sample would occur by chance.

[0058] p(ID) is the probability that two random individuals have the same polymorphic or allelic form at a given polymorphic site. In biallelic loci, four genotypes are possible: AA, AB, BA, and BB. If alleles A and B occur in a haploid genome of the organism with frequencies x and y, the probability of each genotype in a diploid organism is (see WO 95/12607):

[0059] Homozygote: p(AA)=x2

[0060] Homozygote: p(BB)=y2=(1−x)2

[0061] Single Heterozygote: p(AB)=p(BA)=xy=x(1−x)

[0062] Both Heterozygotes: p(AB+BA)=2xy=2x(1−x)

[0063] The probability of identity at one locus (i.e, the probability that two individuals, picked at random from a population will have identical polymorphic forms at a given locus) is given by the equation:

p (ID)=(x2)2+(2xy)2+(y2)2.

[0064] These calculations can be extended for any number of polymorphic forms at a given locus. For example, the probability of identity p(ID) for a 3-allele system where the alleles have the frequencies in the population of x, y and z, respectively, is equal to the sum of the squares of the genotype frequencies:

p (ID)=x4+(2xy)2+(2yz)2+(2xz)2+z4+y4

[0065] In a locus of n alleles, the appropriate binomial expansion is used to calculate p(ID) and p(exc).

[0066] The cumulative probability of identity (cum p(ID)) for each of multiple unlinked loci is determined by multiplying the probabilities provided by each locus.

cum p(ID)=p(ID1)p(ID2)p(ID3) . . . p(IDn)

[0067] The cumulative probability of non-identity for n loci (i.e. the probability that two random individuals will be different at 1 or more loci) is given by the equation:

cum p(nonID)=1−cum p(ID).

[0068] If several polymorphic loci are tested, the cumulative probability of non-identity for random individuals becomes very high (e.g., one billion to one). Such probabilities can be taken into account together with other evidence in determining the guilt or innocence of the suspect.

[0069] B. Paternity Testing

[0070] The object of paternity testing is usually to determine whether a male is the father of a child. In most cases, the mother of the child is known and thus, the mother's contribution to the child's genotype can be traced. Paternity testing investigates whether the part of the child's genotype not attributable to the mother is consistent with that of the putative father. Paternity testing can be performed by analyzing sets of polymorphisms in the putative father and the child.

[0071] If the set of polymorphisms in the child attributable to the father does not match the set of polymorphisms of the putative father, it can be concluded, barring experimental error, that the putative father is not the real father. If the set of polymorphisms in the child attributable to the father does match the set of polymorphisms of the putative father, a statistical calculation can be performed to determine the probability of coincidental match.

[0072] The probability of parentage exclusion (representing the probability that a random male will have a polymorphic form at a given polymorphic site that makes him incompatible as the father) is given by the equation (see WO 95/12607):

p (exc)=xy(1−xy)

[0073] where x and y are the population frequencies of alleles A and B of a biallelic polymorphic site.

[0074] (At a triallelic site p(exc)=xy(1−xy)+yz(1−yz)+xz(1−xz)+3xyz(1−xyz))), where x, y and z and the respective population frequencies of alleles A, B and C).

[0075] The probability of non-exclusion is

p (non-exc)=1−p(exc)

[0076] The cumulative probability of non-exclusion (representing the value obtained when n loci are used) is thus:

cum p(non-exc)=p(non-exc1)p(non-exc2)p(non-exc3) . . . p(non-excn)

[0077] The cumulative probability of exclusion for n loci (representing the probability that a random male will be excluded)

cum p(exc)=1−cum p(non-exc).

[0078] If several polymorphic loci are included in the analysis, the cumulative probability of exclusion of a random male is very high. This probability can be taken into account in assessing the liability of a putative father whose polymorphic marker set matches the child's polymorphic marker set attributable to his/her father.

[0079] C. Correlation of Polymorphisms with Phenotypic Traits

[0080] The polymorphisms of the invention may contribute to the phenotype of an organism in different ways. Some polymorphisms occur within a protein coding sequence and contribute to phenotype by affecting protein structure. The effect may be neutral, beneficial or detrimental, or both beneficial and detrimental, depending on the circumstances. For example, a heterozygous sickle cell mutation confers resistance to malaria, but a homozygous sickle cell mutation is usually lethal. Other polymorphisms occur in noncoding regions but may exert phenotypic effects indirectly via influence on replication, transcription, and translation. A single polymorphism may affect more than one phenotypic trait. Likewise, a single phenotypic trait may be affected by polymorphisms in different genes. Further, some polymorphisms predispose an individual to a distinct mutation that is causally related to a certain phenotype.

[0081] Phenotypic traits include diseases that have known but hitherto unmapped genetic components (e.g., agammaglobulimenia, diabetes insipidus, Lesch-Nyhan syndrome, muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial hypercholesterolemia, polycystic kidney disease, hereditary spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary hemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos syndrome, osteogenesis imperfecta, and acute intermittent porphyria). Phenotypic traits also include symptoms of, or susceptibility to, multifactorial diseases of which a component is or may be genetic, such as autoimmune diseases, inflammation, cancer, diseases of the nervous system, and infection by pathogenic microorganisms. Some examples of autoimmune diseases include rheumatoid arthritis, multiple sclerosis, diabetes (insulin-dependent and non-independent), systemic lupus erythematosus and Graves disease. Some examples of cancers include cancers of the bladder, brain, breast, colon, esophagus, kidney, leukemia, liver, lung, oral cavity, ovary, pancreas, prostate, skin, stomach and uterus. Phenotypic traits also include characteristics such as longevity, appearance (e.g., baldness, obesity), strength, speed, endurance, fertility, and susceptibility or receptivity to particular drugs or therapeutic treatments.

[0082] The correlation of one or more polymorphisms with phenotypic traits can be facilitated by knowledge of the gene product of the wild type (reference) gene. The genes in which SNPs of the present invention have been identified are genes which have been previously sequenced and characterized in one of their allelic forms. Thus, the SNPs of the invention can be used to identify correlations between one or another allelic form of the gene with a disorder with which the gene is associated, thereby identifying causative or predictive allelic forms of the gene.

[0083] Correlation is performed for a population of individuals who have been tested for the presence or absence of a phenotypic trait of interest and for polymorphic markers sets. To perform such analysis, the presence or absence of a set of polymorphisms (i.e. a polymorphic set) is determined for a set of the individuals, some of whom exhibit a particular trait, and some of which exhibit lack of the trait. The alleles of each polymorphism of the set are then reviewed to determine whether the presence or absence of a particular allele is associated with the trait of interest. Correlation can be performed by standard statistical methods such as a κ-squared test and statistically significant correlations between polymorphic form(s) and phenotypic characteristics are noted. For example, it might be found that the presence of allele A1 at polymorphism A correlates with heart disease. As a further example, it might be found that the combined presence of allele A1 at polymorphism A and allele B1 at polymorphism B correlates with increased milk production of a farm animal.

[0084] Such correlations can be exploited in several ways. In the case of a strong correlation between a set of one or more polymorphic forms and a disease for which treatment is available, detection of the polymorphic form set in a human or animal patient may justify immediate administration of treatment, or at least the institution of regular monitoring of the patient. Detection of a polymorphic form correlated with serious disease in a couple contemplating a family may also be valuable to the couple in their reproductive decisions. For example, the female partner might elect to undergo in vitro fertilization to avoid the possibility of transmitting such a polymorphism from her husband to her offspring. In the case of a weaker, but still statistically significant correlation between a polymorphic set and human disease, immediate therapeutic intervention or monitoring may not be justified. Nevertheless, the patient can be motivated to begin simple life-style changes (e.g., diet, exercise) that can be accomplished at little cost to the patient but confer potential benefits in reducing the risk of conditions to which the patient may have increased susceptibility by virtue of variant alleles. Identification of a polymorphic set in a patient correlated with enhanced receptiveness to one of several treatment regimes for a disease indicates that this treatment regime should be followed.

[0085] For animals and plants, correlations between characteristics and phenotype are useful for breeding for desired characteristics. For example, Beitz et al., U.S. Pat. No. 5,292,639 discuss use of bovine mitochondrial polymorphisms in a breeding program to improve milk production in cows. To evaluate the effect of mtDNA D-loop sequence polymorphism on milk production, each cow was assigned a value of 1 if variant or 0 if wildtype with respect to a prototypical mitochondrial DNA sequence at each of 17 locations considered. Each production trait was analyzed individually with the following animal model:

Y ijkpn =μ+YS i +P j +X k +β1+ . . . β17+PEn+an+ep

[0086] where Yijknp is the milk, fat, fat percentage, SNF, SNF percentage, energy concentration, or lactation energy record; μ is an overall mean; YSi is the effect common to all cows calving in year-season; Xk is the effect common to cows in either the high or average selection line; β1 to β17 are the binomial regressions of production record on mtDNA D-loop sequence polymorphisms; PEn is permanent environmental effect common to all records of cow n; an is effect of animal n and is composed of the additive genetic contribution of sire and dam breeding values and a Mendelian sampling effect; and ep is a random residual. It was found that eleven of seventeen polymorphisms tested influenced at least one production trait. Bovines having the best polymorphic forms for milk production at these eleven loci are used as parents for breeding the next generation of the herd.

[0087] D. Genetic Mapping of Phenotypic Traits

[0088] The previous section concerns identifying correlations between phenotypic traits and polymorphisms that directly or indirectly contribute to those traits. The present section describes identification of a physical linkage between a genetic locus associated with a trait of interest and polymorphic markers that are not associated with the trait, but are in physical proximity with the genetic locus responsible for the trait and co-segregate with it. Such analysis is useful for mapping a genetic locus associated with a phenotypic trait to a chromosomal position, and thereby cloning gene(s) responsible for the trait. See Lander et al., Proc. Natl. Acad. Sci. (USA) 83, 7353-7357 (1986); Lander et al., Proc. Natl. Acad. Sci. (USA) 84, 2363-2367 (1987); Donis-Keller et al., Cell 51, 319-337 (1987); Lander et al., Genetics 121, 185-199 (1989)). Genes localized by linkage can be cloned by a process known as directional cloning. See Wainwright, Med. J. Australia 159, 170-174 (1993); Collins, Nature Genetics 1, 3-6 (1992).

[0089] Linkage studies are typically performed on members of a family. Available members of the family are characterized for the presence or absence of a phenotypic trait and for a set of polymorphic markers. The distribution of polymorphic markers in an informative meiosis is then analyzed to determine which polymorphic markers co-segregate with a phenotypic trait. See, e.g., Kerem et al., Science 245, 1073-1080 (1989); Monaco et al., Nature 316, 842 (1985); Yamoka et al., Neurology 40, 222-226 (1990); Rossiter et al., FASEB Journal 5, 21-27 (1991).

[0090] Linkage is analyzed by calculation of LOD (log of the odds) values. A lod value is the relative likelihood of obtaining observed segregation data for a marker and a genetic locus when the two are located at a recombination fraction θ, versus the situation in which the two are not linked, and thus segregating independently (Thompson & Thompson, Genetics in Medicine (5th ed, W. B. Saunders Company, Philadelphia, 1991); Strachan, “Mapping the human genome” in The Human Genome (BIOS Scientific Publishers Ltd, Oxford), Chapter 4). A series of likelihood ratios are calculated at various recombination fractions (θ), ranging from θ=0.0 (coincident loci) to θ=0.50 (unlinked). Thus, the likelihood at a given value of θ is: probability of data if loci linked at θ to probability of data if loci unlinked. The computed likelihoods are usually expressed as the log10 of this ratio (i.e., a lod score). For example, a lod score of 3 indicates 1000:1 odds against an apparent observed linkage being a coincidence. The use of logarithms allows data collected from different families to be combined by simple addition. Computer programs are available for the calculation of lod scores for differing values of θ (e.g., LIPED, MLINK (Lathrop, Proc. Nat. Acad. Sci. (USA) 81, 3443-3446 (1984)). For any particular lod score, a recombination fraction may be determined from mathematical tables. See Smith et al., Mathematical tables for research workers in human genetics (Churchill, London, 1961); Smith, Ann. Hum. Genet. 32, 127-150 (1968). The value of θ at which the lod score is the highest is considered to be the best estimate of the recombination fraction.

[0091] Positive lod score values suggest that the two loci are linked, whereas negative values suggest that linkage is less likely (at that value of θ) than the possibility that the two loci are unlinked. By convention, a combined lod score of +3 or greater (equivalent to greater than 1000:1 odds in favor of linkage) is considered definitive evidence that two loci are linked. Similarly, by convention, a negative lod score of −2 or less is taken as definitive evidence against linkage of the two loci being compared. Negative linkage data are useful in excluding a chromosome or a segment thereof from consideration. The search focuses on the remaining non-excluded chromosomal locations.

IV. Modified Polypeptides and Gene Sequences

[0092] The invention further provides variant forms of nucleic acids and corresponding proteins. The nucleic acids comprise one of the sequences described in the Table, column 5, in which the polymorphic position is occupied by one of the alternative bases for that position. Some nucleic acids encode full-length variant forms of proteins. Similarly, variant proteins have the prototypical amino acid sequences encoded by nucleic acid sequences shown in the Table, column 6, (read so as to be in-frame with the full-length coding sequence of which it is a component) except at an amino acid encoded by a codon including one of the polymorphic positions shown in the Table. That position is occupied by the variant or alternative amino acid shown in the Table.

[0093] Variant genes can be expressed in an expression vector in which a variant gene is operably linked to a native or other promoter. Usually, the promoter is a eukaryotic promoter for expression in a mammalian cell. The transcription regulation sequences typically include a heterologous promoter and optionally an enhancer which is recognized by the host. The selection of an appropriate promoter, for example trp, lac, phage promoters, glycolytic enzyme promoters and tRNA promoters, depends on the host selected. Commercially available expression vectors can be used. Vectors can include host-recognized replication systems, amplifiable genes, selectable markers, host sequences useful for insertion into the host genome, and the like.

[0094] The means of introducing the expression construct into a host cell varies depending upon the particular construction and the target host. Suitable means include fusion, conjugation, transfection, transduction, electroporation or injection, as described in Sambrook, supra. A wide variety of host cells can be employed for expression of the variant gene, both prokaryotic and eukaryotic. Suitable host cells include bacteria such as E. coli, yeast, filamentous fungi, insect cells, mammalian cells, typically immortalized, e.g., mouse, CHO, human and monkey cell lines and derivatives thereof. Preferred host cells are able to process the variant gene product to produce an appropriate mature polypeptide. Processing includes glycosylation, ubiquitination, disulfide bond formation, general post-translational modification, and the like. As used herein, “gene product” includes mRNA, peptide and protein products.

[0095] The protein may be isolated by conventional means of protein biochemistry and purification to obtain a substantially pure product, i.e., 80, 95 or 99% free of cell component contaminants, as described in Jacoby, Methods in Enzymology Volume 104, Academic Press, New York (1984); Scopes, Protein Purification, Principles and Practice, 2nd Edition, Springer-Verlag, New York (1987); and Deutscher (ed), Guide to Protein Purification, Methods in Enzymology, Vol. 182 (1990). If the protein is secreted, it can be isolated from the supernatant in which the host cell is grown. If not secreted, the protein can be isolated from a lysate of the host cells.

[0096] The invention further provides transgenic nonhuman animals capable of expressing an exogenous variant gene and/or having one or both alleles of an endogenous variant gene inactivated. Expression of an exogenous variant gene is usually achieved by operably linking the gene to a promoter and optionally an enhancer, and microinjecting the construct into a zygote. See Hogan et al., “Manipulating the Mouse Embryo, A Laboratory Manual,” Cold Spring Harbor Laboratory. Inactivation of endogenous variant genes can be achieved by forming a transgene in which a cloned variant gene is inactivated by insertion of a positive selection marker. See Capecchi, Science 244, 1288-1292 (1989). The transgene is then introduced into an embryonic stem cell, where it undergoes homologous recombination with an endogenous variant gene. Mice and other rodents are preferred animals. Such animals provide useful drug screening systems.

[0097] In addition to substantially full-length polypeptides expressed by variant genes, the present invention includes biologically active fragments of the polypeptides, or analogs thereof, including organic molecules which simulate the interactions of the peptides. Biologically active fragments include any portion of the full-length polypeptide which confers a biological function on the variant gene product, including ligand binding, and antibody binding. Ligand binding includes binding by nucleic acids, proteins or polypeptides, small biologically active molecules, or large cellular structures.

[0098] Polyclonal and/or monoclonal antibodies that specifically bind to variant gene products but not to corresponding prototypical gene products are also provided. Antibodies can be made by injecting mice or other animals with the variant gene product or synthetic peptide fragments thereof. Monoclonal antibodies are screened as are described, for example, in Harlow & Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1988); Goding, Monoclonal antibodies, Principles and Practice (2d ed.) Academic Press, New York (1986). Monoclonal antibodies are tested for specific immunoreactivity with a variant gene product and lack of immunoreactivity to the corresponding prototypical gene product. These antibodies are useful in diagnostic assays for detection of the variant form, or as an active ingredient in a pharmaceutical composition.

V. Kits

[0099] The invention further provides kits comprising at least one agent for identifying which alleleic form of the SNPs identified herein is present in a sample. For example, suitable kits can comprise at least one antibody specific for a particular protein or peptide encoded by one alleleic form of the gene, or allele-specific oligonucleotide as described herein. Often, the kits contain one or more pairs of allele-specific oligonucleotides hybridizing to different forms of a polymorphism. In some kits, the allele-specific oligonucleotides are provided immobilized to a substrate. For example, the same substrate can comprise allele-specific oligonucleotide probes for detecting at least 10, 100 or all of the polymorphisms shown in the Table. Optional additional components of the kit include, for example, restriction enzymes, reverse-transcriptase or polymerase, the substrate nucleoside triphosphates, means used to label (for example, an avidin-enzyme conjugate and enzyme substrate and chromogen if the label is biotin), and the appropriate buffers for reverse transcription, PCR, or hybridization reactions. Usually, the kit also contains instructions for carrying out the methods.

[0100] The following Examples are offered for the purpose of illustrating the present invention and are not to be construed to limit the scope of this invention. The teachings of all references cited herein are hereby incorporated herein by reference.

EXAMPLES

[0101] The polymorphisms shown in the Table were identified by resequencing of target sequences from individuals of diverse ethnic and geographic backgrounds by hybridization to probes immobilized to microfabricated arrays. The strategy and principles for design and use of such arrays are generally described in WO 95/11995.

[0102] A typical probe array used in this analysis has two groups of four sets of probes that respectively tile both strands of a reference sequence. A first probe set comprises a plurality of probes exhibiting perfect complementarily with one of the reference sequences. Each probe in the first probe set has an interrogation position that corresponds to a nucleotide in the reference sequence. That is, the interrogation position is aligned with the corresponding nucleotide in the reference sequence, when the probe and reference sequence are aligned to maximize complementarily between the two. For each probe in the first set, there are three corresponding probes from three additional probe sets. Thus, there are four probes corresponding to each nucleotide in the reference sequence. The probes from the three additional probe sets are identical to the corresponding probe from the first probe set except at the interrogation position, which occurs in the same position in each of the four corresponding probes from the four probe sets, and is occupied by a different nucleotide in the four probe sets. In the present analysis, probes were 25 nucleotides long. Arrays tiled for multiple different references sequences were included on the same substrate.

[0103] Publicly available sequences for a given gene were assembled into Gap4 (http://www.biozentrum.unibas.ch/˜biocomp/staden/Overview.html). PCR primers covering each exon were designed using Primer 3 (http://www-genome.wi.mit.edu/cgibin/primer/primer3.cgi). Primers were not designed in regions where there were sequence discrepancies between reads. Genomic DNA was amplified in at least 50 individuals using 2.5 pmol each primer, 1.5 mM MgCl2, 100 μM dNTPs, 0.75 μM AmpliTaq GOLD polymerase, and 19 ng DNA in a 15 μl reaction. Reactions were assembled using a PACKARD MultiPROBE robotic pipetting station and then put in MJ 96-well tetrad thermocyclers (96° C. for 10 minutes, followed by 35 cycles of 96° C. for 30 seconds, 59° C. for 2 minutes, and 72° C. for 2 minutes). A subset of the PCR assays for each individual were run on 3% NuSieve gels in 0.5×TBE to confirm that the reaction worked.

[0104] For a given DNA, 5 μl (about 50 ng) of each PCR or RT-PCR product were pooled (Final volume=150-200 μl). The products were purified using QiaQuick PCR purification from Qiagen. The samples were eluted once in 35 μl sterile water and 4 μl 10×One-Phor-All buffer (Pharmacia). The pooled samples were digested with 0.2μ DNaseI (Promega) for 10 minutes at 37° C. and then labeled with 0.5 nmols biotin-N6-ddATP and 15μ Terminal Transferase (GibcoBRL Life Technology) for 60 minutes at 37° C. Both fragmentation and labeling reactions were terminated by incubating the pooled sample for 15 minutes at 100° C.

[0105] Low-density DNA chips (Affymetrix, California) were hybridized following the manufacturer's instructions. Briefly, the hybridization cocktail consisted of 3M TMACl, 10 mM Tris pH 7.8, 0.01% Triton X-100, 100 mg/ml herring sperm DNA (Gibco BRL), 200 pM control biotin-labeled oligo. The processed PCR products were denatured for 7 minutes at 100° C. and then added to prewarmed (37° C.) hybridization solution. The chips were hybridized overnight at 44° C. Chips were washed in 1×SSPET and 6×SSPET followed by staining with 2 μg/ml SARPE and 0.5 mg/ml acetylated BSA in 200 μl of 6×SSPET for 8 minutes at room temperature. Chips were scanned using a Molecular Dynamics scanner.

[0106] Chip image files were analyzed using Ulysses (Affymetrix, California) which uses four algorithms to identify potential polymorphisms. Candidate polymorphisms were visually inspected and assigned a confidence value: high confidence candidates displayed all three genotypes, while likely candidates showed only two genotypes (homozygous for reference sequence and heterozygous for reference and variant). Some of the candidate polymorphisms were confirmed by ABI sequencing. Identified polymorphisms were compared to several databases to determine if they were novel. Results are shown in the Table.

		Genbank or
		TIGR
		Accession	Position in	Gene	Flanking	Mutation
Poly ID	WIAF ID	Number	Sequence	Description	Seq	Type	Ref NT	Alt NT	Ref AA	Alt AA
G1001a4	WIAF-15540	D28135	824	DGKG, diacylglycerol kinase,	GTGAGGCCAACAGCG[C/G]AGATACTAATATACA	M	C	G	A	G
				gamma (90 kD)
G1001a5	WIAF-15541	D26135	941	DGKG, diacylglycerol kinase,	ACCAAGTGGCTGCGA[C/G]CCCCCTGGAACCCCC	M	C	G	T	S
				gamma (90 kD)
G1001a6	WIAF-15542	D26135	2625	DGKG, diacylglycerol kinase,	AGACCTCAGTGACCA[G/A]CTCCTTGAAGTGGTG	S	G	A	Q	Q
				gamma (90 kD)	ITPKB, inosatol 1,4,5-
G1002a3	WIAF-15543	X57206	396	ITPKB, inositol 1,4,5-	GCTGTCATCATTACA[G/A]ACATGGGCACCCAGG	N	G	A	D	N
				triephosphate 3-kinase B
G1006a3	WIAF-15628	HT2690	894	PRKCA, protein kinase C,	GTACTACAACGTACC[C/T]ATTCCGGAAGGGGAC	S	C	T	P	P
				alpha
G1006a4	WIAF-15819	HT2690	301	PRKCA, protein kinase C,	CCGGGTGCGGATAAG[G/T]GACCCGACACTGATG	N	C	T	G	*
				alpha
G1006a5	WIAF-15820	HT2690	379	PRKCA, protein kinase C,	ACCTTCTGCGATCAC[T/C]GTGGGTCACTGCTCT	M	T	C	C	R
				alpha
G1006a6	WIAF-15821	HT2690	420	PRKCA, protein kinase C,	CCATCAAGGGATGAA[A/G]TGTGACACCTGCGAT	S	A	G	K	K
				alpha
G1008a8	WIAF-15629	HT2136	1584	PRKCZ, protein kinase C,	GCAGGCGCTCCCTCC[A/C]TTCCAGCCACAGATC	S	A	C	P	P
				zeta
G1008a9	WIAF-15630	HT2136	1811	PRKCZ, protein kinase C,	TGACCCTTTAACTGT[A/G]TCCTTAACCACCGCA	—	A	G
				zeta
G1011a9	WIAF-15731	X07876	492	WNT2, wingless-type MMTV	GATGCGTGCCATTAG[C/T]CAGGGCGTGGCCGAG	S	C	T	S	S
				integration site family
				member 2
G1012a2	WIAF-15826	H48910	1576	WNT2B, wingless-type MMTV	TCCATACTTGCAAAG[C/T]CCCCAAGAAGGCAGA	M	C	T	A	V
				integration site family,
				member 2B
G1012a3	WIAF-15827	H48910	1604	WNT2B, winglece-type MMTV	AGAGTGGCTGGACCA[G/A]ACCTGAACACACAGA	S	G	A	Q	Q
				integration cite family,
				member 2B
G1012a4	WIAF-15828	HT48910	1651	WNT2B, wingless-type MMTV	CCAATTCAAGCCTCT[C/T]AACTCAAAAGCACAA	—	C	T
				integration site family,
				member 2B
G1012a5	WIAF-15829	HT48910	1730	WNT2B, wingless-type MMTV	GCTTCTATTTAAGGA[T/C]GTAGAGAGTAATCCA	—	T	C
				integration site family,
				member 2B
G1016a10	WIAF-15569	Z22534	1771	ACVR1, activin A receptor,	GACAAGGCAGACGTC[G/A]TACCCAGCCATGTGT	—	G	A
				type I
G1016a3	WIAF-15545	Z22534	164	ACVR1, activin A receptor,	CTCCCCTCCCCTAGT[A/G]TGGAAGATGAGAAGC	M	A	G	M	V
				type I
G1016a4	WIAF-15546	Z22534	277	ACVR1, activin A receptor,	CTTTTCCTCACTGAG[C/T]ATCAACGATGGCTTC	S	C	T	S	S
				type I
G1016a5	WIAF-15547	Z22534	438	ACVR1, activin A receptor,	TGCCCACTAAAGGAA[A/C]ATCCTTCCCTGGAAC	M	A	C	K	T
				type I
G1016a6	WIAF-15548	Z22534	1234	ACVR1, activin A receptor,	CAATCCCCGTGTGGG[C/T[ACCAAGCGCTACATG	S	C	T	G	C
				type I
G1016a7	WIAF-15566	Z22534	1507	ACVR1, activin A receptor,	AGACCCGACATTAAC[C/T]TCTCTGGCCAAGCTA	S	C	T	T	T
				type I
G1016a8	WIAF-15567	Z22534	1616	ACVR1, activin A receptor,	AATTCCCTCGACAAA[T/C]TGAAAACTGACTGTT	S	T	C	L	L
				type I
G1016a9	WIAF-15568	Z22534	1678	ACVR1, activin A receptor,	GACGTTGTTGTCATT[G/T]TCCAGCTGGGACCTA	—	G	T
				type I
G1017a1	WIAF-15570	Z35309	3732	ADCY8, adenylate cyclase 8	ATCTGGAGGAATCCC[C/T]GGGAGGATTCACATT	S	C	T	P	P
				(brain)
G1017a5	WIAF-16708	Z35309	2332	ADCY8, adenylate cyclase 8	GGCCCCAACCACCAC[G/A]CGCCGCAGCTGTCAG	M	G	A	A	T
				(brain)
G1017a6	WIAF-16709	Z35309	3073	ADCY8, adenylate cyclase 8	GTGGCCCAGGCAGTG[C/T]TATTCATGTGTATGA	S	C	T	L	L
				(brain)
G1017a7	WIAF-16710	Z35309	3039	ADCY8, adenylate cyclase 8	ACCCCGGCTGGCGGT[C/T]ATTTCCATCAACCAG	S	C	T	V	V
				(brain)
G1018a2	WIAP-15631	X74210	1463	ADCY2, adenylate cyclase 2	TGGCAAGAAGACTGT[A/C]TTTTCAGGAAGGTAT	—	A	C
				(brain)
G1018a3	WIAF-15632	X74210	1552	ADCY2, adenylate cyclase 2	TATGGAGCCTCTGCA[G/A]ACTCGTTCTCGTGAC	—	C	A
				(brain)
G1018a4	WIAF-15822	X74210	994	ADCY2, adenylate cyclase 2	GGCAGCACATACATG[G/A]CAGCAACAGGTCTGA	M	G	A	A	T
				(brain)
G1018a5	WIAF-15823	X74210	1051	ADCY2, adenylate cyclase 2	CAGGAGCCCGAGCGG[C/T]AGTACATGCACATTG	N	C	T	Q	*
				(brain)
G1019a10	WIAF-15763	U83867	5154	SPTAN1, spectrin, alpha, non	TTATGGCAAAGACCT[G/A]GCTTCTGTGAACAAC	S	G	A	L	L
				erythrocytic 1 (alpha-fodrin)
G1019a6	WIAF-15549	U83867	3615	SPTAN1, spectrin, alpha, non	CATGATGCCCAGGGA[T/C]GAAACTGATTCCAAG	S	T	C	D	D
				erythrocytic 1 (alpha-fodrin)
G1019a7	WIAF-15550	U83867	4479	SPTAN1, spectrin, alpha, non	GGCCTTCTTGAATAC[C/T]GAAGACAAAGGAGAC	S	C	T	T	T
				erythrocytic 1 (alpha-fodrin)
G1019a8	WTAF-15551	U83867	5422	SPTAN1, spectrin, alpha, non	GACGAGGAGTCCTGG[A/C]TCAAGGAGAAGAAGC	M	A	C	I	L
				erythrocytic 1 (alpha-fodrin)
G1019a9	WIAF-15552	U83867	7458	SPTAN1, spectrin alpha, non	CCGCGAGCTCCCCAC[C/T]GCGTTCGACTACGTG	S	C	T	T	T
				erythrocytic 1 (alpha-fodrin)
G1020a1	WIAF-15575	U87558	735	AMPHL, amphiphysin-like	CCGCGTAGGTTTCTA[C/T]GTCAACACGTTCCAG	S	C	T	Y	Y
G1020a2	WIAF-15576	U87558	812	AMPHL, amphiphysin-like	TCAACCAGAACCTCA[A/G]TGATGTGCTGGTCGG	M	A	G	N	S
G1020a3	WIAF-15577	U87558	915	AMPHL, amphiphysin-like	GAACAAGAGCCCTTC[G/A]CCTCCAGATGGCTCC	S	G	A	S	S
G1022a3	WIAF-15578	U45945	701	ATP1B2, ATPase, Na+/K+	TCCCCGCCAACGGCA[A/G]CATCGACCTCATGTA	M	A	G	N	S
				transporting, beta 2
				polypeptide
G1022a4	WIAF-15736	U45945	149	ATP1B2, ATPase, Na+/K+	CCGGGACCAGCTGGG[C/G]CTTTATCCTCCTCTT	M	C	G	A	G
				transporting, beta 2
				polypeptide
G1023a4	WIAF-15553	D89722	1101	ARNTL, aryl hydrocarbon	CAACAGCTATTTTGG[C/G]ATATTTACCACAAGA	M	C	G	A	C
				receptor nuclear translocator
				like
G1023a5	WIAF-15554	D89722	1102	ARNTL, aryl hydrocarbon	AACAGCTATTTTGGC[A/G]TATTTACCACAAGAA	S	A	G	A	A
				receptor nuclear translocator
				like
G1024a2	WIAF-15579	U85946	789	Homo sapiens brain secretory	ATGCCAGCTGATTCA[G/A]GAGTTTACCAGTGCT	S	G	A	Q	Q
				protein hSec10p (HSEC10)
				mRNA, complete cds., ?
G1024a3	WIAF-15580	U85946	1428	Homo sapiens brain secretory	TGGGGAGACTTTTCT[A/C]TCCCAAGAAGTGGTG	S	A	C	L	L
				protein hSec10p (HSEC10)
				mRNA, complete cds., ?
G1024a4	WIAF-15581	U85945	1975	Homo sapiens brain secretory	AAGATTAAAAATTCC[A/C]TGGATGGGAAGAATG	M	A	C	M	L
				protein hSec10p (HSEC10)
				mRNA, complete cds., ?
G1024a5	WIAF-15582	U85946	1743	Homo sapiens brain secretory	TCCTAAGTTATCTGA[A/C]TGCCTTCAGAAGAAA	M	A	C	E	D
				protein hSec10p (HSEC10)
				mRNA, complete cds., ?
G1029a1	WIAF-15586	U96136	2837	CTNND2, catenin (cadherin-	TTCCAGGAGGGAACA[A/T]CAGCAACAACACTGC	M	A	T	N	I
				associated protein) , delta 2
				(neural plakophilin-related
				arm-repeat protein)
G1029a2	WIAF-15587	U96136	2841	CTNND2, catenin (cadherin-	AGGAGGGAACAACAG[C/T]AACAACACTGCAAGC	S	C	T	S	S
				associated protein) , delta 2
				(neural plakophilin-related
				arm-repeat protein)
G1029a3	WIAF-15588	U96136	2977	CTNND2, catenin (cadherin-	GAGAAGTTGGTCGGC[A/T]TCTCCAAAAGCAAAG	M	A	T	I	F
				associated protein) , delta 2
				(neural plakophilin-related
				arm-repeat protein)
G1029a4	WIAF-15737	U96136	3371	CTNND2, catenin (cadherin-	GAATTTCAACTTTGT[A/G]TAGGAATTCTTATGG	M	A	G	Y	C
				associated protein) , delta 2
				(neural plakophilin-related
				arm-repeated protein)
G1029a5	WIAF-15738	U96136	3381	CTNND2, catenin (cadherin-	TTTGTATAGGAATTC[T/A]TATGGTGCGCCCGCT	S	T	A	S	S
				associated protein) , delta 2
				(neural plakophilin-related
				arm-repeat protein)
G1029a7	WIAF-16711	U96136	2540	CTNND2, catenin (cadherin-	GGCACCCATCAATAG[T/A]CAAACCCTACCTCAC	M	T	A	V	D
				associated protein) , delta 2
				(neural plakophilin-related
				arm-repeated protein)
G1030a3	WIAF-15556	U07358	296	ZPK, zipper (leucine)	AGCTGGGTCACCTGA[G/T]AGTCGGGCATCCAGA	M	G	T	E	D
				protein kinase
G1030a4	WIAF-15557	U07358	433	ZPK, zipper (leucine)	CCACTGAGCACAAGC[A/T]GCAGCAGGAAGACCT	M	A	T	Q	L
				protein kinase
G1030a5	WIAF-15589	U07358	1785	ZPK, zipper (leucine)	GACCTGCCTGGGCTT[C/A]GTACAGCTGTGCCAC	M	C	A	R	S
				protein kinase
G1031a10	WIAF-14342	Y12476.0	2094	GPR37, G protein-coupled	CCGGGGAAACAGCAC[G/T]AACCGGCGTGTGAGA	S	G	T	T	T
				receptor 37 (endothelin
				receptor type B-like)
G1031a11	WIAF-15590	U87460	3472	GPR37, G protein-coupled	TCATGGAGTGCTGCT[G/A]CTGTTGCTGTGAGGA	M	G	A	C	Y
				receptor 37 (endothelin
				receptor type B-like)
G1031a12	WIAF-15739	U87460	2906	GPR37, G protein-coupled	AATGATCGAAAACTG[T/C]TCCTCAACAACTGCC	S	T	C	C	C
				receptor 37 (endothelin
				receptor typr B-like)
G1031e13	WIAF-15740	U87460	3073	GPR37, G protein-coupled	TACCAGACACCATCT[A/G]TGTTCTAGCCCTCAC	M	A	G	Y	C
				receptor 37 (endothelin
				receptor type B-like)
G1031a14	WIAF-15741	U87460	3076	GPR37, G protein-coupled	CAGACACCATCTATG[T/C]TCTAGCCCTCACCTA	M	T	C	V	A
				receptor 37 (endothelin
				receptor type B-like)
G1031a16	WIAF-16712	U87460	2006	GPR37, G protein-coupled	ACCCAGGGAGGAGCA[C/T]GGGGCAGCGTTTCTT	M	G	T	Q	H
				receptor 37 (endothelin
				receptor type B-like)
C1031a3	WTAF-14335	Y12477.0	324	GPR37, G protein-coupled	CGACAGTGCGAGACT[G/C]TGGTGGTATTTTGGC	—	G	C
				receptor 37 (endothelin
				receptor type B-like)
G1031e4	WIAF-14336	Y12477.0	1574	GPR37, G protein-coupled	GAATACTTATAAAAT[A/G]TGAATAAATAGCAGA	—	A	G
				receptor 37 (endothelin
				receptor type B-like)
G1031a5	WIAF-14337	Y12476.0	665	GPR37, G protein-coupled	CGCCGTCCAGCAGCC[T/C]GCTTCGCCCCGTCGT	—	T	C
				receptor 37 (endothelin
				receptor type B-like)
G1031a6	WIAF-14338	Y12476.0	727	GPR37, G protein-coupled	CAGTGGCCGCGGGGT[T/G]GGAATCCCGCTTCTC	—	T	G
				receptor 37 (endothelin
				receptor type B-like)
G1031e7	WIAF-14339	Y12476.0	1611	GPR37, G protein-coupled	GCAGGGGGCAGCGTT[T/C]CTTGCGGGACCCTCC	S	T	C	F	F
				receptor 37 (endothelin
				receptor type B-like)
G1031a8	WIAF-14340	Y12476.0	1694	GPR37, G protein-coupled	AGGCGTCGGCAGCCG[C/A]ACCCCCGGGACCTCC	M	G	A	C	E
				receptor 37 (endothelin
				receptor type B-like)
G1031a9	WIAF-14341	Y12476.0	2054	GPR37, G protein-coupled	GATCCTTGGGTGAAG[G/T]AATCCATGAGCCTGG	M	G	T	G	V
				receptor 37 (endothelin
				receptor type B-like)
G1033a23	WIAF-15591	M65188	608	GJA1, gap junction protein,	GTAAGGTGAAAATGC[G/A]AGGGGGGTTGCTGCG	M	G	A	R	Q
				alpha 1, 43 kD (connexin 43)
G1033a24	WTAF-15592	M65188	667	GJA1, gap junction protein,	TCTATCTTTGAGGTG[G/A]CCTTCTTGCTGATCC	M	G	A	A	T
				alpha 1, 43 kD (connexin 43)
G1033a25	WIAF-15593	M65188	718	GJA1, gap junction protein,	AGCTTGAGTGCTGTT[T/C]ACACTTGCAAAAGAG	M	T	C	Y	H
				alpha 1, 43 kD (connexin 43)
G1033a26	WIAF-15594	M65188	759	GJA1, gap junction protein,	ACATCAGGTGGACTG[T/C]TTCCTCTCTCGCCCC	S	T	C	C	C
				alpha 1, 43 kD (connexin 43)
G1033a27	WIAF-15595	M65188	769	GJA1, gap function protein,	GACTGTTTCCTCTCT[C/T]GCCCCACGGAGAAAA	M	C	T	R	C
				alpha 1, 43 kD (connexin 43)
G1033a28	WTAF-15596	M65188	776	GJA1, gap junction protein,	TCCTCTCTCGCCCCA[C/T]CGAGAAAACCATCTT	M	C	T	T	M
				alpha 1, 43 kD (connexin 43)
G1033a29	WIAF-15597	M65188	537	GJA1, gap junction protein,	TGGTGTCAATGTGGA[C/G]ATGCACTTGAAGCAG	M	C	G	D	E
				alpha 1, 43 kD (connexin 43)
G1033a30	WIAF-15742	M65188	181	GJA1, gap junction protein,	ATGGGTGACTGGAGC[G/A]CCTTAGGCAAACTCC	M	G	A	A	T
				alpha 1, 43 kD (connexin 43)
G1033a31	WIAF-15743	M65188	183	GJA1, gap junction protein,	GGGTGACTGGAGCGC[C/T]TTAGGCAAACTCCTT	S	C	T	A	A
				alpha 1, 43 kD (connexin 43)
G1033a32	WIAF-15744	M65188	277	GJA1, gap junction protein,	CGAATCCTGCTGCTG[G/A]GGACAGCGGTTGAGT	M	G	A	G	R
				alpha 1, 43 kD (connexin 43)
G1033a33	WIAF-15745	M65188	278	GJA1, gap junction protein,	GAATCCTGCTGCTGG[G/A]GACAGCGGTTGAGTC	M	G	A	G	E
				alpha 1, 43 kD (connexin 43)
G1033a34	WIAF-15746	M65188	284	GJA1, gap junction protein,	TGCTGCTGGGGACAG[C/T]GGTTGAGTCAGCCTG	M	C	T	A	V
				alpha 1, 43 kD (connexin 43)
G1033a35	WIAF-15747	M65188	317	GJA1, gap junction protein,	GAGATGAGCAGTCTG[C/T]CTTTCGTTGTAACAC	M	C	T	A	V
				alpha 1, 43 kD (connexin 43)
G1033a36	WIAF-15748	M65188	394	GJA1, gap function protein,	ATCTCTCATGTGCGC[T/C]TCTGGGTCCTGCAGA	M	T	C	F	L
				alpha 1, 43 kD (connexin 43)
G1033a37	WIAF-15749	M65188	118	GJA1, gap junction protein,	AAGGAGTTCAATCAC[T/C]TGGCGTGACTTCACT	—	T	C
				alpha 1, 43 kD (connexin 43)
G1033e38	WIAF-15750	M65188	134	GJA1, gap junction protein,	TGGCGTGACTTCACT[A/T]CTTTTAAGCAAAAGA	—	A	T
				alpha 1, 43 kD (connexin 43)
G1033a39	WIAF-15761	M65188	1013	GJA1, gap junction protein,	TCTCGCCTATGTCTC[C/T]TCCTGGGTACAAGCT	M	C	T	P	L
				alpha 1, 43 kD (connexin 43)
G1033a40	WIAF-15762	M65188	1079	GJA1, gap junction protein,	ATTACAACAAGCAAG[C/T]AAGTGAGCAAAACTG	M	C	T	A	V
				alpha 1, 43 kD (connexin 43)
G1034a13	WIAF-15558	J03544	1339	PYGB, phosphorylase,	GGCCGCGCTGTTTCC[C/T]GGCGATGTGGACCGC	S	C	T	P	P
				glycogen; brain
G1034a14	WIAF-15559	J03544	2049	PYGB, phosphorylase,	CCTTGGCTGAGAAAG[T/C]GATCCCGGCCGCTGA	M	T	G V	G
				glycogen; brain
G1034a15	WTAF-15560	J03544	2108	PYGB, phosphorylase,	ACCGAGGCCTCAGGC[A/T]CAGGCAACATGAAGT	M	A	T	T	S
				glycogen; brain
G1034a16	WIAF-15561	J03544	2237	PYGB, phosphorylase,	CGGGTGGAGGATGTC[G/C]AGGCCTTGGACCGGA	M	G	C	E	Q
				glycogen; brain
G1035a4	WIAF-15751	U97105	1688	DPYSL2, dihydropyrimidinase	GGGACAAGCCTGCTC[G/A]CTGCCTTTGACCAGT	M	G	A	A	T
				like 2
G1035a5	WIAF-15752	U97105	2332	DPYSL2, dihydropyrimidinase	GGTCACGGGCAGTGC[C/G]CATTGCACGTTTAAC	S	C	G	A	A
				like 2
G1039e3	WIAF-15851	HT2747	124	serine/threonine kinase,	GCCTCCCTGTCAGAC[A/C]TTGGCTTTGGGAAAC	M	A	C	I	L
				PCTAIRE-3, ?
G1039a4	WIAP-15864	HT2747	1180	serine/threonine kinase,	CCAAGCCACAAGAGA[C/T]CACATGGAGCACAAA	—	C	T
				PCTAIRE-3, ?
G1043a16	WIAF-15598	M94055	543	Human voltage-gated sodium	CAACTGTGTATTTAT[G/A]ACCATGAGTAACCCT	M	C	A	M	I
				channel mRNA, complete cds.,
				?
G1043a17	WIAF-15599	M94055	711	Human voltage-gated sodium	AGTCATTACTTTTGC[A/G]TATGTGACAGAGTTT	S	A	G	A	A
				channel mRNA, complete cds.,
				?
C1043a18	WIAF-15500	M94055	717	Human voltage-gated sodium	TACTTTTGCATATGT[G/A]ACACAGTTTGTGGAC	S	G	A	V	V
				channel mRNA, complete cds.,
				?
G1043a19	WIAF-15601	M94055	723	Human voltage-gated sodium	TGCATATGTGACAGA[G/A]TTTGTGGACCTGGGC	S	G	A	E	E
				channel mRNA, complete cds.,
				?
G1043a20	WIAF-15602	M94055	735	Human voltage-gated sodium	AGAGTTTGTGGACCT[G/A]GGCAATGTCTCAGCG	S	G	A	L	L
				channel mRNA, complete cds.,
				?
G1043a21	WIAF-15603	M94055	744	Human voltage-gated sodium	GGACCTGGGCAATGT[C/T]TCAGCGTTGAGAACA	S	C	T	V	V
				channel mRNA, complete cds.,
				?
G1043a22	WIAF-15604	M94055	777	Human voltage-gated sodium	CAGAGTTCTCCGAGC[A/T]TTGAAAACAATTTCA	S	A	T	A	A
				channel mRNA, complete cds.,
				?
G1043a23	WIAF-15605	M94055	786	Human voltage-gated sodium	CCGAGCATTGAAAAC[A/T]ATTTCAGTCATTCCA	S	A	T	T	T
				channel mRNA, complete cds.,
				?
G1043a24	WIAF-15753	M94055	945	Human voltage-gated sodium	AAATAAATGTTTGCA[A/G]TGGCCTCCAGATAAT	S	A	G	Q	Q
				channel mRNA, complete cds.,
				?
G1043a25	WIAF-15754	M94055	1259	Human voltage-gated sodium	TCATGACTCAAGACT[T/A]CTGGGAAAACCTTTA	M	T	A	F	Y
				channel mRNA, complete cds.,
				?
G1043a26	WIAF-15755	M94055	1275	Human voltage-gated sodium	CTGGGAAAACCTTTA[T/C]CAACTGACACTACGT	S	T	C	Y	Y
				channel mRNA, complete cds.,
				?
G1043a27	WIAF-15756	M94055	1278	Human voltage-gated sodium	GGAAAACCTTTATCA[A/G]CTGACACTACGTGCT	S	A	G	Q	Q
				channel mRNA, complete cds.,
				?
G1043a28	WIAF-15757	M94055	1279	Human voltage-gated sodium	GAAAACCTTTATCAA[C/T]TGACACTACGTGCTG	S	C	T	L	L
				channel mRNA, complete cds.,
				?
G1043a29	WIAF-15758	M94055	1285	Human voltage-gated sodium	CTTTATCAACTGACA[C/T]TACGTGCTGCTGGGA	S	C	T	L	L
				channel mRNA, complete cds.,
				?
G1043a30	WIAF-15759	M94055	882	Human voltage-gated sodium	GACTGTGTTCTGTCT[A/G]AGCGTGTTTGCGCTA	s	A	G	L	L
				channel mRNA, complete cds.,
				?
G1043a31	WIAF-16363	M94055	5214	Human voltage-gated sodium	GACCTTTGGCAACAG[C/A]ATGATCTGCCTGTTC	M	C	A	S	R
				channel mRNA, complete cds.,
				?
G1048a5	WIAF-16440	HT5174S	1925	REST, RE1-silencing	GTTCAGAAGGGGCCC[G/A]TTCAGGTGGAGCTGC	M	G	A	V	I
				transcription factor
G1051a7	WIAF-17084	HT28321	1969	SCNN1G, sodium channel,	GATGCTGGATGAGCT[C/G]TGAGGCAGGGTTGAG	S	C	G	L	L
				nonvoltage-gated 1, gamma
G1051a8	WIAF-17085	HT28321	2001	SCNN1G, sodium channel,	AGACAGATCTAGTCA[G/A]GACCACCAGCCATGG	—	G	A
				nonvoltage-gated 1, gamma
G1051a9	WIAF-17086	HT28321	2131	SCNN1G, sodium channel,	CCGCAAGATGGGGCC[T/G]GGGCATGCGCAGGAG	—	T	G
				nonvoltage-gated 1, gamma
G1054a13	WIAF-16364	HT2202	3926	SCN4A, sodium channel,	CATCATCTTTGGCTC[C/T]TTCTTCACCCTCAAC	S	C	T	S	S
				voltage-gated, type IV, alpha
				polypeptide
G1054a14	WIAF-16365	HT2202	4904	SCN4A, sodium channel,	CACAGAGGAGAGCAG[C/T]GAGCCCCTTGGTGAA	S	C	T	S	S
				voltage-gated, type IV, alpha
				polypeptide
G1054a15	WIAF-16366	HT2202	4939	SCN4A, sodium channel,	ACTTTGAGATGTTCT[A/C]CGAGACATGGGAGAA	M	A	C	Y	S
				voltage-gated, type IV, alpha
				polypeptide
G1054a16	WIAF-16367	HT2202	4946	SCN4A, sodium channel,	GATGTTCTACGAGAC[A/G]TGGGAGAAGTTCGAC	S	A	G	T	T
				voltage-gated, type IV, alpha
				polypeptide
G1054a17	WIAF-16368	HT2202	4981	SCN4A, sodium channel,	ACGCCACCCAGTTCA[T/C]CGCCTACAGCCGCCT	M	T	C	I	T
				voltage-gated, type IV, alpha
				polypeptide
G1054e18	WIAF-17087	HT2202	5611	SCN4A, sodium channel,	CATCGGGGTGGCCCC[A/G]CTGAGTCTCGGCATA	—	A	G
				voltage-gated, type IV, alpha
				polypeptide
G1054a19	WIAF-17088	HT2202	5703	SCN4A, sodium channel,	GACTGTGCCTGGCTC[C/G]CTGATGGGGGACAGG	—	C	G
				voltage-gated, type IV, alpha
				polypeptide
G1054a20	WIAF-17089	HT2202	5711	SCN4A, sodium channel,	CTGGCTCCCTGATGG[G/A]GGACAGGATTTGGCC	—	G	A
				voltage-gated, type IV, alpha
				polypeptide
G1054a21	WIAF-17094	HT2202	2468	SCN4A, sodium channel,	GGTCCTGAACCTGTT[C/T]CTGGCTCTGCTGCTG	S	C	T	F	F
				voltage-gated, type IV, alpha
				polypeptide
G1054a22	WIAF-17095	HT2202	2631	SCN4A, sodium channel,	AAGATCCTGAGCCCC[A/T]AGGACATCATGCTCA	N A	T	K	*
				voltage-gated, type IV, alpha
				polypeptide
G1054a23	WIAF-17096	HT2202	2659	SCN4A, sodium channel,	TCAGCCTCGGGGAGG[C/T]TGACGGGGCCGGGGA	M	C	T	A	V
				voltage-gated, type IV, alpha
				polypeptide
G1054a24	WIAF-17097	HT2202	2345	SCN4A, sodium channel,	CCTCATCGTCTTCCG[C/T]ATCCTGTGCGGGGAG	S	C	T	R	R
				voltage-gated, type IV, alpha
				polypeptide
G1054a25	WIAF-17098	HT2202	4286	SCN4A, sodium channel,	GGAGTGCGTGCTCAA[G/T]ATGCTCGCCCTGCGC	M	G	T	K	N
				voltage-gated, type IV, alpha
				polypeptide
G1059a10	WIAF-15614	HT33704	1757	APLP1, amyloid beta (A4)	GATGAGCTGGCACCA[G/C]CTGGGACAGGGGTGT	M	G	C	A	P
				precursor-like protein 1
G1059a11	WIAF-15615	HT33704	1829	APLP1, amyloid beta (A4)	GGAGGCTCCCTCATC[G/A]TCCTCTCCATGCTGC	M	G	A	V	I
				precursor-like protein 1
G1059a12	WIAF-15616	HT33704	1512	APLP1, amyloid beta (A4)	ACTCTGAACACCTGG[G/T]TCCCAGTGAATTGGA	M	G	T	G	V
				precursor-like protein 1
G1059a13	WIAF-16369	HT33704	448	APLP1, amyloid beta (A4)	CCACCACCAGGTTGT[G/A]CCCTTCCGCTGCCTG	S	G	A	V	V
				precursor-like protein 1
G1059a7	WIAF-15608	HT33704	1297	APLP1, amyloid beta (A4)	GCGCTACCTGCGTGC[G/T]GAGCAGAAGGAACAG	S	G	T	A	A
				precursor-like protein 1
G1059a8	WIAF-15612	HT33704	926	APLP1, amyloid beta (A4)	ACAGACGGTGTGGAT[A/G]TTTACTTTGGCATGC	M	A	G	I	V
				precursor-like protein 1
G1059a9	WIAF-15613	HT33704	617	APLP1, amyloid beta (A4)	CTGCACGGCTCGGGC[A/C]TGCTCTTACCCTGTG	M	A	C	M	L
				precursor-like protein 1
G1060a7	WIAF-15617	HT1418	2390	APLP2, amyloid beta (A4)	GCGCGGCAGCCCTGG[C/T]GGAGGGATGCAGGTG	—	C	T
				precursor-like protein 2
G1060e8	WIAF-16370	HT1418	404	APLP2, amyloid beta (A4)	CAAACCAGCGGGTTA[G/T]TATTGACAACTGGTG	M	G	T	S	I
				precursor-like protein 2
G1061a1	WTAF-17090	HT3834	1087	HP, haptoglobin	GCCTTTGCCGTTCAC[G/A]ACCTGGAGGAGGACA	M	G	A	D	N
G1067a5	WIAF-15618	HT0830	611	KCNA1, potassium voltage-	CGGGCACCGTCCACC[G/A]CATCGACAACACCAC	M	G	A	R	H
				gated channel, shaker-related
				subfamily, member 1 (episodic
				ataxia with myokymia)
G1068a2	WIAF-15619	HT0831	550	KCNA1, potassium voltage-	AGCTTCTGTCTGGAA[A/G]CATTGCCCATCTTCC	M	A	G	T	A
				gated channel, shaker-related
				subfamily, member 2
G1072a2	WIAF-17091	HT48682	1286	KCNJ10, potassium inwardly-	TACGGAGACCCTGAA[A/T]AGCTCAAGTTGGAGG	N	A	T	K *
				rectifying channel,
				subfamily, member 10
G1072a3	WIAF-17092	HT48682	1374	KCNJ10, potassium inwardly-	ATGTCTGATGACCTG[T/C]TCCCACTCCCCCATT	—	T	C
				rectifying channel,
				subfamily, member 10
G1072a4	WIAF-17093	HT48682	1418	KCNJ10, potassium inwardly-	TTCCTCTCTTCCAAT[G/A]CCCTGGTAAGGAATA	—	G	A
				rectifying channel,
				subfamily, member 10
G1073a2	WIAF-15620	HT4556	1306	KCNJ1, potassium inwardly-	ATTATGAAGCAGTCA[A/T]CAATTTAGGGGTACG	—	A	T
				rectifying channel,
				subfamily J, member 10
G1074a3	WIAF-15609	HT27804	296	KCNJ10, potassium voltage-	CTCTTCGATACAGCA[G/A]AAGTCTACGCAGCCG	M	G	A	E	K
				gated channel, shaker-related
				subfamily, beta member 2
G1074a4	WIAF-15610	HT27804	310	KCNJ10, potassium voltage-	AGAAGTCTACGCAGC[C/T]GGCAAGGCTGAAGTG	S	C	T	A	A
				gated channel, shaker-related
				subfamily, beta member 2
G1074a5	WIAF-15611	HT27804	400	KCNAB2, potassium voltage-	CAAGATCTTCTGGGG[C/T]GGAAAGGCGGAGACG	S	C	T	G	G
				gated channel, shaker-related
				subfamily, beta member 2
G1075a2	WIAF-16381	HT28405	1153	potassium channel, beta	GTGGTGCCTGAGAAA[T/C]GAAGGTGTGAGTTCT	S	T	C	N	N
				subunit, alt. transcript 1,
				?
G1075a3	WIAF-16382	HT28405	1201	potassium channel, beta	CACTCCTGAACAACT[C/T]ATTGAAAACCTTGGT	S	C	T	L	L
				subunit, alt. transcript 1,
				?
G1076a1	WTAF-16371	HT48838	476	KCNN1, potassium	CTCTGTACTCATTCG[C/T]ACTCAAATGCCTCAT	M	C	T	A	V
				intermediate/small
				conductance calcium-activated
				channel, subfamily N, member
				1
G1076a2	WIAF-16372	HT48838	131	KCNN1, potassium	TGGGACGAGACCCTC[C/T]GGACCCTGAGGCCGG	M	C	T	P	L
				intermediate/small
				conductance calcium-activated
				channel, subfamily N, member
				1
G1079a10	WIAF-15768	HT27383	1424	potassium channel, inwardly	GCGTGTGTACACACG[G/A]ACCATGTGGTATGTA	—	G	A
				rectifing (GB: D50582), ?
G1079a11	WIAF-15769	HT27383	1444	potassium channel, inwardly	TGTGGTATGTAGCCC[A/G]GCCAGGGCCTGGTGT	—	A	G
				rectifying (GB: D50582), ?
G1079a12	WIAF-15770	HT27383	807	potassium channel, inwardly	CGCCTCTGCTTCATG[C/T]TACGTGTGGGTGACC	S	C	T	L L
				rectifing (GB: D50582), ?
G1079a13	WIAF-15771	HT27383	914	potassium channel, inwardly	GGTGCCCCTCCACCA[G/T]GTGGACATCCCCATG	M	G	T	Q	H
				rectifing (GB: D50582), ?
G1079a14	WIAF-15772	HT27383	1002	potassium channel, inwardly	GTCATTGATGCCAAC[A/T]GCCCACTCTACGACC	M	A	T	S	C
				rectifing (GB: D50582), ?
G1079a15	WIAF-15773	HT27383	1010	potassium channel, inwardly	TGCCAACAGCCCACT[C/G]TACGACCTGGCACCC	S	C	G	L	L
				rectifing (GB: D50582), ?
G1079a7	WIAF-15764	HT27383	256	potassium channel, inwardly	AATACGTGCTCACAC[C/T]CCTGGCAGAGGACCC	M	G	T	R	L
				rectifing (GB: D50582), ?
G1079a8	WIAF-15766	HT27383	1218	potassium channel, inwardly	AAGTTTGGCAACACC[A/G]TCAAAGTGCCCACAC	M	A	G	I	V
				rectifing (GB: D50582), ?
G1079a9	WIAF-15767	HT27383	1352	potassium channel, inwardly	CAAGGCCAAGCCCAA[G/A]TTCAGCATCTCTCCA	S	G	A	K	K
				rectifing (GB: D50582), ?
G1080a4	WIAF-16373	HT4412	1066	KCNJ4, potassium inwardly-	TGAGCCTGTGGTCTT[C/T]GAGGAGAAGAGCCAC	S	C	T	F	F
				rectifying channel, subfamily
				J, member 4
G1080a5	WIAF-16374	HT4412	1281	KCNJ4, potassium inwardly-	AGGCAGCTGCGGCGG[C/T]CGCGGTGGCCGCAGG	M	C	T	A	V
				rectifying channel, subfamily
				J, member 4
G1080a6	WIAF-16375	HT4412	1330	KCNJ4, potassium inwardly-	TTCCAAGGAGGAGGC[G/A]GGCATCATCCGGATG	S	G	A	A	A
				rectifying channel, subfamily
				J, member 4
G1080a7	WIAF-16376	HT4412	1345	KCNJ4, potassium inwardly,	GGGCATCATCCGGAT[G/C]CTGGAGTTCGGCAGC	M	G	C	M	I
				rectifying channel, subfamily
				J, member 4
G1081a2	WIAF-15621	HT27724	628	KCNJ2, potassium inwardly,	TGGGCTGCATCATCG[A/G]TGCTTTCATCATTGG	M	A	G	D	G
				rectifying channel, subfamily
				J, member 2
G1081a3	WIAF-16377	HT27724	1014	KCNJ2, potassium inwardly,	GTCATACTGGAAGGC[A/C]TGGTGGAAGCCACTG	M	A	C	M	L
				rectifying channel, subfamily
				J, member 2
G1081a4	WIAF-16378	HT27724	1032	KCNJ2, potassium inwardly,	GTGGAAGCCACTGCC[A/C]TGACGACACAGTGCC	M	A	C	M	L
				rectifying channel, subfamily
				J, member 2
G1081a5	WIAF-16379	HT27724	1144	KCNJ2, potassium inwardly,	TGGACTATTCCAGGT[T/C]CCACAAAACTTACGA	M	T	C	F	S
				rectifying channel, subfamily
				J, member 2
G1081a6	WIAF-16380	HT27724	1259	KCNJ2, potassium inwardly,	AAATGAAGTTGCCCT[C/T]ACAAGCAAAGAGGAA	S	C	T	L	L
				rectifying channel, subfamily
				J, member 2
G1081a7	WIAF-17077	HT27724	263	KCNJ2, potassium inwardly,	CCGCTTTGTGAAGAA[A/T]GATGGCCACTGTAAT	M	A	T	K	N
				rectifying channel, subfamily
				J, member 2
G1081a8	WIAF-17078	HT27724	299	KCNJ2, potassium inwardly,	GTTCATCAATGTGGG[T/A]GAGAAGGGGCAACGG	S	T	A	G	G
				rectifying channel, subfamily
				J, member 2
G1081a9	WTAF-17079	HT27724	308	KCNJ2, potassium inwardly,	TGTGGGTGAGAAGGG[G/A]CAACGGTACCTCGCA	S	G	A	G	G
				rectifying channel, subfamily
				J, member 2
G1082a4	WIAF-16386	HT28319	734	potassium channel, inwardly	ACATTGTGGAGGCCC[A/T]TGTGCGCGCGCAGCT	M	A	T	H	L
				rectifying high conductance,
				alpha subunit, ?
G1082a5	WIAF-16387	HT28319	824	potassium channel, inwardly	ATGTGGGCTTCGACA[A/G]GGGCCTGGACCGCAT	M	A	G	K	R
				rectifying high conductance,
				alpha subunit, ?
G1082a6	WIAF-16388	HT28319	873	potassium channel, inwardly	CACCATCTTGCATGA[G/A]ATTGACGAGGCCAGC	S	G	A	E	E
				rectifying, high conductance,
				alpha subunit, ?
G1082a7	WIAF-16389	HT28319	976	potassium channel, inwardly	GAGGCCACAGCCATG[A/G]CCACCCAGGCCCGCA	M	A	G	T	A
				rectifying, high conductance,
				alpha subunit, ?
G1083a1	WIAF-16390	HT27805	774	KCNK1, potassium channel,	TCCTGCTTCTTCTTC[A/C]TCCCGGCCGCTGTCT	M	A	C	I	L
				subfamily K, member 1	(TWIK-
				1)
G1083a2	WIAF-16391	HT27805	795	KCNK1, potassium channel,	GCCGCTGTCTTCTCA[G/T]TCCTGGAGGATGACT	M	G	T	V	F
				subfamily K, member 1 (TWIK-
				1)
G1083a3	WIAF-16392	HT27805	824	KCNK1, potassium channel,	CTGGAACTTCCTGGA[A/C]TCCTTTTATTTTTGT	M	A	C	E	D
				subfamily K, member 1 (TWIK-
				1)
G1083a4	WIAF-16393	HT27805	843	KCNK1, potassium channel,	TTTTATTTTTGTTTT[A/C]TTTCCCTGAGCACCA	M	A	C	I	L
				subfamily K, member 1 (TWIK-
				1)
G1087a1	WIAF-16383	HT3546	130	KCNE1, potassium voltage-	AGGTCCCCCCGCAGC[G/A]GTGACGGCAAGCTGG	M	G	A	G	S
				gated channel, Isk-related
				family, member 1
G1087a2	WIAF-16384	HT3546	275	KCNE1, potassium voltage-	ACATCGAGTCCGATG[C/T]CTGGCAAGAGAAGGA	M	C	T	A	V
				gated channel, Isk-related
				family, member 1
G1088a5	WIAF-15774	HT0522	1682	KCNA5, potassium voltage,	CTGTGGGCTACGGGG[A/G]CATGAGGCCCATCAC	M	A	G	D	G
				gated channel, shaker-related
				subfamily, member 5
G1088a6	WIAF-15775	HT0522	1683	KCNA5, potassium voltage-	TGTGGGCTACGGGGA[C/A]ATGAGGCCCATCACT	M	C	A	D	E
				gated channel, shaker-related
				subfamily, member 5
G1088a7	WIAF-15776	HT0522	1726	KCNA5, potassium voltage-	ATCGTGGGCTCGCTG[T/A]GTGCCATCGCCGGGG	M	T	A	C	S
				gated channel, shaker-related
				subfamily, member 5
G1089a1	WIAF-15765	HT0009	2189	KCNA2, potassium voltage-	GGCACTGAGTGCTGG[C/T]GGGCATGGTGGGTTG	S	C	T	G	G
				gated channel, shaker-related
				subfamily, member 2
G1089a2	WIAF-15777	HT0009	2624	KCNA2, potassium voltage-	CTTCATTGGGGTCAT[C/A]CTCTTTTCTAGTGCT	S	C	A	I	I
				gated-channel, shaker-related
				subfamily, member 2
G1089a3	WIAF-15778	HT0009	2696	KCNA2, potassium voltage-	AAGCATCCCAGATGC[A/C]TTTTGGTGGGCTGTG	S	A	C	A	A
				gated channel, shaker-related
				subfamily, member 2
G1089a4	WIAF-15779	HT0009	2697	KCNA2, potassium voltage-	AGCATCCCAGATGCA[T/A]TTTGGTGGGCTGTGG	M	T	A	F	I
				gated channel, shaker-related
				subfamily, member 2
G1090a2	WIAF-15852	HT1497	2035	KCNA6, potassium voltage-	GGTCATCCTCTTCTC[C/T]AGTGCCGTCTACTTC	S	C	T	S	S
				gated channel, shaker-related
				subfamily, member 6
G1091a2	WIAF-15853	HT0222	358	KCNA3, potassium voltage,	ACTTCGACCCGCTCC[G/A]CAACGAGTACTTCTT	M	C	A	R	H
				gated channel, shaker-related
				subfamily, member 3
G1091a3	WIAF-15854	HT0222	410	KCNA3, potassium voltage-	CGACGCCATCCTCTA[C/G]TACTATCAGTCCGGG	N	C	G	Y	*
				gated channel, shaker-related
				subfamily, member 3
G1091a4	WIAF-15666	HT0222	847	KCNA3, potassium voltage-	GCATCATCTGGTTCT[C/T]CTTCGAACTGCTGGT	M	C	T	S P
				gated channel, shaker-related
				subfamily, member 3
G1095a11	WIAF-15855	HT2629	530	KCNMA1, potassium large	ATGAAAAAGAGGAGG[C/T]AGTGGCCGCCGAGGT	M	C	T	A	V
				conductance calcium-activated
				channel, subfamily M, alpha
				member 1
G1095a12	WIAF-15867	HT2629	926	KCNMA1, potassium large	GACTGATACAGTTTT[C/T]AGAAATTTTGCAGTT	M	C	T	S	L
				conductance calcium-activated
				channel, subfamily M, alpha
				member 1
G1095a13	WIAF-15868	HT2629	1758	KCNMA1, potassium large	GTTGGGCTTCATAGC[C/A]CAGAGCTGCCTGGCT	S	C	A	A	A
				conductance calcium-activated
				channel, subfamily M, alpha
				member 1
G1095a14	WIAF-15869	HT2629	2469	KCNMA1, potassium large	CAGCTCAGCCCTGAT[C/T]GGCCTCCGGAACCTG	S	C	T	I	I
				conductance calcium-activated
				channel, subfamily M, alpha
				member 1
G1098a2	WIAF-15633	L19711	435	DAG1, dystroglycan	TGCTGCTGCCCCTCT[G/C]GGGGAGGACCTTTCT	M	C	C	W	S
				(dystrophan-associated
				glycoprotein 1)
G1098a3	WIAF-15634	L19711	503	DAG1, dystroglycan 1	CCCAGTGAACCCTCA[G/T]AGGCTGTCAGGGACT	N	G	T	E	*
				(dystrophin-associated
				glycoprotein 1)
G1098a4	WIAF-15635	L19711	1580	DAG1, dystroglycan 1	TCAGAAGCTGGCACC[A/G]CAGTTCCTGGCCAGA	M	A	G	T	A
				(dystrophin-associated
				glycoprotein 1)
G1098a5	WIAF-15636	L19711	2357	DAG1, dystroglycan 1	ATCACCCGGGGCTCC[A/C]TCGTGGTGGAATGGA	M	A	C	I	L
				(dystrophin-associated
				glycoprotein 1)
G1098a6	WIAF-15637	L19711	2568	DAG1, dystroglycan 1	CTGTGGTACCACCCA[G/A]GAGAGTGCCCTCAGA	M	G	A	R	K
				(dystrophin-associated
				glycoprotein 1)
G1098a7	WIAF-15638	L19711	2167	DAG1, dystroglycan 1	GGCTGTGGATGCCTT[C/T]GAGATCCACGTCCAC	S	C	T	F	F
				(dystrophin-associated
				glycoprotein 1)
G1098a8	WIAF-15643	L19711	948	DAG1, dystroglycan 1	CTGCCTGTGCTGCGG[A/C]TGAACCTGTGACTGT	M	A	C	D	A
				(dystrophin-associated
				glycoprotein 1)
G1099a6	WIAF-15640	J04569	1330	GFAP, glial fibrillary	CTGGTGGCCTCTGCC[C/G]CGTCTCATGAGGGGC	—	C	G
				acidic protein
G1106a16	WIAF-15678	HT5073	186	MAP1B, microtubule-	CTTGCTGGTGGTCGT[C/G]GGCGAGATCGTGACC	S	C	G	V	V
				associated protein 1B
G1106a17	WIAF-15679	HT5073	1284	MAP1B, microtubule-	TACTATTGATCCTGT[C/T]ATTCTTTTCCAAAAA	S	C	T	V	V
				associated protein 1B
G110Ea18	WIAF-15680	HT5073	2146	MAP1B, microtubule-	GAGAAAAAAGAACCC[A/C]AGAAAGAGGTTAAGA	M	A	C	K	Q
				associated protein 1B
G1106a19	WIAF-15681	HT5073	2731	MAP1B, microtubule-	GGTCCTGCCGAGTCC[C/G]CTGATGAGGGAATCA	M	C	G	P	A
				associated protein 1B
G1106a20	WIAF-15682	HT5073	5569	MAP1B, microtubule-	CGTGCCTCAGTGTTA[T/C]TCGATACAATGCAAC	M	T	C	F	L
				associated protein 1B
G1106a21	WIAF-16444	HT5073	3005	MAP1B, microtubule-	CCAAGGCGGAGGCTG[A/C]TGCATACATCAGGGA	M	A	C	D	A
				associated protein 1B
G1106a22	WIAF-16445	HT5073	3458	MAP1B, microtubule-	AGCCCACCCCCATGG[A/C]TGAGATGTCTACCCC	M	A	C	D	A
				associated protein 1B
G1110a10	WIAF-17122	HT1096	1332	myelin associated	CCAGAGGGCCACCGC[C/T]TTCAACCTGTCTGTG	S	C	T	A	A
				glycoprotein, ?
G1110a4	WIAF-15870	HT1096	1579	myelin associated	GCCCCGCCCCGCGTC[A/C]TCTGCACCGCGAGGA	M	A	C	I	L
				glycoprotein, ?
G1110a5	WIAF-15871	HT1096	1601	myelin associated	CCGCGAGGAACCTCT[A/C]TGGCGCCAAGAGCCT	M A	C	Y	S
				glycoprotein, ?
G1110a6	WIAF-15872	HT1096	1537	myelin associated	CTCGTGCTCACCAGC[A/C]TCCTCACGCTGCGgG	M	A	C	I	L
				glycoprotein, ?
G1110a7	WIAF-17119	HT1096	1283	myelin associated	CACCCGAGGATGATG[G/A]AGAGTACTGGTGTGT	M	G	A	G	E
				glycoprotein, ?
G1110a8	WIAF-17120	HT1096	1290	myelin associated	GGATGATGGAGAGTA[C/T]TGGTGTGTGGCTGAG	S	C	T	Y	Y
				glycoprotein, ?
G1110a9	WIAF-17121	HT1096	1329	myelin associated	TGGCCAGAGGGCCAC[C/T]GCCTTCAACCTGTCT	S	C	T	T	T
				glycoprotein, ?
G1120a2	WIAF-15857	HT3695	1387	neurofilament, subunit H, ?	GAGGAACAGACAGAG[G/A]AGACCCAAGTGACTC	M	G	A	E	K
G1123a2	WIAF-15856	HT2569	1304	OMG, oligodendrocyte myelin	TGTCCTCTCCAATGT[A/C]TATGCACAGAGAGGC	M	A	C	I	L
				glycoprotein
G1123a3	WIAF-15873	HT2569	2200	OMG, oligodendrocyte myelin	TACTAGCACTGATAA[G/A]GCTTTTGTGCCCTAT	S	G	A	K	K
				glycoprotein
G1125a2	WIAF-15858	L76517	1494	PSEN1, presenilin 1	CCAAGTATAATGCAG[A/G]AAGCACAGAAAGGGA	M	A	G	E	G
				(Alzheimer disease 3)
G1125a3	WIAF-15859	L76517	1627	PSEN1, presenilin 1	ACGAGCTGCTGTCCA[G/A]GAACTTTCCAGCAGT	S	G	A	Q	Q
				(Alzheimer disease 3)
G1132a1	WIAF-15865	HT4340	382	SNCB, synuclein, beta	GAACCACTGATTGAG[C/T]CCCTGATGGAGCCAG	M	C	T	P	S
G1527a10	WIAF-15876	HT0086	556	GSTM2, glutathione S-	GGATGCCTTCCCAAA[C/T]CTGAAGGACTTCATC	S	C	T	N	N
				transferase M2 (muscle)
C1527a11	WIAF-15877	HT0086	534	GSTM2, glutathione S-	AAGTATTTGAGCCCA[G/A]CTGCCTGGATGCCTT	M	G	A	S	N
				transferase M2 (muscle)
G1527a12	WIAF-15878	HT0086	535	GSTM2, glutathione S-	AGTATTTGAGCCCAG[C/G]TGCCTGGATGCCTTC	M	C	G	S	R
				transferase M2 (muscle)
G1527a7	WIAF-15860	HT0086	250	GSTM2, glutathione S-	CAATGCCATCCTGCG[G/C]TACATTGCCCGCAAG	S	G	C	R	R
				transferase M2 (muscle)
G1527a8	WIAF-15874	HT0086	539	GSTM2, glutathione S-	TTTGAGCCCAGCTGC[C/T]TGGATGCCTTCCCAA	S	C	T	L	L
				transferase M2 (muscle)
G1527a9	WIAF-15875	HT0086	544	GSTM2, glutathione S-	GCCCAGCTGCCTGGA[T/C]GCCTTCCCAAACCTG	S	T	C	D	D
				transfrease M2 (muscle)
G1529a10	WIAF-15892	HT2006	1069	GSTM4, glutathione S-	CCAAGACTTTATTGG[G/C]CCTCTTCACTTCCCC	—	G	C
				transferase M4
G1529a11	WIAF-15893	HT2006	1080	GSTM4, glutathione S-	TTGGGCCTCTTCACT[T/C]CCCCTAAACCCCTGT	—	T	C
				transferase M4
G1529a2	WIAF-15884	HT2006	880	GSTM4, glutathione S-	GCCGCTTCCTCCCAA[A/G]ACCTCTGTACACAAG	M	A	G	K	R
				transferase M4
G1529a3	WIAF-15885	HT2006	885	GSTM4, glutathione S-	TTCCTCCCAAAACCT[C/G]TGTACACAAGGGTGG	M	C	G	L	V
				transferase M4
G1529a4	WIAF-15886	HT2006	889	GSTM4, glutathione S-	TCCCAAAACCTCTGT[A/T]CACAAGGGTGGCTGT	M	A	T	Y	F
				transferase M4
G1529a5	WIAF-15887	HT2006	895	GSTM4, glutathione S-	AACCTCTGTACACAA[G/A]GGTGGCTGTCTGGGG	M	G	A	R	K
				transferase M4
G1529a6	WIAF-15888	HT2006	897	GSTM4, glutathione S-	CCTCTGTACACAAGG[G/A]TGGCTGTCTGGGGCA	M	G	A	V	M
				transferase M4
G1529a7	WIAF-15889	HT2006	920	GSTM4, glutathione S-	CTGGGGCAACAAGTA[A/G]TGCCTTGAAGGCCAG	N	A	G	*	*
				transferase M4
G1529a8	WIAF-15890	HT2006	921	GSTM4, glutathione S-	TGGGGCAACAAGTAA[T/G]GCCTTGAAGGCCAGG	—	T	G
				transferase M4
G1529a9	WIAF-15891	HT2006	1068	GSTM4, glutathione S-	CCCAAGACTTTATTG[G/T]GCCTCTTCACTTCCC	—	G	T
				transferase M4
G153a6	WIAF-16651	HT3856	1109	HSPA1B, heat shock 70 kD	CCGACGAGGCTGTGG[C/T]CTACGGGGCGGCGGT	M	C	T	A	V
				protein 1
G153a7	WIAF-16652	HT3856	1019	HSPA1B, heat shock 70 kD	TCCTGGTCGGGGGCT[C/G]CACCCGCATCCCCAA	M	C	G	S	C
				protein 1
G153a8	WIAF-16654	HT3856	1710	HSPA1B, heat shock 70 kD	CGACAAGAAGAAGGT[T/G]CTGGACAAGTGTCAA	S	T	G	V	V
				protein 1
G154a1	WIAF-17068	HT3951	1738	proto-oncogene c-kit, alt.	TATGTTTACATAGAC[C/G]CAACACAACTTCCTT	M	C	G	P	A
				protein 1
G154a2	WIAF-17069	HT3951	1642	proto-oncogene c-kit, alt.	ATGTGCATTATTGTG[A/C]TGATTCTGACCTACA	M	A	C	M	L
				transcript 1, ?
G154a3	WIAF-17070	HT3951	2682	proto-oncogene c-kit, alt.	TTTTCTTTGGGAGCT[G/C]TTCTCTTTAGGAAGC	S	G	C	L	L
				transcript 1, ?
G154a4	WIAF-17117	HT3951	2943	proto-oncogene c-kit, alt.	CAACCGACAGAAGCC[C/T]GTGGTAGACCATTCT	S	C	T	P	P
				transcript 1, ?
G154a5	WIAF-17118	HT3951	3070	proto-oncogene c-kit, alt.	CAGGAATGATCTCTT[C/G]TTTTGGCTTCCATGA	—	C	G
				transcript 1, ?
G1551a1	WIAF-15641	L11353	1907	NF2, neurofibromin 2	TGGATATTCTGCACA[A/C]TGAGAACTCCGACAG	M	A	C	N	T
				(bilateral acoustic neuroma)
G1551a2	WIAF-15642	L11353	1897	NF2, neurofibromin 2	GAGACAGCTCTGGAT[A/C]TTCTGCACAATGAGA	M	A	C	I	L
				(bilateral acoustic neuroma)
G1551a3	WIAE-15861	L11353	1179	NF2, neurofibromin 2	TTTGGAAGTTCAGCA[G/A]ATGAAAGCCCAGGCC	S	G	A	Q	Q
				(bilateral acoustic neuroma)
G1551a4	WIAP-15882	L11353	1251	NF2, neurofibromin 2	CGCTCGAGAGAAGCA[G/C]ATGAGGGAGGAGGCT	M	G	C	Q	H
				(bilateral acoustic neuroma)
G1551a5	WIAF-15863	L11353	1277	NF2, neurofibromin 2	AGGCTGAACGCACGA[G/A]GGATCAGTTGGAGAG	M	G	A	R	K
				(bilaterial acoustic neuroma)
G1551a6	WIAF-15879	L11353	749	NF2, neurofibromin 2	GGGTAATAAATCTGT[A/C]TCAGATGACTCCGGA	M	A	C	Y	S
				(bilateral acoustic neuroma)
G18a1	WIAF-16655	857793	1730	LHCGR, luteinizing	CAATCCTCATCTTCA[C/T]CGATTTCACCTGCAT	M	C	T	T	I
				hormone/chorigonadotropin
				receptor
G18a2	WIAF-16656	S57793	1839	LHCGR, luteinizing	GGTTCTTTTTTATCC[C/T]ATCAATTCTTGTGCC	S	C	T	P	P
				hormone/chorigonadotropin
				receptor
G2274a1	WIAF-16012	AF005418	1127	CYP26A1, cytochrome P450,	TGTTATTAAGGAGAC[C/T]CTTCGACTGAATCCC	S	C	T	T	T
				subfamily XXVIA, polypeptide
				1
G2274a2	WIAF-16013	AF005418	1352	CYP26A1, cytochrome P450,	TCCATTTGGAGGAGG[C/G]CTTAGGAGCTGTGTA	S	C	G	G	G
				subfamily XXVIA, polypeptide
				1
G2275a1	WIAF-16565	AF016535	358	PGY1 P glycoprotein	TGACAGATATCTTTG[C/A]AAATGCAGGAAATTT	M	C	A	A	E
				1/multiple drug resistance 1
G2275a10	WIAF-16573	AF016535	3897	PGY1, P glycoprotein	ACGCATCAGCAGCTG[C/T]TGGCACAGAAAGGCA	S	C	T	L	L
				1/multiple drug resistance 1
G2275a11	WIAF-16574	AF016535	3537	PGY1, P glycoprotein	AACAGCCGGGTGGTG[T/A]CACAGGAAGAGATTG	M	T	A	S	T
				1/multiple drug resistance 1
G2275a12	WIAF-16575	AF016535	3551	PGY1, P glycoprotein	GTCACAGGAAGAGAT[T/C]GTGAGGGCAGCAAAG	S	T	C	I	I
				1/multiple drug resistance 1
G2275a13	WIAF-16627	AF016535	1107	PGY1, P glycoprotein	GAATATTCTATTGGA[C/T]AAGTACTCACTGTAT	N	C	T	Q	*
				1/multiple drug resistance 1
G2275a14	WIAF-16834	AF016535	1315	PGY1, P glycoprotein	GAAATGTTCACTTCA[G/A]TTACCCATCTCGAAA	M	G	A	S	N
				1/multiple drug resistance 1
G2275a15	WIAF-16835	AF016535	2249	PGY1, P glycoprotein	TGAATGGCCTTATTT[T/G]GTTGTTGGTGTATTT	M	T	G	F	L
				1/multiple drug resistance 1
G2275a2	WIAF-16566	AF016535	1058	PGY1, P glycoprotein	ATCTTATGCTCTGGC[C/T]TTCTGGTATGGGACC	S	C	T	A	A
				1/multiple drug resistance 1
G2275a4	WIAF-16567	AP016535	2028	PGY1, P glycoprotein	AATGAAGTTGAATTA[G/T]AAAATGCAGCTGATG	N	G	T	E	*
				1/multiple drug resistance 1
G2275a5	WIAF-16568	AF016535	2126	PGY1, P glycoprotein	AAGATCAACTCGTAG[G/A]AGTGTCCGTGGATCA	S	G	A	R	R
				1/multiple drug resistance 1
G2275a6	WIAF-16569	AF016535	2793	PGY1, P glycoprotein	AAAGAACTAGAAGGT[T/G]CTGGGAAGATCGCTA	M	T	G	A	S
				1/multiple drug resistance 1
G2275a7	WIAF-16570	AF016535	2950	PGY1, P glycoprotein	TTACATTTTCCTTCA[C/T]CCAGGCAATGATGTA	M	C	T	T	I
				1/multiple drug resistance 1
G2275a8	WIAF-16571	AF016535	3299	PGY1, P glycoprotein	GAGCCTGGAGGTGAA[G/C]AAGGGCCAGACGCTG	M	G	C	K	N
				1/multiple drug resistance 1
G2275a9	WIAF-16572	AF016535	3812	PGY1, P glycoprotein	CATTGTGATTGCTCA[C/T]CGCCTGTCCACCATC	S	C	T	H	H
				1/multiple drug resistance 1
G2278a10	WIAF-16017	AF034611	1793	CUBN, cubilin (intrinsic	GCAACCAGAGTGTGG[A/G]GGTATCCTGACTGGT	S	A	G	G	G
				factor-cobalamin receptor)
G2278a11	WIAF-16018	AF034611	2106	CUBN, cubilin (intrinsic	AGTGACCAAGGCTTC[C/T]ATATCACCTACTTAA	M	C	T	H	Y
				factor-cobalamin receptor)
G2278a12	WIAF-16019	AF034611	2215	CUBN, cubilin (intrinsic	CTTTCACTCACACCA[G/A]GCAATGCGTCTATAT	M	G	A	R	K
				factor-cobalamin receptor)
G2278a13	WIAF-16020	AF034611	2751	CUBN, cubilin (intrinsic	CTTTATGTCACATTC[G/A]TGAAAAGTTCTTCTA	M	G	A	V	M
				factor-cobalamin receptor)
G2278a14	WIAF-16021	AF034611	7543	CUBN, cubilin (intrinsic	CGTCCTGCAACAATG[A/G]GCATGTGATAGTATT	M	A	G	E	G
				factor-cobalamin receptor)
G2278a15	WIAF-16022	AF034611	7682	CUBN, cubilin (intrinsic	GGATGGATCCAGGCC[A/G]TATGGCGGCTTCACT	S	A	G	P	P
				factor-cobalamin receptor)
G2278a16	WIAF-16023	AF034611	9213	CUBN, cubilin (intrinsic	AATGATATGCACTGT[C/T]TGTATACCATCACCG	S	C	T	L	L
				factor-cobalamin receptor)
G2278a31	WIAF-16685	AF034611	4923	CUBN, cubilin (intrinsic	GATACTGTTTCCTCT[C/T]CACGGTTCCCTGCCA	M	C	T	P	S
				factor-cobalamin receptor)
G2278s32	WIAF-16686	AF034611	5823	CUBN, cubilin (intrinsic	CAGACTGAATCTTTC[A/G]GCTCCACTGGAAATT	M	A	G	S	G
				factor-cobalamin receptor)
G2278a33	WIAF-16687	AF034611	5876	CUBN, cubilin (intrinsic	CGACTCTTCAATCTC[G/A]GGGAAGGGATTCCTT	S	G	A	S	S
				factor-cobalamin receptor)
G2278a34	WIAF-16688	AF034611	6735	CUBN, cubilin (intrinsic	TCCCCCAACCACCCT[C/T]ATAATTATCCCCCGC	M	C	T	H	Y
				factor-cobalamin receptor)
G2278a35	WIAF-16689	AF034611	7075	CUBN, cubilin (intrinsic	TTGAAAGCATTGGAC[A/G]TCCAACACTTCCATA	M	A	G	H	R
				factor-cobalamin receptor)
G2278a36	WIAF-16690	AF034611	7385	CUBN, cubilin (intrinsic	AGAGTGTGGTGGGGA[T/A]CTTCAGGGCTCTATT	M	T	A	D	E
				factor-cobalamin receptor)
G2278a37	WIAF-16691	AF034811	8430	CUBN, cubilin (intrinsic	AACACACAAACTTTA[G/A]GTTGTGGTGGAATAT	M	G	A	G	S
				factor-cobalamin receptor)
G2278a38	WIAF-16692	AF034611	8592	CUBN, cubilin (intrinsic	ATCCCCAGCGGTGAT[G/A]GACAATGTCAGAATA	M	G	A	G	R
				factor-cobalamin receptor)
G2278a39	WIAF-16693	AF034611	8250	CUBN, cubilin (intrinsic	CATACAACTTGTGCT[T/C]GGGACTCTGTCACTG	M	T	C	W	R
				factor-cobalamin receptor)
G2278a40	WIAF-16694	AF034611	8655	CUBN, cubilin (intrinsic	GTGGACAAAGCCCTG[C/A]TAGCCACTGGCTGTG	M	C	A	L	I
				factor-cobalamin receptor)
G2278a41	WIAF-16695	AF034611	9866	CUBN, cubilin (intrinsic	GCCTTGTGGTGGAAC[G/A]TACAATGCAACTTGG	S	G	A	T	T
				factor-cobalamin receptor)
G2278a42	WIAF-16696	AF034611	10002	CUBN, cubilin (intrinsic	GTGTGGGCATTACAG[C/G]TGACCTCGCAAGACT	M	C	G	L	V
				factor-cobalamin receptor)
G2278a43	WIAF-16697	AF034611	10944	CUBN, cubilin (intrinsic	CCTCTGCAGCACGCT[G/A]GACAGCACTCTGCCA	—	G	A
				factor-cobalamin receptor)
G2278a44	WIAF-16698	AF034611	11029	CUBN, cubilin (intrinsic	TTTTCACCAAACCAT[G/A]GATAGAATCAATATT	—	G	A
				factor-cobalamin receptor)
G2278a45	WIAF-16716	AF034611	7366	CUBN, cubilin (intrinsic	GATTTGAATCCAGTA[T/C]GGAAGAGTGTGGTGG	M	T	C	M	T
				factor-cobalamin receptor)
G2278a7	WIAF-16014	AF034611	679	CUBN, cubilin (intrinsic	ATGACCACTGTGAAG[G/A]GGGTTCTGTGGCACG	M	G	A	G	E
				factor-cobalamin receptor)
G2278a8	WIAF-16015	AF034611	1385	CUBN, cubilin (intrinsic	CGTTGATTCTTTCAG[T/A]TGTGAATGCACACGT	M	T	A	S	R
				factor-cobalamin receptor)
G2278a9	WIAF-16016	AF034611	1631	CUBN, cubilin (intrinsic	TCAGGTTTATGATGG[A/G]GATTCCTCTTCTGCT	S	A	G	G	G
				factor-cobalamin receptor) 3
G2280a10	WIAF-16024	AJ001515	1180	RYR3, ryanodine receptor 3	CTACAAAGCACAAGA[C/T]GCCAAAACTTCCCGC	S	C	T	D	D
G2280e11	WIAF-16025	AJ001515	1273	RYR3, ryanodine receptor 3	ACTGCAGAGATGCCA[G/A]CGTGAGGAGTCCCAG	S	C	A	Q	Q
G2280e12	WIAF-16026	AJ001515	1339	RYR3, ryanodine receptor 3	CAGCCAGTTTGTCAG[T/C]GGAAACAATCGCACA	S	T	C	S	S
G2280a13	WIAF-16027	AJ001515	4781	RYR3, ryanodine receptor 3	AGCGCGGTGTGCGCC[C/T]TGGGAAACAGCCGCG	S	C	T	L	L
G2280a14	WIAF-16028	AJ001515	4894	RYR3, ryanodine receptor 3	ATCTGGTTTCTATGA[C/T]CTGCTCATCAGCATC	S	C	T	D	D
G2280e15	WIAF-16029	AJ001515	6574	RYR3, ryanodine receptor 3	GACCTACTTGGCAGG[C/T]TGTGGCCTACAGAGC	S	C	T	G	G
G2280a16	WIAF-16030	AJ001515	6787	RYR3, ryanodine receptor 3	TGAGGGGGGAAACGG[G/A]CTCTTGGCAGCCATG	S	G	A	G	G
G2280a17	WIAF-16031	AJ001515	6972	RYR3, ryanodine receptor 3	TGGGCCGCTGTGCTC[C/T]TGAAATGCACCTCAT	M	C	T	P	L
G2280a18	WIAF-16032	AJ001515	12321	RYR3, ryanodine receptor 3	AGGAAAAGATGGAGC[T/A]GTTTGTGAACTTCTG	M	T	A	L	Q
G2280a19	WIAF-16033	AJ001515	13076	RYR3, ryanodine receptor 3	AAAGCAGCAAATGAA[G/A]CAGAAGGAAAAGTAG	M	G	A	A	T
G2280a20	WIAF-16034	AJ001515	13091	RYR3, ryanodine receptor 3	GCAGAAGGAAAAGTA[G/A]AATCCGAGAAGGCAG	M	G	A	E	K
G2280e21	WIAF-16035	AJ001515	13095	RYR3, ryanodine receptor 3	AAGGAAAAGTAGAAT[C/T]CGAGAAGGCAGACAT	M	C	T	S	F
G2280a22	WIAF-16036	AJ001515	13196	RYR3, ryanodine receptor 3	AAAAAGAAGAAGCGG[C/T]GGTGTGGTCAGAAGG	M	C	T	R	W
G2280a23	WIAF-16037	AJ001515	13420	RYR3, ryanodine receptor 3	TGCAAACCTATGGAA[T/G]TCCTTTAATGACGAG	M	T	G	N	K
G2280e24	WIAF-16038	AJ001515	14338	RYR3, ryanodine receptor 3	TACCTTTTTCTTCTT[C/T]GTCATTGTCATCTTG	S	C	T	F	F
G2280a26	WIAF-16699	AJ001515	11899	RYR3, ryanodine receptor 3	GTAAAGGAATTATCT[C/T]CAAAAAAGAATTCCA	M	C	T	S F
G2282a3	WIAF-16912	D00726	316	FECH, ferrochelatase	GACTCTTCTTGGACC[A/C]AGACCTCATGACACT	M	A	G	Q	R
				(protoporphyria)
G2282a4	WIAF-16913	D00726	353	FECH, ferrochelatase	TCAGAATAAGCTGGC[A/T]CCATTCATCGCCAAA	S	A	T	A	A
				(protoporphyria)
G2282a5	WIAF-16914	D00726	827	FECH, ferrochelatase	TGCTCACTCACTGCC[G/C]ATGTCTGTGGTCAAC	S	G	C	P	P
				(protoporphyria)
G2282a6	WIAF-16915	D00726	950	FECH, ferrochelatase	ATCCAAGGTTGGTCC[G/A]ATGCCCTGGTTGGGT	S	G	A	P	P
				(protoporphyria)
G2282a7	WIAF-16916	D00726	1126	FECH, ferrochelatase	GAGTTGAAAACATCA[G/A]AAGAGCTGAGTCTCT	M	G	A	R	K
				(protoporphyria)
G2285a3	WIAF-16926	D16611	307	CPO, coproporphyrinogen	CTGGCACAGGTAGAC[G/C]GGGGCGCCAACTTTT	M	G	C	G	R
				oxidase (coproporphyria,
				harderoporphyria)
G2285a4	WIAF-16927	D16611	394	CPO, coproporphyrinogen	GATGGGTGTGTTTTC[G/A]AAAAGGCTGGGGTGA	M	G	A	E	K
				oxidase (coproporphyria,
				harderoporphyria)
G2285a5	WIAF-16928	D16611	410	CPO, coproporphyrinogen	AAAAGGCTGGGGTGA[G/A]CATTTCTGTTGTTCA	M	G	A	S	N
				oxidase (coproporphyria,
				harderoporphyria)
G2285a6	WIAF-16929	D16611	416	CPO, coproporphyrinogen	CTGGGGTGAGCATTT[C/T]TGTTGTTCATGGAAA	M	C	T	S	F
				oxidase (coproporphyria,
				harderoporphyria)
G2285a7	WIAF-16930	D16611	607	CPO, coproporphyrinogen	GAAGAAGCTGATGGC[A/C]ACAAGCAGTGGTGGT	M	A	C	N	H
				oxidase (coproporphyria,
				harderoporphyria)
G2285a8	WIAF-16931	D16611	1252	CPO, coproporphyrinogen	TGTGTCGAGTTACCC[G/A]TGCCTTAGTCTTCTC	—	G	A
				oxidase (coproporphyria,
				harderoporphyria,
G2287a5	WIAF-16934	D28472	789	PTGER4, prostglandin E	GGCCGCGGCCGCCTC[G/T]GTTGCCTCCCGGGGC	S	G	T	S	S
				receptor 4 (subtype EP4)
G2287a6	WIAF-16935	D28472	1447	PTGER4, prostaglandin E	AGTGTCTTACTGGTG[G/A]ATGAGGCTGGTGGGA	M	G	A	D	N
				receptor 4 (subtype EP4)
G2303a4	WIAF-15943	J03571	956	ALOX5, arachidonate 5-	CTCCAGTTCCTGGCC[C/A]CTCCCATCTGCTTGC	M	C	A	A	T
				lipoxygenase
G2303a5	WIAF-15944	J03571	1086	ALOX5, arachidonate 5-	ACGACTGGCTTTTGG[C/G]CAAAATCTGGGTGCG M	C	G	A	G
				lipoxygenase
G2313a24	WIAF-15946	J05200	5725	RYR1, ryanodine receptor 1	GTCTTCACTGAGGAA[G/A]AAGAGGAGGAGGACG	M	G	A	E	K
				(skeletal)
G2313a25	WIAF-15947	J05200	5733	RYR1, ryanodine receptor 1	TGAGGAAGAAGAGGA[G/A]GAGGACGAGGAGGAA	S	G	A	E	E
				(skeletal)
52313a26	WIAF-15948	J05200	5493	RYR1, ryanodine receptor 1	AGAGGCCCCGGCCCG[C/T]CTCAGCCCTGCCATC	S	C	T	R	R
				(skeletal)
G2313a27	WIAF-15949	J05200	6943	RYR1, ryanodine receptor 1	GCTGCTGCCTCCGTC[A/C]TTGACAACAATGAGC	M	A	C	I	L
				(skeletal)
G2313a28	WIAF-15950	J05200	6969	RYR1, ryanodine receptor 1	TGAGCTGGCCTTGGC[A/C]TTGCAGGAGCAGGAC	S	A	C	A	A
				(skeletal)
G2313a29	WIAF-15951	J05200	7200	RYR1, ryanodine receptor 1	TGAGTGCTTCGGACC[C/T]GCCCTGCGGGGTGAG	S	C	T	P	P
				(skeletal)
G2313a30	WIAF-15952	J05200	7211	RYR1, ryanodine receptor 1	GACCCGCCCTGCGGG[G/A]TGAGGGTGGCTCAGG	M	G	A	G	D
				(skeletal)
G2313a31	WIAF-15953	J05200	7629	RYR1, ryanodine receptor 1	CTTCCTGGACCGTGT[G/A]TATGGCATCGAGAAC	S	G	A	V	V
				(skeletal)
G2313a32	WIAF-15954	J05200	9383	RYR1, ryanodine receptor 1	AGCCTGGCCTCCGCT[C/T]CTTCTTCGAGAGTGC	M	C	T	S	F
				(skeletal)
G2313a33	WIAF-15955	J05200	13748	RYR1, ryanodine receptor 1	GGGTGAAGTTCCTGA[A/T]CTACCTGTCCCGGAA	M	A	T	N	I
				(skeletal)
G2313a34	WIAF-15956	J05200	14689	RYR1, ryanodine receptor 1	TTCTACAACAAGAGC[G/A]AGGATGAGGATGAAC	M	G	A	E	K
				(skeletal)
G2313a35	WIAF-15957	J05200	15102	RYR1, ryanodine receptor 1	TGAGACAGAACACAC[G/A]GGTCAGGAGTCTTAT	S	G	A	T	T
				(skeletal)
G2342a3	WIAF-15698	M12530	654	TF, transferrin	ATACTTCGGCTACTC[G/A]GGAGCCTTCAAGTGT	S	G	A	S	S
G2342a4	WIAF-15699	M12530	1558	TF, transferrin	CCTGGGTCTAAGAAA[G/A]ACTCCAGTCTCTGTA	M	G	A	D	N
G2342a5	WIAF-15700	M12530	1559	TF, transferrin	CTGGGTCTAAGAAAG[A/G]CTCCAGTCTCTGTAA	M	A	G	D	G
G2342a6	WIAF-15701	M12530	1632	TF, transferrin	CAAAGAGGGATACTA[C/T]GGCTACACAGGCGCT	S	C	T	Y	Y
G2342a7	WIAF-15702	M12530	1715	TF, transferrin	TCCCACAGAACACTG[G/A]GGGAAAAAACCCTGA	M	G	A	G	E
G2342a8	WIAF-15703	M12530	1716	TF, transferrin	CACAGAACACTGGGG[G/A]AAAAAACCCTGATCC	M	G	A	G	E
G2342a9	WIAF-15704	M12530	1805	TF, transferrin	GGAAACCTGTGCACC[A/C]GTATGCCAACTCCCA	M	A	C	E	A
G2363a6	WIAF-15528	M37435	1672	CSF1, colony stimulating	TACAGGTGGAGGCGG[C/A]GGAGCCATCAAGAGC	S	C	A	R	R
				factor 1 (macrophage)
G2366a1	WIAF-15979	M29872	1049	ADH5, alcohol dehydrogenase	GAAAGTGTCCCAAAG[T/C]TGGTGTCTGAATATA	S	T	C	L	L
				S (class III) , chi
				polypeptide
G2381a10	WIAF-16449	M59941	1207	CSF2RB, colony stimulating	CGAGACCCTCCAGAA[C/T]GCCCACAGCATGGCC	S	C	T	N	N
				factor 2 receptor, beta, low-
				affinity (granulocyte-
				macrophage)
G2381a7	WIAF-15984	M59941	826	CSF2RB, colony stimulating	CTGGGAGGTGAGGAA[G/A]GAGGTGGCCAGCTCC	S	G	A	K	K
				factor 2 receptor, beta, low-
				affinity (granulocyte-
				macrophage)
G2381a8	WIAF-15985	M59941	920	CSF2RB, colony stimulating	CTGAGGGAGGGGCTC[G/A]GCAGCCTCCACACCA	M	G	A	G	S
				factor 2 receptor, beta, low-
				affinity (granulocyte-
				macrophage)
G2381a9	WIAF-16448	M59941	1035	CSF2RS, colony stimulating	ACATAAAGAGCTCAG[T/A]GAACATCCAGATGGC	M	T	A	V	E
				factor 2 receptor, beta, low-
				affinity (granulocyte-
				macrophage)
G2387a10	WIAF-16450	M63967	2627	ALDH5, aldehyde	GAGTCTACTTGGCCT[C/A]ACTCGAGACCTTGGA	N	C	A	S	*
				dehydrogenase 5
G2387a11	WIAF-16451	M63967	3392	ALDH5, aldehyde	TAGGCTACATCCAGC[T/G]TGGCCAGAAGGAGGG	M	T	G	L	R
				dehydrogenase 5
G2387a12	WIAF-16452	M63967	3437	ALDH5, aldehyde	GTGGCGGAGAGCGTT[T/A]CGGGGAGCGTGGTTT	M	T	A	F	Y
				dehydrogenase 5
G2387a9	WIAF-15986	M63967	2984	ALDH5, aldehyde	TGAACATCATCACGG[G/A]GTATGGCCCAACAGC	M	G	A	G	E
				dehydrogenase 5
G2388a13	WIAF-15987	M64590	709	GLDC, glycine dehydrogenase	ATGGTGTGTGACATC[A/G]CAGGCCTGGACATGG	M	A	G T	A
				(decarboxylating; glycine
				decarboxylase, glycine
				cleavage system protein P)
G2388a14	WIAF-15988	M64590	1992	GLDC, glycine dehydrogenase	CCAGGTCTGTTTCCA[G/A]CCAAACAGCGGAGCC	S	G	A	Q	Q
				(decarboxylating; glycine
				decarboxylase, glycine
				cleavage system protein P)
G2388a15	WIAF-15989	M64590	2285	GLDC, glycine dehydrogenase	AAGAGAACATCAGTG[A/G]CGTGTGTGACCTCAT	M	A	G	D	G
				(decarboxylating; glycine
				decarboxylase, glycine
				cleavage system protein P)
G2388a16	WIAF-15990	M64590	2439	GLDC, glycine dehydrogenase	TCCCCACGGAGGAGG[T/A]GGTCCTGGCATGGGG	S	T	A	G	G
				(decarboxylating; glycine
				decarboxylase, glycine
				cleavage system protein P)
G2388a17	WIAF-15991	M64590	3231	GLDC, glycine dehydrogenase	CTCTCTCCCTAAGTT[T/A]AAAGGACTGATTTGA	—	T	A
				(decarboxylating; glycine
				decarboxylase, glycine
				cleavage system protein P)
G2388a18	WIAF-15992	M64590	3359	GLDC, glycine dehydrogenase	TGTCAAGGTAAATGT[A/G]AATACAGTAGCTGGA	—	A	G
				(decarboxylating; glycine
				decarboxylase, glycine
				cleavage system protein P)
G2391a4	WIAF-15993	M69238	804	ARNT, aryl hydrocarbon	AAAAAGGAAGGTCAG[C/G]ACTCTTCCATGAGAA	M	C	G	Q	E
				receptor nuclear translocator
G2391a5	WIAF-15994	M69238	1248	ARNT, aryl hydrocarbon	GGAAAGAATATTGTA[G/A]AATTCTGTCATCCTG	M	G	A	E	K
				receptor nuclear translocator
G2391a6	WIAF-15995	M69238	1345	ARNT, aryl hydrocarbon	TCATGTTCCGGTTCC[G/A]GTCTAAGAACCAAGA	M	G	A	R	Q
				receptor nuclear translocator
G2391a7	WIAF-15998	M69238	1359	ARNT, aryl hydrocarbon	CGGTCTAAGAACCAA[G/A]AATGGCTCTGGATGA	M	G	A	E K
				receptor nuclear translocator
G2394a3	WIAF-15824	HT1114	1932	TSHR, thyroid stimulating	TCACAGTCCGAAATC[C/T]GCAGTACAACCCAGG	M	C	T	P	L
				hormone receptor
G2394a4	WIAF-15825	HT1114	2069	TSHR, thyroid stimulating	CCTCTCATCACTGTT[A/G]GCAACTCCAAAATCT	M	A	G	S	G
				hormone receptor
G2427a4	WIAF-16458	U07919	997	ALDH6, aldehyde	AGGCCAGTGTTGCAC[G/T]GCAGCCTCCAGGGTG	S	G	T	T	T
				dehydrogenase 6
G2438a1	WIAF-16464	U23942	178	CYP51, cytochrome P450, 51	AGGCGGGTGGGTCGG[T/C]GCTGGGCCAGGCGAT	M	T	C	V	A
				(lanosterol 14-alpha-
				demethylase)
G2443a10	WIAF-16471	U37143	966	CYP2J2, cytochrome P450,	ACTTCCACAACTCTG[C/A]GATGGGCTCTGCTTT	S	C	A	R	R
				subfamily IIJ (arachidonic
				acid epoxygenase) polypeptide
				2
G2443a11	WIAF-16472	U37143	1226	CYP2J2, cytochrome P450,	GACCAATTTGACGGC[G/A]CTGCACAGGGACCCC	S	G	A	A	A
				subfamily IIJ (arachidonic
				acid epoxygenase) polypeptide
				2
G2443a12	WIAF-16473	U37143	1316	CYP2J2, cytochrome P450,	TAAGAAAAGGGAAGC[C/T]TTTATGCCTTTCTCA	S	C	T	A	A
				subfamily IIJ (arachidonic
				acid epoxygenase) polypeptide
				2
G2443a13	WIAF-16474	U37143	1524	CYP2J2, cytochrome P450,	GTGTAATATTGTTAA[G/A]AAAGAAAGGGGCAAG	—	G	A
				subfamily IIJ (arachidonic
				acid epoxygenase) polypeptide
				2
G2443a4	WIAF-16465	U37143	188	CYP2J2, cytochrome P450,	CTTCCTTGTGGACTT[C/T]GAGCAGTCGCACCTG	S	C	T	F	F
				subfamily IIJ (arachidonic
				acid epoxygenase) polypeptide
				2
G2443a5	WIAF-16466	U37143	200	CYP2J2, cytochrome P450,	CTTCGAGCAGTCGCA[C/T]CTGGAGGTTCAGCTG	S	C	T	H	H
				subfamily IIJ (arachidonic
				acid epoxygenase) polypeptide
				2
G2443a6	WIAF-16467	U37143	314	CYP2J2, cytochrome P450,	AGAAGCCCTTATCCA[C/T]ATGGACCAAAACTTT	S	C	T	H	H
				subfamily IIJ (arachidonic
				acid epoxygenase) polypeptide
				2
G2443a7	WIAF-16468	U37143	342	CYP2J2, cytochrome P450,	TTTGGGAACCGGCCC[G/T]TGACCCCTATGCGAG	M	G	T	V	L
				subfamily IIJ (arachidonic
				acid epoxygenase) polypeptide
				2
G2443a8	WIAF-16469	U37143	153	CYP2J2, cytochrome P450,	CCGGGGCCCTGGCGC[C/T]TGCCCTTCCTTGGCA	S	C	T	L	L
				subfamily IIJ (arachidonic
				acid epoxygenase) polypeptide
				2
G2443a9	WIAF-16470	U37143	758	CYP2J2, cytochrome P450,	TCTCTTCAGCAACTG[G/A]AAAAAACTGAAATTG	N	G	A	W	*
				subfamily IIJ (arachidonic
				acid epoxygenase) polypeptide
				2
G2444a3	WIAF-16087	U37519	1762	ALDH3, aldehyde	GGGCTCCCAGAGCTG[C/T]ACCCTCCTGTGAGCG	S	C	T	C	C
				dehydrogenase 3
G2444a4	WIAF-16088	U37519	1871	ALDH3, aldehyde	CCTCCAGACCGCAGG[C/T]TCCCCCAGCCTCAGG	—	C	T
				dehydrogenase 3
G2473a3	WIAF-16475	X06990	733	ICAM1, intercellular	GTCTGTTCCCTGGAC[G/A]GGCTGTTCCCAGTCT	M	G	A	G	R
				adhesion molecule 1 (CD54),
				human rhinovirus receptor
G2473a4	WIAF-16476	X06990	1067	ICAM1, intercellular	CCCAGCCACTGGGCC[C/T]GAGGGCCCAGCTCCT	M	C	T	P	L
				adhesion molecule 1 (CD54),
				human rhinovirus receptor
G2485a8	WIAF-16477	X59543	2419	RRM1, ribonucleotide	AAGGACGAGACCAGC[A/G]GCTAATCCAATCCAG	S	A	G	A	A
				reductase M1 polypeptide
G2485a9	WIAF-16478	X59543	2520	RRM1, ribonucleotide	ACACAGCAGCCATGG[T/C]GTGCTCTTTGGAGAA	M	T	C	V	A
				reductase M1 polypeptide
G257a1	WIAF-16631	HT0729	402	IL1B, interleukin 1, beta	AGAACCTATCTTCTT[C/T]GACACATGGGATAAC	S	C	T	F	F
G258a1	WIAF-16640	HT0877	675	TNFSF5, tumor necrosis	AGCTGCAAATACCCA[C/T]AGTTCCGCCAAACCT	S	C	T	H	H
				factor (ligand superfamily,
				member 5
G258a2	WIAF-16641	HT0877	TNFSF5, tumor necrosis	TGACTGATCCAAGCC[A/G]AGTGAGCCATGGCAC	M	A	G	Q	R
				factor (ligand) superfamily,
				member 5
G260e2	WIAF-16632	HT1090	1078	IL1R1, interleukin 1	AATATATCCAGTCAC[T/G]AATTTCCAGAAGCAC	S	T	G	T	T
				receptor, type I
G260a3	WIAF-16633	HT1090	1117	IL1R1, interleukin 1	TATATGTGTCACGTT[G/A]ACAGTCATAATTGTG	S	G	A	L	L
				receptor, type I
G272a3	WIAF-17072	HT2661	1174	Human Fc-gamma receptor I B1	TAGCAGCGGCTCAGT[G/T]GGTGGCCATCGATCT	—	G	T
				mRNA, complete cds., ?
G279a1	WIAF-16219	U16350	329	SAH, SA (rat hypertension-	GTTTTGAGGAACTGG[G/T]ATCTCTGTCCAGAAA	M	G	T	G	V
				associated) homolog
G278a2	WIAF-16220	D16350	1148	SAH, SA (rat hypertension-	GCCTGGATATCTACG[A/G]AGGATATGGACAGAC	M	A	G	E	G
				associated) homolog
G278a3	WIAF-16221	D16350	1197	SAH, SA (rat hypertension-	TGGAAATTTTAAGGG[A/G]ATGAAAATTAAACCT	S	A	G	G	G
				associated) homolog
G278a4	WIAF-16222	D16350	1242	SAH, SA (rat hypertension-	ACCTTCTCCTGCTTT[C/T]GATGTTAAGATTGTA	S	C	T	F	F
				associated) homolog
G278a5	WIAF-16252	D16350	1467	SAH, SA (rat hypertension-	AAGAGCAGATGATGT[C/T]ATATTATCCTCTGGC	S	C	T	V	V
				associated) homolog
G278a6	WIAF-16253	D16350	1482	SAH, SA (rat hypertension-	CATATTATCCTCTGG[C/T]TATCGAATTGGACCA	S	C	T	G	G
				associated) homolog
G278a7	WIAF-16254	D16350	1620	SAH, SA (rat hypertension-	AAATCCTGATTACAA[G/T]TCACATGATCAAGAA	M	G	T	K	N
				associated) homolog
G279a16	WIAF-15535	K01740	6670	FBC, coagulation factor	CGTTTGCACCCAACT[C/T]ATTATAGCATTCGCA	M	C	T	H	Y
				VIIIc, procoagulant component
				(hemophilia A)
G279a17	WIAF-17064	K01740	2479	FBC, coagulation factor	CAAAAGCAATTTAAT[G/A]CCACCACAATTCCAG	M	G	A	A	T
				VIIc, procoagulant component
				(hemophilia A)
G279a18	WIAF-17065	K01740	5310	FBC, coagulation factor	ACACTATTTTATTGC[T/G]GCAGTGGAGAGGCTC	S	T	G	A	A
				VIIIc, procoagulant component
				(hemophilia A)
G281a1	WIAF-16209	L06105	245	FDFT1, farnesyl-diphosphate	TGGGGAAATGCGCAA[C/T]GCAGTGTGCATATTT	S	C	T	N	N
				farnesyltransferase 1
G281a2	WIAF-16210	L06105	294	FDFT1, farnesyl-diphosphate	CTGGACACACTGGAA[G/T]ATGACATGACCATCA	M	G	T	D	Y
				farnesyltransferase 1
G285a2	WIAF-16236	M28372	620	ZNF9, zinc finger protein 9	CACGGGAATGCACAA[T/A]TGAGGCTACAGCCTA	M	T	A	I	N
				(a cellular retroviral
				nucleic acid binding protein)
G290a3	WIAF-15719	M63959	763	LRPAP1, low density	CTACAGCACTGAGGC[C/T]GAGTTCGAGGAGCCC	S	C	T	A	A
				lipoprotein-related protein-
				associated protein 1 (alpha-2
				macroglobulin receptor-
				associated protein 1)
G290a4	WIAF-17062	M63959	1093	LRPAP1, low density	CGAACTCTGAAGGCA[C/T]TGGGGAGCCCAGCCC	—	C	T
				lipoprotein-related protein-
				associated protein 1 (alpha-2
				macroglobulin receptor-
				associated protein 1)
G290a5	WIAF-17063	M63959	1196	LRPAP1, low density	GTGGCTGGGGCTGGC[A/T]CGGGTGTCGAGGCAG	—	A	T
				lipoprotein-related protein-
				associated protein 1 (alpha-2
				macroglobulin receptor-
				associated protein 1)
G293a4	WIAF-17061	M74775	1054	LIPA, lipase A, lysosomal	GCTTGTGCCGACTGC[A/T]GTCTGGAGCGGGGGT	S	A	T	A	A
				acid, cholesterol esterase
				(Wolman disease)
G295a6	WIAF-16779	U04270	1186	KCNH2, potassium voltage-	ATTAGCAAGATTCCC[C/T]AAATCACCCTCAACT	N	C	T	Q	*
				gated channel, subfamily H,
				member 2
G295a7	WIAF-16780	U04270	2154	KCNH2, potassium voltage-	TGCTAGCATCTTCGG[C/T]AACGTGTCGGCCATC	S	C	T	G	G
				gated channel, subfamily H,
				member 2
G295a8	WIAF-16781	U04270	2272	KCNH2, potassium voltage-	CCCCTGCGCCAGCGC[C/T]TCGAGGAGTACTTCC	M	C	T	L	F
				gated channel, subfamily H,
				member 2
G295a9	WIAF-16840	U04270	1722	KCNH2, potassium voltage-	CGACCTGCTCATCTT[C/T]GGCTCTGGCTCTGAG	S	C	T	F	F
				gated channel, subfamily H,
				member 2
G2966a1	WIAF-16675	HT0219	659	serum response factor	GATAAAGACTGAGAA[T/C]CCAGCCGAGAAACTG	S	T	C	N	N
				(GB: M85164), ?
G2966a2	WIAF-16676	HT0219	749	serum response factor	TTCCAAAAAGCCACC[A/G]GTTGAACCTGTTGCT	S A	G	P	P
				(GB: M85164), ?
G2987a1	WIAF-16679	HT0239	593	ISGF3G, interferon-	AGCAGCAGCAGCAGC[A/T]GCCCTGAGCCACAGG	M	A	T	S	C
				stimulated transcription
				factor 3, gamma (48 kD)
G2967a2	WIAF-16680	HT0239	772	ISGF3G, interferon-	CCGCCTTGTGGCTGA[G/C]CCCTCAGGCTCTGAG	M	G	C	E	D
				stimulated transcription
				factor 3, gamma (48kD)
G2967a3	WIAF-16681	HT0239	856	ISGF3G, interferon-	GCGCCTGCTGAGCCA[G/A]CTTGAGAGGGGCATC	S	G	A	Q	Q
				stimulated transcription
				factor 3, gamma (48kD)
G2968a3	WIAF-16684	HT0244	1710	SMARCA1, SWI/SNF related,	GAACCCACAGGTTGA[T/C]CTACAAGCTATGGAT	S	T	C	D	D
				matrix associated, actin
				dependent regulator of
				chromatin, subfamily a,
				member 1
G2968a4	WIAF-16880	HT0244	956	SMARCA1, SWI/SNF related,	ATAACCTGCATGAAC[T/C]GTGGGCCTTACTCAA	M	T	C	L	P
				matrix associated, actin
				dependent regulator of
				chromatin, subfamily a,
				member 1
G2968a5	WIAF-16881	HT0244	1097	SMARCA1, SWI/SNF related,	AACCATTTTTGTTAC[G/C]CCGTATAAAAACTGA	M	G	C	R	P
				matrix associated, actin
				dependent regulator of
				chromatin, subfamily a,
				member 1
G2968a6	WIAF-16882	HT0244	889	SMARCA1, SWI/SNF related,	CTTTCAGAGATTGTT[C/T]GTGAGTTCAAGTCCA	M	C	T	R	C
				matrix associated, actin
				dependent regulator of
				chromatin, subfamily a,
				member 1
G2968a7	WIAF-16883	HT0244	2683	SMARCA1, SWI/SNF related,	CGTGGAGAAGCAAGA[A/T]TTCAACGAAGGATCA	M	A	T	I	F
				matrix associated, actin
				dependent regulator of
				chromatin, subfamily a,
				member 1
G296a2	WIAF-16637	U12778	654	ACADSB, acyl-Coenzyme A	CAGCAGTGCTGAGCA[T/C]GCAGGGCTCTTTCTG	S	T	C	H	H
				dehydrogenase, short branched
				chain
G2970a2	WIAF-16885	HT0281	307	?, ?	GGTGATGAGCTATGC[A/C]CAGGCCCAGCGCATG	S	A	C	A	A
G1970a3	WIAF-16886	HT0281	339	?, ?	TGGAGGTGGACTTGC[A/T]TGGCCGCGTCCACCG	M	A	T	H	L
G2970a4	WIAF-16887	HT0281	356	?, ?	GGCCGCGTCCACCGC[A/T]TCAGCATCTTTGACA	M	A	T	I	F
G2970a5	WIAF-16888	HT0281	362	?, ?	GTCCACCGCATCAGC[A/T]TCTTTGACAACCTGG	M	A	T	I F
G2970a6	WIAF-16889	HT0281	372	?, ?	TCAGCATCTTTGACA[A/C]CCTGGATGTGGTGTC	M	A	C	N	T
G2970a7	WIAF-16890	HT0281	401	?, ?	TCAGAGGATGAGGAA[G/C]CCCCCGAGGAGGCCC	M	G	C	A	P
G2970a8	WIAF-16891	HT0281	1968	?, ?	AGCAGCTCCAAGAGA[A/G]GGACACAGGCAACAT	M	A	G	K	R
G2975a3	WIAF-16900	HT0334	290	B-cell-specific transcription	AAATTCTTGGCACGT[A/T]TTATGAGACAGGAAG	M	A	T	Y	F
				factor, ?
G2975a4	WIAF-16901	HT0334	976	B-cell-specific transcription	CCGCAGTCCTACCCC[A/T]TTGTGACAGGCCGTG	M	A	T	I	F
				factor, ?
G2975a5	WIAF-16902	HT0334	1362	B-cell-specific transcription	GTCCCCCAGCATCCC[C/T]CACTTGCCTGAAGCT	—	C	T
				factor, ?
G2976a3	WIAF-16903	HT0340	1703	SATB1, special AT-rich	ATGAACATTAATGCT[T/C]CCATTTATGATGAGA	M	T	C	S	P
				sequence binding protein 1
				(binds to nuclear
				matrix/scaffold-associating
				DNA's)
G2976a4	WIAF-16904	HT0340	1884	SATB1, special AT-rich	TCCGAAGGTTCCTCA[G/T]TCTTCCTCAGCCAGA	M	G	T	S	I
				sequence binding protein 1
				(binds to nuclear
				matrix/scaffold-associating
				DNA's)
G2976a5	WIAF-16905	HT0340	2030	SATB1, special AT-rich	CAGCAGCAGCAGCAG[C/G]AGCAGGCACCGCCGC	M	C	G	Q	E
				sequence binding protein 1
				(binds to nuclear
				matrix/scaffold-associating
				DNA's)
G2978a2	WIAF-16918	HT0346	1203	MSX1, msh (Drosphila) homeo	TACCCCCGACGTGCT[C/T]CCCTGCTCGGCACCG	—	C	T
				box homolog 1 (formerly homeo
				box 7)
G297a3	WIAF-16228	U10660	1031	ECH1, enoyl Coenzyme A	AGCCCTCGCGTCCCA[G/T]CCCCAGCCAGGGGGC	—	G	T
				hydratase 1, peroxisomal
G2980a10	WIAF-16932	HT0356	2011	TLE1, transducin-like	CTCCCAGATCTTCTC[C/T]CTGGGGTACTGCCCC	S	C	T	S	S
				enhancer of split 1, homolog
				of Drosophila E(sp1)
G2980a11	WIAF-16933	HT0356	2029	TLE1, transducin-like	GGGGTACTGCCCCAC[C/T]GGGGAGTGGCTGGCA	S	C	T	T	T
				enhancer of split 1, homolog
				of Drosophila E(sp1)
G2980a12	WIAF-16937	HT0356	1714	TLE1, transducin-like	CCTGGCGGCTCCAAC[C/T]CCGCGCATCAAGGCG	S	C	T	T	T
				enhancer of split 1, homolog
				of Drosophila E(sp1)
G2980a13	WIAF-16938	HT0356	1557	TLE1, transducin-like	GCGTCAAGGTCTGGG[A/G]CATCAGCCACCCTGG	W	A	G	D	G
				enhancer of split 1, homolog
				of Drosophila E(sp1)
G2980a7	WIAF-16801	HT0356	1171	TLE1, transducin-like	CGCTGGCATGAACGG[C/G]GAGCTGACCAGCCCA	S	C	G	G	G
				enhancer of split 1, homolog
				of Drosophila E(sp1)
G2980a8	WIAF-16802	HT0356	1230	TLE1, transducin-like	TGTCGCCCCAGATGA[G/A]CGCCGCAGCCGCCCG	M	G	A	S	N
				enhancer of split 1, homolog
				of Drosophila E(sp1)
G2980a9	WIAF-16803	HT0356	1325	TLE1, transducin-like	GTACCTACCATTCCT[C/A]CAAACCTGGCAGGAA	M	C	A	P	T
				enhancer of split 1, homolog
				of Drosophila E(sp1)
G2983a4	WIAF-16936	HT0360	747	TLE1, transducin-like	ATACGACAGTGATGG[A/G]GACAAGAGTGATGAT	S	A	G	G	G
				enhancer of split 1, homolog
				of Drosophila E(sp1)
G298a15	WIAF-16787	U33837	2129	Human glycoprotein receptor	TGAGCAGGTCTGTGT[T/C]CTCAGCCACAGAACA	S	T	C	V	V
				gp330 precursor, mRNA,
				complete cds., ?
G298a16	WIAF-16788	U33837	7003	Human glycoprotein receptor	GGAATTTGAAAAAGA[T/A]CTTCCAAGCCAGCAA	M	T	A	I	N
				gp330 precursor, mRNA,
				complete cds., ?
G298a17	WIAF-16789	U33837	7086	Human glycoprotein receptor	CTAAGAGATGTGACC[A/T]TCTTTGACAAGCAAG	M	A	T	I	F
				gp330 precursor, mRNA,
				complete cds., ?
G298a18	WIAF-16790	U33837	8907	Human glycoprotein receptor	GACTGTGGGGATATG[A/G]GTGACGAGGATAAAA	M	A	G	S	G
				gp330 precursor, mRNA,
				complete cds., ?
G298a19	WIAF-16791	U33837	10429	Human glycoprotein receptor	ATGGATCAAATAGAC[A/C]GACACTGGTGAACAC	M	A	C	Q	P
				gp330 precursor, mRNA,
				complete cds., ?
G298a20	WIAF-16792	U33837	10607	Human glycoprotein receptor	CTTCCGCACCCTTCA[A/G]CTGAGTGGCAGCACC	S A	G	Q	Q
				gp330 precursor, mRNA,
				complete cds., ?
G298a21	WIAF-16793	U33837	12100	Human glycoprotein receptor	GGTTCGAAACCAATG[T/G]TTTTGACAGAACCTC	M	T	G	V	G
				gp330 precursor, mRNA,
				complete cds., ?
G298a22	WIAF-16794	U33837	13062	Human glycoprotein receptor	CTCACTCAAGTTCGA[A/T]TCTTTCATCAACTCA	M	A	T	I	F
				gp330 precursor, mRNA,
				complete cds., ?
G29a23	WIAF-16795	U33837	13064	Human glycoprotein receptor	CACTCAAGTTCGAAT[C/T]TTTCATCAACTCAGA	S	C	T	I	I
				gp330 precursor, mRNA,
				complete cds., ?
G298a24	WIAF-16804	U33837	13862	Human glycoprotein receptor	TCTCTTCAAACGAAA[A/T]TCTAAACAAACTACC	M	A	T	K	N
				gp330 precursor, mRNA,
				complete cds., ?
G298a25	WIAF-16841	U33837	743	Human glycoprotein receptor	CCAAGACGGCAGTGA[T/C]GAACATGCTTGCAAC	S	T	C	D	D
				gp330 precursor, mRNA,
				complete cds., ?
G298a26	WIAF-16844	U33837	2428	Human glycoprotein receptor	TTGATGGCACAGGAA[G/A]AGAAATTCTCGCAGC	M	G	A	R	K
				gp330 precursor, mRNA,
				complete cds., ?
G298a27	WIAF-16845	U33837	2564	Human glycoprotein receptor	TAAAACGAGACGCAC[A/G]GTAGTTCAGTATTTA	S	A	G	T	T
				gp330 precursor, mRNA,
				complete cds., ?
G298a28	WIAF-16847	U33837	4979	Human glycoprotein receptor	TTACATGGACTTTTG[C/T]GATTATAATGGACAC	S	C	T	C	C
				gp330 precursor, mRNA,
				complete cds., ?
G298a29	WIAF-16850	U33837	11705	Human glycoprotein receptor	TGGCGATGATGACTG[T/C]GGCGATGGTTCAGAT	S	T	C	C	C
				gp330 precursor, mRNA,
				complete cds., ?
G298a30	WIAF-16851	U33837	12384	Human glycoprotein receptor	TATGATTGGGATCCC[A/G]AGGACATAGGCCTCA	M	A	G	K	E
				gp330 precursor, mRNA,
				complete cds., ?
G298a31	WIAF-16852	U33837	12394	Human glycoprotein receptor	ATCCCAAGGACATAG[G/A]CCTCAGTGTTGTGTA	M	G	A	G	D
				gp330 precursor, mRNA,
				complete cds., ?
G298e32	WIAF-16853	U33837	12445	Human glycoprotein receptor	GCTCTAGGTTTGGTG[C/T]TATCAAACGTGCCTA	M	C	T	A	V
				gp330 precursor, mRNA,
				complete cds., ?
G298a33	WIAF-16854	U33837	12693	Human glycoprotein receptor	GTGAATCCCAAACTA[G/A]GGCTTATGTTCTGGA	M	G A	G	R
				gp330 precursor, mRNA,
				complete cds., ?
G298a34	WIAF-16855	U33837	12732	Human glycoprotein receptor	GGAAAGGAACCTAAA[A/C]TCGAGTCTGCCTGGA	M	A	C	I	L
				gp330 precursor, mRNA,
				complete cds., ?
G299a1	WIAF-16868	U50929	711	BHMT, betaine-homocysteine	AGTTTAAAAACAGTG[A/G]AGCTCATGAAGGAGG	M	A	G	K	E
				methyltransferase
G299a2	WIAF-16859	U50929	742	BHMT, betaine-homocysteine	GCTTGGAGGCTGCCC[A/G]ACTGAAAGCTCACCT	M	A	G	Q	R
				methyltransferase
G300a1	WIAF-16204	U63623	144	AQP4, aquaporin 4	AGAAAAGCCTTTACC[G/T]GTCGACATGGTTCTC	S	G	T	P	P
G301a10	WIAF-16317	U71285	3207	MTR, 5-	CATTCACCTGTACGC[A/G]GAGGCTGCTGTGCCC	S	A	G	A	A
				methyltetrahydrofolate-
				homocysteine
				methyltransferase
G301a2	WIAF-16269	U71285	326	MTR, 5-	AGGAATACTTGCTGG[C/G]TGGGGCAGATATCAT	M	C	G	A	G
				methyltetrahydrofolate-
				homocysteine
				methyltransferase
G301a3	WIAF-16270	U71285	339	MTR, 5-	GGCTGGGGCAGATAT[C/T]ATTGAAACAAATACT	S	C	T	I	I
				methyltetrahydrofolate-
				homocysteine
				methyltransferase
G301a4	WIAF-16271	U71285	363	MTR, 5-	AAATACTTTTAGCAG[C/T]ACTAGTATTGCCCAA	S	C	T	S	S
				methyltetrahydrofolate-
				homocysteine
				methyltransferase
G301a5	WIAF-16272	U71285	374	MTR, 5-	GCAGCACTAGTATTG[C/A]CCAAGCTGACTATGG	M	C	A	A	D
				methyltetrahydrofolate-
				homocysteine
				methyltransferase
G301a6	WIAF-16273	U71285	1003	MTR, 5-	AAGGATTTTGCTATG[G/A]ATGGCTTGGTCAATA	M	G	A	D	N
				methyltetrahydrofolate-
				homocysteine
				methyltransferase
G301a7	WIAF-16303	U71285	3540	MTR, 5-	CAGTGAGCAGCTGGA[C/T]GTCGCAGACCTGCGA	S	C	T	D	D
				methyltetrahydrofolate-
				homocysteine
				methyltransferase
G301a8	WIAF-16304	U71285	3555	MTR, 5-	CGTCGCAGACCTGCG[A/C]AGGTTGCGGTACAAG	S	A	C	R	R
				methyltetrahydrofolate-
				homocysteine
				methyltransferase
G301a9	WIAF-16316	U71285	1548	MTR, 5-	GTATGGAGCTGCTAT[G/A]GTGGTCATGGCTTTT	M	G	A	M	I
				methyltetrahydrofolate-
				homocysteine
				methyltransferase
G3038a4	WIAF-15977	HT1373	678	NFKB1, nuclear factor of	CGTGTATAAGGGGCT[A/G]TAATCCTGGACTCTT	M	A	G	Y	C
				kappa light polypeptide gene
				enhancer in B-cells 1 (p105)
G3038a5	WIAF-15978	HT1373	822	NFKB1, nuclear factor of	ACCTCAGCGTGGTGC[G/A]GCTCATGTTTACAGC	M	G	A	R	Q
				kappa light polypeptide gene
				enhancer in B-cells 1 (p105)
G3042a1	WIAF-16614	HT1471	225	POU2F1, POU domain, class 2,	CTCCATCAGGTCCA[C/T]TCGCTGGAACAAGTT	M	C	T	L	F
				transcription factor 1
G3042a2	WIAF-16615	HT1471	2272	POU2F1, POU domain class 2,	CGTCCACCACCACCA[C/T]CGCCTCCAAGGCACA	M	C	T	T	I
				transcription factor 1
G3042a3	WIAF-16829	HT1471	1601	POU2F1, POU domain, class 2,	TTCCACAGCGCCTCC[A/G]GCTTCCTCAGCAGTC	S	A	G	P	P
				transcription factor 1
G305a4	WIAF-16284	HT0034	366	prolyl 4-hydroxylase, beta	GCGCGGCTATCCCAC[C/T]ATCAAGTTCTTCAGG	S	C	T	T	T
				subunit/protein disulfide
				isomerase/thyroid hormone-
				binding protein, alt.
				transcript 1, ?
G305a5	WIAF-16335	HT0034	1560	prolyl 4-hydroxylase, beta	CATGGAGGAAGACGA[T/C]GATCAGAAAGCTGTG	S	T	C	D	D
				subunit/protein disulfide
				isomerase/thyroid hormone-
				binding protein, alt.
				transcript 1, ?
G306a2	WIAF-16208	HT0040	1571	CPT2, carnitine	GCACAAACCGCTGGT[T/G]TGATAAATCCTTTAA	M	T	G	F	C
				palmitoyltransferase II
G306a3	WIAF-16232	HT0040	1027	CPT2, carnitine	CTCCGGGCTGGCCTT[C/T]TGGAGCCAGAAGTGT	S	C	T	L	L
				palmitoyltransferase II
G306a4	WIAF-16233	HT0040	1210	CPT2, carnitine	CCCAAACCCAGTCGG[G/A]ATGAACTCTTCACTG	M	G	A	D	N
				palmitoyltransferase II
G306a5	WIAF-16234	HT0040	1283	CPT2, carnitine	TTTATATCTTTCATG[T/C]CCTGGATCAAGATGG	M	T	C	V	A
				palmitoyltransferase II
G306a6	WIAF-16235	HT0040	2033	CPT2, carnitine	CCATCCGCCCGGCCT[C/A]CGTCTATACAAAGAG	M	C	A	S	Y
				palmitoyltransferase II
G3071a6	WTAF-15980	HT2086	1268	AGER, advanced glycosylation	GACCGCCGTGTCAGT[C/G]ACCCAGGGGGGCCAC	S	C	G	V	V
				end product-specific receptor
G3071a7	WIAF-15981	HT2086	1285	AGER, advanced glycosylation	CCCAGGGGGGCCACA[G/T]CCGCACCAGCTCCCC	M	G	T	S	I
				end product-specific receptor
G3071a8	WIAF-15982	HT2086	1295	AGER, advanced glycosylation	CCACAGCCGCACCAG[C/A]TCCCCGACACCCCCT	M	C	A	S	R
				end product-specific receptor
G3071a9	WIAF-15983	HT2086	1379	AGER, advanced glycosylation	TCTGGGGATGCCTGG[G/A]CTCAACGGAGATTCC	S	G	A	G	G
				end product-specific receptor
G307a2	WIAF-16773	HT0114	394	EDN2, endothelin 2	CCCCGCCTGTGCCAC[C/T]TTCTGCCTTCGAACC	S C	T	T	T
G308a3	WIAF-16201	HT0192	219	ANK4, annexin IV (placental	CCTACCGCAACACCG[C/T]CCAGCGCCAGGAGAT	M	C	T	A	V
				anticoagulant protein II)
G308a4	WIAF-16202	HT0192	347	ANK4, annexin IV (placental	ACGCCCACGGTGCTG[T/A]ATGACGTGCAAGAGC	M	T	A	Y	N
				anticoagulant protein II)
G310e1	WIAF-16067	HT0389	740	complement component 4-	TTTTGAAGGAAATAA[C/T]TTCACCTTAGGATCC	S	C	T	N	N
				binding protein, beta, ?
G310a2	WIAF-16068	HT0389	746	complement component 4-	AGGAAATAACTTCAC[C/T]TTAGGATCCACCATT	S	C	T	T	T
				binding protein, beta, ?
G311a10	WIAF-16815	HT0402	2302	A2M, alpha-2-macroglobulin	AGCAGGGGTGGCTGA[G/T]GTAGGAGTAACAGTC	M	G	T	E	D
G311a11	WIAF-16816	HT0402	2307	A2M, alpha-2-macroglobulin	GGGTGGCTGAGGTAG[G/T]AGTAACAGTCCCTGA	M	G	T	G	V
G311a12	WIAF-16817	HT0402	3288	A2M, alpha-2-macroglobulin	ATGGCTGTTTCAGGA[G/A]CTCTGGGTCACTGCT	M	G	A	S	N
G311a13	WIAF-16818	HT0402	3418	A2M, alpha-2-macroglobulin	TGTCCGCAATGCCCT[G/A]TTTTGCCTGGAGTCA	S	G	A	L	L
G311a14	WIAF-16819	HT0402	4235	A2M, alpha-2-macroglobulin	AAGCCAACAGTGAAA[A/G]TGCTTGAAAGATCTA	M	A	G	M	V
G311a8	WIAF-16767	HT0402	1121	A2M, alpha-2-macroglobulin	GTGGACTCACACTTT[C/T]GACAGGGAATTCCCT	N	C	T	R	*
G311a9	WIAF-16768	HT0402	2147	A2M, alpha-2-macroglobulin	ATGCATGGACCTGAA[G/A]GTCTACGTGTAGGTT	M	G	A	G	S
G314a2	WIAP-16223	HT0467	2004	ALOX15, arachidonate 15-	CTAAGCGTCGCCACC[C/T]TTTGGTTATTTCAGC	—	C	T
				lipoxygenase
G314a3	WIAF-16224	HT0457	2053	ALOX15, arachidonate 15-	AAGCTGACCCCTTCG[T/C]GGTTATAGCCCTGCC	—	T	C
				lipoxygenase
G315a1	WIAF-16265	HT0501	164	IVD, isovaleryl Coenzyme A	AGCAGAGGCAGCTTC[G/A]TCAGACCATGGCTAA	M	G	A	R	H
				dehydeogenase
G315a2	WIAF-16311	HT0501	706	IVD, isovaleryl Coenzyme A	ATTGTGGAGAAGGGT[A/G]TGCCTGGCTTTAGCA	M	A	G	M	V
				dehydrogenase
G315a3	WIAF-16312	HT0501	738	IVD, isovaleryl Coenzyme A	CTCTAAGAAGCTGGA[C/T]AAGCTGGGGATGAGG	S	C	T	D	D
				dehydrogenase
G319a1	WIAF-15531	HT0746	983	PLI, alpha-2-plasmin	AACCTGAGTTGGGAC[A/G]CCCTGCACCCACCTC	M	A	G	T	A
				inhibitor
G319a2	WIAF-15532	HT0746	1117	PLI, alpha-2-plasmin	CCAGGCCCCAGACCT[G/A]CGTGGGATCTCCGAG	S	G	A	L	L
				inhibitor
G319a3	WIAF-15533	HT0746	1301	PLI, alpha-2-plasmin	GACACCACAGGCCTT[C/T]CCCTCTTCGTGGGCA	M	C	T	P	S
				inhibitor
G319a4	WIAF-15534	HT0746	1323	PLI, alpha-2-plasmin	TCGTGGGCAGCGTGA[G/A]GAACCCCAACCCCAG	M	G	A	R	K
				inhibitor
G319a5	WIAF-16820	HT0746	1504	PLI, alpha-2-plasmin	CCCCAAGTGAGGGGC[C/T]GTGGCTGTGGCATCC	—	C	T
				inhibitor
G319a6	WIAF-16821	HT0746	1569	PLI, alpha-2-plasmin	TGACTCTTTCCAACC[G/T]GCTTTGTGGCACTGG	—	G	T
				inhibitor
G320a3	WIAF-16343	HT0791	771	ANX7, annexin VII (synexin)	CTTCATGCCTCCTAC[G/A]TATTACGATGCCTGG	S	G	A	T	T
G3217a1	WIAF-16713	HT28083	163	zinc finger protein, Kruppel-	AAGTATAACTCGCTG[C/A]TCCTGAAGCACCAGC	M	C	A	L	I
				like (GB: M20678), ?
G3218a2	WIAF-16714	HT28104	185	zinc finger protein ZNF169,	AGAAGGCCCCGACAG[C/A]TCATTAAGAAAGAGG	M	C	A	A	D
				Krueppel-type, ?
G3218a3	WIAF-16715	HT28104	214	zinc finger protein ZFN169,	GGCCAAGCAGAATTT[C/A]TAGGACATTCTTCAG	M	C	A	L	I
				Krueppel-type, ?
G324a1	WIAF-16737	HT0949	317	CEL, carboxyl ester lipase	ACCTACGGGGATGAA[G/A]ACTGCCTGTACCTCA	M	G	A	D	N
				(bile salt-stimulated lipase)
G325a10	WIAF-16247	HT0962	3537	FBN1, fibrillin 1 (Marfan	AAGTGCAGAAACACC[A/G]TTGGCAGCTTTAAGT	M	A	G	I	V
				syndrome)
G325a11	WIAF-16248	HT0962	3701	FBN1, fibrillin 1 (Marfan	TGACGAAGGCTATGA[A/G]AGTGGATTCATGATG	S	A	G	E	E
				syndrome)
G325a12	WIAF-16249	HT0962	3837	FBN1, fibrillin 1 (Marfan	GGCCATCAGCTGTCC[C/G]CCAACATCTCCGCGT	M	C	G	P	A
				syndrome)
G325a13	WIAF-16250	HT0962	7100	FBN1, fibrillin 1 (Marfan	CAAATGTCCCGTGGG[A/C]TATGTGCTCAGAGAA	S	A	C	G	G
				syndrome)
G325a14	WIAF-16251	HT0962	7227	FBN1, fibrillin 1 (Marfan	ATGTGCATCTGTGGA[C/T]CCGGGTATCAGCGGA	M	C	T	P	S
				syndrome)
G325a6	WIAF-16214	HT0962	369	FBN1, fibrillin 1 (Marfan	GGCGCGGCAAGAGGC[G/A]GCGGGAGCCGGTGGC	—	G	A
				syndrome)
G325a7	WIAF-16215	HT0962	4292	FBN1, fibrillin 1 (Marfan	GACCTGTGAAAACAC[G/A]AAAGGCTCATTTATC	S	G	A	T	T
				syndrome)
G325a8	WIAF-16216	HT0962	8379	FBN1, fibrillin 1 (Marfan	GCCCCCTGCAGCTAT[G/A]GCTGTTCCAATACCG	M	G	A	G	S
				syndrome)
G325a9	WIAF-16246	HT0962	875	FBN1, fibrillin 1 (Marfan	CAATGGAGGAAGGTG[T/C]GTGGCCCCAAATCGA	S	T	C	C	C
				syndrome)
G327a4	WIAF-15713	HT1011	1463	HRG, histidine-rich	CCAGGTAAAGGACCC[C/T]GTCCCTTCCATTGCA	M	C	T	R C
				glycoprotein
G327a5	WIAF-15720	HT1011	1661	HRG, histidine-rich	AAGAGTGGGTTTCCA[C/T]AAGTTTCCATGTTTT	N	C	T	Q	*
				glycoprotein
G327a6	WIAF-16797	HT1011	1374	HRG, histidine-rich	ACTATGGACCTTGTG[A/G]CCCACCACCCCATAA	M	A	G	D	G
				glycoprotein
G327a7	WIAF-16798	HT1011	1427	HRG, histidine-rich	CACGGCCCACCACCT[G/A]GGCACTTAAGAAGGC	M	G	A	G	R
				glycoprotein
G327a8	WIAF-16858	HT1011	1816	HRG, histidine-rich	TCATACTGAAGATGC[A/G]GCAAAATGTGAATGG	—	A	G
				glycoprotein
G327a9	WIAF-16859	HT1011	1824	HRG, histidine-rich	AAGATGCAGCAAAAT[G/A]TGAATGGGAAAAGAG	—	G	A
				glycoprotein
G328a10	WIAF-16309	HT1087	343	SAA1, serum amyloid A1	GATCAGGCTGCCAAT[G/A]AATGGGGCAGGAGTG	M	G	A	E	K
G328a11	WIAF-16310	HT1087	362	SAA1, serum amyloid A1	GGGGCAGGAGTGGCA[A/G]AGACCCCAATCACTT	M	A	G	K	R
G328a6	WIAF-16305	HT1087	239	SAA1, serum amyloid A1	CTGCCAAAAGGGGAC[C/T]TGGGGGTGCCTGGGC	M	C	T	P	L
G328a7	WIAF-16306	HT1087	263	SAA1, serum amyloid A1	CCTGGGCTGCAGAAG[T/C]GATCAGCGATGCCAG	M	T	C	V	A
G328a8	WIAF-16307	HT1087	271	SAA1, serum amyloid A1	GCAGAAGTGATCAGC[G/A]ATGCCAGAGAGAATA	M	G	A	D	N
G328a9	WIAF-16308	HT1087	318	SAA1, serum amyloid A1	CCATGGTGCGGAGGA[C/T]TCGCTGGCTGATCAG	S	C	T	D	D
G331a1	WIAF-16867	HT1184	819	APOA1, apolapoprotein A-I	GCACCTCCGCCAAGG[C/A]CTGCTGCCCGTGCTG	S	C	A	G	G
G335a1	WIAF-16205	HT1233	1515	CPE, carboxypeptidase E	TCCGCAAAGGATGGT[G/A]ATTACTGGAGATTGC	M	G	A	D	N
G339a1	WIAF-16866	HT1290	256	APOE, apolipoprotein E	GCAGACACTGTCTGA[G/T]CAGGTGCAGGAGGAG	M	C	T	E	D
G342a1	WIAF-16778	HT1483	204	glutathione reductase, ?	GGCGGCTCGGGCGGG[C/T]TGGCCAGCGCGCGCA	S	C	T	L	L
G343a3	WIAF-16217	HT1552	2121	HK1, hexokinase 1	ACTCATTGTTGGGAC[C/T]GGCAGCAATGCCTGC	S	C	T	T	T
G343a4	WIAF-162291	HT1552	2897	HK1, hexokinase 1	AAGCGGCGACCCCCT[A/T]CCCTCCCAGCGAGTT	—	A	T
G343a5	WIAF-16230	HT1552	2904	HK1, hexokinase 1	GACCCCCTACCCTCC[C/T]AGCGAGTTGCGCTGG	—	C	T
G344a3	WIAF-16069	HT1679	1831	EDNRA, endothelin receptor	CATAATCCTCTCGGA[G/A]AAAAAAATCACAAGG	—	G	A
				type A
G348a10	WIAF-17124	HT1906	PECAM1, platelet/endothelial	GTCAACATAACAGAA[C/A]TATTTTCCAAGCCCG	M	C	A	L	I
				cell adhesion molecule (CD31
				antigen
G348a4	WIAF-10493	HT1906	1151	PECAM1, platelet/endothelial	TATCCAAGGTCAGCA[T/G]CATCGTGGTCAACAT	M	T	G	S	I
				cell adhesion molecule (CD31
				antigen
G348a6	WIAF-15716	HT1906	1743	PECAM1, platelet/endothelial	GTCAAGTAAGGTGGT[G/A]GAGTCTGGAGAGGAC	S	G	A	V	V
				cell adhesion molecule (CD31
				antigen
G348a7	WIAF-15717	HT1906	1892	PECAM1, platelet/endothelial	CCAAGCAGAAGGCTA[A/G]CAAGGAACAGGAGGG	M	A	G	N	S
				cell adhesion molecule (CD31
				antigen
G348e8	WIAF-16805	HT1906	2479	PECAM1, platelet/endothelial	CCGAGAAGAACAGAT[G/A]ATCCCTGTATTTCAA	—	G	A
				cell adhesion molecule (CD31
				antigen
G348e9	WIAF-17123	HT1906	1413	PECAM1, platelet/endothelial	CACAGTCCAGATAGT[C/T]GTATGTGAAATGCTC	S	C	T	V	V
				cell adhesion molecule (CD31
				antigen
G349a1	WIAF-16225	HT1971	1043	CPB2, carboxypeptidase B2	GCCAGTGAAGCAGTT[C/T]GTGCTATTGAGAAAA	M	C	T	R	C
				(plasma)
G349a2	WIAF-16226	HT1971	1059	CPB2, carboxypeptidase B2	GTGCTATTGAGAAAA[C/T]TAGTAAAAATACCAG	M	C	T	T	I
				(plasma)
G351a4	WIAF-16274	HT1990	1556	OSBP, oxysterol binding	ATGATGAGAATGAAT[T/A]TTTTGATGCACCTGA	M	T	A	F Y
				protein
G351a5	WIAF-16275	HT1990	1710	OSBP, oxysterol binding	GAGAACCAGAATACC[A/G]TACAAGCCAAACTAT	S	A	G	P	P
				protein
G351a6	WIAF-16318	HT1990	1979	OSBP, oxysterol binding	TCAACCCACTGCTTG[G/T]GGAGACCTTTGAGCT	M	G	T	G	V
				protein
G351a8	WIAF-16320	HT1990	2818	OSBP, oxysterol binding	AAGAAGGACCCTGTT[A/C]CCAAGGAGTTAACCC	M	A	C	T	P
				protein
G3522a3	WIAF-15684	HT2007	1135	GJA4, gap junction protein,	GGGATGCCCCCTGCC[C/T]CCTCCTGGAAGGCTC	—	C	T
				alpha 4, 37 kD (connexin 37)
G3522a4	WIAF-15685	HT2007	1179	GJA4, gap junction protein,	GGGCTGGGGAAGCAG[A/G]TGCTTGCTGGCCATG	—	A	G
				alpha 4, 37 kD (connexin 37)
G355a10	WIAF-16300	HT2143	2207	THBS4, thrombospondin 4	ACGCAGAGGTCACCC[T/C]GACCGACTTCAGGGC	M	T	C	L	P
G355a11	WIAF-16301	HT2143	2236	THBS4, thrombospondin 4	GCTTACCAGACCGTG[G/A]GCCTGGATCCTGAAG	M	G	A	G	S
G355a12	WIAF-17066	HT2143	1630	THBS4, thrombospondin 4	GACCAAAGGAACAGC[G/A]ATAAAGATATCTTTG	M	G	A	D	N
G355a5	WIAF-16295	HT2143	314	THBS4, thrombospondin 4	TGATGGGACGCTTAA[G/A]CAAAGCCATCCTCCG	M	G	A	S	N
G355a6	WIAF-16296	HT2143	1090	THBS4, thrombospondin 4	TGTGACGCCTGCCCA[G/A]TGGGCTTCACAGGGC	M	G	A	V	M
G355a7	WIAF-16297	HT2143	2082	THBS4, thrombospondin 4	AGACAACTGCCGGCT[G/A]GTCCCCAACCCAGCC	S	G	A	L L
G355a8	WIAF-16298	HT2143	2106	THBS4, thrombospondin 4	CCCAGCCCAGGAGGA[T/G]AGCAACAGCGACGGA	M	T	G	D	E
G355a9	WIAF-16299	HT2143	2145	THBS4, thrombospondin 4	CATCTGTGAGTCTGA[C/T]TTTGACCAGGACCAG	S	C	T	D	D
G3571a1	WIAF-16893	HT33730	357	?, ?	CAATAGTGGTGAGTT[G/A]GTGGCCATTATGGGT	S	G	A	L	L
G3571a2	WIAF-16894	HT33730	1829	?, ?	TCTCCTATGTCAGGT[A/G]TGGGTTCGAAGGGGT	M	A	G	Y	C
G357a20	WIAF-15507	HT2244	2917	C4B, complement component 4B	AGGCCGGACCTTGGA[A/C]ATACCTGGCAACTCT	M	A	C	E	D
G357a21	WIAF-15706	HT2244	1318	C4B, complement component 4B	TCAGCAAAACACAGA[C/T]GGGAGCGGCCAAGTC	S	C	T	D	D
G357a22	WIAF-15707	HT2244	1434	C4B, complement component 4B	TCACTGTGGCAGCCC[C/T]ACCTTCAGGAGGCCC	M	C	T	P L
G357a23	WIAF-15708	HT2244	1525	C4B, complement component 4B	CCTGAATTGCGAGC[C/T]GTGGGCAGTGGGGCC	S	C	T	A	A
G357a24	WIAF-15709	HT2244	1581	C4B, complement component 4B	TCCTATCCCGAGGGC[A/G]GATCGTGTTCATGAA	M	A	G	Q	R
G357a25	WIAF-15710	HT2244	2080	C4B, complement component 4B	CCGGAAAAAGAGAAA[C/T]GTGAACTTCCAAAAG	S	C	T	N	N
G357a26	WIAF-15711	HT2244	2217	C4B, complement component 4B	CCCGCGTGCAGCAGC[C/T]GGACTGCCGGGAGCC	M	C	T	P	L
G357a27	WIAF-15712	HT2244	2277	C4B, complement component 4B	GTCTGCGCAAGAAGA[G/T]CAGGGACAAGGGCCA	M	G	T	S	I
G357a28	WIAF-16061	HT2244	3669	C4B, complement component 4B	CGCCTGTGGACCTGC[T/G]CGGTGTTGCCCACAA	M	T	G	L	R
G357a29	WIAF-16062	HT2244	3870	C4B, complement component 4B	GCCTGTGGACCTGCT[C/G]GGTGTTGCCCACAAC	S	C	G	L	L
G3S7a30	WIAF-16063	HT2244	3775	C4B, complement component 4B	CGTGTCGCCCACCCC[A/G]GCTCCTCGCAACCCA	S	A	G	P	P
G357a31	WIAF-16064	HT2244	3927	C4B, complement component 4B	GTCAGGGCAGCTTCC[A/T]AGGGGGGATTCCGCAC	M	A	T	Q	L
G357a32	WIAF-16065	HT2244	4629	C4B, complement component 4B	CGGTCCCCACCTCCC[C/T]GGAGTGCGTGGGCTT	M	G	T	R	L
G357a33	WIAF-16066	HT2244	5286	C4B, complement component 4B	TGCCCTCCCACCTCC[G/A]CTGGGAGGAACCTGA	—	G	A
G3592a3	WIAF-15688	HT4214	1365	CLCN4, chloride channel 4	TACCACACGCCCTGG[T/C]ACATGGCTGAACTCT	M	T	C	Y	H
G3S92a4	WIAF-15689	HT4214	2276	CLCN4, chloride channel 4	CAAGGAGACCGACTA[C/T]AACGGCTTCCCCGTG	S	C	T	Y	Y
G3592a5	WIAF-15690	HT4214	2487	CLCN4, chloride channel 4	CTGAACCTCAGCCCCG[T/G]TTACAGTGACAGACC	M	T	G	F	V
G3592a6	WIAF-15691	HT4214	2219	CLCN4, chloride channel 4	GCCACTGTCGGTGCT[C/T]ACCCAGGACAGCATG	S	C	T	L	L
G359a10	WIAF-14360	K03021.0	23822	PLAT, plasminogen activator,	CCCTGTGAGAAGCTG[C/T]TACAGCTGGGGAAAG	—	C	T
				tissue
G359a11	WIAF-14361	K03021.0	23616	PLAT, plasminogen activator,	AGATACCAGGGCCAC[G/A]TGCTACGAGGACCAG	S	G	A	T	T
				tissue
G359a3	WIAF-143301	K03021.0	18178	PLAT, plasminogen activator,	TGCTGTCAGGGAGCA[G/A]AGAGGCACAGGGACG	—	G A
				tissue
G359a4	WIAF-14331	K03021.0	31379	PLAT, plasminogen activator,	GTTCCTCCCCTCCCG[G/A]GGACGCGGCCCTCAC	—	G	A
				tissue
G359a5	WIAF-14332	K03021.0	31085	PLAT, plasminogen activator,	ATCCCACAGCAAAAA[A/T]AGCATTCTAAGGCTG	—	A	T
				tissue
G359a6	WIAF-14333	K03021.0	20041	PLAT, plasminogen activator,	ACAGGTGTTTCCCCC[C/A]CAAGGGGCCAGGCTG	—	C	A
				tissue
G359a7	WIAF-14334	K03021.0	32432	PLAT, plasminogen activator,	TCCCCTTTCAGTGTC[T/C]CCTTTCTATTCGGAG	S	T	C	S	S
				tissue
G359a8	WIAF-14358	K03021.0	23739	PLAT, plasminogen activator,	CGGGCGGAGGCCAGA[T/C]GCCATCAGGCTGGGC	S	T	C	D	D
				tissue
G359a9	WIAF-14359	K03021.0	23796	PLAT, plasminogen activator,	AGGGCACATCCCCAA[G/A]GAGGGATTCCCCCTG	—	C	A
				tissue
G361a3	WIAF-15714	HT2479	1238	cystathionine beta synthase,	GGTGGCCGTGAACGC[C/T]GGCCAGGAGCTGCTG	S	C	T	A	A
				alt. transcript 1, ?
G361a4	WIAF-15715	HT2479	1340	cystathionine beta synthase,	CAGGTGGATGCTGCA[G/A]AAGGGCTTTCTGAAG	S	G	A	Q	Q
				alt. transcript 1, ?
G361a6	WIAF-16706	HT2479	1826	cystathionine beta synthase,	AAGTGAAGTCCGGAG[C/A]GCTGGCGTGCGGACG	M	C	A	S	R
				alt. transcript 1, ?
G361a7	WIAF-16799	HT2479	367	cystathionine beta synthase,	ATCACCACACTGCCC[C/T]GGCAAAATCTCCAAA	M	C	T	P	L
				alt. transcript 1, ?
G361a8	WIAF-16800	HT2479	462	cystathionine beta synthase,	AAGAAGTTCGGCCTC[A/C]AGTGTGAGCTCTTGG	M	A	C	K	Q
				alt. transcript 1, ?
G3633a1	WIAF-16906	HT97525	174	TIM, ?	CAGGGAGTTTGACAG[C/T]TATTAAAACCAGGGC	M	C	T	A	V
G3633a2	WIAF-16907	HT97525	310	TIM, ?	AAGTGGTGCCTTAAC[G/C]GGAGCCATACTGGCA	S	G	C	T	T
G3633a3	WIAF-16908	HT97525	350	TIM, ?	GGACCAGTGGCCATG[G/A]TTGGGTCAGCCGCAA	M	C	A	V	I
G366a5	WIAF-16774	HT2764	517	BDKRB2, bradykinin receptor	CCTGGTGAAAACCAT[G/C]TCCATGGGCCGGATG	M	G	C	M	I
				B2
G368a1	WIAF-16231	HT27686	285	FABP6, fatty acid binding	CAATGGGGGGCAAGA[C/T]GTTCAAGGCCACTGT	M	C	T	T	M
				protein 6, ileal
				(gastrotropin)
G370a10	WIAF-16808	HT27888	3106	LEPR, leptin receptor	GGCTGAGGGTACTGA[G/T]GTAACCTATGAGGCC	M	C	T	E	D
G370a11	WIAF-17113	HT27888	3217	LEPR, leptin receptor	GCTTATAAATAGTTC[A/G]GTCACCAAGTGCTTC	S	A	G	S	S
G370a12	WIAF-17114	HT27888	3338	LEPR, leptin receptor	CCCAACATAATTTCA[C/T]CACACCTCACATTCT	M	C	T	P	S
G370a7	WIAF-16766	HT27888	861	LEPR, leptin receptor	GTGGAGTAATTTTCC[A/G]GTCACCTCTAATGTC	M	A	G	Q	R
G370a8	WIAF-16806	HT27888	2833	LEPR, leptin receptor	TCCGAACCCCAAGAA[T/A]TGTTCCTGGGCACAA	M	T	A	N	K
G370a9	WIAF-16807	HT27888	2924	LEPR, leptin receptor	GTGACATGTGGTCCT[C/T]TTCTTTTGGAGCCTG	M	C	T	L	F
G371a3	WIAF-16206	HT27943	167	CRAT, carnitine	GCGCTGCAGCCCATC[G/C]TGAGTGAGGAGGAGT	M	G	C	V	L
				acetyltransferase
G371a4	WIAF-16207	HT27943	1126	CRAT, carnitine	GGTGCCCCTGCCCAT[A/C]CCCAAGAAGCTGCGG	M	A	C	M	I
				acetyltransferase
G371a5	WIAF-16227	HT27943	1922	CRAT, carnitine	AGCCAAGCCCACCCT[G/A]GGATGGGCCACCCAC	—	C	A
				acetyltransferase
G372a2	WIAF-16218	HT28247	231	HADHA, hydroxyacyl-Coenzyme	ACTGAGTAAAGAGCT[A/G]CATTCAGAGTTCTCA	S	A	G	L	L
				A dehydrogenase/3-ketoacyl-
				Coenzyme A thiolase/enoyl-
				Coenzyme A hydratase
				(trifunctional protein),
				alpha subunit
G373a1	WIAF-16344	HT28397	597	thrombospondin 3, ?	GAAAATTATTCTGGG[T/G]GGGTCCATGGCCCGG	S T	G	G	G
G373a2	WIAF-16345	HT28397	800	thrombospondin 3, ?	AAATGTCCCTGATCC[G/C]AAACACCATTATGGA	M	G	C	R	P
G374a10	WIAF-16240	HT28496	3491	FASN, fatty acid synthase	TGCCGGACTGGACGG[G/T]GCCCAGATCCCCCCG	M	G	T	G	V
G37a11	WIAF-16241	HT28496	3261	FASN, fatty acid synthase	GAGGGTCACAGTGGC[G/C]GGAGGCGTCCACATC	S	G	C	A	A
G374a12	WIAF-16242	HT28496	5065	FASN, fatty acid synthase	CTCAGTCTGGGCTGC[C/T]GCGTCTTCACCACCG	M	C	T	R	C
G374a13	WIAF-16243	HT28496	5066	FASN, fatty acid synthase	TCAGTCTGGGCTGCC[G/A]CGTCTTCACCACCGT	M	G	A	R	H
G374a14	WIAF-16244	HT28496	5253	FASN, fatty acid synthase	GAAGCTGCAGGCCAG[C/T]GTGAGGTGCTTCGGT	S	C	T	S	S
G374a15	WIAF-16245	HT28496	5321	FASN, fatty acid synthese	TTTCTCAGAACCACC[C/T]GCTCGGCATGGCTAT	M	C	T	P	L
G374e16	WIAF-16507	HT28496	1238	FASN, fatty acid synthase	AGTCCGCCCCCGCAC[C/T]CGCCCCCACATGCCAC	M	C	T	P	L
G374a17	WIAF-16508	HT28496	1242	FASN, fatty acid synthase	CGCCCCCGCACCCGC[C/T]CCACATGCCACCCTG	S	C	T	A	A
G374a18	WIAF-16509	HT28496	1244	FASN, fatty acid synthase	CCCCCGCACCCCGCCC[C/T]ACATGCCACCCTGCC	M	C	T	P	L
G374a7	WIAF-16212	HT28496	3735	FASN, fatty acid synthase	GGTGGAGGTGCTGGC[C/T]GGCCACGGTCACCTG	S	C	T	A	A
G374a8	WIAF-16213	HT28496	6656	FASN, fatty acid synthase	TGCGCTCCCTGCTGG[T/G]GAAACCGGAGGGCCC	M	T	G	V	G
G374a9	WIAF-16239	HT28496	3429	FASN, fatty acid synthase	GTGCAAGGGGCTGGT[G/A]GAGGCACTCGAGACC	S	G	A	V	V
G377a3	WIAF-16286	HT2996	179	PCCB, propionyl Coenzyme A	GCCACCTCTGTTAAC[G/A]AACGCATCGAAAACA	M	G	A	E	K
				carboxylase, beta polypeptide
G377a4	WIAF-16287	HT2996	242	PCCB, propionyl Coenzyme A	CGCCGTATTGACGCG[C/T]AGCACAAGCGACGAA	N	C	T	Q	*
				carboxylase, beta polypeptide
G377a5	WIAF-16288	HT2996	442	PCCB, propionyl Coenzyme A	TTATGTCTTCAGTCA[G/A]GATTTTACAGTTTTT	S	G	A	Q	Q
				carboxylase, beta polypeptide
G377a6	WIAF-16337	HT2996	666	PCCB, propionyl Coenzyme A	CTCTGATCATGGGCC[C/T]ATGTGCTGGTGGGGC	M	C	T	P	L
				carboxylase, beta polypeptide
G377a7	WIAF-16338	HT2996	673	PCCB, propionyl Coenzyme A	CATGGGCCCATGTGC[T/C]GGTGGGGCCGTCTAC	S	T	C	A	A
				carboxylase, beta polypeptide
G378a1	WIAF-16863	HT3146	172	elastin, alt. transcript 5,	GCCCTTGGAGGAGGA[G/T]CGCTGGGGCCTGGAC	M	G	T	A	S
				?
G378a2	WIAF-16864	HT3146	1201	elastin, alt. transcript 5,	GGCATTCCTACTTAC[G/T]GGGTTGGAGCTGGGG	M	G	T	G	W
				?
G378a3	WIAF-16865	HT3146	1066	elastin, alt. transcript 5,	GGAGCTGGGATTCCA[G/T]TTGTCCCAGGTGCTG	M	G	T	V	F
				?
G385a3	WIAF-16285	HT3383	365	PRCP, prolylcarboxypeptidase	GGATGTGGCTGAGGA[A/C]CTGAAAGCTATGTTG	M	A	C	E	D
				(angiotensinase C)
G385a4	WIAF-16336	HT3383	652	PRCP, prolylcarboxypeptidase	CTGCCCCTATCTGGC[A/C]GTTTGAGGATTTAGT	M	A	C	Q	P
				(angiotensinase C)
G387a3	WIAF-16292	HT3439	483	SREBF2, sterol regulatory	TCCCACCTCAGTTCC[C/A]ACCACACCCAGGGCA	S	C	A	P	P
				element binding transcription
				factor 2
G387a4	WIAF-16293	HT3439	1229	SREBF2, sterol regulatory	AGTCTGGCGTTCTGA[G/A]GAAGGCCATTGATTA	M	G	A	R	K
				element binding transcription
				factor 2
G387a5	WIAF-16294	HT3439	1984	SREBF2, sterol regulatory	AGCCTCTCCTGGAAC[G/A]TGATCCGCTACAGCC	M	G A	V	M
				element binding transcription
				factor 2
G387a6	WIAF-16341	HT3439	816	SREBF2, sterol regulatory	GCAGACAGTTGCTGC[G/A]CCACAGGTGCAGCAG	S	G	A	A	A
				element binding transcription
				factor 2
G387a7	WIAF-16342	HT3439	3627	SREBF2, sterol regulatory	TGAGAGTGGTGGGGA[A/G]GAGCCTTGTCTTCTT	—	A	G
				element binding transcription
				factor 2
G388a2	WIAF-16772	HT3440	1072	SELPLG, selectin P ligand	TCCGCCTCTCCCGCA[A/G]GGGCCACATGTACCC	M	A	G	K	R
G395a11	WIAF-15508	HT4158	604	ECE1, endothelin converting	GTTGATTGAGAGGCT[C/G]GGGGGCTGGAACATC	S	C	G	L	L
				enzyme 1
G395a12	WIAF-15509	HT4158	611	ECE1, endothelin converting	GAGAGGCTCGGGGGC[T/G]GGAACATCACAGGTC	M	T	G	W	G
				enzyme 1
G395a13	WIAF-15510	HT4158	809	ECE1, endothelin converting	AACAAAACTGAAAAC[G/A]AGAAGGTGCTGACCG	M	G	A	E	K
				enzyme 1
G395a4	WIAF-14351	U10686.0	2765	ECE1, endothelin converting	GCCCAAGAGGCTCCT[T/C]ACCCAAAATTGGGTG	—	T	C
				enzyme 1
G395a5	WIAF-14352	U10686.0	3212	ECE1, endothelin converting	TTTGTTTTTGTTTCC[C/T]TTTGGTAATTTTCAA	—	C	T
				enzyme 1
G3967a2	WIAF-16044	HT2958	1156	ACTC, actin, alpha, cardiac	TTCTCTCTCCATCTA[C/T]CTTCCAGTCAGGATG	—	C	T
				muscle
G396a1	WIAF-16327	HT4215	648	PLTP, phospholipid transfer	GCAGATCTGCCCTGT[C/T]CTCTACCACGCAGGG	S	C	T	V	V
				protein
G396a2	WIAF-16328	HT4215	694	PLTP, phospholipid transfer	TCCCTCCTGGACACC[G/A]TGCCTGTGCGCAGTT	M	G	A	V	M
				protein
G398a1	WIAF-15718	HT4554	679	BDKRB1, bradykinin receptor	TTCTTCAACTACCAC[A/T]TCCTGGCCTCCCTGC	M	A	T	I	F
				B1
G398a2	WIAF-16775	HT4554	202	BDKRB1, bradykinin receptor	GTCTTCCTCCTGCCC[C/A]GGCGGCAACTGAACG	S	C	A	R	R
				B1
G398a3	WIAF-16776	HT4554	338	BDKRB1, bradykinin receptor	GAGCCCTCCTCTGCC[G/A]TGTCATCAACGGGGT	M	G	A	R	H
				B1
G398a4	WIAF-16777	HT4554	129	BDKRB1, bradykinin receptor	GCACAGAGTGCTGCC[G/A]ACATTTATCATCTCC	S	G	A	P	P
				B1
G398a5	WIAF-16830	HT4554	705	BDKRB1, bradykinin receptor	CCTGCGAACGCGGGA[G/A]GAGGTCAGCAGGACA	S	G	A	E	E
				B1
G398a6	WIAF-16831	HT4554	755	BDKRB1, bradykinin receptor	ATAGCAAGACCACAG[C/T]GCTGATCCTCACGCT	M	C	T	A	V
				B1
G3995a1	WIAF-16053	HT27842	348	CNN1, calponin 1, basic,	GGAGAACATCGGCAA[C/T]TTCATCAAGGCCATC	S	C	T	N	N
				smooth muscle
G3995a2	WIAF-16054	HT27842	431	CNN1, calponin 1, basic,	AGAACACCAACCATA[C/T]ACAGGTGCAGTCCAC	M	C	T	T	I
				smooth muscle
G3995a3	WIAF-16055	HT27842	900	CNN1, calponin 1, basic,	CCCCAAGTACTGTCT[G/T]ACTCCCGAGTACCCA	S	G	T	L	L
				smooth muscle
G3995a4	WIAF-16056	HT27842	1067	CNN1, calponin 1, basic,	CCCTCTCCCTGCATG[G/A]CATCCTCCAGCCCCT	—	G	A
				smooth muscle
G400a1	WIAF-16515	HT48833	1047	GCDH, glutaryl-Coenzyme A	TCAGAAGAAGCTGGC[A/G]GACATGCTCACTGAG	S	A	G	A	A
				dehydrogenase
G400a2	WIAF-16516	HT48833	1209	GCDH, glutaryl-Coenzyme A	AGACATGCTGGGGGG[G/T]AATGGGATTTCTGAC	S	G	T	G	G
				dehydrogenase
G4137a1	WIAF-16090	HT28074	579	smoothelin, ?	CGGCCAGGGGAGGGG[C/T]GCGGCAACACAGCCA	S	C	T	G	G
G4137a2	WIAF-16091	HT28074	335	smoothelin, ?	CTGCAGCAGTGGAAG[C/T]GGCCAATGGGGCTGA	M	C	T	A	V
G4170a6	WIAF-16717	HT5069	334	Golgi protein, peripheral	CAACAAACTTGGTTG[G/T]CATGGACAAAGCCCT	M	G	T	G	V
				brefeldin A-sensitive, ?
G4170a7	WIAF-16718	HT5069	335	Golgi protein, peripheral	AACAAACTTGGTTGG[C/T]ATGGACAAAGCCCTC	S	C	T	G	G
				brefeldin A-sensitive, ?
G4176a10	WIAF-16720	HT33754	450	TNR, tenascin R (restrictin,	CAACTTCCCCAAAAA[G/A]GCCTGTCCATGTGCC	S	G	A	K	K
				janusin)
G4176a11	WIAF-16721	HT33754	1345	TNR, tenascin R (restrictin,	ACTCCTCAAGGGCTA[C/T]AATTTAAGACGATCA	N	C	T	Q	*
				janusin)
G4176a12	WIAF-16722	HT33754	2042	TNR, tenascin R (restrictin,	CCAGGGCCACCCTGA[C/T]AGATCTGGTACCTGG	M	C	T	T	I
				janusin)
G4176a13	WIAF-16723	HT33754	3783	TNR, tenascin R (restrictin,	CATGCGGGATGGCCA[G/A]GAGGCCGCCTTCGCC	S	G	A	Q	Q
				janusin)
G4176a9	WIAF-16719	HT33754	170	TNR, tenascin R (restrictin,	TGATCAAGCCTTCAG[A/G]GTGTCAGCTGGAGGT	M	A	G	E	G
				janusin)
G4178a3	WIAF-16724	HT0224	1229	ACTN2, actinin, alpha 2	GCTGCAGACCAAGCT[G/C]CGGATCAGCAACCGT	S	G	C	L	L
G4179a1	WIAF-16725	HT0063	1755	erythroid membrane protein	AGGCAAGCTAGTGCT[C/A]TAATTGACAGGCCTG	M	C	A	L	I
				4.1, ?
G4179a2	WIAF-16726	HT0063	2723	erythroid membrane protein	CGTCCACCAGGAGAC[C/T]GAGATTGCTGATGAG	S	C	T	T	T
				4.1, ?
G4181a10	WIAF-16731	HT2008	3790	SPTBN1, spectrin beta, non-	CAAGATGTGGGAGAA[C/T]AGACAAAATCTCCTA	S	C	T	N	N
				erythrocytic 1
G4181a11	WIAF-16732	HT2008	3755	SPTBN1, spectrin beta, non-	CTGCAGGCCCTGGAC[A/T]CTGGATGGAACGAGC	M	A	T	T	S
				erythrocytic 1
G4181a12	WIAF-16733	HT2008	7336	SPTBN1, spectrin beta, non-	CAGCGAGTCCAGTCC[C/G]GGCAAGCGGGAAAAG	S	C	G	P	P
				erythrocytic 1
G4181a13	WIAF-16734	HT2008	7381	SPTBN1, spectrin beta, non-	CAAAGAGAAGCGGTT[C/T]AGCCTTTTTGGCAAA	S	C	T	F	F
				erythrocytic 1
G4181a14	WIAF-16940	HT2008	922	SPTBN1, spectrin beta, non-	CACTAGCTGGAGGGA[C/T]GGCATGGCCTTCAAT	S	C	T	D	D
				erythrocytic 1
G4181a15	WIAF-16941	HT2008	1640	SPTBN1, spectrin beta, non-	AGCGAAAACCAGCGT[C/G]TGGTGTCTCAGGACA	M	C	G	L	V
				erythrocytic 1
G4181a6	WIAF-16727	HT2008	2053	SPTBN1, spectrin beta, non-	CATTGGCATCCAGGC[A/T]GAGCGGGTGAGAGGT	S	A	T	A	A
				erythrocytic 1
G4181a7	WIAF-16728	HT2008	2933	SPTBN1, spectrin beta, non-	CAGTGGCTCAACAAC[A/T]TGCAGATCCCAGAGA	M	A	T	M	L
				erythrocytic 1
G4181a8	WIAF-16729	HT2008	3064	SPTBN1, spectrin beta, non-	CCAGCTGATGCACAG[C/T]GGCCACCCAAGTGAG	S	C	T	S	S
				erythrocytic 1
G4181a9	WIAF-16730	HT2008	3664	SPTBN1, spectrin beta, non-	CTACGAGGAGGACTA[C/T]CAGAAGATGAGGGAC	S	C	T	Y	Y
				erythrocytic 1
G4185a4	WIAF-16735	HT3451	226	MFAP1, microfibrillar-	GGAAAAAGTGAAGGT[A/C]AAGCGTTATGTGTCC	S	A	C	V	V
				associated protein 1
G4185a5	WIAF-16736	HT3451	227	MFAP1, microfibrillar-	GAAAAAGTGAAGGTA[A/C]AGCGTTATGTGTCCG	M	A	C	K	Q
				associated protein 1
G4185a6	WIAF-16939	HT3451	830	MFAP1, microfibrillar-	GCTGAGGAAAGGCGC[A/T]AGTACACACTCCAGA	N	A	T	Q	*
				associated protein 1
G4208a5	WIAF-16738	HT1122	995	VCL, vinculin	TGAACTCTGTGCAGG[C/A]AAAGAACGCAGGGAG	S	C	A	G	G
G4208a6	WIAF-16739	HT1122	1457	VCL, vinculan	ACAGGTGGCCACGGC[C/T]CTGCAGAACCTGCAG	S	C	T	A	A
G4208a7	WIAF-16740	HT1122	2315	VCL, vinculin	TGCTGGGGCAACCAG[T/G]ATTGCTCGTCGGGCC	M	T	G	S	R
G4213a10	WIAF-16744	HT2813	1890	NUP153, nucleoporin 153 kD	TGCTGCTCAGCCCAC[C/T]GCAACAAGCCCAGTA	S	C	T	T	T
G4213a11	WIAF-16745	HT2813	3279	NUP153, nucleoporin 153 kD	GCCTGCCTCTCTGCC[A/C]TCTGCCTCAGTGTTT	S	A	C	P	P
G4213a7	WIAF-16741	HT2813	1045	NUP153, nucleoporin 153 kD	GGGATAGATATCACA[G/C]ATTTTCAGGCCAAAA	M	G	C	D	H
G4213a8	WIAF-16742	HT2813	1053	NUP153, nucleoporin 153 kD	TATCACAGATTTTCA[G/C]GCCAAAACAGAAAAG	M	G	C	Q	H
G4213a9	WIAF-16743	HT2813	1827	NUP153, nucleoporin 153 kD	AGAAGGAAGTGTTCT[A/T]GATATTCTGAAAAGC	S	A	T	L	L
G4243a5	WIAF-16746	HT2901	153	KRT17, keratin 17	CCCGCACCTCCTGCC[G/A]GCTGTCTGGCGGCCT	M	G	A	R	Q
G4243a6	WIAF-16747	HT2901	205	KRT17, keratin 17	GGGATCTGCTGGCGG[C/A]CTGGGCAGCACCCTC	S	C	A	G	G
G4246a3	WIAF-16748	HT97492	265	SLN, sarcolipin	TCCTATCAGTACTGA[G/C]AGGCCATGCCATGGT	—	G	C
G4254a3	WIAF-16749	HT3393	449	TNNI2, troponin I, skeletal,	CCTGAGGGCCAACCT[G/A]AAGCAGGTCAAGAAG	S	G	A	L	L
				fast
G4264a10	WIAF-16756	HT0968	5137	TJP1, tight junction protein	CTTCTCAGAATCAAT[T/C]CAGTGAACATGACAA	M	T	C	F	S
				1 (zona occludens 1)
G4264a11	WIAF-16757	HT0968	5138	TJP1, tight junction protein	TTCTCAGAATCAATT[C/A]AGTGAACATGACAAA	M	C	A	F	L
				1 (zona occludens 1)
G4254a12	WIAF-16758	HT0968	5140	TJP1, tight junction protein	CTCAGAATCAATTCA[G/A]TGAACATGACAAAAC	M	G	A	S	N
				1 (zona occludens 1)
G4254a4	WIAF-16750	HT0968	1600	TJP1, tight junction protein	ATGATGAGGAAATAC[A/T]TGATCCAAGAAGTGG	M	A	T	H	L
				1 (zona occludens 1)
G4264a5	WIAF-16751	HT0968	2158	TJP1, tight junction protein	AGCGGTCAGAGCCTT[C/T]TGATCATTCCAGGCA	M	C	T	S	F
				1 (zona occludens 1)
G4264a6	WIAF-16752	HT0968	2276	TJP1, tight junction protein	GCATGCTGATGATCA[C/T]ACACCTAAAACAGTG	S	C	T	H	H
				1 (zona occludens 1)
G4264a7	WIAF-16753	HT0968	2456	TJP1, tight junction protein	TCTTCGGCCCAGCAT[G/A]AAATTGGTAAAATTC	M	G	A	M	I
				1 (zona occludens 1)
G4264a8	WIAF-16754	HT0968	3558	TJP1, tight junction protein	GCGCTGAAAGAAGCA[G/A]TTCAACAACAGCAAA	M	G	A	V	I
				1 (zona occludens 1)
G4264a9	WTAF-16755	HT0968	3593	TJP1, tight junction protein	GCTGGTATGGGTTTC[C/T]GAGGGAAAGGCGGAT	S	C	T	S	S
				1 (zona occludens 1)
G435a3	WIAF-16646	M63121	242	TNFRSF1A, tumor necrosis	TGACCTGCTGCTGCC[A/G]CTGGTGCTCCTGGAG	S	A	G	P	P
				factor receptor superfamily,
				member 1A
G4403a1	WIAF-16042	HT1468	1196	ACAA, acetyl-Coenzyme A	CTGGGGCACGACAGG[T/C]CATCACGCTGCTCAA	M	T	C	V	A
				acyl transferase (peroxisomal
				3-oxoacyl-Coenzyme A
				thiolase)
G4403a2	WIAF-16043	HT1468	1287	ACAA, acetyl-Coenzyme A	AATGGGAGCCGCTGC[C/T]GTCTTTGAATACCCT	S	C	T	A	A
				acyltransferase (peroxisomal
				3-oxoacyl-Coenzyme A
				thiolase)
G4508a10	WIAF-16059	HT28557	791	ARSD, arylsulfatase D	GCCGGCGTGGGCTGC[C/T]TGTTTTTCATCTCTT	S	C	T	L	L
G4508a11	WIAF-16060	HT28557	1573	ARSD, arylsulfatase D	GCTAACGGCCGAGGC[G/A]TCTGCCCATGCTGAA	S	G	A	A	A
G4508a9	WIAF-16058	HT28557	293	ARSD, arylsulfatase D	AATATTGACCAGCTT[G/A]CAGAGGAAGGTGTGA	M	G	A	A	T
G452a4	WIAF-14353	J02758.0	2355	APOA4, apolipoprotein A-IV	AGAAGTGAACACTTA[C/T]GCAGGTGACCTGCAG	S	C	T	Y	Y
G452a5	WIAF-14354	J02758.0	3238	APOA4, apolipoprotein A-IV	GAGAGCCAGGACAAG[A/T]CTCTCTCCCTCCCTG	M	A	T	T	S
G452a6	WIAF-14355	J02758.0	1449	APOA4, apolipoprotein A-IV	TGACCAGGTGGCCAC[A/G]GTGATGTGGGACTAC	S	A	G	T	T
G452a7	WIAF-14356	J02758.0	1559	APOA4, apolipoprotein A-IV	AGGGACTACAGTGTG[T/C]GGTGGTGACGGGGAA	—	T	C
G452a8	WIAF-14357	J02758.0	1560	APOA4, apolipoprotein A-IV	GGGACTACAGTGTGT[G/A]GTGGTGACGGGGAAT	—	G	A
G455a1	WIAF-15705	HT1387	1045	TFCOUP2, transcription	ATCCCCTTCTTCCCC[G/T]ACCTGCAGATCACGG	M	G	T	D	Y
				factor COUP 2 (chicken
				ovalbumin upstream promoter
				2, apolipoprotein regulatory
				protein)
G456a4	WIAF-14324	M25379.0	64	EDN1, endothelin 1	TTAAAGACTATTAAT[T/C]ACACTAATATAGTTT	—	T	C
G456a5	WIAF-16198	HT2834	359	EDN1, endothelin 1	CTGAGCTCAGCGCGG[T/G]GGGTGAGAACGGCGG	M	T	G	V	G
G456a6	WIAF-16199	HT2834	372	EDN1, endothelin 1	GGTGGGTGAGAACGG[C/G]GGGGAGAAACCCACT	S	C	G	G	G
G456a7	WIAF-16200	HT2834	378	EDN1, endothelin 1	TGAGAACGGCGGGGA[G/A]AAACCCACTCCCAGT	S	G	A	E	E
G466a2	WIAF-16290	U00968	1415	SREBF1, sterol regulatory	GTGCTCATGGAGGGC[G/A]TGAAGACTGAGGTGG	M	G	A	V	M
				element binding transcription
				factor 1
G466a3	WIAF-16291	U00968	3063	SREBF1, sterol regulatory	CCAGCAGCTCCATTG[A/G]CAAGGCCGTGCAGCT	M	A	G	D	G
				element binding transcription
				factor 1
G466a4	WIAF-16340	U00968	1832	SREBF1, sterol regulatory	CTGCTCAATGGGCTG[T/C]TGGTGCTCGTCTCCT	S	T	C	L	L
				element binding transcription
				factor 1
G4699a2	WIAF-16084	HT4277	1177	BAAT, bile acid Coenzyme A:	AGGTGATAAGACTAT[C/T]AACAGCAAAGCACAC	S	C	T	I	I
				amino acid N-acyltransferase
				(glycine N-
				choloyltransferase)
G4699a3	WIAF-16085	HT4277	1190	BAAT, bile acid Coenzyme A:	ATCAACAGCAAAGCA[C/T]ACGCTGAACAAGCCA	M	C	T	H	Y
				amino acid N-acyltransferase
				(glycine N-
				choloyltransferase
G4699a4	WIAF-16086	HT4277	1487	BAAT, bile acid Coenzyme A:	GCAAATCTCTTTACC[G/A]GGACCTTCTCTCAAT	—	G	A
				amino acid N-acyltransferase
				(glycine N-
				choloyltransferase
G4726a4	WIAF-16494	HT48614	1571	AOC3, amine oxidase, copper	TCCACCTTGCTCAAC[T/C]ATGACTATGTGTGGG	M	T	C	Y	H
				containing 3 (vascular
				adhesion protein 1)
G4726a5	WIAF-16495	HT48614	1572	AOC3, amine oxidase, copper	CCACCTTGCTCAACT[A/T]TGACTATGTGTGGGA	M	A	T	Y	F
				containing 3 (vascular
				adhesion protein 1)
G4750a2	WIAF-16089	HT48417	318	CYB5, cytochrome b-5	GAACTTTGAGGATGT[C/G]GGGCACTCTACAGAT	S	C	G	V	V
G480a2	WIAF-16394	HT336	220	GRB2, growth factor receptor	GGAAAACACGGCTTC[A/C]TTCCCAAGAACTACA	M	A	C	I	L
				bound protein 2
G480a3	WIAF-16395	HT336	235	GRB2, growth factor receptor	ATTCCCAAGAACTAC[A/C]TAGAAATGAAACCAC	M	A	C	I	L
				bound protein 2
G480a4	WIAF-16396	HT336	315	GRB2, growth factor receptor	TAGCAAACAGCGGCA[C/T]GATGGGGCCTTTCTT	S	C	T	H	H
				bound protein 2
G480a5	WIAF-16418	HT336	688	GRB2, growth factor receptor	CACGGGCAGACCGGC[A/C]TGTTTCCCCGCAATT	M	A	C	M	L
				bound protein 2
G484a3	WIAF-16415	HT5111	1461	?, ?	CTTGAGGTCCCCCAG[C/A]GGCACTACCACCCTC	M	C	A	S	R
G484a4	WIAF-16419	HT5111	858	?, ?	CGACATCAAGCCCCA[G/T]AACCTGCTGGTGGAC	M	G	T	Q	H
G489a5	WIAF-16397	HT2607	2071	IRS1, insulin receptor	CCTGTGAGTCCCAGC[A/C]CCAACAGAACCCACG	M	A	C	T	P
				substrate 1
G489a6	WIAF-16416	HT2607	4725	IRS1, insulin receptor	CAGCATCAGTTTCCA[G/A]AAGCAGCCAGAGGAC	S	G	A	Q	Q
				substrate 1
G489a7	WIAF-16420	HT2607	3432	IRS1, insulin receptor	CTATGCTGCAACAGC[A/G]GATGATTCTTCCTCT	S	A	G	A	A
				substrate 1
G489a8	WIAF-16421	HT2607	4265	IRS1, insulin receptor	TCAGTCCTAACCGCA[A/T]CCAGAGTGCCAAAGT	M	A	T	N	I
				substrate 1
G489a9	WIAF-16422	HT2607	4430	IRS1, insulin receptor	GCAGCAGCAGCGAGG[A/C]TGTGAAACGCCACAG	M	A	C	D	A
				substrate 1
G505a6	WIAF-16057	HT1113	1230	PRLR, prolactin receptor	CTGGTGGAGTATTTA[G/A]AAGTAGATGATAGTG	M	G	A	E	K
G509a2	WIAF-15515	M32313	339	SRD5A1, steroid-5-alpha-	GTGCTTAATTTACCC[G/A]TTTCTGATGCGAGGA	S	G	A	P	P
				reductase, alpha polypeptide
				1(3-oxo-5 alpha-steroid
				delta 4-dehydrogenase alpha
				1)
G5143a1	WIAF-16523	HT2428	1146	ITPR3, inositol 1,4,5-	TCTCTTTGAGCTGGA[C/T]CCCACCACCTTGCAG	S	C	T	D	D
				triphosphate receptor, type 3
G5143e10	WIAF-16532	HT2428	4383	ITPR3, inositol 1,4,5-	CACCCTGGACATGGC[T/C]CGGGTCTGCAGCAAG	S	T	C	A	A
				triphosphate receptor, type 3
G5143a11	WIAF-16533	HT2428	4779	ITPR3, inositol 1,4,5-	CCCCCGCGTCACCCC[C/T]ACCGCCAACCAGTGG	S	C	T	P	P
				triphosphate receptor, type 3
G5143a12	WIAF-16534	HT2428	5547	ITPR3, inositol 1,4,5-	CTTCTCGATACCTGG[C/T]TCCTCATCCCGCTAC	S	C	T	G	G
				triphosphate receptor, type 3
G5143a13	WIAF-16535	HT2428	7228	ITPR3, inositol 1,4,5-	GATGACTTCATTCTC[G/C]AGGTCGACCGGCTGC	M	G	C	E	Q
				triphosphate receptor, type 3
G5143a14	WIAF-16536	HT2428	7342	ITPR3, inositol 1,4,5-	GACTGTGTCTCAGGG[C/G]TCTCGGTGCCTCAGG	M	C	G	L	V
				triphosphate receptor, type 3
G5143a15	WIAF-16537	HT2428	7587	ITPR3, inositol 1,4,5-	CTTTGGGGTAATCAT[C/A]GACACCTTCGCTGAC	S	C	A	I	I
				triphosphate receptor, type 3
G5143a16	WIAF-16538	HT2428	8076	ITPR3, inositol 1,4,5-	ACCGAAGGCCCCAAC[A/G]GGGGATGCTCATCAC	—	A	G
				triphosphate receptor, type 3
G5143a17	WIAF-16539	HT2428	8114	ITPR3, inositol 1,4,5-	TGCGACTGGGAAGAA[C/T]ACTGCCCCCTCCCTC	—	C	T
				triphosphate receptor, type 3
G5143e18	WIAF-16540	HT2428	8211	ITPR3, inositol 1,4,5-	CAGGCTTTGAAGAGC[A/G]TGGAGGGGGAGCCTC	—	A	G
				triphosphate receptor, type 3
G5143a2	WIAF-16524	HT2428	1167	ITPR3, inositol 1,4,5-	CACCTTGCAGAAAAC[C/T]GACTCTTTCGTGCCC	S	C	T	T	T
				triphosphate receptor, type 3
G5143a3	WIAF-16525	HT2428	2199	ITPR3, inositol 1,4,5-	GGCCGGCAACGCCCA[C/T]GACGAGAATGTGCTC	S	C	T	H	H
				triphosphate receptor, type 3
G5143a4	WIAF-16526	HT2428	2262	ITPR3, inositol 1,4,5-	CCGCATGTGCTTGGA[C/A]CGCCAGTACTTGGCC	M	C	A	D	E
				triphosphate receptor, type 3
G5143e5	WIAF-16527	HT2428	2304	ITPR3, inositol 1,4,5-	CTCCCAGCAGCTGGG[C/T]GTGGACCTGATTTTC	S	C	T	G	G
				triphosphate receptor, type 3
G5143a6	WIAF-16528	HT2428	2544	ITPR3, inositol 1,4,5-	CAACACCATGGAGTT[C/T]GTGGAGGACTACCTC	S	C	T	F	F
				triphosphate receptor, type 3
G5143a7	WIAF-16529	HT2428	2976	ITPR3, inositol 1,4,5-	TCAGTTCATCCTCAA[C/T]GTCCGCCTGGATTAC	S	C	T	N	N
				triphosphate receptor, type 3
G5143a8	WIAF-16530	HT2428	3091	ITPR3, inositol 1,4,5-	CCTGCCTTCGACTCT[A/T]CCACTGCCAACATGA	M	A	T	T	S
				triphosphate receptor, type 3
G5143a9	WIAF-16531	HT2428	3243	ITPR3, inositol 1,4,5-	GCACGACTATGCGCC[A/G]CTGGTCTCGGGTGCC	S	A	G	P	P
				triphosphate receptor, type 3
G523a3	WIAF-16398	HT4996	442	OXTR, oxytocin receptor	GCCGGGGGCCGAGGG[C/T]AACCGCACCGCCGGA	S	C	T	G	G
G523a4	WIAF-16399	HT4996	467	OXTR, oxytocin receptor	GCCGGACCCCCGCGG[C/T]GCAACGAGGCCCTGG	M	C	T	R	C
G523a5	WIAF-16400	HT4996	408	OXTR, oxytocin receptor	GGAGCGCCGAGGCAG[C/T]CAACGCCAGCGCCGC	M	C	T	A	V
G5282a1	WIAF-16541	HT97393	1781	MEKK3, MAP/ERK kinase kinase 3	GACAGAGAAACCACC[G/A]TGGGCAGAGTATGAA	S	G	A	P	P
G535a3	WIAF-16401	HT5001	366	?, ?	GGGTGCTAAGGGGGC[G/T]ACAAGGAGGAGAAAG	S	G	T	A	A
G535a4	WIAF-16402	HT5001	374	?, ?	AGGGGGCGACAAGGA[G/C]GAGAAAGCCCTGTAG	M	G	C	R	T
G535a5	WIAF-16423	HT5001	1457	?, ?	TGCCCATCATCTCTG[C/T]GGGCAGCGAACTGTG	M	C	T	A	V
G539a3	WIAF-16403	K03195	1145	Human (HepG2) glucose	CACGGCCTTCACTGT[C/T]GTGTCGCTGTTTGTG	S	C	T	V	V
				transporter gene mRNA,
				complete cds., ?
G539a4	WIAF-16404	K03195	1190	Human (HepG2) glucose	CCGGCGGACCCTGCA[C/T]CTCATAGGCCTCGCT	S	C	T	H	H
				transporter gene mRNA,
				complete cds., ?
G539a5	WIAF-16424	K03195	767	Human (HepG2) glucose	CATCATCTTCATCCC[G/A]GCCCTGCTGCAGTGC	S	G	A	P	P
				transporter gene mRNA,
				complete cds., ?
G539a6	WIAF-16425	K03195	1680	Human (HepG2) glucose	CCAGATCACCAGCCC[G/A]GCCTGCTCCCAGCAG	—	G	A
				transporter gene mRNA,
				complete cds., ?
G539a7	WIAF-16426	K03195	1718	Human (HepG2) glucose	GATCTCTCAGGAGCA[C/T]AGGCAGCTGGATGAG	—	C	T
				transporter gene mRNA,
				complete cds., ?
G5448a1	WIAF-16548	HT2004	1135	PLCB2, phospholipase C, beta 2	ATCATTACTTCATCA[A/T]CTCGTCCCACAACAC	M	A	T	N	I
G5448a2	WIAF-16549	HT2004	1163	PLCB2, phospholipase C, beta 2	CACCTACCTGACAGC[C/T]GGCCAGTTCTCAGGC	S	C	T	A	A
G5448a3	WIAF-16550	HT2004	1346	PLCB2, phospholipase C, beta 2	GGCTATTGCAGAAAG[T/C]GCCTTTAAGACCTCC	S	T	C	S	S
G5448a4	WIAF-16551	HT2004	1595	PLCB2, phospholipase C, beta 2	CTCCAGTAAGGATAC[C/T]GGTGGGGAGGCTGAG	S	C	T	T	T
G5448a5	WIAF-16552	HT2004	2286	PLCB2, phospholipase C, beta 2	CTGTTTGGCCTTCCT[G/A]GGGACCCCAAGAGGC	M	G	A	G	R
G5448a6	WIAF-16553	HT2004	3436	PLCB2, phospholipase C, beta 2	TGACGGAGAACTTGG[A/G]GAGGCACCAGGAGAA	M	A	G	E	G
G5448a7	WIAF-16554	HT2004	3482	PLCB2, phospholipase C, beta 2	GGCGGCTTGCCTGGA[A/G]CAGATACGGGAGATG	S	A	G	E	E
G549a1	WIAF-16405	HT704	359	LTB, lymphotoxin beta (TNF	TCTGACCAGCGGGAC[G/T]CAGTTCTCGGACGCC	S	G	T	T	T
				superfamily, member 3)
G549a2	WIAF-16406	HT704	373	LTB, lymphotoxin beta (TNF	CGCAGTTCTCGGACG[C/A]CGAGGGGCTGGCGCT	M	C	A	A	D
				superfamily, member 3)
G549a3	WIAF-16407	HT704	490	LTB, lymphotoxin beta (TNF	CCGTCACGCTGCGCA[G/C]CTCTCTGTACCGGGC	M	G	C	S T
				superfamily, member 3)
G551a6	WIAF-16642	HT1118	783	TNFRSF1B, tumor necrosis	ACGCAGCCAACTCCA[G/A]AACCCAGCACTGCTC	M	G	A	E	K
				factor receptor superfamily,
				member 1B
G551a7	WIAF-16643	HT1118	880	TNFRSF1B, tumor necrosis	CTCTTCCAGTTGGAC[T/C]GATTGTGGGTGTGAC	M	T	C	L	P
				factor receptor superfamily,
				member 1B
G556a5	WIAF-15727	AF001787	471	UCP2, uncoupling protein 2	CGCCTCCATCCGCAT[C/T]GGCCTCTATGACTCC	S	C	T	I	I
				(mitochondrial proton
				carrier)
G556a7	WIAF-15728	AF001787	487	UCP2, uncoupling protein 2	GGCCTCTATGACTCC[G/A]TCAAGCAGGTGTACA	M	G	A	V	I
				(mitochondrial proton
				carrier)
G556a8	WIAF-15729	AF001787	555	UCP2, uncoupling protein 2	GATTTTGGCCGGCTG[C/T]ACCACAGGAGCCATG	S	C	T	C	C
				(mitochondrial proton
				carrier)
G556a9	WIAF-15730	AF001787	211	UCP2, uncoupling protein 2	AAGCCTTCAGACGTG[C/T]CTCCCACCATGGCTG	M	C	T	P	S
				(mitochondrial proton
				carrier)
G558a2	WIAF-16408	HT27821	1240	, insulin receptor	GATAGAGAATCCGGC[G/A]GAGGCCCAGAGCGCA	S	G	A	A	A
				inhibitor, muscle
G558a3	WIAF-16427	HT27821	1666	, insulin receptor	GCACCACTGCATCCG[A/T]GTGGCCTTATGACCG	S	A	T	R	R
				inhibitor, muscle
G561a3	WIAF-16409	HT1176	168	IDE, insulin-degrading	TGGTTTCCAAAAAAA[G/A]ACTTACAGCAAAATG	S	G	A	K	K
				enzyme
G561a4	WIAF-16410	HT1176	405	IDE, insulin-degrading	ACATATGCTTTTTTT[G/T]GGAACAAAGAAATAC	M	G	T	L	F
				enzyme
G561a5	WIAF-16411	HT1176	1776	IDE, insulin-degrading	AAAGCCGAAGGCTTG[T/G]CTCAACTTTGAATTT	M	T	G	C	W
				enzyme
G561a6	WIAF-16412	HT1176	1891	IDE, insulin-degrading	TATGCATATGCAGCA[G/A]AGCTAGCAGGCTTGA	M	G	A	E	K
				enzyme
G561a7	WIAF-16413	HT1176	1956	IDE, insulin-degrading	TCTTTCAGTGAAAGG[T/G]TACAATGACAAGCAG	S	T	G	G	G
				enzyme
G561a8	WIAF-16428	HT1176	494	IDE, insulin-degrading	TTACTAGTGGAGAGC[A/G]TACCAATTACTATTT	M	A	G	H	R
				enzyme
G561a9	WIAF-17099	HT1176	3080	IDE, insulin-degrading	CACTGTTTCCCCTTG[T/A]GAAACCACATATTAA	M	T	A	V	E
				enzyme
G5623a1	WIAF-16620	HT0887	406	RPS6KA1, ribosomal protein	CCTGGCTGATGTAAA[T/G]CACCCATTCGTGGTG	M	T	G	N	K
				S6 kinase, 90 kD, polypeptide 1
G5623a2	WIAF-16621	HT0887	1444	RPS6KA1, ribosomal protein	GATTCTTCTGCGGTA[T/C]GGCCAGCACCCCAAC	S	T	C	Y	Y
				S6 kinase, 90 kD, polypeptide 1
G5623a3	WIAF-16622	HT0887	1050	RPS6KA1, ribosomal protein	ACCGTCGTGAGATCA[C/A]GCCACCCTTCAAGCC	M	C	A	T	K
				S6 kinase, 90 kD, polypeptide 1
G5623a4	WIAF-16623	HT0887	2182	RPS6KA1, ribosomal protein	CTCCAAGCCCACCCC[C/G]CAGCTGAAGCCCATC	S	C	G	P	P
				S6 kinase, 90 kD, polypeptide 1
G5623a5	WIAF-16624	HT0887	2270	RPS6KA1, ribosomal protein	GGCACCAGGGCATTC[G/A]GGCCACAGGGCGGTG	—	G	A
				S6 kinase, 90 kD, polypeptide 1
G5623a6	WIAF-16625	HT0887	2297	RPS6KA1, ribosomal protein	GGTGCTAGCTTGACA[C/G]AGTCAGATGCTTCCA	—	C	G
				S6 kinase, 90 kD, polypeptide 1
G5623a7	WIAF-16626	HT0887	2326	RPS6KA1, ribosomal protein	CAGAGGGAGCAGGCC[G/A]GAACCACAGGGCCAG	—	G	A
				S6 kinase, 90 kD, polypeptide 1
G5709a1	WIAF-16563	HT3730	2055	SMPD1, sphingomyelin	TTGATGTAGGAAAGG[G/A]TGAAAAAGCCCAAAT	—	G	A
				phosphodiesterase 1, acid
				lysosomal (acid
				sphingoayelinase)
G5709a2	WIAF-16564	HT3730	2084	SMPD1, sphingomyelin	ATGCTGCTGTGGTTC[A/C]ACCAGGCAAGATCAT	—	A	C
				phosphodiesterase 1, acid
				lysosomal (acid
				sphingomyelinase)
G5709a3	WIAF-16796	HT3730	1636	SMPD1, sphingomyelin	GATGGAAACTACTCC[G/A]GGAGCTCTCACGTGG	M	G	A	G	R
				phosphodiesterase 1, acid
				lysosomal (acid
				sphingomyelinase)
G5709a4	WIAF-17060	HT3730	227	SMPD1, sphingomyelin	TTTGGATGGGCCTGG[C/T]GCTGGCGCTGGCGCT	M	C	T	A	V
				phosphodiesterase 1, acid
				lysosomal (acid
				sphingomyelinase)
G573a4	WIAF-17100	HT28094	765	SSTR1, somatostatin receptor 1	GCGCATGGTGGCCCT[C/T]AAGGCCGGCTGGCAG	S	C	T	L	L
G575a3	WIAF-16414	HT28095	95	SSTR3, somatostatin receptor 3	CCCTGGGCAACGTGT[C/T]GGCGGGCCCAAGCCC	M	C	T	S	L
G575a4	WIAF-16417	HT28095	1068	SSTR3, somatostatin receptor 3	GGATGAGGAGGAGGA[G/C]GATGGGGAGGAGAGC	M	G	C	E	D
G593a1	WIAF-15625	HT385	1226	BRS3, bombesin-like receptor 3	GCCTCCTGTTGCTGA[C/T]ACCTCTCTCTTACCACC	S	C	T	D	D
G593a2	WIAF-15626	HT385	1299	BRS3, bombesin-like receptor 3	ATGTCTGAAATTAGT[G/T]TGACCTCGTTCACTG	M	G	T	V	L
G594a6	WIAF-16203	HT3921	783	annexin V, alt. transcript 2, ?	CTTCAAGGACACCTG[A/T]AGAACTGAGAGCCAT	M	A	T	E	V
G595a12	WIAF-15622	HT27983	3390	NRIP1, nuclear receptor	TTGAATGGGTGTTCC[A/T]TGCCCAGTGAGAAG	M	A	T	M	L
				interacting protein 1
G595a13	WIAF-15783	HT27983	1939	NRIP1, nuclear receptor	ATCGGACTACTCCAG[T/G]GAGCACTCCACCTTT	M	T	G	V	G
				interacting protein 1
G595a14	WIAF-15786	HT27983	985	NRIP1, nuclear receptor	AGGTCATGAGTGAAC[C/T]GTTGTCATGTGCTGC	M	C	T	P	L
				interacting protein 1
G612a3	WIAF-16351	HT1436	2159	RAF1, v-raf-1 murine	CCCTTTCTCCAGAGG[C/T]AGAACACATGTTTTC	—	C	T
				leukemia viral oncogene
				homolog 1
G616a6	WIAF-15623	HT48746	1231	, TRAF-interacting protein	CCTCACTCGATTCCC[C/T]GGGAAAAGCAATCCG	M	C	T	P	L
				(I-TRAF)
G645a4	WIAF-15787	HT5191	1073	retinoic acid-binding protein	AGTGAAAAATCACGA[A/T]TAATGCAGGATCAAA	M	A	T	I	L
				II, ?
G645a5	WIAF-15788	HT5191	1143	retinoic acid-binding protein	TTCAGGAGAGATGC[A/T]TGAAGCGGATGCCAC	M	A	T	H	L
				II, ?
G645a6	WIAF-15831	HT5191	2322	retinoic acid-binding protein	AGCGGCTCTTCAACC[T/C]TCTGAAGACCGGCCA	M	T	C	L	P
				II, ?
G645a7	WIAF-15832	HT5191	2378	retinoic acid-binding protein	AGCGAGGAGATGTAC[C/T]GCCTGATGCTGCAAT	M	C	T	R	C
				II, ?
G646a11	WIAF-15789	X81479	358	EMR1, egf-like module	GGAGGTACAAGTGCA[G/T]CTGTTTAGATGGTTT	M	G	T	S	I
				containing, mucin-like,
				hormone receptor-like
				sequence 1
G646a12	WIAF-15790	X81479	416	EMR1, egf-like module	CCCAGGAAAGCCGGG[C/A]AATTTCTCCTGTACT	S	C	A	G	G
				containing,mucin-like,
				hormone receptor-like
				sequence 1
G646a13	WIAF-15791	X81479	1107	EMR1, egf-like module	CAAATAAATAACATC[T/C]TCAGCGTTCTGGACA	M	T	C	F	L
				containing, mucin-like,
				hormone receptor-like
				sequence 1
G646a14	WIAF-15792	X81479	2110	EMR1, egf-like module	AGGCTGTGATACTGT[T/G]CTTGATGGTCAGAAA	M	T	G	F	C
				containing, mucin-like,
				hormone receptor-like
				sequence 1
G646a15	WIAF-15833	X81479	662	EMR1, egf-like module	TGAATCCAGCAGTGG[C/T]CACTTGAGTTGCCAG	S	C	T	G	G
				containing, mucin-like,
				hormone receptor-like
				sequence 1
G646a16	WIAF-15834	X81479	838	EMR1, egf-like module	AAGGAGTGGAATGTA[G/T]AGATATTGATGAGTG	M	G	T	R	I
				containing, mucin-like,
				hormone receptor-like
				sequence 1
G646a17	WIAF-15835	X81479	931	EMR1, egf-like module	GCTGTGGCTGCATTG[T/C]AGGCTTTCATCCCAA	M	T	C	V	A
				containing, mucin-like,
				hormone receptor-like
				sequence 1
G647a2	WIAF-15793	HT5190	333	RARA, retinoic acid	GCCCAGCCCTCCCTC[G/A]CCACCCCCTCTACCC	S	G	A	S	S
				receptor, alpha
G647a3	WIAF-15836	HT5190	1582	RARA, retinoic acid	CGCACCAGCCCTGCC[C/G]CCACCTGCCCTCCCG	—	C	G
				receptor, alpha
G647a4	WIAF-15837	HT5190	1493	RARA, retinoic acid	CCCACTCCCCGTGAC[C/T]GCCCACGCCACATGG	—	C	T
				receptor, alpha
G650a5	WIAF-15794	X52773	281	RXRA, retinoid X receptor,	CTTTCTCGGTCATCA[G/A]CTCCCCCATGGGCCC	M	G	A	S	N
				alpha
G650a6	WIAF-15838	X52773	807	RXRA, retinoid X receptor,	GCTGGCCGTGGAGCC[C/T]AAGACCGAGACCTAC	S	C	T	P	P
				alpha
G672a1	WIAF-15795	U93237	2524	MEN1, multiple endocrine	CCTCACCTACTTTCC[C/T]GTGGCCGACCTGTCT	S	C	T	P	P
				neoplasia I
G672a2	WIAF-15796	U93237	3556	MEN1, multiple endocrine	GCTGCGATTCTACGA[C/T]GGCATCTGCAAATGG	S	C	T	D	D
				neoplasia I
G672a3	WIAF-15839	U93237	2854	MEN1, multiple endocrine	GGATCATGCCTGGGT[A/C]GTGTTTGGGCCCAAT	S	A	C	V	V
				neoplasia I
G672a4	WIAF-15840	U93237	2868	MEN1, multiple endocrine	TAGTGTTTGGGCCCA[A/T]TGGGGAGCAGACAGC	M	A	T	N	I
				neoplasia I
G672a5	WIAF-15841	U93237	3032	MEN1, multiple endocrine	ATGGTGTGTGCCATC[A/T]ACCCTTCCATTGACC	M	A	T	N	Y
				neoplasia I
G688a2	WIAF-16352	HT0639	497	CALB2, calbindin 2, (29 kD,	TACGATGAGCCCAAG[C/T]TCCAGGAATACACCC	M	C	T	L F
				calretinin)
G698a4	WIAF-15906	X61598	198	CBP1, collagen-binding	CTTCAGCCTGTATCA[G/A]GCAATGGCCAAGGAC	S	G	A	Q	Q
				protein 1
G698a5	WIAF-15907	X61598	723	CBP1, collagen-binding	GACTCGGTCCTATAC[T/C]GTGGGTGTTACGATG	S	T	C	T	T
				protein 1
G698a6	WIAF-15908	X61598	732	CBP1, collagen-binding	CTATACTGTGGGTGT[T/C]ACGATGATGCACCCG	S	T	C	V	V
				protein 1
G698a7	WIAF-15909	X61598	734	CBP1, collagen-binding	ATACTGTGGGTGTTA[C/T]GATGATGCACCGGAC	M	C	T	T	M
				protein 1
G698a8	WIAF-15910	X61598	768	CBP1, collagen-binding	CCTCTACAACTACTA[C/T]GACGACGAGAAGGAG	S	C	T	Y	Y
				protein 1
G701a3	WIAF-15842	HT27657	1329	?, ?	TGCTGGATCAGTTCT[G/A]ATACCCATCTCCTCT	M	G	A	D	N
G701a4	WIAF-15843	HT27657	1398	?, ?	AATCTTTTTTTCTTG[T/G]TAAATATTGTACGCG	M	T	G	L	V
G701a5	WIAF-15844	HT27657	1458	?, ?	CAAGCGGAATCCAAT[C/T]TGTACATGAAAGCTG	S	C	T	L	L
G702a1	WIAF-16358	HT2966	216	calcitonin-related peptide	GCTGAAGCAGGAGCA[G/A]GAGACACAGGGCTCC	S	G	A	Q	Q
				II, ?
G704a5	WIAF-15911	X60382	1576	COL10A1, collagen, type X,	CCAGGTCAAGCAGTC[A/C]TGCCTGAGGGTTTTA	M	A	C	M	L
				alpha 1 (Schmid metaphyseal
				chondrodysplasia)
G704a6	WIAF-15912	X60382	1591	COL10A1, collagen, type X,	ATGCCTGAGGGTTTT[A/C]TAAAGGCAGGCCAAA	M	A	C	I	L
				alpha 1 (Schmid metaphyseal
				chondrodysplasia)
G705a19	WIAF-16070	J04177	5561	COL11A1, collagen, type XI,	CGGATTTGAAGTTGG[T/C]CCTGTTTGTTTTCTT	S	T	C	G	G
				alpha 1
G705a20	WIAF-16953	J04177	3417	COL11A1, collagen, type XI,	GGTCCTCCTGGTCCA[G/A]CTGGAGAGAAAGGTG	M	G	A	A	T
				alpha 1
G705a21	WIAF-16954	J04177	3440	COL11A1, collagen, type XI,	GAAAGGTGCTCCTGG[A/C]GAAAAAGGTCCCCAA	S	A	G	G	G
				alpha 1
G705a22	WIAF-16955	J04177	3536	COL11A1, collagen, type XI,	CTCCCCTGGGGAAGA[C/T]GGAGACAAGGGTGAA	S	C	T	D	D
				alpha 1
G705a23	WIAF-16956	J04177	3882	COL11A1, collagen, type XI,	GATGGACCACAAGGA[C/T]CCCCAGGTTCTGTTG	M	C	T	P	S
				alpha 1
G705a24	WIAF-16957	J04177	4064	COL11A1, collagen, type XI,	GGGGCCGCCAGGTGA[T/A]GATGGCCCTAAGGGT	M	T	A	D	E
				alpha 1
G707a10	WIAF-15810	U32169	2136	COL11A2, collagen, type XI,	CTCTGGACCTCAGGG[T/A]CCTCTAGGATACCCA	S	T	A	G	G
				alpha 2
G707a11	WIAF-15811	U32169	2904	COL11A2, collagen, type XI,	AGGAACAAAGGGTGA[C/T]CCTGGTCCCCCTGGG	S	C	T	D	D
				alpha 2
G707a12	WIAF-15812	U32169	2907	COL11A2, collagen, type XI,	AACAAAGGGTGACCC[T/C]GGTCCCCCTGGGGCC	S	T	C	P	P
				alpha 2
G707a13	WIAF-15813	U32169	3129	COL11A2, collagen, type XI,	GGGTCCCCCTGGAGC[A/C]GCAGGAGAGAAAGGT	S	A	G	A	A
				alpha 2
G707a14	WIAF-15814	U32169	3174	COL11A2, collagen, type XI,	GGGCCCCATTGGCCC[A/C]ACTGGCCGAGATGGA	S	A	G	P	P
				alpha 2
G707a15	WIAF-15815	U32169	4801	COL11A2, collagen, type XI,	CGGGATGCCTTCCGA[C/A]TTTTCTGCAACTTCA	M	G	A	V	I
				alpha 2
G707a16	WIAF-15816	U32169	4884	COL11A2, collagen, type XI,	TTACGTGGACTCAGA[G/C]GGCTCCCCAGTGGGT	M	G	C	E	D
				alpha 2
G707a17	WIAF-15817	U32169	4973	COL11A2, collagen, type XI,	ACCCCTGCTCTGGAG[C/T]AGCCCGTGACGGTCC	M	C	T	A	V
				alpha 2
G707a18	WIAF-15818	U32169	4633	COL11A2, collagen, type XI,	CTGGAGGAGATCTTT[G/A]GCTCACTCGACTCCC	M	G	A	G	S
				alpha 2
G707a19	WIAF-15845	U32169	3384	COL11A2, collagen, type XI,	AGCAGATGGGGAGCC[C/T]GGAGCTCGGGGACCC	S	C	T	P	P
				alpha 2
G707a20	WIAF-15846	U32169	4218	COL11A2, collagen, type XI,	GGGCGATGCTGGAGC[C/T]AAGGGAGAGAAGGGC	S	C	T	A	A
				alpha 2
G707a21	WIAF-15847	U32169	4326	COL11A2, collagen, type XI,	GGGCTCCCCTGGGCA[G/A]AAGGGTGAGATGGGT	S	G	A	Q	Q
				alpha 2
G707a22	WIAF-15848	U32169	4351	COL11A2, collagen, type XI,	ATGGGTATCCCAGGA[G/C]CATCCGGCCCCATTG	M	G	C	A	P
				alpha 2
G707a23	WIAF-15849	U32169	5165	COL11A2, collagen, type XI,	ACCTGGGAGCCCCAC[C/T]GAGGCGGGGAGGGGT	M	C	T	P	L
				alpha 2
G707a24	WIAF-15850	U32169	5191	COL11A2, collagen, type XI,	GGGGTGCTGCTGGGG[C/T]CTGTCTGCTTCATGG	M	C	T	P	S
				alpha 2
G707a6	WIAF-15806	U32169	1087	COL11A2, collagen, type XI,	ACAGAGCTTGGCCCT[G/T]CCCTCTCTGCGGAGA	M	G	T	A	S
				alpha 2
G707a7	WIAF-15807	U32169	1034	COL11A2, collagen, type XI,	CTGAAGGGCCCTACG[A/C]TTACACCTATGGCTA	M	A	C	D	A
				alpha 2
G707a8	WIAF-15808	U32169	1980	COL11A2, collagen, type XI,	GACCCAGGGTCTTCC[C/T]GGGCCCCAGGGTGCC	S	C	T	P	P
				alpha 2
G707a9	WIAF-15809	U32169	2057	COL11A2, collagen, type XI,	CCGGCATGCCTGGCT[C/T]AGACGGACCCCCGGG	M	C	T	S	L
				alpha 2
G708a21	WIAF-16357	U73778	5326	COL12A1, collagen, type XII,	AAAGTGATGACCTGA[T/C]TGGCAGTGAGCGCAC	M	T	C	I	T
				alpha 1
G711a16	WIAF-16359	L25286	2286	COL15A1, collagen, type XV,	CCCCCAGGCCCTGGA[T/C]GCACAATGGGACTTG	M	T	C	C	R
				alpha 1
G712a12	WIAF-15913	M92642	212	COL16A1, collagen, type XVI,	GGGCTACCTTCGGCC[A/C]TGGGGCAAATACAGG	M	A	C	H	P
				alpha 1
G712a13	WIAF-15914	M92642	234	COL16A1, collagen, type XVI,	AAATACAGGTGCACA[A/T]TGCCCACCTTCACAG	M	A	T	Q	H
				alpha 1
G712a14	WIAF-15915	M92642	264	COL16A1, collagen, type XVI,	GCAGGAAGGACTCAA[A/C]TTGGAACACAGTAGT	M	A	C	K	N
				alpha 1
G712a15	WIAF-15916	M92642	266	COL16A1, collagen, type XVI,	AGGAAGGACTCAAAT[T/C]GGAACACAGTAGTAG	M	T	C	L	S
				alpha 1
G712a16	WIAF-15917	M92642	718	COL16A1, collagen, type XVI,	GTGGACTGCAGCTCA[G/T]CCTCCTCCCAGCCTC	M	G	T	A	S
				alpha 1
G712a17	WIAF-15918	M92642	1212	COL16A1, collagen, type XVI,	AGGCTCCAAGGGAGA[G/T]AAGGGAGCACGGGGC	M	G	T	E	D
				alpha 1
G712a18	WIAF-15919	M92642	1225	COL16A1, collagen, type XVI,	GAGAAGGGAGCACGG[G/A]GCAATGACTGTGTTC	M	G	A	G	S
				alpha 1
G712a19	WIAF-15920	M92642	1250	COL16A1, collagen, type XVI,	GTGTTCGAATCTCCC[C/T]GGATGCCCCGCTTCA	M	C	T	P	L
				alpha 1
G712a20	WIAF-15921	M92642	1293	COL16A1, collagen, type XVI,	CCCGAAGGGAGAGAA[G/A]GGGGAGTCAGGAGCT	S	G	A	K	K
				alpha 1
G712a21	WIAF-15922	M92642	1654	COL16A1, collagen, type XVI,	CCAGGTGTGAAGGGA[G/A]AGAAGGGTGACCCCT	M	G	A	E	K
				alpha 1
G712a22	WIAF-15923	M92642	2529	COL16A1, collagen, type XVI,	AGTCCAGGGACCCCA[G/T]GGGGAGCCTGGAGCC	M	G	T	Q	H
				alpha 1
G712a23	WIAF-15924	M92642	2604	COL16A1, collagen, type XVI,	ACCTGGCCCCACTGG[A/G]GAGAAGGGTGCCCAG	S	A	G	G	G
				alpha 1
G712a24	WIAF-15925	M92642	2607	COL16A1, collagen, type XVI,	TGGCCCCACTGGAGA[G/T]AAGGGTGCCCAGGGA	M	G	T	E	D
				alpha 1
G712a25	WIAF-15926	M92642	3418	COL16A1, collagen, type XVI,	CCTCCAGGGCAACCA[G/A]GTTACCCAGGTGCCA	M	G	A	G	S
				alpha 1
G712a26	WIAF-15927	M92642	3495	COL16A1, collagen, type XVI,	CGGGTCAGCGGGAGA[G/T]AAAGGAGAGCCGGGC	M	G	T	E	D
				alpha 1
G712a27	WIAF-15928	M92642	4263	COL16A1, collagen, type XVI,	CAAGGGTGATCCAGG[A/T]GCTGCAGGACAGAAG	S	A	T	G	G
				alpha 1
G712a28	WIAF-15929	M92642	4320	COL16A1, collagen, type XVI,	CGGCATGCCTGGTGG[A/T]CCTGGCAAGAGTGGT	S	A	T	G	G
				alpha 1
G712a29	WIAF-15930	M92642	4454	COL16A1, collagen, type XVI,	TGGGAGACATGGTGA[A/T]TTATGATGAAATCAA	M	A	T	N	I
				alpha 1
G712a30	WIAF-16429	M92642	2876	COL16A1, collagen, type XVI,	GCCCGCAGGGTCCAC[C/T]AGGTATTCCCGGACC	M	C	T	P	L
				alpha 1
G715a3	WIAF-16005	Z74615	3922	COL1A1, collagen, type I,	AGATGTGCCACTCTG[A/T]CTGGAAGAGTGGAGA	M	A	T	D	V
				alpha 1
G717a10	WIAF-15644	Z74616	1937	COL1A2, collagen, type I,	GGTGAGAGTGGTGCT[G/T]CCGGTCCTACTGGTC	M	G	T	A	S
				alpha 2
G717a11	WIAF-15645	Z74616	1943	COL1A2, collagen, type I,	AGTGGTGCTGCCGGT[C/T]CTACTGGTCCTATTG	M	C	T	P	S
				alpha 2
G717a12	WIAF-15646	Z74616	3820	COL1A2, collagen, type I,	CAAGAAACACGTCTG[G/A]CTAGGAGAAACTATC	N	G	A	W	*
				alpha 2
G720a10	WIAF-15564	X14420	4159	COL3A1, collagen, type III,	GATGTCCTTGATGTG[C/T]AGCTGGCATTCCTTC	N	C	T	Q	*
				alpha 1 (Ehlers-Danlos
				syndrome type IV, autosomal
				dominant)
G720a11	WIAF-15565	X14420	4247	COL3A1, collagen, type III,	CATACATGGATCAGG[G/A]CAGTGGAAATGTAAA	M	C	A	A	D
				alpha 1 (Ehlers-Danlos
				syndrome type IV, autosomal
				dominant)
G720a7	WIAF-15544	X14420	2972	COL3A1, collagen, type III,	TCACTGGAGCACGGG[G/A]TCTTGCAGGACCACC	M	G	A	G	D
				alpha 1 (Ehlers-Danlos
				syndrome type IV, autosomal
				dominant)
G720a8	WIAF-15562	X14420	4082	COL3A1, collagen, type III,	AGAAGAAACACGTTT[G/A]GTTTGGAGAGTCCAT	N	G	A	W	*
				alpha 1 (Ehlers-Danlos
				syndrome type IV, autosomal
				dominant)
G720a9	WIAF-15563	X14420	4112	COL3A1, collagen, type III,	TGGATGGTGGTTTTC[A/T]GTTTAGCTACGGCAA	M	A	T	Q	L
				alpha 1 (Ehlers-Danlos
				syndrome type IV, autosomal
				dominant)
G722a2	WIAF-16071	HT3162	1175	COL4A2, collagen, type IV,	GAGAACCAGGTTTTC[T/C]TGGGGCTCCAGGGAA	M	T	C	R	P
				alpha 2
G722a3	WIAF-16072	HT3162	1285	COL4A2, collagen, type IV,	CCGATTGGCCAAGAA[A/C]GTGCACCAGGCCGTC	M	A	C	G	R
				alpha 2
G722a4	WIAF-16073	HT3162	1400	COL4A2, collagen, type IV,	AGCCCATGTGCCCRG[G/A]GGGCATGAACAAACT	M	G	A	V	E
				alpha 2
G722a5	WIAF-16074	HT3162	1501	COL4A2, collagen, type IV,	GGCTCCTGCCTGGCG[G/A]GGTTCAGCACCATGC	S	G	A	R	R
				alpha 2
G722a6	WIAF-16075	HT3162	1757	COL4A2, collagen, type IV,	GGATCGGATATTCCT[T/C]CCTCATGCACACGGC	M	T	C	F	S
				alpha 2
G722a7	WIAF-16076	HT3162	2098	COL4A2, collagen, type IV,	CAACCCAAAAATTGG[T/C]TTTATTTTTTTCTTA	—	T	C
				alpha 2
G724a13	WIAF-15571	X81053	1652	COL4A4, collagen, type IV,	CCAGGAGGAAGAGGC[C/T]CAAAAGGAGAAAAAG	M	C	T	P	S
			alpha 4
G724a14	WIAF-15572	X81053	1690	COL4A4, collagen, type IV,	AGGACTCTGTGCCTG[T/A]GAGCCTGGACCCATG	N	T	A	C	*
				alpha 4
G724a15	WIAF-15573	X81053	2647	COL4A4,collagen, type IV,	CAAAGGCAGAGAGGG[A/T]CATGCTGGGTTTCCA	S	A	T	G	G
				alpha 4
G724a16	WIAF-15574	X81053	3694	COL4A4, collagen, type IV,	GGATCCAGGGATACC[A/G]GGTCCTCCGGGAATA	S	A	G	P	P
				alpha 4
G724a17	WIAF-15733	X81053	225	COL4A4, collagen, type IV,	TGTGGTCTCTGCACA[T/C]AGTACTAATGAGGTG	M	T	C	I	T
				alpha 4
G724a18	WIAF-15734	X81053	3132	COL4A4,collagen, type IV,	AAAAGGGAACACCTG[G/A]GGAACCTGGACCTCC	M	G	A	G	E
				alpha 4
G724a19	WIAF-15735	X81053	3219	COL4A4, collagen, type IV,	GGAGAAGAGGAGAGC[T/C]GGGAAGATACGGACC	M	T	C	L	P
				alpha 4
G727a7	WIAF-16360	D90279	4571	COL5A1, collagen, type V,	GTCCCAAAGGTGAAA[A/G]GGGTCATCCAGGCCT	M	A	G	K	R
				alpha 1
G727a8	WIAF-16361	D90279	4572	COL5A1, collagen, type V,	TCCCAAAGGTGAAAA[G/A]GGTCATCCAGGCCTG	S	G	A	K	K
				alpha 1
G727a9	WIAF-16362	D90279	5396	COL5A1, collagen, type V,	GGCAGGACGCAGCCA[C/T]GGGCAGCTACGACAA	M	C	T	T	M
				alpha 1
G729a38	WIAF-15516	L02870	1123	COL7A1, collagen, type VII,	AACTGACCATCCAGA[A/C]TACCACAGCCCACAG	M	A	C	N	T
				alpha 1 (epidermolysis
				bullosa, dystrophic, dominant
				and recessive)
G729a39	WIAF-15517	L02870	1988	COL7A1, collagen, type VII,	CGTCCCTGGAGCCAG[T/C]GGATTTCGGATTAGC	S	T	C	S	S
				alpha 1 (epidermolysis
				bullosa, dystrpphic, dominant
				and recessive)
G729a40	WIAF-15518	L02870	1752	COL7A1, collagen, type VII,	CGCAGCACCCAGGGG[G/T]TGGAGCGGACCCTGG	M	G	T	V	L
				alpha 1 (epidermolysis
				bullosa, dystrophic, dominant
				and recessive
G729a41	WIAF-15519	L02870	2658	COL7A1, collagen, type VII,	GTGACTGCACTTGTC[G/T]GGGACCGCGAGGGCA	M	G	T	G	W
				alpha 1 (epidermolysis
				bullosa, dystriphic, dominant
				and recessive
G729a42	WIAF-15520	L02870	4258	COL7A1, collagen, type VII,	GACCTCGTGGACCAC[T/C]GGGGGACCCAGGACC	M	T	C	L	P
				alpha 1 (epidermolysis
				bullosa, dystriphic, dominant
				and recessive)
G729a43	WIAF-15521	L02870	4259	COL7A1, collagen, type VII,	ACCTCGTGGACCACT[G/T]GGGGACCCAGGACCC	S	G	T	L	L
				alpha 1 (epidermolysis
				bullosa, dystriphic, dominant
				and recessive
G729a44	WIAF-15522	L02870	4726	COL7A1,collagen, type VII	AGGGGGAGCCTGGTC[G/A]CCCTGGGGACCCTGC	M	G	A	R	H
				alpha 1 (epidermolysis
				bullosa, dystrophic, dominant
				and recessive)
G729a45	WIAF-15523	L02870	4923	COL7A1, collagen, type VII,	CTTACTGGCAGACGA[G/A]GACCCCCAGGTGACT	M	G	A	G	R
				alpha 1 (eouderniktsus
				bullosa, dystriphic, dominant
				and recessive)
G729a46	WIAF-15524	L02870	5558	COL7A1, collagen, type VII,	TCCAGGCCTCCGTGG[A/T]GAACAAGGCCTCCCT	S	A	T	G	G
				alpha 1 (epidermolysis
				bullosa, dystrophic, dominant
				and recessive)
G729a47	WIAF-15525	L02870	6247	COL7A1, collagen, type VII,	GTATTCCCGGGCTCC[C/T]AGGCAGGGCTGGGGG	M	C	T	P	L
				alpha 1 (epidermolysis
				bullosa, dystrophic, dominant
				and recessive)
G729a48	WIAF-15526	L02870	6301	COL7A1, collagen, type VII,	GAGAGAGGGGAGAAC[G/C]GGGAGAGAAAGGAGA	M	G	A	R	Q
				alpha 1 (epidermolysis
				bullosa, dystrophic, dominant
				and recessive)
G730a2	WIAF-15760	X57527	2093	COL8A1, collagen, type VIII,	AAAAGGGCTTCCTGG[A/G]CCAGGCATCTGGGAG	M	A	G	D	G
				alpha 1
G732a5	WIAF-15931	M95610	709	COL9A2, collagen, type IX,	GACGGGCCCTCATGG[A/C]TATAAAGGCATGGTG	M	A	C	I	L
				alpha 2
G732a6	WIAF-15932	M95610	716	COL9A2, collagen, type IX,	CCTCATGGATATAAA[G/A]GCATGGTGGGCGCTA	M	G	A	R	K
				alpha 2
G732a7	WIAF-16430	M95610	1960	COL9A2, collagen, type IX,	CTTCTGTGAACCTGC[C/T]GCCTGCCTTGGAGCT	M	C	T	R	C
				alpha 2
G732a8	WIAF-16431	M95610	2150	COL9A2, collagen, type IX,	CCTTCTGTCTGGGAC[T/C]CAGGAGTCCTAAGGA	—	T	C
				alpha 2
G734a1	WIAF-15555	M58051	2207	FGFR3, fibroblast growth	ACTGCACACACGACC[T/C]GTACATGATCATGCG	M	T	C	L	P
				factor receptor 3
				(achondroplasia,
				thanatophoric dwarfism)
G734a2	WIAF-15583	M58051	806	FGFR3, fibroblast growth	ACCGGCCCATCCTGC[A/G]GGCGGGGCTGCCGGC	M	A	G	Q	R
				factor receptor 3
				(achondroplasia,
				thanatophoric dwarism)
G734a3	WIAF-15584	M58051	921	FGFR3, fibroblast growth	GCACGTGGAGGTGAA[C/T]GGCAGCAAGGTGGGC	S	C	T	N	N
				factor receptor 3
				(achondroplasia,
				thanatophoric dwarfism)
G734a4	WIAF-15585	M58051	1686	FGFR3, fibroblast growth	CTGCACGCAGGGCGG[G/T]CCCCTGTACGGCTG	S	G	T	G	G
				factor receptor 3
				(achondroplasia,
				thanatophoric dwarfism)
G735a1	WIAF-16432	L10641	4324	GC, group-specific component	TACTGCTTGCTGTGG[C/T]ATTTGGACATGCTTT	M	C	T	A	V
				(vitamin D binding protein)
G748a4	WIAF-15647	HT0157	319	VDR, vitamin D (1,25-	CGGGGACTGCCGCAT[C/T]ACCAAGGACAACCGA	S	C	T	I	I
				dihydroxyvitamin D3) receptor
G748a5	WIAF-15648	HT0157	559	VDR, vitamin D (1,25-	cgaccccacctactc[c/t]gacttctgccagttc	s	c	t	s	s
				dihydroxyvitamin D3) receptor
G748a6	WIAF-15649	HT0157	1321	VDR, vitamin D (1,25-	CTCCAAGCAGTACCG[C/A]TGCCTCTCCTTCCAG	S	C	A	R	R
				dihydroxyvitamin D3) receptor
G748a7	WIAF-15650	HT0157	1092	VDR, vitamin D (1,25-	AGAAGCTGAACTTGC[A/C]TGAGGAGGAGCATGT	M	A	C	H	P
				dihydroxyvitamin D3) receptor
G749a10	WIAF-14282	D14813.0	9235	osteopontin, alt. transcript	CAAGCAGTCCAGATT[A/G]TATAAGCGGAAAGCT	S	A	G	L	L
				1, ?
G749a11	WIAF-14283	D14813.0	9250	osteopontin, alt. transcript	ATATAAGCGGAAAGC[T/C]AATGATGAGAGCAAT	S	T	C	A	A
				1, ?
G749a12	WIAF-14284	D14813.0	9583	osteopontin, alt. transcript	AGTCTGGAAATAACT[A/G]ATGTGTTTGATAATT	—	A	G
				1, ?
G749a13	WIAF-14285	D14813.0	9739	osteopontin, alt. transcript	AGAAATTTATGTAGA[A/C]GCAAACAAAATACTT	—	A	C
				1, ?
G749a14	WIAF-14286	D14813.0	8090	osteopontin, alt. transcript	TGATGAAGATGATGA[T/C]GACCATGTGGACAGC	S	T	C	D	D
				1, ?
G749a15	WIAF-14287	D14813.0	8123	osteopontin, alt. transcript	GGACTCCATTGACTC[G/A]AACGACTCTGATGAT	S	G	A	S	S
				1, ?
G749a17	WIAF-16098	HT3734	449	osteopontin, alt. transcript	TGTAGATGACACTGA[T/G]GATTCTCACCAGTCT	M	T	G	D	E
				1, ?
G749a7	WIAF-14279	D14813.0	2202	osteopontin, alt. transcript	TTCATGACACAATCTC[T/G]CCGCCTCCCTGTGTT	—	T	G
				1, ?
G749a8	WIAF-14280	D14813.0	3287	osteopontin, alt. transcript	TTAACTTGAAAGACT[G/A]TAATACTAAAAAGAA	—	G	A
				1, ?
G749a9	WIAF-14281	D14813.0	9171	osteopontin, alt. transcript	GCCGTGGGAAGGACA[G/A]TTATGAAACGAGTCA	M	G	A	S	N
				1, ?
G751a2	WIAF-15651	HT5036	728	ADM, adrenomedullin	AGGATTTAGGCGCCC[A/C]TGGTACAAGGAATAG	—	A	C
G752a3	WIAF-16094	HT1782	303	CHGA, chromogranin A	TTCTGAGACATCAGA[C/T]TTTACTGAAGGAGCT	M	A	C	N	T
				(parathyroid secretory
				protien 1)
G752a4	WIAF-16095	HT1782	1077	CHGA, chromogranin A	AGGAGGAGGAGCGGC[T/C]CTCCAAGGAGTGGGA	M	T	C	L	P
				(parathyroid secretory
				protein 1)
G752a5	WIAF-16096	HT1782	1179	CHGA, chromogranin A	AGGAGGAGGAGGAGG[A/G]CAACCGGGACAGTTC	M	A	G	D	G
				(parathyroid secretory
				protein 1)
G752a6	WIAF-16097	HT1782	1277	CHGA, chromogranin A	TGGAGGCCATCCTCC[C/T]GGGAGGACAGCCTTG	M	C	T	R	W
				(parathyroid secretory
				protein 1)
G756a2	WIAF-17080	HT3508	1973	SCNN1A, sodium channel	ACCCCATGTCTCTGT[C/T]CTTGTCCCAGCCAGG	M	C	T	S	F
				nonvoltage-gated 1 alpha
G756a3	WIAF-17081	HT3508	2028	SCNN1A, sodium channel,	AGCCCCTCCCCCTGC[C/A]TATGCCACCCTGGGC	S	C	A	A	A
				nonvoltage-gated 1 alpha
G756a4	WIAF-17082	HT3508	2044	SCNN1A, sodium channel,	TATGCCACCCTGGGC[C/T]CCCGCCCATCTCCAG	M	C	T	P	S
				nonvoltage-gated 1 alpha
g756A5	wiaf-17083	ht3508	2210	SCNN1A, sodium channel,	GCTTCCTCTCAGAGC[C/T]GCCCAAACTGCCGTT	—	C	T
				nonvoltage-gated 1 alpha
g757A7	wiaf-15606	ht28563	406	SCNN1B, sodium channel,	GACCATGGACTTCCC[C/T]GCCGTCACCATCTGC	S	C	T	P	P
				nonvoltage-gated 1, beta
				(Liddle syndrome)
g757a8	WIAF-15607	HT28563	1454	SCNN1B, sodium channel,	GAGACCTGCATTGGC[A/G]TGTGCAAGGAGTCCT	M	A	G	M	V
				nonvoltage-gated 1, beta
				(Liddle syndrome)
G757a9	WIAF-16385	HT28563	1927	SCNN1B, sodium channel,	CCCCCGCAGCCCCAA[C/T]ACTGGGCCCTACCCC	S	C	T	N	N
				nonvoltage-gated 1, beta
				(Liddle syndrome)
G758a10	WIAF-15657	HT27856	783	SCNN1D, sodium channel,	CGGCCACTTCGTCCT[C/A]TCCTGCAGTTACGAT	S	C	A	L	L
				nonvoltage-gated 1, delta
G758a11	WIAF-15658	HT27856	1578	SCNN1D, sodium channel,	GCCGCAGCTGCTCTC[C/G]GCCATGGGCAGCCTC	S	C	G	S	S
				nonvoltage-gated 1, delta
G758a12	WIAF-15659	HT27856	1617	SCNN1D, sodium channel,	GTGGTTTGGGGCCTC[C/T]GTCCTCTCCCTCCTG	S	C	T	S	S
				nonvoltage-gated 1, delta
G758a13	WIAF-15660	HT27856	1816	SCNN1D, sodium channel,	GACCCGGAGCCCAGC[G/A]GGCCTCATCTCCCAC	M	G	A	G	R
				nonvoltage-gated 1, delta
G758a5	WIAF-15652	HT27856	171	SCNN1D, sodium channel,	GCCCGCCTCGTTCCG[G/A]GAGCTGCTCACCTTC	S	G	A	R	R
				nonvoltage-gated 1, delta
G758a6	WIAF-15653	HT27856	197	SCNN1D, sodium channel,	CCTTCTTCTGCACCA[A/T]TGCCACCATCCACGG	M	A	T	N	I
				nonvoltage-gated 1, delta
G758a7	WIAF-15654	HT27856	233	SCNN1D, sodium channel,	TCCGCCTGGTCTGCT[C/T]CCGCGGGAACCGCCT	M	C	G	S	C
				nonvoltage-gated 1, delta
G758a8	WIAF-15655	HT27856	645	SCNN1D, sodium channel,	CAACAGCACGGGCGG[C/T]GACTGCTTTTACCGA	S	C	T	G	G
				nonvoltage-gated 1, delta
G758a9	WIAF-15656	HT27856	733	SCNN1D, sodium channel,	ATCCTGGCCCTGCTG[C/T]CCGCGGCATGGGAGG	M	C	T	P	S
				nonvoltage-gated 1, delta
G761a4	WIAF-15933	M16801	841	MLR, mineralocorticoid	GTTTGCAGCCCTGCT[G/C]GAATCAACTCTGTGT	M	G	C	G	R
				receptor (aldosterone
				receptor)
G762a5	WIAF-15661	HT27531	1750	NPR3, natriuretic peptide	GAATAGATGAAAACC[G/A]AATTGTAGAGCATAC	M	G	A	R	Q
				receptor C/guanylate cyclase
				C (atrionatriuretic peptide
				receptor C)
G763a4	WIAF-15662	HT3183	1192	NPR2, natriuretic peptide	ATGACCGGCCTCACT[A/T]CTTCACCATCGAGGG	M	A	T	Y	F
				receptor B/guanylate cyclase
				B (atrionatriuretic peptide
				receptor B)
G763a5	WIAF-15663	HT3183	1436	NPR2, natriuretic peptide	CTTTGGGGAGAGTCT[C/T]CGTGCAGGCCCCACA	S	C	A	L	L
				receptor B/guanylate cyclase
				B (atrionatriuretic peptide
				receptor B)
G763a6	WIAF-15664	HT3183	2094	NPR2, natriuretic peptide	ATTTTCCGAAACCTG[A/G]TGCTGGAGAAGGAGC	M	A	G	M	V
				receptor B/guanylate cyclase
				B (atrionatriuretic peptide
				receptor B)
G763a7	WIAF-15665	HT3183	2605	NPR2, natriuretic peptide	CCTCCAACTGTGTGG[T/A]GGATAGTCGTTTTGT	M	T	A	V	E
				receptor B/guanylate cyclase
				B (atrionatriuretic peptide
				receptor B)
G763a8	WIAF-15666	HT3183	2683	NPR2, natriuretic peptide	AACCTGATGACAGCC[A/T]TGCCCTCTATGCCAA	M	A	T	H	L
				receptor B/guanylate cyclase
				B (atrionatriuretic peptide
				receptor B)
G763a9	WIAF-16433	HT3183	1801	NPR2, natriuretic pepetide	TGGTTGTCATGGACA[A/T]GAACAATGACCGAGA	M	A	T	K	M
				receptor B/guanylate cyclase
				B (atrionatriuretic peptide
				receptor B)
G764a4	WIAF-15667	HT1221	445	NPR1, natriuretic peptide	CGCGCACTGGCGGGT[C/T]CCGCTGCTGACCGCC	S	C	T	V	V
				receptor A/guanylate cyclase
				A (atrionatriuretic peptide
				receptor A)
G764a5	WIAF-15668	HT1221	452	NPR1, natriuretic peptide	TGGCGGGTCCCGCTG[C/T]TGACCGCCGGCGCCC	S	C	T	L	L
				receptor A/guanylate cyclase
				A (atrionatriuretic peptide
				receptor A)
G764a6	WIAF-15669	HT1221	2825	NPR1, natriuretic peptide	ATTGGCGATGCCTAC[A/C]TGGTGGTGTCAGGGC	M	A	C	M	L
				receptor A/guanylate cyclase
				A (atrionatriuretic peptide
				receptor A)
G764a7	WIAF-16434	HT1221	2430	NPR1, natriuretic peptide	GGCCACCATTCCAGC[A/T]GATCCGCCTGACGTT	M	A	T	Q	L
				receptor A/guanylate cyclase
				A (atrionatriuretic peptide
				receptor A)
G764a8	WIAF-16435	HT1221	2449	NPR1, natriuretic peptide	CCGCCTGACGTTGCG[C/T]AAATTTAACAGGGAG	S	C	T	R	R
				receptor A/guanylate cyclase
				A (atrionatriuretic peptide
				receptor A)
G764a9	WIAF-16436	HT1221	3320	NPR1, natriuretic peptide	ACCCACAGCAGCCCC[A/C]TCGCCAAAGGATGGA	—	A	C
				receptor A/guanylate cyclase
				A (atrionatriuretic peptide
				receptor A)
G765a10	WIAF-14290	AF118569.0	5321	DCP1, dipeptidyl	CCTCACCGACCCTGC[C/T]TGCCTGTGTCTCAGA	—	C	T
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a11	WIAF-14291	AF118569.0	4504	DCP1, dipeptidyl	TGTGGGCTCCTCCTT[G/C]TAGCAGCGAGGGGAG	—	G	C
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a12	WIAF-14292	AF118569.0	14488	DCP1, dipeptidyl	GCTCAAGGCATTCAA[A/C]CCCCTACCAGATCTG	—	A	C
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a13	WIAF-14293	AF118569.0	14521	DCP1, dipeptidyl	GAATGTGATGGCCAC[A/G]TCCCGGAAATATGAA	S	A	G	T	T
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a14	WIAF-14294	AF118569.0	14480	DCP1, dipeptidyl	GGGCTGGAGCTCAAG[G/C]CATTCAAACCCCTAC	—	G	C
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a15	WIAF-14295	AF118569.0	22982	DCP1, dipeptidyl	GTCTCCTTGCTTCCC[A/G]CTCAGCTCGCTCAGA	—	A	G
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a16	WIAF-14296	AF118569.0	3659	DCP1, dipeptidyl	GCCCCTGGCTAAGCG[G/T]CAGCAGGTGGGCTGA	S	G	T	R	R
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a17	WIAF-14297	AF118569.0	3872	DCP1, dipeptidyl	TTTCTGTTAAAGGAA[G/A]CATTCTGGAGTAGGA	—	G	A
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a18	WIAF-14298	AF118569.0	14860	DCP1, dipeptidyl	GAGCAAGACCTGGAG[A/C]GGCTCTTCCAGGAGC	S	A	C	R	R
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a19	WIAF-14299	AF18569.0	14892	DCP1, dipeptidyl	GCAGCCACTCTACCT[C/G]AACCTGCATGCCTAC	S	C	G	L	L
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
g765A20	wiaf-14300	af118569.0	6857	SCP1, dipeptidyl	GGTTTCGGGTACTGA[G/T]CAGCAGCCTGGTGTG	—	G	T
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a21	WIAF-14301	AF118569.0	20397	DCP1, dipeptidyl	CTGCGGCCACTGCCC[G/A]GTCCACAAGCTCTGT	—	G	A
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a22	WIAF-14302	AF118569.0	19942	DCP1, dipeptidyl	ATGATGGTGTGGTG[T/C]AAGTGATGGGGAAAA	—	T	C
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a24	WIAF-14304	AF118569.0	8968	DCP1, dipeptidyl	CCTTTTCTACAAAAG[C/T]TAAATCCATCTGTTT	—	C	T
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a25	WIAF-14305	AF118569.0	12257	DCP1, dipeptidyl	CCTAGAACGGGCAGC[A/G]CTGCCTGCCCAGGAG	S	A	G	A	A
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a26	WIAF-14306	AF118569.0	16984	DCP1, dipeptidyl	CCTCCAGTTTAGCCC[T/A]CCCCCGGGATCCCCA	—	T	A
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a27	WIAF-14307	AF118569.0	16988	DCP1, dipeptidyl	CAGTTTAGCCCTCCC[C/G]CGGGATCCCCACGGC	—	C	G
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a28	WIAF-14308	AF118569.0	17067	DCP1, dipeptidyl	GCTTGCAGGGCTGGA[C/T]GCCCAGGAGGATGTT	M	C	T	T	M
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a29	WIAF-14309	AF118569.0	17107	DCP1, dipeptidyl	TGATGATTTCTTCAC[C/T]TCCCTGGGGCTGCTG	S	C	T	T	T
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a30	WIAF-14310	AF118569.0	7150	DCP1, dipeptidyl	CTGGAACGCCACGCA[C/A]ATGTTCCGGGTGGCA	M	C	A	H	Q
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a31	WIAF-14311	AF118569.0	7239	DCP1, dipeptidyl	CGATGCTGGAGAAGC[C/T]GGCCGACGGGCGGGA	M	C	T	P	L
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a32	WIAF-14312	AF118569.0	8128	DCP1, dipetidyl	GTACAAGGATCTGCC[C/T]GTCTCCCTGCGTCGG	S	C	T	P	P
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a33	WIAF-14313	AF118569.0	8142	DCP1, dipeptidyl	CCGTCTCCCTGCGTC[G/A]GGGGGCCAACCCCGG	M	G	A	R	Q
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a34	WIAF-14314	AF118569.0	22251	DCP1, dipetidyl	CTGCTCCAGGTACTT[C/T]GTCAGCTTCATCATC	S	C	T	F	F
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a35	WIAF-14315	AF118569.0	12727	DCP1, dipeptidyl	GAGCACAGAGTTGGG[T/C]TCCCCTCGCTCTTGG	—	T	C
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a36	WIAF-14316	AF118569.0	5979	DCP1, dipeptidyl	ATCTGGAACACCTCT[A/G]CCAACAGCTAGAGCC	M	A	G	Y	C
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a37	WIAF-14317	AF118569.0	16784	DCP1, dipeptidyl	TTTCCTCTCTCTGCC[G/A]TCCCCCACACTCGCC	—	G	A
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a8	WIAF-14288	AF118569.0	5406	DCP1, dipeptidyl	GGAGGGCTGGCACAA[C/T]GCTGCGGGCATCCCG	S	C	T	N	N
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G765a9	WIAF-14289	AF18569.0	5492	DCP1, dipeptidyl	ACGGTGAGCAGGCCT[C/T]TCCCTGTCCAGGAAC	—	C	T
				carboxypeptidase 1
				(angiotensin I converting
				enzyme)
G773a5	WIAF-16437	HT2141	817	SLC6A6, solute carrier	GGTCCGAGGGCTGAC[G/T]CTGCCGGGCGCGGGC	S	G	T	T	T
				family 6 (neurotransmitter
				transporter, taurine), member
				6
G776a10	WIAF-16093	U66088	1797	SLC5A5, solute carrier	TCGGCTGCCCGCTGC[G/A]TGGCTCTCTCAGTCA
				family 5 (sodium iodide
				symporter), member 5
G776a7	WIAF-15512	U66088	1553	SLC5A5, solute carrier	CTGCTCACCGTGGC[A/C]GCCCTGTCCTCACTG	S	A	G	A	A
				family 5 (sodium iodide
				symporter), member 5
G776a8	WIAF-15513	U66088	1630	SLC5A5, solute carrier	TCAGCGGCCCCCTGC[T/C]GGGAGCCTTCATCTT	M	T	C	L	P
				family 5 (sodium iodide
				symporter), member 5
G776a9	WIAF-15514	U66088	1718	SLC5A5, solute carrier	CTTGGCGCTGTCGCT[G/A]TGGGTGGCCTTGGGC	S	G	A	L	L
				family 5 (sodium iodide
				symporter), member 5
G777a10	WIAF-15672	HT27843	3439	?, ?	GCGAAGAACCTCGCA[C/T]CTCACCACGCCAGCC	M	C	T	P	S
G777a11	WIAF-16438	HT27843	2107	?, ?	CCACGACGTTCGCCC[G/A]TGACCATGCGGGAGC	M	G	A	V	M
G777a12	WIAF-16439	HT27843	3156	?, ?	CTCACCCGTTCGCCC[A/G]GCTGCCACATTCCCA	S	A	G	P	P
G777a8	WIAF-15670	HT27843	3402	?, ?	TCCTGTCTCTGGCCA[C/T]GCCACCATCGCCCGC	S	C	T	H	H
G777a9	WIAF-15671	HT27843	3436	?, ?	CCTGCGAAGAACCTC[G/A]CACCTCACCACGCCA	M	G	A	A	T
G778a10	WIAF-16080	HT1449	2651	TG, thyroglobulin	CTACCTCTTCTGGCA[G/T]ATCTTAAATGGCCAA	M	G	T	Q	H
G778a11	WIAF-16081	HT1449	2364	TG, thyroglobulin	AGACAAGTGCAATGC[A/G]ATGGGCCTCCTGAGC	M	A	G	N	D
G778a12	WIAF-16082	HT1449	6048	TG, thyroglobulin	CGGTGCGATGCGGAC[C/T]CATGCTGCACTGGCT	M	C	T	P	S
G778a13	WIAF-16083	HT1449	8251	TG, thyroglobulin	AGGGCGGGCAGTCAG[C/T]AGAGAGTGAAGAGGA	M	C	T	A	V
G778a7	WTAF-16077	HT1449	2218	TG, thyroglobulin	GGAAGCCCAAGAAAT[G/C]CCCCACGCCCTGTCA	M	G	C	C	S
G778a8	WIAF-16078	HT1449	2241	TG, thyroglobulin	CCCTGTCAATTACAG[T/G]CTGAGCAAGCTTTCC	M	T	G	S	A
G778a9	WIAF-16079	HT1449	1916	TG, thyroglobulin	CACGACAGAAGGAAG[C/T]TATGAGGATGTCCAA	S	C	T	S	S
G773a4	WIAF-15673	X97674	4710	H. sapiens mRNA for	GGTTCCCAGGGTGGC[G/A]TCCACTCGGCTGTGG	—	G	A
				transcriptional intermediary
				factor 2., ?
G785a2	WIAF-16101	HT1291	162	TTR, transthyretin	CGAGGCAGTCCTGCC[A/C]TCAATGTGGCCGTGC	M	A	C	I	L
				(prealbumin, amyloidosis type
				I)
G785a3	WIAF-16102	HT1291	178	TTR, transthyretin	TCAATGTGGCCGTGC[A/C]TGTGTTCAGAAAGGC	M	A	C	H	P
				(prealbumin, amyloidosis type
				I)
G785a4	WIAF-16103	HT1291	253	TTR, transthyretin	AGTCTGGAGAGCTGC[A/C]TGGGCTCACAACTGA	M	A	C	H	P
				(prealbumin, amyloidosis type
				I)
G788a1	WIAF-15674	HT5121	361	thyroid receptor interactor	TTCTGGGCCACGGGG[A/G]GCCCCAGGACCTATG	—	A	G
				10, ?
G788a2	WIAF-15675	HT5121	363	thyroid receptor interactor	CTGGGCCACGGGGAG[C/T]CCCAGGACCTATGCA	—	C	T
				10, ?
G788a3	WIAF-25676	HT5121	375	thyroid receptor interactor	GAGCCCCAGGACCTA[T/G]GCACTTTATTTCTGA	—	T	G
				10, ?
G788a4	WIAF-15677	HT5121	402	thyroid receptor interactor	CTGACCCCGTGGCTT[C/G]GGCTGAGACCTGTGT	—	C	G
				10, ?
G804a11	WIAF-15529	Z26653	9012	LAMA2, laminin, alpha 2	AAAAAATGGATGGAA[T/A]GGGTATTGAAATGAT	M	T	A	M	K
				(merosin, congenital muscular
				dystrophy)
G804a12	WIAF-15530	Z26653	9013	LAMA2, laminin, alpha 2	AAAAATGGATGGAAT[G/T]GGTATTGAAATGATT	M	G	T	M	I
				(merosin, congenital muscular
				dystrophy)
G804a13	WIAF-16121	Z26653	6812	LAMA2, laminin, alpha 2	GGACCCAAAGCCAGC[A/T]TTGTGCCCAGCACAC	M	A	T	I	F
				(merosin, congenital muscular
				dystrophy)
G804a14	WIAF-16122	Z26653	7290	LAMA2, laminin, alpha 2	CTTCCGTTGTCAGCA[A/C]TCAAAACCATAATGA	M	A	C	N	T
				(merosin, congenital muscular
				dystrophy)
G804a15	WIAF-16123	Z26653	7299	LAMA2, laminin, alpha 2	TCAGCAATCAAAACC[A/C]TAATGATGGGAAATG	M	A	C	H	P
				(merosin, congenital muscular
				dystrophy)
G806a15	WIAF-15527	AF026547	399	CSPG3, chondroitin sulfate	GGCCACTGAGGGCCA[G/A]TGACTCTGGGCTGTA	M	G	A	S	N
				proteoglycan 3 (neurocan)
G8113A1	WIAF-17111	U15637	336	TRAF3, TNF RECEPTOR-	AGGTTACAAGGAAAA[G/C]TTTGTGAAGACCGTG	M	G	C	K	N
				associated factor 3
G8113a2	WIAF-17112	U15637	596	TRAF3, TNF receptor-	GTGCAGAGCAGTTAA[T/C]GCTGGGACATCTGGT	M	T	C	M	T
				associated factor 3
G825a10	WIAF-14346	U75503.0	1275	ADAR, adenosine deaminase,	CGTCACTGTTCCACC[C/T]GGTGTAATATCTCTC	—	C	T
				RNA-specific
G825a11	WIAF-14347	U75503.0	1501	ADAR, adenosine deaminase,	GCAGACCTGATCTTT[C/A]TAGGGTTGACATAGA	—	C	A
				RNA-specific
G825a12	WIAF-14348	U75503.0	1808	ADAR, adensidne deaminase,	TTGGTGCCGTGGTGA[T/A]GGCTGCAGTCCAGTT	—	T	A
				RNA-specific
G825a13	WIAF-14349	U75503.0	2049	ADAR, adenosine deaminase,	CTTTGCTTTTATTCT[A/G]TGCTCTCTGTACTTT	—	A	G
				RNA-specific
G825a14	WIAF-14350	U75503.0	1788	ADAR, adenosine deaminase,	GGAAGAGCCCAAGCA[T/C]AGACTTGGTGCCGTG	—	T	C
				RNA-specific
G825a7	WIAF-14343	U75503.0	744	ADAR, adenosine deaminase,	TTCTTTCCTTGTGAT[C/T]TGAATGTCTCCTTTT	—	C	T
				RNA-specific
G825a8	WIAF-14344	U75503.0	1116	ADAR, adenosine deaminase,	CAGCTGCCTCTTCTC[C/T]TAAAGCATTCCTAGG	—	C	T
				RNA-specific
G825a9	WIAF-14345	U75503.0	878	ADAR, adenosine deaminase,	GCCTGCAGATAATGC[C/T]CAGCCATCCTCCCAT	—	C	T
				RNA-specific
G829a2	WIAF-15883	U4962	1106	DVL3, dishevelled 3	CACAAACCGGGGCCC[A/C]TCACCCTGACTGTAG	M	A	C	I	L
				(homologous to Drosophila
				dsh)
G839a5	WIAF-14583	X67734	667	TAX, transiently-expressed	ACCTGCCCACTACCC[A/C]GGCTTGTCCTACCGC	S	A	C	P	P
				axonal glycoprotein
G8683a1	WIAF-16616	AF042838	1227	?, ?	ATCTAGTACTTCTAC[A/G]TCTAGTTCAGAAAAC	S	A	G	T	T
G8683a2	WIAF-16617	AF042838	1509	?, ?	TGCACAGCAGCAAAC[C/T]GTACAGCAGCAGCCT	S	C	T	T	T
G8683a3	WIAF-16618	AF042838	1860	?, ?	ATGCTGCAGCGTTCT[G/A]TCAATGGTCTGTGCT	S	G	A	L	L
G8683a4	WIAF-16619	AF042838	2359	?, ?	GCTTTGCAGTCCATT[G/A]ATAATTCCCACTCAA	M	G	A	D	N
G8683a5	WIAF-16832	AF042838	3121	?, ?	CCCTCCAGTAACATA[C/T]ACAGGCCAAAGCCAT	M	C	T	H	Y
G8683a6	WIAF-16833	AF042838	3139	?, ?	AGGCCAAAGCCATCT[C/A]GACCTACCCCAGGTA	S	C	A	R	R
G868a1	WIAF-15732	U90278	4748	GRIN2B, glutamate receptor,	CGGAGGGTGACGGGG[G/T]TGAACTTGGTTCCCA	—	G	T
				ionotropic, N-methyl D-
				aspartate 2B
G8706A1	WIAF-16612	NM_004587	1940	?, ?	TCGGAGAAGCAGCTC[T/C]GTCTGATTGAGGCGC	M	T	C	C	R
G8706a2	WIAF-16613	NM_004587	2877	?, ?	GGCGCGCCGCCACGA[G/A]ACTGCAGGAGCTTCT	M	G	A	R	K
G8706a3	WIAF-16822	NM_004587	1678	?, ?	GGAGGCGGGCCAGGC[G/A]CGGGATGCCCAGGAC	S	G	A	A	A
G8706a4	WIAF-16823	NM_004587	2357	?, ?	TCGGACCAGGTGAGG[G/A]AGCACACGTCGCATT	M	G	A	E	K
G8706a5	WIAF-16824	NM_004587	2367	?, ?	TGAGGGAGCACACGT[C/T]GCATTTGGAGGCAGA	M	C	T	S	L
G8706a6	WIAF-16825	NM_004587	2461	?, ?	GCTGAGGCAACTTCT[C/T]CTAGAATCTCAATCT	S	C	T	L	L
G8706a7	WIAF-16826	NM_004587	2533	?, ?	TGAGCTTGCCCTGGT[C/T]AGGCAGCAGTTGAGT	S	C	T	V	V
G8706a8	WIAF-16827	NM_004587	2633	?, ?	GCCGAGCAGGACCCC[G/A]TTCAGCTGAAGACGC	M	G	A	V	I
G8706a9	WIAF-16828	NM_004587	2706	?, ?	AGCGGCAGAAGCTCA[T/C]GGCCGAGTTTGAGGA	M	T	C	M	T
G8729a1	WIAF-16628	NM_000214	1555	?, ?	ATGACTGTTCTCCTA[A/T]TAACTGTTCCCACGG	M	A	T	N	I
G8729a2	WIAF-16836	NM_000214	2817	?, ?	TGTGTGGATGGAGAC[A/T]ACTGGTACCGGTGCG	M	A	T	N	Y
G8729a3	WIAF-16837	NM_000214	3179	?, ?	CATCCCCATCCTGGA[C/T]GACCAGTGCTTCGTC	S	C	T	D	D
G8729a4	WIAF-16838	NM_000214	3830	?, ?	CCCCATCAAGGATTA[C/T]GAGAACAAGAACTCC	S	C	T	Y	Y
G8729a5	WIAF-16839	NM_000214	3941	?, ?	CAAGCAGCCGGCGTA[T/C]ACGCTGGTAGACAGA	S	T	C	Y	Y
G879a10	WIAF-15721	HT28317	1283	GRM2, glutamate receptor,	TGTGCTCAACGTCAA[G/A]TTTGATGCCCCCTTT	S	G	A	K	K
				metabotropic 2
G879a11	WIAF-15722	HT28317	1305	GRM2, glutamate receptor,	GCCCCCTTTCGCCCA[G/A]CTGACACCCACAATG	M	G	A	A	T
				metabotropic 2
G879a12	WIAF-15723	HT28317	2002	GRM2, glutamate receptor,	GTGGGGCCCGGGAGG[G/A]TGCCCAGCGGCCACG	M	G	A	G	D
				metabotropic 2
G879a13	WIAF-15724	HT28317	2087	GRM2, glutamate receptor,	GCTGCTCATCGTGGT[C/T]GCCTGGCTGGTGGTG	S	C	T	V	V
				metabotropic 2
G879a14	WIAF-15725	HT28317	2253	GRM2, glutamate receptor,	GCCTTCAATACTCGC[A/T]AGTGCCCCGAAAACT	N	A	T	K	*
				metabotropic 2
G879a15	WIAF-15726	HT28317	2298	GRM2, glutamate receptor,	TTCATTGGCTTCACC[A/G]TGTACACCACCTGCA	M	A	G	M	V
				metabotropic 2
G885a6	WIAF-15536	AF002700	1169	GFRA2, GDNF family receptor	CCAGGCCCCTCGGGT[G/A]GAGAAGACGCCTTCT	S	G	A	V	V
				alpha 2
G885a7	WIAF-15537	AF002700	1452	GFRA2, GDNF family receptor	GGAACCGAGTCAGAA[G/T]ATTTTTGAAAGCTAC	—	G	T
				alpha 2
G885a8	WIAF-15538	AF002700	1064	GFRA2, GDNF family receptor	CCTCAGGGACTTCAC[C/T]GAGAACCCATGCCTC	S	C	T	T	T
				alpha 2
G887a1	WIAF-15894	L19063	284	GDNF, glial cell derived	GATTTTTAGGTACTG[C/A]AGCGGCTCTTGCGAT	N	C	A	C	*
				neurotrophic factor
G908a2	WIAF-15627	HT3665	623	RAB5A, RAB5A, member RAS	TGAACCACAAAATCC[A/G]GGAGCAAATTCTGCC	S	A	G	P	P
				oncogene family
G90a1	WIAF-13378	M13144	284	INHA, inhibin, alpha	GGAGGCTGAGGAGGG[C/T]CTCTTCAGATACATG	M	C	T	A	V
G90a2	WIAF-13379	M13144	406	INHA, inhibin, alpha	CCAATAGCTCTGAGC[C/T]CCTGCTAGGCCTGCT	M	C	T	P	S
G90a3	WIAF-13380	M13144	488	INHA, inhibin, alpha	TCCCCCTCACTGGGC[C/T]GTGCTGCACCTGGCC	M	C	T	P	L
G90a4	WIAF-13381	M13144	1070	INHA, inhibin, alpha	CTAAGGGTGGGGGGT[C/G]TTCCTTCTTAATCCC	—	C	G
G911a1	WIAF-15780	HT33613	2034	DNM2, dynamin 2	GGACCAGGCAGAAAA[C/T]GAGGATGGGGCCCAG	S	C	T	N	N
G911a2	WIAF-15781	HT33613	2238	DNM2, dynamin 2	CTACCTATACTCCTC[G/A]GCAGACCAGAGCAGC	S	G	A	S	S
G911a3	WIAF-15784	HT33613	810	DNM2, dynamin 2	CATGGAGGAGTCGGC[T/C]GACCAGGCACAGCGG	S	T	C	A	A
G911a4	WIAF-15784	HT33613	810	DNM2, dynamin 2	GGACGTCTTGGAGAA[C/T]AAGTTGCTCCCGTTG	S	C	T	N	N
G911a5	WIAF-15785	HT33613	1600	DNM2, dynamin 2	ATTGAGCAGTCCTAC[A/C]TCAACACGAACCATG	M	A	C	I	L
G913a1	WIAF-15624	HT3671	261	synaptobrevin 2, ?	CAAGCTCAAGCGCAAA[A/C]TACTGGTGGAAAAAC	M	A	C	K	N
G950a4	WIAF-15896	U64871	816	Human putative G protein-	GTGGACGCTGGGTAG[T/C]GCAACGTGCAAGGTT	S	T	C	S	S
				coupled receptor (GPR19)
				gene, complete cds., ?
G951a4	WIAF-15830	HT0866	1604	calcium channel, L type, beta	CAGGGCCTGGAGACC[C/T]TGCAGGGGGAGGTAC	M	C	T	P	L
				2 polypeptide, ?
G953a4	WIAF-14636	HT0310	7245	CACNA1B, calcium channel,	ATCCACACGGGGCAG[T/C]CGGCCCTCGGGGGAG	—	T	C
				voltage-dependent, L type,
				alpha 1B subunit
G953a7	WIAF-16707	HT0310	1633	CACNA1B, calcium channel,	GGTGGCCCTGAACAC[A/T]CTGTGTGTGGCCATG	S	A	T	T	T
				voltage-dependent, L type,
				alpha 1B subunit
G956a15	WIAF-15897	HT2199	1464	calcium channel, voltage-	CCCAGCTCCATGTGC[G/A]TTCTCAGGGAATGGA	S	G	A	A	A
				gated, alpha 1D subunit, DHP-
				sensitive, ?
G956a16	WIAF-15898	HT2199	2372	calcium channel, voltage-	CTGTGTTTCGGTGTG[T/C]GCGCCTCTTAAGAAT	M	T	C	V	A
				gated, alpha 1D subunit, DHP-
				sensitive, ?
G956a17	WIAF-15899	HT2199	2396	calcium channel, voltage-	TAAGAATCTTCAAAG[T/A]GACCAGGCACTGGAC	M	T	A	V	E
				gated, alpha 1D subunit, DHP-
				sensitive, ?
G956a18	WIAF-15900	HT2199	2778	calcium channel, voltage-	TGTAGACAATTTGGC[T/C]GATGCTGAAAGTCTG	S	T	C	A	A
				gated, alpha 1D subunit, DHP-
				sensitive, ?
G956a19	WIAF-15901	HT2199	3096	calcium channel, voltage-	TGCCCCCATCCCTGA[A/C]GGGAGCGCTTTCTTC	M	A	C	E	D
				gated, alpha 1D subunit, DHP-
				sensitive, ?
G956a20	WIAF-15902	HT2199	3148	calcium channel, voltage-	ATCCGCGTAGGCTGC[C/T]ACAAGCTCATCAACC	M	C	T	H	Y
				gated, alpha 1D subunit, DHP-
				sensitive, ?
G956a21	WIAF-15903	HT2199	3475	calcium channel, voltage-	AGGGTCTTAAGGGTC[C/T]TGCGTCCCCTCAGGG	S	C	T	L	L
				gated, alpha 1D subunit, DHP-
				sensitive, ?
G956a22	WIAF-15904	HT2199	3833	calcium channel, voltage-	GGCCTGCGTTGCTGT[A/C]TAAAGCCATCGACTC	M	A	C	Y	S
				gated, alpha 1D subunit, DHP-
				sensitive, ?
G956a23	WIAF-15905	HT2199	7014	calcium channel, voltage-	CCCAGCGAGGGGCAG[A/G]CTGGCTCTGGCCTCA	—	A	G
				gated, alpha 1D subunit, DHP-
				sensitive, ?
G960a6	WIAF-16346	HT3336	1306	CACNB3, calcium channel,	CACAGCGTAGCTCCC[G/A]CCACCTGGAGGAGGA	M	G	A	R	H
				voltage-dependent, beta 3
				subunit
G961a4	WIAF-16347	095019	1443	CACNB2, calcium channel,	TGCAAGAACATTGCA[G/T]TTGGTGGTCCTTGAC	M	G	T	Q	H
				voltage-dependent, beta 2
				subunit
G961a5	WIAF-16873	U95019	1324	CACNB2, calcium channel,	ATCTCGCTTGCCAAA[C/T]GCT
				voltage-dependent, beta 2
				subunit
G962a4	WIAF-16874	U95020	830	CACNB4, calcium channel,	GTTTGATGGGAGGAT[T/A]TCAATAACGAGAGTG	S	T	A	I	I
				voltage-dependent, beta 4
				subunit
G971a1	WIAF-16001	M80333	804	Human m5 muscarinic	GATGAGTGCCAGATC[C/G]AGTTTCTCTCTGAGC	M	C	G	Q	E
				acetylcholine receptor gene,
				complete cds., ?
G971a2	WIAF-16002	M80333	820	Human m5 muscarinic	AGTTTCTCTCTGAGC[C/T]CACCATCACTTTTGG	M	C	T	P	L
				acetylcholine receptor gene,
				complete cds., ?
G971a3	WIAF-16003	M80333	836	Human m5 muscarinic	CACCATCACTTTTGG[C/G]ACTGCCATTGCTGCC	S	C	G	G	G
				acetylcholine receptor gene,
				complete cds., ?
G971a4	WIAF-16004	M80333	852	Human m5 muscarinic	ACTGCCATTGCTGCC[T/C]TCTACATCCCTGTTT	M	T	C	F	L
				acetylcholine receptor gene,
				complete cds., ?
G977a2	WIAF-15539	Y08419	400	CHRNA5, cholinergic	TGGACACCAGACATC[G/A]TTTTGTTTGATAATG	M	G	A	V	I
				receptor, nicotinic, alpha
				polypeptide 5
G991a2	WIAF-15797	HT97376	219	Notch2, ?	CCTGAATGATGGAAC[G/A]TGTGTTGATGGCCTG	S	G	A	T	T
G991a3	WIAF-15798	HT97376	267	Notch2, ?	CTGCCCCCTGGGCTA[C/T]ACTGGGAAAAACTGT	S	C	T	Y	Y
G993a10	WIAF-15805	U95299	5665	NOTCH4, Notch (Drosophila)	GGGGGCGGGGCTCTG[C/T]CGCGTGCCGGACGC	M	C	T	P	S
				homolog 4
G993a4	WIAF-15799	U95299	1134	NOTCH4, Notch (Drosophila)	TGTGAGTGGCTGGGG[C/G]GGCACAAGCTGTGAG	S	C	G	G	G
				homolog 4
G993a5	WIAF-15800	U95299	1048	NOTCH4, Notch (Drosophila)	GTGGATGAGTGTGAG[A/G]CCCAGGGTCCCCCTC	M	A	G	T	A
				homolog 4
G993a6	WIAF-15801	U95299	2142	NOTCH4, Notch (Drosophila)	TGACGTGGGTTGGAC[G/A]GGGCCAGAGTGTGAG	S	G	A	T	T
				homolog 4
G993a7	WIAF-15802	U95299	2183	NOTCH4, Notch (Drosophila)	GGGGCTGCATCTCTG[C/T]ACCCTGTGCCCATGG	M	C	T	A	V
				homolog 4
G993a8	WIAF-15803	U95299	2358	NOTCH4, Notch (Drosophila)	CTACTGCACCTGCCC[T/G]CCAAGCCACACAGGG	S	T	G	P	P
				homolog 4
G993a9	WIAF-15804	U95299	1982	NOTCH4, Notch (Drosophila)	TTCCCCTGTGTGCTC[C/T]CAACCTGTGCCAGCC	M	C	T	P	L
				homolog 4
G998a1	WIAF-16353	X97370	375	PNOC, prepronocieceptin	CCTGGCATGGAGGAG[G/C]CTGGTGAGATGGAGC	M	G	C	A	P
G999a1	WIAF-16354	L38707	1350	DGKQ, diacylglycerol kinase,	CTGCTCGGCCGCCAG[G/A]CCGAGAGTCCCGAGA	M	G	A	A	T
				theta (110 kD)
G999a2	WIAF-16355	L38707	2111	DGKQ, diacylglycerol kinase,	CCGCTGGGGGGCGGG[C/G]TACAGCGGCGAGGAC	S	C	G	G	G
				theta (110 kD)
G999a3	WIAF-16356	L38707	2313	DGKQ, diacylglycerol kinase,	CTGAGCCTGGACTTC[C/T]ACCAGGCACGGGAAG	M	C	T	H	Y
				theta (110 kD)
DRD5a56	WIAF-17421	M67439	704	DRD1, dopamine receptor D1	ACAGGGACCAGGCGG[C/T]CTCTTGGGGCGGGCT	M	C	T	A	V
DRD5a57	WIAF-17422	M67439	711	DRD1, dopamine receptor D1	CCAGGCGGCCTCTTG[G/A]GGCGGGCTGGACCTG	N	G	A	W	*
DRD5a58	WIAF-17423	M67439	714	DRD1, dopamine receptor D1	GGCGGCCTCTTGGGG[C/T]GGGCTGGACCTGCCA	S	C	T	G	G
DRD5a59	WIAF-17424	M67439	764	DRD1, dopamine receptor D1	CGCCCTGGGAGGAGG[A/C]CTTTTGGGAGCCCGA	M	A	C	D	A
DRD5a60	WIAF-17425	M67439	1002	DRD1, dopamine receptor D1	CGACACCAGCCTGCG[C/G]GCTTCCATCAAGAAG	S	C	G	R	R
DRD5a61	WIAF-17426	M67439	1003	DRD1, dopamine receptor D1	GACACCAGCCTGCGC[G/T]CTTCCATCAAGAAGG	M	G	T	A	S
DRD5a62	WIAF-17427	M67439	1024	DRD1, dopamine receptor D1	ATCAAGAAGGAGACC[A/G]AGGTTCTCAAGACCC	M	A	G	K	E
DRD5a63	WIAF-17428	M67439	1028	DRD1, dopamine receptor D1	AGAAGGAGACCAAGG[T/C]TCTCAAGACCCTGTC	M	T	C	V	A
G103a17	WIAF-17646	HT2269	2297	ERCC5, excision repair cross-	TGAGTCCGAGAGCCT[C/A]CTGAGGGACAACTCT	S	C	A	L	L
				complementing rodent repair
				deficiency, complementation
				group 5 (xeroderma
				pigmentosum, complementation
				group G (Cockayne syndrome))
G1089a5	WIAF-17413	HT0009	3042	KCNA2, potassium voltage-	AAGGAGGAGAAGTGT[C/T]AGGCCAAGGGGGATG	N	C	T	Q	*
				gated channel, shaker-related
				subfamily, member 2
G1096a2	WIAF-15639	L26318	1111	PRKM8, protein kinase mitogen-	GTTATGGACTTGGAG[G/A]AGAGAACCAAGAATG	M	G	A	E	K
				activated 8 (MAP kinase)
G1101a1	WIAF-16441	M9752	1644	KAL1, Kallmann syndrome 1	ATTTTCCTGCAAGTA[T/C]AAGGTGACTGTCCAA	S	T	C	Y	Y
				sequence
G1101a2	WIAF-16442	M97252	1750	KAL1, Kallmann syndrome 1	AAGAGCCACAAGCCT[A/G]TTGGCTGCCTGGGCG	M	A	G	I	V
				sequence
G1101a3	WIAF-16443	M97252	1828	KAL1, Kallmann syndrome 1	TCTGCTTCATTCATC[G/A]TCCAGGATGTGAACA	M	G	A	V	I
				sequence
G117a7	WIAF-17634	HT27765	3009	GTBP, G/T mismatch-binding	TAACTTTGATAAAAA[T/A]TACAAGGACTGGCAG	M	T	A	N	K
				protein
G117a8	WIAF-17642	HT27765	3732	GTBP, G/T mismatch-binding	CCAGGAGACTATTAC[G/T]TTCCTCTATAAATTC	S	G	T	T	T
				protein
G125a16	WIAF-17635	HT28632	2382	ATM, ataxia telangiectasia	TGGCTGCTACTGTTA[C/T]ATGGGTGTAATAGCT	S	C	T	Y	Y
				mutated (includes
				complementation groups A, C
				and D)
G125a17	WIAF-17636	HT28632	2499	ATM, ataxia telangiectasia	TAAGACAAATGAGGA[A/G]TTCAGAATTGGTTCC	S	A	G	E	E
				mutated (includes
				complementation groups A, C
				and D)
G125a18	WIAF-17637	HT28632	3572	ATM, ataxia telangiectasia	CATACTTGAAAGCTC[A/G]GGAAGGAATGAGAGA	M	A	G	Q	R
				mutated (includes
				complementation groups A, C
				and D)
G125a19	WIAF-17638	HT28632	4468	ATM, ataxia telangiectasia	ATATGTGAGCAAGCA[G/A]CTGAAACAAATAATG	M	G	A	A	T
				mutated (includes
				complementation groups A, C
				and D)
G125a20	WIAF-17639	HT28632	4497	ATM, ataxia telangiectasia	TGTTTATAAGAAGCA[C/T]AGAATTCTTAAAATA	S	C	T	H	H
				mutated (includes
				complementation groups A, C
				and D)
G125a21	WIAF-17640	HT28632	8567	ATM, ataxia telangiectasia	ATAAAAGATACAGGC[C/G]AAATGATTTCAGTGC	M	C	G	P	R
				mutated (includes
				complementation groups A, C
				and D)
G125a22	WIAF-17647	HT28632	2683	ATM, ataxia telangiectasia	AAAAAGCCATTTGAC[C/T]GTGGAGAAGTAGAAT	M	C	T	R	C
				mutated (includes
				complementation groups A, C
				and D)
G136a3	WIAF-17648	HT3337	696	MLH1, mutL (E. coli) homolog	GACAATATTCGCTCC[G/A]TCTTTGGAAATGCTG	M	G	A	V	I
				1 (colon cancer, nonpolyposis
				type 2)
G144a2	WIAF-17651	HT3625	405	FOS, v-fos FBJ murine	CGCCCTCGTCTCCTC[T/C]GTGGCCCCATCGCAG	S	T	C	S	S
				osteosarcoma viral oncogene
				homolog
G144a3	WIAF-17672	HT3625	999	FOS, v-fos FBJ murine	ATCCAGGCCCAGTGG[C/G]TCTGAGACAGCCCGC	S	C	G	G	G
				osteosarcoma viral oncogene
				homolog
G144a3	WI-18095	HT4986	3150	apoptosis inhibitor, neuronal,	AGGAGCATCCACTTC[T/C]CAATACGAGGAAATA	M	T	C	S	P
				?
G1469a1	WI-18099	HT27558	407	DAD1, defender against cell	TGAACTTTGTTGGCT[G/A]AATCATTCTCATTTA	S	G	A	*	*
				death 1
G1469a2	WI-18100	HT27558	464	DAD1, defender against cell	GAATGTTCACTCTTT[G/C]AATTTCCTTGGATAAG	—	G	C
				death 1
G1472a3	WI-18102	HT28478	908	BAK1, BCL2-antagonist/killer	TCTTTGCCTTCTCTG[T/G]TCCCTTGCAGGGTCC	—	T	C
				1
G1479a9	WI-18096	Y09077	7353	ATR, ataxia telangiectasia	AACTCAAAGTATTCC[G/A]AGAATTTCTCCTGCC	M	G	A	R	Q
				and Rad3 related
G1479a10	WI-18103	Y09077	970	ATR, ataxia telangiectasia	AGAGCCATTATCAAA[G/C]CTGATAAAGACACTA	M	G	C	K	N
				and Rad3 related
G1480a1	WI-18097	HT1406	254	G22P1, thyroid autoantigen	TCAGTAAGATCATAA[G/C]CAGTGATCGAGATCT	M	G	C	S	T
				70kD	(Ku antigen)
G1482a4	WI-18101	HT27870	3202	BLM, Bloom syndrome	GAATACAGCTTTTGG[C/A]CTACTTTGGTGAAAA	M	C	A	A	D
G1483a4	WI-18098	HT1470	365	MYBL2, v-myb avian	AGAGTTTTGAATCCA[G/A]ACCTTGTCAAGGGGC	M	G	A	D	N
				myeloblastosis viral oncogene
				homolog-like 2
G1483a5	WI-18104	HT1470	712	MYBL2, v-myb avian	GAGCGAGTCCAAAGA[C/T]TGCAAGCCCCCAGTG	S	C	T	D	D
				myeloblastosis viral oncogene
				homolog-like 2
G1483a6	WI-18105	HT1470	1033	MYBL2, v-myb avian	TAACCTCCTCATCCC[C/T]GCTGTGGGTTCTAGC	S	C	T	P	P
				myeloblastosis viral oncogene
				homolog-like 2
G1487a11	WIAF-17903	HT27632	2430	BRCA1, breast cancer 1, early	AGTAGCAGTATTTCA[T/C]TGGTACCTGGTACTG	S	T	C	L	L
				onset
G1487a12	WIAF-17904	HT27632	2201	BRCA1, breast cancer 1, early	TAAAAGACATGACAG[C/T]GATACTTTCCCAGAG	S	C	T	S	S
				onset
G1487a13	WIAF-17905	HT27632	3551	BRCA1, breast cancer 1, early	TAGTCATGCATCTCA[G/A]GTTTGTTCTGAGACA	S	G	A	Q	Q
				onset
G1487a14	WIAF-17906	HT27632	5075	BRCA1, breast cancer 1, early	CAAAAGAATGTCCAT[G/A]GTGGTGTCTGGCCTG	M	G	A	M	I
				onset
G1487a15	WIAF-17907	HT27632	5128	BRCA1, breast cancer 1, early	TGTACAAGTTTGCCA[G/A]AAAACACCACATCAC	M	G	A	R	K
				onset
G1487a16	WIAF-17915	HT27632	2731	BRCA1, breast cancer 1, early	GCCAGTCATTTGCTC[C/T]GTTTTCAAATCCAGG	M	C	T	P	L
				onset
G1487a17	WIAF-17916	HT27632	3232	BRCA1, breast cancer 1, early	AAAATGTTTTTAAAG[A/G]AGCCAGCTCAAGCAA	M	A	G	E	G
				onset
G1492a5	WIAF-17908	HT3506	450	cell death-associated kinase,	AAGTACCGGCCTCCA[G/A]TATCCCGCCAAATTC	S	G	A	Q	Q
				?
G1492a6	WIAF-17909	HT3506	1521	cell death-associated kinase,	CATTAAAAGAGGCTC[G/A]AGAATCGATGTCCAG	S	G	A	S	S
				?
G1492a7	WIAF-17910	HT3506	1558	cell death-associated kinase,	GGCGGGTCCAATGCC[G/A]TCTACTGGGCTGCTC	M	G	A	V	I
				?
G1492a8	WIAF-17911	HT3506	3873	cell death-associated kinase,	CGAGCTGCTGGTGCT[G/C]CTGGTCAACCACGGC	S	G	C	L	L
				?
G1492a8	WIAF-17917	HT3506	1923	cell death-associated kinase,	CGAACATGGAGCCGA[C/T]CTTAATGCTTGCGAC	S	C	T	D	D
				?
G1492a10	WIAF-17918	HT3506	3444	cell death-associated kinase,	CTGGCTCTGCACAAA[C/T]GTCCTGGGGAAGTTG	S	C	T	N	N
				?
G1494a2	WIAF-17912	HT28507	440	cell death-inducing protein	GAACAGGTGCTGCTG[G/C]CGCTGCTGCTGCTGC	M	G	C	A	P
				Bik, ?
G1495a4	WIAF-17913	HT27803	2383	CSE1L, chromosome segregation	TATCTTCTAAACAGT[A/G]TAATAGAGCACATGC	M	A	G	I	V
				1 (yeast homolog) - like
G1495a5	WIAF-17919	HT27803	890	CSE1L, chromosome segregation	AGCTTTTACAAACTG[A/G]TGATGAAGAGGAAGC	M	A	G	D	G
				1 (yeast homolog) - like
G1502a2	WIAF-17920	HT1547	913	CCND1, cyclin D1 (PRAD1:	ATCGAAGCCCTGCTG[G/A]AGTCAAGCCTGCGCC	M	G	A	E	K
				parathyroid adenomatosis 1)
G1515a1	WIAF-17914	HT2912	2170	CDH1, cadherin 1, E-cadherin	CTGTGAAGGGGCCGC[C/T]GGCGTCTGTAGGAAG	S	C	T	A	A
				(epithelial)
G1515a2	WIAF-17921	HT2912	2728	CDH1, cadherin 1, E-cadherin	TGACATGTACGGAGG[C/T]GGCGAGGACGACTAG	S	C	T	G	G
				(epithelial)
G152a5	WIAF-17507	HT3854	1221	HSPA1L, heat shock 70 kD	CCTGGGTCTGGAGAC[G/A]GTTGGGGGCGTGATG	S	G	A	T	T
				protein-like 1
G152a6	WIAF-17527	HT3854	919	HSPA1L, heat shock 70 kD	GCTCGATTTGAAGAG[T/C]TGTGTGCAGACCTGT	S	T	C	L	L
				protein-like 1
G1534a1	WI-18111	HT3135	2830	DDIT1, DNA-damage-inducible	CTGAACGGTGATGGC[A/T]TCTGAATGAAAATAA	—	A	T
				transcript 1
G1534a2	WI-18112	HT3135	2886	DDIT1, DNA-damage-inducible	TGAAATACCTTTGTA[G/T]TTACTCAAGCAGTTA	—	G	T
				transcript 1
G1534a3	WI-18113	HT3135	2919	DDIT1, DNA-damage-inducible	CCCTACACTGATGCA[A/G]GGATTACAGAAACTG	—	A	G
				transcript 1
G1535a8	WI-17997	HT0436	1167	HCK, hemopoietic cell kinase	GGGCAGCAAGCAGCC[A/T]TTGCCAAAACTCATT	S	A	T	P	P
G1535a9	WI-17998	HT0436	1210	HCK, hemopoietic cell kinase	CAGATTGCAGAAGGC[A/T]TGGCCTTCATCGAGC	M	A	T	M	L
G1535a10	WI-17999	HT0436	1420	HCK, hemopoietic cell kinase	TTCACCATCAAGTCA[G/A]ACGTCTGGTCCTTTG	M	G	A	D	N
G1535a11	WI-18014	HT0436	936	HCK, hemopoietic cell kinase	GTTTGGGGAAGTCTG[G/A]ATGGCCACCTACAAC	N	G	A	W	*
G1535a12	WI-18106	HT0436	234	HCK, hemopoietic cell kinase	AAAAACTGAAACCAG[C/G]GCCAGCCCACACTGT	M	C	G	S	R
G1537a6	WI-18000	U04045	361	MSH2, mutS (E. coli) homolog	TTCTGGTTCGTCAGT[A/T]TAGAGTTGAAGTTTA	M	A	T	Y	F
				2 (colon cancer, nonpolyposis
				type 1)
G1537a7	WI-18001	U04045	401	MSH2, mutS (E. coli) homolog	AGCTGGAAATAAGGC[A/T]TCCAAGGAGAATGAT	S	A	T	A	A
				2 (colon cancer, nonpolyposis
				type 1)
G1537a8	WI-18011	U04045	2403	MSH2, mutS (E. coli) homolog	ATTGGTGCTTTTTGC[A/T]TGTTTGCAACCCATT	M	A	T	M	L
				2 (colon cancer, nonpolyposis
				type 1)
G1537a9	WI-18012	U04045	2403	MSH2, mutS (E. coli) homolog	TTGCAACCCATTTTC[A/T]TGAACTTACTGCCTT	M	A	T	H	L
				2 (colon cancer, nonpolyposis
				type 1)
G1537a10	WI-18013	U04045	2450	MSH2, mutS (E. coli) homolog	CTTGGCCAATCAGAT[A/C]CCAACTGTTAATAAT	S	A	C	I	I
				2 (colon cancer, nonpolyposis
				type 1)
G1537a11	WI-18107	U04045	1756	MSH2, mutS (E. coli) homolog	CTTTAAATGAAGAGT[A/T]TACCAAAAATAAAAC	M	A	T	Y	F
				2 (colon cancer, nonpolyposis
				type 1)
G1537a12	WI-18108	U04045	1922	MSH2, mutS (E. coli) homolog	TGGAGCACCTGTTCC[A/T]TATGTACGACCAGCC	S	A	T	P	P
				2 (colon cancer, nonpolyposis
				type 1)
G1537a13	WI-18114	U04045	1446	MSH2, mutS (E. coli) homolog	GAAACAACTTTAGAT[A/T]TGGATCAGGTGGAAA	M	A	T	M	L
				2 (colon cancer, nonpolyposis
				type 1)
G1537a15	WI-18116	U04045	2271	MSH2, mutS (E. coli) homolog	TTGGAAACTGCTTCT[A/G]TCCTCAGGTCTGCAA	M	A	G	I	V
				2 (colon cancer, nonpolyposis
				type 1)
G1544a14	WI-18002	U59464	2801	PTCH, patched (Drosophila)	ACGACCCCGTCGCGT[A/T]TGCTGCCTCCCAGGC	M	A	T	Y	F
				homolog
G1544a15	WI-18003	U59464	2866	PTCH, patched (Drosophila)	GACAAAGCCGACTAC[A/T]TGCCTGAAACAAGGC	M	A	T	M	L
				homolog
G1544a16	WI-18004	U59464	2878	PTCH, patched (Drosophila)	TACATGCCTGAAACA[A/G]GGCTGAGAATCCCGG	M	A	G	R	G
				homolog
G1544a17	WI-18005	U59464	2913	PTCH, patched (Drosophila)	AGAGCCCATCGAGTA[T/C]GCCCAGTTCCCTTTC	S	T	C	Y	Y
				homolog
G1544a18	WI-18006	U59464	3944	PTCH, patched (Drosophila)	GCTTGTGGCCACCCC[T/C]CTACAGACCGCGCAG	M	T	C	L	P
				homolog
G1544a19	WI-18015	U59464	3141	PTCH, patched (Drosophila)	GTGCGCTGTCTTCCT[T/G]CTGAACCCCTGGACG	S	T	G	L	L
				homolog
G1544a20	WI-18016	U59464	3425	PTCH, patched (Drosophila)	TGCTGATGCTGGCGG[G/A]ATCTGAGTTCGACTT	M	G	A	G	E
				homolog
G1544a21	WI-18109	U59464	1199	PTCH, patched (Drosophila)	TCCTGGAGGCCTGGC[A/C]GAGGACATATGTGGA	M	A	C	Q	P
				homolog
G1544a22	WI-18110	U59464	2034	PTCH, patched (Drosophila)	CGTGTACTACACCAC[C/T]GCTGAGCCGCGCTCC	S	C	T	T	T
				homolog
G1545a10	WI-18007	HT0473	2851	RAG1, recombination	CCTCTGCCAGTACAG[T/C]TTCAATTCACAGCGT	S	T	C	S	S
				activating gene 1
G1545a11	WI-18008	HT0473	3037	RAG1, recombination	GTTTAGGCGCTTCCG[G/A]AAAATGAATGCCAGG	S	G	A	R	R
				activating gene 1
G155a6	WIAF-17641	HT3962	655	CHCl, chromosome condensation	GGAGAGGAAGAAGCC[G/C]GCCCTGGTATCCATT	S	G	C	P	P
				1
G1552a13	WI-18009	HT4578	1744	PMS1, postmeiotic segregation	CAAATGTAATAGATA[A/T]TAAATCTGGAAAAGT	M	A	T	N	I
				increased (S. cerevisiae) 1
G1552a14	WI-18010	HT4578	1761	PMS1, postmeiotic segregation	AAATCTGGAAAAGTT[A/C]CAGCTTATGATTTAC	M	A	C	T	P
				increased (S. cerevisiae) 1
G1552a15	WI-18017	HT4578	629	PMS1, postmeiotic segregation	CTTTGGTATCCTTAA[A/C]CCTGACTTAAGGATT	M	A	C	K	N
				increased (S. cerevisiae) 1
G1552a16	WI-18018	HT4578	2136	PMS1, postmeiotic segregation	CTCCTTCAGTCCCAA[A/T]TTGAAAAAAGAAGGA	M	A	T	I	F
				increased (S. cerevisiae) 1
G1562a3	WIAF-17926	HT28220	621	PDCD1, programmed cell death	CAGGCGCACCGGCCA[G/T]CCCCTGAAGGAGGAC	M	G	T	Q	H
				1
G1573a10	WIAF-17922	HT0642	1910	CBL, Cas—Br—M (murine)	TCTAGCCGCCTTGGA[G/T]ACTCATGGCTGCCCC	M	G	T	D	Y
				ecotropic retroviral
				transforming sequence
G1573a11	WTAF-17927	HT0642	1633	CBL, Cas—Br—M (murine)	AGCTTCCCTTCCCCC[G/A]GTGCCACCACGACTT	S	G	A	P	P
				ecotropic retroviral
				transforming sequence
G1573a12	WIAF-17928	HT0642	2493	CBL, Cas—Br—M (murine)	CAAAGCCACCTGTGC[C/T]GGCCGTGCTGGCCCG	M	C	T	P	L
				ecotropic retroviral
				transforming sequence
G1574a8	WIAF-17929	HT1508	1601	FES, feline sarcoma (Snyder-	TCATCATCCAGTCCT[T/C]GGATAACCTGTACCG	M	T	C	L	S
				Theilen)viral (v-
				fes)/Fujinami avian sarcoma
				(PRCII) viral (v-fps) oncogene
				homolog
G1574a9	WIAF-17930	HT1508	1663	FES, feline sarcoma (Snyder-	TTGCTCATCGACCAC[C/T]TACTGAGCACCCAGC	S	C	T	L	L
				Theilen)viral (v-
				fes)/Fujinami avian sarcoma
				(PRCII) viral (v-fps) oncogene
				homolog
G1585a3	WIAF-17923	HT1675	478	CRK, v-crk avian sarcoma	AGATCCAGGCAGGGT[A/G]GTGGAGTGATTCTCA	M	A	G	S	G
				virus CT10 oncogene homolog
G1585a4	WIAF-17924	HT1675	154	CRK, v-crk avian sarcoma	AGCTGGTACTGGGGG[C/A]GGTTGAGTCGGCAGG	S	C	A	R	R
				virus CT10 oncogene homolog
G1587a10	WIAF-17931	HT0590	1300	proto-oncogene dbl, ?	GAAATGGCTCTACCC[T/C]TTATAAATTATGAAC	M	T	C	F	L
G1591a2	WIAF-15895	HT2333	692	HRAS, v-Ha-ras Harvey rat	TGGGGAACAAGTGTG[A/G]CCTGGCTGCACGCAC	M	A	G	D	G
				sarcoma viral oncogene homolog
G1594a1	WIAF-17925	HT0640	1284	proto-oncogene junD	GGGCGCCCCGGACTT[G/A]GAGAGGGTGCGGCCC	—	G	A
				(GB:X51346), ?
G1631a1	WIAF-16348	HT33685	326	MADH4, MAD (mothers against	AACTACAAATGGAGC[T/C]CATCCTAGTAAATGT	S	T	C	A	A
				decapentaplegic, Drosophila)
				homolog 4
G1631a2	WIAF-16349	HT33685	429	MADH4, MAD (mothers against	GCCCGTCTCTGGAGG[T/G]GGCCTGATCTTCACA	M	T	G	W	G
				decapentaplegic, Drosophila)
				homolog 4
G200a1	WIAF-16629	J03241	360	TGFB3, transforming growth	CCACCTTGGACTTCG[G/A]CCACATCAAGAAGAA	M	G	A	G	D
				factor, beta 3
G201a2	WIAF-17500	J03779	1048	MME, membrane metallo-	AGGAAGATGTGGTTG[T/C]TTATGCTCCAGAATA	M	T	C	V	A
				endopeptidase	(neutral
				endopeptidase, enkephalinase,
				CALLA, CD10)
G202a1	WIAF-17741	J04130	431	SCYA4, small inducible	AAGGTCACCTGAGCC[C/T]GGATGCTTCTCCATG	—	C	T
				cytokine A4 (homologous to
				mouse Mip-1b)
G210a1	WIAF-17742	M23452	263	SCYA4, small inducible	CCAGTGCTCCAAGCC[C/T]GGTGTCATCTTCCTA	S	C	T	P	P
				cytokine A3 (homologous to
				mouse Mip-1a)
G216a1	WIAF-16630	M31172	359	TGFA, transforming growth	GTGGTGGTCTCCATC[G/A]TGGCCCTGGCTGTCC	M	G	A	V	M
				factor, alpha
G216a2	WIAF-16638	M31172	565	TGFA, transforming growth	TGTGGCAGATCAATA[A/T]AGAAAGGCTTCTTCA	—	A	T
				factor, alpha
G216a3	WIAF-16639	M31172	567	TGFA, transforming growth	TGGCAGATCAATAAA[G/C]AAAGGCTTCTTCAGG	—	G	C
				factor, alpha
G22A35	WIAF-17644	U86136	4301	Human telomerase-associated	CTGGAGAAGGAGCAC[G/A]GGCCTGATGTCCTTC	M	G	A	G	R
				protein TP-1mRNA, complete
				cds., ?
G22a36	WIAF-17645	6085	Human telomerase-associated	CAAGGAATGCTCCCT[T/G]CAGTCCCTCTGGCTC	S	T	G	L	L
				protein TP-1mRNA, complete
				cds., ?
G226a8	WIAF-16647	M85079	488	TGFBR2, transforming growth	GTTTCCACAACTGTG[T/G]AAATTTTGTGATGTG	S	T	C	C	C
				factor, beta receptor II (70-
				80 kD)
G226a9	WIAF-16648	M85079	1334	TGFBR2, transforming growth	CGCCAAGGGCAACCT[A/G]CAGGAGTACCTGACG	S	A	G	L	L
				factor, beta receptor II (70-
				80 kD)
G226a10	WIAF-16649	M85079	1354	TGFBR2, transforming growth	AGTACCTGACGCGGC[A/T]TGTCATCAGCTGGGA	M	A	T	H	L
				factor, beta receptor II (70-
				80 kD)
G226a11	WIAF-16650	M85079	1358	TGFBR2, transforming growth	CCTGACGCGGCATGT[C/G]ATCAGCTGGGAGGAC	S	C	G	V	V
				factor, beta receptor II (70-
				80 kD)
G2270a1	WIAF=16006	AB005038	218	CYP27B1, cytochrome P450,	CGAGAGTACCACTCA[G/C]CACGCCGGAGCTTGG	M	G	C	A	P
				subfamily XXVIIB (25-
				hydroxyvitamin D-1-alpha-
				hydroxylase), polypeptide 1
G2270a2	WIAF-16007	AB005038	337	CYP27B1, cytochrome P450,	GGGCGCCGCGCACTT[C/T]GGGCCGGTGTGGCTA	S	C	T	F	F
				subfamily XXVIIB (25-
				hydroxyvitamin D-1-alpha-
				hydroxylase), polypeptide 1
G2270a3	WIAF-16008	AB005038	811	CYP27B1, cytochrome P450,	GGGCTCGGTGTTTGT[G/A]TCCACGCTGTTGACC	S	G	A	V	V
				subfamily XXVIIB (25-
				hydroxyvitamin D-1-alpha-
				hydroxylase), polypeptide 1
G2270a4	WIAF-16009	AB005038	1242	CYP27B1, cytochrome P450,	TGCTGAAGGCGGTGG[T/C]CAAGGAAGTGCTAAG	M	T	C	V	A
				subfamily XXVIIB (25-
				hydroxyvitamin D-1-alpha-
				hydroxylase), polypeptide 1
G2273a1	WIAF-17789	AF004883	5017	CACNA1A, calcium channel,	AGTTCTATGGGGCTT[C/T]TGTTGCTTATGAAAA	M	C	T	S	F
				voltage-dependent, P/Q type,
				alpha 1A subunit
G2275a3		AF016535	1352	PGY1, P glycoprotein	TAAGATCTTGAAGGG[T/C]CTGAACCTGAAGGTG	S	T	C	G	G
				/1multiple drug resistance 1
G2278a46	WIAF-17567	AF034611	7366	CUBN, cubilin (intrinsic	GATTTGAATCCAGTA[T/C]GGAAGAGTGTGGTGG	M	T	C	M	T
				factor-cobalamin receptor
G2288a1	WIAF-17776	D29634	139	PTGIR, prostaglandin I2	AGCACCCTGATGTTC[G/A]TGGCCGGTGTGGTGG	M	G	A	V	M
				(prostacyclin) receptor (IP)
G2288a2	WIAF-17777	D29634	225	PTGIR, prostaglandin I2	CTTCGCGGTGCTGGT[C/G]ACCGGACTGGCGGCC	S	C	G	V	V
				(prostacyclin) receptor (IP)
G2288a3	WIAF-17778	D29634	1050	PTGIR, prostaglandin I2	TTCCCAGCTCGCCTC[C/A]GGGAGGAGGGACCCA	S	C	A	S	S
				(prostacyclin) receptor (IP)
G2288a4	WIAF-17779	D29634	1185	PTGIR, prostaglandin I2	CAGCGCCGTGGGAAC[G/A]TCGTCCAAAGCAGAA	S	G	A	T	T
				(prostacyclin) receptor (IP)
G2289a1	WI-18019	D32143	329	BLVRB, biliverdin reductase B	GACGCTGTCATCGTG[C/T]TGCTGGGCACCCGCA	S	C	T	L	L
				flavin reductase (NADPH))
G2289a2	WI-18020	D32143	361	BLVRB, biliverdin reductase B	TGACCTCAGTCCCAC[G/A]ACAGTTATGTCCGAG	S	G	A	T	T
				flavin reductase (NADPH))
G2295a4	WIAF-17746	D89079	513	LTB4R, leukotriene b4	CCTGGCCCTGGCCGA[C/T]CTGGCCGTATTGCTC	S	C	T	D	D
				receptor (chemokine receptor-
				like 1)
G23a1	WIAF-17673	V00568	1251	MYC, v-myc avian	GACGGAGTCCTCCCC[G/A]CAGGGCAGCCCCGAG	S	G	A	P	P
				myelocytomatosis viral
				oncogene homolog
G23a2	WIAF-17674	V00568	1270	MYC, v-myc avian	GGCAGCCCCGAGCCC[C/A]TGGTGCTCCATGAGG	M	C	A	L	M
				myelocytomatosis viral
				oncogene homolog
G2300a3	WI=18123	J02959	1473	LTA4H, leukotriene A4	GATTACTGCCAAAGA[A/T]GATGATTTAAATTCA	M	A	T	E	D
				hydrolase
G2304a3	WIAF-17932	J03575	889	PDHA1, pyruvate dehydrogenase	AAGGGGCCCATCCTG[A/C]TGGAGCTGCAGACTT	M	A	C	M	L
				(lipoamide) alpha 1
G2314a2	WIAF-17936	J05272	1429	IMPDH1, IMP (inosine	GTCTTCCACTCGTCC[C/T]AAGGGAATTCGGTGT	N	C	T	Q	*
				monophosphate) dehydrogenase 1
G2319a2	WIAF-17937	K03191	319	CYP1A1, cytochrome P450,	TGCTGCAGATCCGAA[T/C]TGGCTCCACACCCGT	M	T	C	I	T
				subfamily I (aromatic compound-
				inducible), polypeptide 1
G2319a3	WIAF-17938	K03191	363	CYP1A1, cytochrome P450,	GGCCTGGACACCATC[C/T]GGCAGGCCCTGGTGC	M	C	T	R	W
				subfamily I (aromatic compound-
				inducible), polypeptide 1
G2319a4	WIAF-17939	K03191	436	CYP1A1, cytochrome P450,	TCACCCTCATCAGTA[A/T]TGGTCAGAGCATGTC	M	A	T	N	I
				subfamily I (aromatic compound-
				inducible), polypeptide 1
G2319a5	WIAF-17940	K03191	887	CYP1A1, cytochrome P450,	GCAGAAGATGGTCAA[G/T]GAGCACTACAAAACC	M	G	T	K	N
				subfamily I (aromatic compound-
				inducible), polypeptide 1
G2319a6	WIAF-17941	K03191	599	CYP1A1, cytochrome P450,	GGCTGAGGTCCTGAT[A/C]AGCACGTTGCAGGAG	S	A	C	I	I
				subfamily I (aromatic compound-
				inducible), polypeptide 1
G2319a7	WIAF-17942	K03191	1174	CYP1A1, cytochrome P450,	GGCTCTCTGACAGAT[C/T]CCATCTGCCCTATAT	M	C	T	S	F
				subfamily I (aromatic compound-
				inducible), polypeptide 1
G2319a8	WIAF-17943	K03191	1185	CYP1A1, cytochrome P450,	AGATCCCATCTGCCC[T/C]ATATGGAGGCCTTCA	M	T	C	Y	H
				subfamily I (aromatic compound-
				inducible), polypeptide 1
G2319a9	WIAF-17944	K03191	1470	CYP1A1, cytochrome P450,	TGTATCGGTGAGACC[G/A]TTGCCCGCTGGGAGG	M	G	A	V	I
				subfamily I (aromatic compound-
				inducible), polypeptide 1
G232A7	WIAF-17501	U58917	1220	Homo sapiens IL-17 receptor	CGTGGACGTGGTCCT[G/A]AAATTCGCCCAGTTC	S	G	A	L	L
				MRNA, complete cds., ?
G232a8	WIAF-17518	U58917	984	Homo sapiens IL-17 receptor	ATTCCGGACTACATC[C/T]CCCTGTGGGTGTACT	M	C	T	P	S
				MRNA, complete cds., ?
G232a9	WIAF-17519	U58917	1717	Homo sapiens IL-17 receptor	ACTACCTGCGGAGCC[C/A]GGGCGGCAGGCAGCT	M	C	A	P	Q
				MRNA, complete cds., ?
G232a10	WIAF-17520	U58917	2667	Homo sapiens IL-17 receptor	CGCCCAGATCCCAGC[T/C]TTGAGAGAGGAGTGT	—	T	C
				MRNA, complete cds., ?
G2322a2	WIAF-15695	:01406	1022	GHRHR, growth hormone	ATACCCAGTCTCAGT[A/T]TTGGCGTCTCTCCAA	M	A	T	Y	F
				releasing hormone receptor
G2324a1	WIAF-17948	L07548	198	ACY1, aminoacylase 1	CAGCCCGCCAGCTGG[G/A]CCTGGGCTGTCAGAA	M	G	A	G	D
G2324a2	WI-18126	L07548	1217	ACY1, aminoacylase 1	GAGGCTGTGTTCCTC[C/T]GTGGGGTGGACATAT	M	C	T	R	C
G2328a2	WIAF-15697	L20316	1774	GCGR, glucagon receptor	TCGCTGGACAACCCA[G/A]AACTGGACGCCCAGC	—	G	A
G2328a3	WIAF-15966	L20316	527	GCGR, glucagon receptor	ATCTCCTGCCCCTGG[T/G]ACCTGCCTTGGCACC	M	T	G	Y	D
G2328a4	WIAF-15967	L20316	1319	GCGR, glucagon receptor	TACAAGTTCCGGCTG[G/A]CCAAGTCCACGCTGA	M	G	A	A	T
G2328a5	WIAF-15968	L20316	1372	GCGR, glucagon receptor	CCACGAAGTGGTCTT[T/C]GCCTTCGTGACGGAC	S	T	C	F	F
G2329a3	WIAF-15976	L22214	1241	ADORA1, adenosine A1 receptor	TGCCATCTTCCTCAC[G/T]CACGGCAACTCGGCC	S	G	T	T	T
G2330a1	WI-18127	L22607	392	ADORA3, adenosine A3 receptor	AAGCTGAACCCCAGC[C/T]TGCAGACCACCACCT	S	C	T	L	L
G2330a2	WI-18128	L22607	1300	ADORA3, adenosine A3 receptor	GGCCTGTATGCCTGG[G/A]CCAAGGGATTTTTAC	—	G	A
G2330a3	WI-18129	L22607	1317	ADORA3, adenosine A3 receptor	CAAGGGATTTTTACA[T/C]CCTTGATTACTTCCA	—	T	C
G2330a4	WI-18130	L22607	1344	ADORA3, adenosine A3 receptor	TCCACTGAGGTGGGA[G/A]CATCTCCATGGCTCC	—	G	A
G2330a5	WI-18131	L22607	1162	ADORA3, adenosine A3 receptor	TTTGATCCTCAAAGC[C/T]TGTGTGGTCTGCCAT	S	C	T	A	A
G2335a7	WIAF-17949	L32961	233	ABAT, 4-aminobutyrate	TTATGATGGGCCTCT[G/A]ATGAAGACGGAAGTC	S	G	A	L	L
				aminotransferase
G2335a8	WI-18033	L32961	770	ABAT, 4-aminobutyrate	GAGGACCATGGGTTC[C/T]TTAGCGACCACGCAC	S	C	T	C	C
				aminotransferase
G234a1	WIAF-17743	077180	418	Human macrophage inflammatory	CTGCACCAGACCTGA[C/T]CAGCCAGGACAGGGC	—	C	T
				protein 3 beta (MIP-3beta)
				mRNA, complete cds., ?
G235a2	WIAF-17509	U83171	250	SCYA22, small inducible	TAAGGAGATCTGTGC[C/T]GATCCCAGAGTGCCC	S	C	T	A	A
				cytokine subfamily A (Cys-
				Cys), member 22
G2355a1	WIAF-17755	M16405	2048	CHRM4, cholinergic receptor,	CTGGACGCCCTACAA[C/T]GTCATGGTCCTGGTG	S	C	T	N	N
				muscarinic 4
G2355a2	WIAF-17756	M16405	2126	CHRM4, cholinergic receptor,	CTACTGGCTCTGCTA[C/T]GTCAACAGCACCATC	S	C	T	Y	Y
				muscarinic 4
G2355a3	WIAF-17757	M16405	2138	CHRM4, cholinergic receptor,	CTACGTCAACAGCAC[C/T]ATCAACCCTGCCTGC	S	C	T	T	T
				muscarinic 4
G236a2	WIAF-17744	U84487	1055	SCYD1, small inducible	CCCCAGAGGCTGGGC[G/A]TCCTTATCACTCCTG	M	G	A	V	I
				cytokine subfamily D (Cys-X3-
				Cys), member 1 (fractalkine,
				Neurotactin)
G236a3	WIAF-17745	U84487	1334	SCYD1, small inducible	GGATCCCTCATCCTC[A/T]TACCCACCCCCACCC	—	A	T
				cytokine subfamily D (Cys-X3-
				Cys), member 1 (fractalkine,
				Neurotactin)
G2383A1	WI-18141	M61764	1053	TUBG, tubulin, gamma	GAGGATCCGGGAACG[C/G]AAGTTGGCCAACTTC	S	C	G	R	R
				polypeptide
G2403a2	WI-18154	M83670	749	CA4, carbonic anhydrase IV	CGATGAGAAGGTCGT[C/T]TGGACTGTGTTCCGG	S	C	T	V	V
G2403a3	WI-18155	M83670	756	CA4, carbonic anhydrase IV	AAGGTCGTCTGGACT[G/T]TGTTCCGGGAGCCCA	M	G	T	V	L
G2411a2	WI-18158	M97759		1044	AD0RA2B, adenosine A2b	CTACACTTTTCACAA[A/C]ATTATCTCCAGGTAT	M	A	C	K	N
				receptor
G243a10	WIAF-17521	X57522	633	TAP1, transporter 1, ABC (ATP	CCCTACCGCCTTCGT[T/C]GTCAGTTATGCAGCG	S	T	C	V	V
				binding cassette)
G243a11	WIAF-17522	X57522	2534	TAP1, transporter 1, ABC (ATP	CACAGCTGCAGAGTA[G/T]CAGCTGCCTCCAGGA	—	G	T
				binding cassette)
G2433a1	WIAF-16459	U19487	231	PTGER2, prostaglandin E	CCCAGGCGAAAGCCC[A/T]GCCATCAGCTCCGTC	S	A	T	P	P
				receptor 2 (subtype EP2), 53 kD
G2433a2	WIAF-16460	U19487	375	PTGER2, prostaglandin E	CGTGCTGGTGACCGA[G/A]CTGGTGTTCACCGAC	S	G	A	E	E
				receptor 2 (subtype EP2), 53 kD
G2433A3	WIAF-16461	U19487	1154	PTGER2, prostaglandin E	CAGTCCTCTGTTGTC[G/A]GATTTCATTAAGAAC	M	G	A	R	Q
				receptor 2 (subtype EP2), 53 kD
G2433a4	WIAF-16462	U19487	1295	PTGER2, prostaglandin E	TTTTGAAATTGTTCC[C/T]TGGAGAAATGAAAAC	—	C	T
				receptor 2 (subtype EP2), 53 kD
G2433a5	WIAF-16463	U19487	1068	PTGER2, prostaglandin E	AGCTCTTAGGTTTTT[A/G]TCAATTAATTCAATA	S	A	G	L	L
				receptor 2 (subtype EP2), 53 kD
G2445a7	WIAF-17529	U38178	398	CNP, 2′,3′-cyclic nucleotide	CCTTCTTCTTCCTCA[C/G]CTGCTTCCTCACCCG	M	C	G	T	S
				3′ phosphodiesterase
G2445a8	WIAF-17530	U38178	664	CNP, 2′,3′-cyclic nucleotide	CGGCACTGCGTTCTG[G/A]TGCTGCTCCTGGCCA	M	G	A	V	M
				3′ phosphodiesterase
G2445a9	WIAF-17531	U38178	756	CNP, 2′,3′-cyclic nucleotide	GCTCTCCGGCCTGGT[G/A]GGGGGCGCTGGCTGC	S	G	A	V	V
				3′ phosphodiesterase
G2445a10	WIAF-17532	U38178	772	CNP, 2′,3′-cyclic nucleotide	GGGGGCGCTGGCTGC[C/T]TGCTGGCCCTGGGGT	S	C	T	L	L
				3′ phosphodiesterase
G2445a11	WIAF-17533	U38178	563	CNP, 2′,3′-cyclic nucleotide	CCGCGGCCCCGCACA[C/T]GCCCCCGGAGGCGGC	M	C	T	T	M
				3′ phosphodiesterase
G2445a12	WIAF-17534	U38178	1465	CNP, 2′,3′-cyclic nucleotide	AATCTACTGACTATC[C/T]CGAAGCAAAGGTCAT	M	C	T	P	S
				3′ phosphodiesterase
G2445 a13	WIAF-17535	U38178	1786	CNP, 2′,3′-cyclic nucleotide	GAATCAGATGGTACA[G/A]ATTGCTGCAGTGGAA	M	G	A	D	N
				3′ phosphodiesterase
G2445a14	WIAF-17536	U38178	1912	CNP, 2′,3′-cyclic nucleotide	TTATTTCAGGAAGGT[G/A]ATAAGTGGCTAACAG	M	G	A	D	N
				3′ phosphodiesterase
G2445a15	WIAF-17537	U38178	2499	CNP, 2′,3′-cyclic nucleotide	GACAAATGCATTTCT[A/G]GTGGCTACAAATGCC	S	A	G	L	L
				3′ phosphodiesterase
G2450a1	WIAF-17540	U62435	269	?, ?	TTCCACAAACTGTTT[T/C]CTCATTACAACCAGT	M	T	C	S	P
G2457a7	WIAF-17550	U90277	1585	GRIN2A, glutamate receptor,	AGACATAGACCCCCT[G/A]ACCGAGACGTGTGTG	S	G	A	L	L
				ionotropic, N-methyl D-
				aspartate 2A
G2457a8	WIAF-17551	U90277	1898	GRIN2A, glutamate receptor,	TCTGTGCCCTTTGTG[G/A]AAACGGGAATCAGTG	M	G	A	E	K
				ionotropic, N-methyl D-
				aspartate 2A
G2457a9	WIAF-17552	U90277	2035	GRIN2A, glutamate receptor,	CATAGCTGTTTTTGT[C/T]TTTGAATACTTCAGC	S	C	T	V	V
				ionotropic, N-methyl D-
				aspartate 2A
G2457a10	WIAF-17553	U90277	4624	GRIN2A, glutamate receptor,	AAATAAGAATAATAT[G/A]TACTCTACCCCCAGG	M	G	A	M	I
				ionotropic, N-methyl D-
				aspartate 2A
G2457a11	WI-18034	U90277	1485	GRIN2A, glutamate receptor,	ACGCCGTGTGGCCCA[G/A]GTACAAGTCCTTCTC	M	G	A	R	K
				ionotropic, N-methyl D-
				aspartate 2A
G246a1	WIAF-17510	Y00787	246	IL8, interleukin 8	TTCCACCCCAAATTT[A/C]TCAAAGAACTGAGAG	M	A	C	I	L
G2472a1	WIAF-17555	X05908	401	ANX1, annexin I (lipocortin	TGAGGAGGTTGTTTT[A/G]GCTCTGCTAAAAACT	S	A	G	L	L
				I)
G2488a6	WIAF-17556	X63563	1311	POLR2B, polymerase (RNA) II	ATGCACAGAAATTTA[T/C]TGATCGAGGAAAGGA	M	T	C	I	T
				(DNA directed) polypeptide B
				(140 kD)
G2488a7	WIAF-17557	X63563	1891	POLR2B, polymerase (RNA) II	GATTCGGATCTATAC[G/A]GATGCAGGCCGTATT	S	G	A	T	T
				(DNA directed) polypeptide B
				(140 kD)
G2489a8	WIAF-17558	X63564	596	POLR2B, polymerase (RNA) II	TGAGCGGACTGGCCG[C/T]TGCCAAACATGTGCA	S	C	T	R	R
				(DNA directed) polypeptide B
				(140 kD)
G2489a9	WIAF-17559	X63564	1260	POLR2B, polymerase (RNA) II	AACAATCAGCTGCGG[C/T]GCAATGAGCAGAACG	M	C	T	R	C
				(DNA directed) polypeptide B
				(140 kD)
G2489a10	WIAF-17560	X63564	2451	POLR2B, polymerase (RNA) II	GGTCATACTATTGGC[A/T]TTGGGGACTCCATTG	M	A	T	I	F
				(DNA directed) polypeptide B
				(140 kD)
G2489a11	WI-18035	X63564	5102	POLR2B, polymerase (RNA) II	CACACCGGGCTCCCC[G/A]GGGTCCCCAGGTCCC	S	G	A	P	P
				(DNA directed) polypeptide B
				(140 kD)
G2489a12	WI-18036	X63564	6049	POLR2B, polymerase (RNA) II	CCACCACCCCAAAAT[A/G]CTCCCCAACATCTCC	M	A	G	Y	C
				(DNA directed) polypeptide B
				(140 kD)
G2489a12	WIAF-17502	HT1162	431	CD9, CD9 antigen (p24)	AGGAGTTTTACAAGG[A/G]CACCTACAACAAGCT	M	A	G	D	G
G267a3	WIAF-17496	HT1877	1304	IL2RB, interleukin 2	TCATTCAGAGGAAGA[C/A]CCTGATGAGGGTGTG	M	C	A	D	E
				receptor, beta
G268a3	WIAF-17523	HT1985	1737	CD19 antigen, ?	CCGCATGGGCACCTG[G/A]AGCACCAGGTGATCC	N	G	A	W	*
G268a4	WIAF-17524	HT1985	1769	CD19 antigen, ?	CAGGTGGCCAGCCTG[G/T]ATCTCCTCAAAGTCCC	—	C	T
G270a7	WIAF-16644	HT2415	647	IL6R, interleukin 6 receptor	GGCTGCAGGCTCCCA[C/T]CCCAGCAGATGGGCT	S	C	T	H	H
G270a8	WIAF-16645	HT2415	1504	IL6R, interleukin 6 receptor	CGACAAGCCTCCCAG[T/G]GCAAGATTCTTCTTC	M	T	G	V	G
G270a9	WIAF-16653	HT2415	1884	IL6R, interleukin 6 receptor	GGACCCTGTGGATGA[C/T]AAAACACAAACGGGC	—	C	T
G271a5	WIAF=17508	HT2531	1216	CD2, CD2 antigen (p50), sheep	TGTTTTCTGTGTGCA[G/C]AACATTGTCACCTCC	—	G	C
				red blood cell receptor
G271a6	WIAF-17513	HT2531	774	CD2, CD2 antigen (p50), sheep	CTATATCACCAAAAG[G/A]AAAAAACAGAGGAGT	S	G	A	R	R
				red blood cell receptor
G271A7	WIAF-17514	HT2531	990	CD2, CD2 antigen (p50), sheep	TCAGCACCAGCCTCA[G/A]AAGAGGCCTCCTGCT	S	G	A	Q	Q
				red blood cell receptor
G272a1	WIAF-14888	HT2661	594	Human Fc-gamma receptor I B1	ATCTGTCACTGTGAA[A/G]GAGCTATTTCCAGCT	M	A	G		Q
				mRNA, complete cds., ?
G272a2	WIAF-17071	HT2661	1006	Human Fc-gamma receptor I B1	AGAAAGAAAAAGTGG[G/A]ATTTAGAAATCTCTT	M	G	A		Q
				mRNA, complete cds., ?
G279a19	WIAF-17282	K01740	6105	FBC, coagulation factor	TGTGTTCACTGTACG[A/G]AAAAAAGAGGAGTAT	S	A	G	R	R
				VIIIc, procoagulant component
				(hemophilia A)
G279a20	WUAF-17283	K01740	7135	FBC, coagulation factor	TACCTTCGAATTCAC[C/T]CCCAGAGTTGGGTGC	M	C	T	P	S
				VIIIc, procoagulant component
				(hemophilia A)
G280a1	WIAF-16276	L02932	1399	PPARA, peroxisome	GGCCTTCTAAACGTA[G/C]GACACATTGAAAAAA	M	G	C	G	R
				proliferative activated
				receptor, alpha
G281a3	WIAF-17305	L06105	644	FDFT1, farnesyl-diphosphate	CTTAGTTGGTGAAGA[T/C]ACAGAACGTGCCAAC	S	T	C	D	D
				farnesyltransferase 1
G281a4	WIAF-17306	L06105	675	FDFT1, farnesyl-diphosphate	TCTATGGGCCTGTTT[C/T]TGCAGAAAACAAACA	S	C	T	L	L
				farnesyltransferase 1
G288a1	WIAF-16211	M59979	1191	PTGS1, prostaglandin-	CCTGACTCCTTCAAG[G/A]TGGGCTCCCAGGAGT	M	G	A	V	M
				endoperoxide synthase 1
				(prostaglandin G/H synthase
				and cyclooxygenase)
G288a2	WIAF-16237	M59979	644	PTGS1, prostaglandin-	CTTCAAAACTTCTGG[C/A]AAGATGGGTCCTGGC	S	C	A	G	G
				endoperoxide synthase 1
				(prostaglandin G/H synthase
				and cyclooxygenase)
G288a3	WIAF-16238	M59979	1565	PTGS1, prostaglandin-	TATCTTTGGGGAGAG[T/C]ATGATAGAGATTGGG	S	T	C	S	S
				endoperoxide synthase 1
				(prostaglandin G/H synthase
				and cyclooxygenase)
G2951a3	WI-18162	HT0030	1665	ZNF42, zinc finger protein 42	GCGAACAGCCTTTCC[G/C]TTGCGCTGAGTGCGG	M	G	C	R	P
				(myeloid-specific retinoic
				acid-responsive)
G297a4	WIAF-17303	U16660	676	ECH1, enoyl Coenzyme A	CTGCCCAAGGTCATC[G/A]GGAACCAGAGCCTGG	M	G	A	G	R
				hydratase 1, peroxisomal
G297a5	WIAF-17304	U16660	875	ECH1, enoyl Coenzyme A	ACCTGCTGTATTCCC[G/A]CGACCATTCGGTGGC	M	G	A	R	H
				hydratase 1, peroxisomal
G2970a9	WIAF-17308	HT0281	1840	?, ?	GCGAGCTCGGCTGCT[C/T]GTGGAATTGATCCGC	S	C	T	L	L
G298a35	WIAF-17571	U33837	2129	Human glycoprotein receptor	TGAGCAGGTCTGTGT[T/C]CTCAGCCACAGAACA	S	T	C	V	V
				gp330 precursor, mRNA,
				complete cds., ?
G298a36	WIAF-17572	U33837	10429	Human glycoprotein receptor	ATGGATCAAATAGAC[A/C]GACACTGGTGAACAC	M	A	C	Q	P
				gp330 precursor, mRNA,
				complete cds., ?
G298a37	WIAF-17573	U33837	10607	Human glycoprotein receptor	CTTCCGCACCCTTCA[A/G]CTGAGTGGCAGCACC	S	A	G	Q	Q
				gp330 precursor, mRNA,
				complete cds., ?
G298a38	WIAF-17574	U33837	13862	Human glycoprotein receptor	TCTCTTCAACGAAA[A/T]TCTAAACAAACTACC	M	A	T	K	N
				gp330 precursor, mRNA,
				complete cds., ?
G298a39	WIAF-17580	U33837	743	Human glycoprotein receptor	CCAACAGGGCAGTGA[T/C]GAACATGCTTGCAAC	S	T	C	D	D
				gp330 precursor, mRNA,
				complete cds., ?
G298a40	wiaF-17581	u33837	2428	Human glycoprotein receptor	TTGATGGCACAGGAA[G/A]AGAAATTCTCGCAGC	M	G	A	R	K
				gp330 precursor, mRNA,
				complete cds., ?
G298a41	WIAF-17582	U33837	2564	Human glycoprotein receptor	TAAAACGAGACGCAC[A/G]GTAGTTCAGTATTTA	S	A	G	T	T
				gp330 precursor, mRNA,
				complete cds., ?
G298a42	WIAF-17583	U33837	4979	Human glycoprotein receptor	TTACATGGACTTTTG[C/T]GATTATAATGGACAC	S	C	T	C	C
				gp330 precursor, mRNA,
				complete cds., ?
G2951a3	WI-18162	HT0030	1665	ZNF42, zinc finger protein 42	GCGAACAGCCTTTCC[G/C]M	G	C	R	P
				(myeloid-specific retinoic
				acid-response
G297a4	WIAF-17303	U16660	676	ECH1, enoyl Coenzyme A	CTGCCCAAGGTCACT[G/A]GGAACCAGAGCCTGG	M	G	A	G	R
				hydratase 1, peroxisomal
G297a5	WIAF-17304	U16660	875	ECH1, enoyl Coenzyme A	ACCTGCTGTATTCCC[G/A]CGACCATTCGGTGGC	M	G	A	R	H
				hydratase 1, peroxisomal
G2970a9	WIAF-17308	HT0291	1840	?, ?	GCGAGCTCGGCTGCT[C/T]GTGGAATTGATCCGC	S	C	T	L	L
G298a35	WIAF-17571	U33837	2129	Human glycoprotein receptor	TGAGCAGGTCTGTGT[T/C[CTCAGCCACAGAACA	S	T	C	V	V
				gp330 precursor, mRNA,
				complete cds., ?
G298a36	WIAF-17572	U33837	10429	Human glycoprotein receptor	ATGGTCAAATAGAC[A/C]GACACTGGTGAACAC	m	A
				gp330 precursor, mRNA,
				complete cds., ?
G298a37	WIAF-17573	U33837	10607	Human glycoprotein receptor	CTTCCGCACCCTTCA[A/G]CTGAGTGGCAGCACC	S	A	G	Q	Q
				gp330 precursor, mRNA,
				complete cds., ?
G298a38	WIAF-17574	U33837	13862	Human glycoprotein receptor	TCTCTTCAAACGAAA[A/T]TCTAAACAAACTACC	M	A	T	K	N
				gp330 precursor, mRNA,
				complete cds., ?
G298a39	WIAF-17580	U33837	743	Human glycoprotein receptor	CCAAGACGGCAGTGA[T/C]GAACATGCTTGCAAC	S	T	C	D	D
				gp330 precursor, mRNA,
				complete cds., ?
G298a40	WIAF-17581	U33837	2428	Human glycoprotein receptor	TTGATGGCACAGGAA[G/A]AGAAATTCTCGCAGC	M	G	A	R	K
				gp330 precursor, mRNA,
				complete cds., ?
G298a41	WIAF-17582	U33837	2564	Human glycoprotein receptor	TAAAACGAGACGCAC[A/G]GTAGTTCAGTATTTA	S	A	G	T	T
				gp330 precursor, mRNA,
				complete cds., ?
G298a42	WIAF-17583	U33837	4979	Human glycoprotein receptor	TTACATGGACTTTTG[C/T]GATTATAATGGACAC	S	C	T	C	C
				gp330 precursor, mRNA,
				complete cds., ?
G298a43	WIAF-17584	U33837	11705	Human glycoprotein receptor	TGGCGATGATGACTG[T/C]GGCGATGGTTCAGAT	S	T	C	C	C
				gp330 precursor, mRNA,
				complete cds., ?
G2982a1	WIAF-17780	HT0358	1654	homeotic protein 7, notch	CCCACTGCCATGATG[C/G]CCCAGCAGGACGGGC	M	C	G	P	A
				group, ?
G2986a2	WIAF-17781	HT0468	764	CSDA, cold shock domain	GCTACTATGGAAGGC[G/A]CCGTGGCCCTCCCCG	M	G	A	R	H
				protein A
G2987a4	WI-18118	HT0474	1342	ZNF7, zinc finger protein 7	TTGCAAGGAGTGTGG[G/A]AAGGCCTTCAGCCAG	S	G	A	G	G
				(KOX 4, clone HF.16)
G2987a5	WI-18119	HT0474	1642	ZNF7, zinc finger protein 7	CACTGGAGAAAAACC[A/C]TTTAAATGTGATGAG	S	A	C	P	P
				(KOX 4, clone HF.16)
G2987a6	WI-18120	HT0474	1663	ZNF7, zinc finger protein 7	ATGTGATGAGTGTGG[C/A]AAAGGCTTTGTTCAG	S	C	A	G	G
				(KOX 4, clone HF.16)
G2987a7	WI-18121	HT0474	1795	ZNF7, zinc finger protein 7	CCATCAGAGAATCCA[T/C]AAAGGAGAGAAGCCC	S	T	C	H	H
				(KOX 4, clone HF.16)
G299a3	WIAF-17593	U50929	711	BHMT, betaine-homocysteine	AGTTTAAAAACAGTG[A/G]AGCTCATGAAGGAGG	M	A	G	K	E
				methyltransferase
G299a4	WIAF-17594	U50929	742	BHMT, betaine-homocysteine	GCTTGGAGGCTGCCC[A/G]ACTGAAAGCTCACCT	M	A	G	Q	R
				methyltransferase
G3008a5	WIAF-17933	HT0753	1653	ATF4, activating	TGTGGGTCTGCCCGT[G/T]CCAAACCTTACGATC	M	C	G	P	A
				transcription factor 4 (tax-
				responsive enhancer element
				B67)
G3011a1	WIAF-17934	HT0859	839	?, ?	CTCAGGCACCTTCCA[C/T]CAACCGCCAGATCGG	M	C	T	T	I
G3011a2	WIAF-17935	HT0859	1461	?, ?	AACCCAGACAATACA[G/C]CCACCCCAGCCCACA	M	G	C	Q	H
G3012a2	WI-18125	HT0873	444	MAD, MAX dimerization protein	GTTGAGTTTATTAAC[A/G]AAAGCCAAATTGCAC	S	A	G	T	T
G3023a7	WIAF-17782	HT0966	480	zinc finger, X-linked	TGGCTGGAACTTCAC[C/T]AGCATGTCCAAACTC	S	C	T	T	T
				duplicated A, ?
G3023a7	WIAF-17783	HT0966	1149	zinc finger, X-linked	GGCCACTGGTTTTCA[G/A]CAGAGCTCCTTAAAT	S	G	A	Q	Q
				duplicated A, ?
G3028a2	WIAF-17946	HT1037	664	homeotic protein C8, ?	GAGCGGACCGGAGGC[G/A]CGGCCGCCAGATCTA	M	G	A	R	H
G3029a3	WIAF-17784	HT1100	1134	zinc finger protein 8, ?	zinc finger protein 8, ?	CTTCAGGCACAGCTC[A/T]TCCCTGGCCCAGCAC	S	A	T	S	S
G3033a1	WIAF-15969	HT1181	1292	PAX6, paired box gene 6	GGTTTCCTCCTTCAC[A/C]TCTGGCTCCATGTTG	S	A	C	T	T
				(aniridia, keratitis)
G3033a2	WIAF-15970	HT1181	1302	PAX6, paired box gene 6	TTCACATCTGGCTCC[A/C]TGTTGGGCCTAACAG	M	A	C	M	L
				(aniridia, keratitis)
G3033a3	WIAF-15971	HT1181	1356	PAX6, paired box gene 6	AGCGCTCTGCCGCCT[A/C]TGCCCAGCTTCACCA	M	A	C	M	L
				(aniridia, keratitis)
G3033a4	WIAF-15972	HT1181	1389	PAX6, paired box gene 6	GCAAATAACCTGCCT[A/C]TGCAACCCCCAGTCC	M	A	C	M	L
				(aniridia, keratitis)
G3033a5	WIAF-15973	HT1181	1395	PAX6, paired box gene 6	AACCTGCCTATGCAA[C/G]CCCCAGTCCCCAGCC	M	C	G	P	A
				(aniridia, keratitis)
G3033a6	WIAF-15974	HT1181	1401	PAX6, paired box gene 6	CCTATGCAACCCCCA[G/T]TCCCCAGCCAGACCT	M	G	T	V	F
				(aniridia, keratitis)
G3033a7	WIAF-15975	HT1811	1403	PAX6, paired box gene 6	TATGCAACCCCCAGT[C/T]CCCAGCCAGACCTCC	S	C	T	V	V
				(aniridia, keratitis)
G3039a3	WI-18132	HT1375	2880	GLI3, GLI-Kruppel family	AGGAGGGCCGCCGCC[G/C]ACGCCCCTGCCCAAC	S	G	C	P	P
				member GLI3 (Greig
				cephalopolysyndactyly
				syndrome)
G3039a4	WI-18133	HT1375	3047	GLI3, GLI-Kruppel family	AGCCGCACGATGCGC[T/C]GGGCCACGGCGTGAG	M	T	C	L	P
				member GLI3 (Greig
				cephalopolysyndactyly
				syndrome)
G3047a4	WI-18137	HT1518	2551	transcription factor 1,	CCCCCTGGCCTCCCC[C/G]ACTTTCTTTCTTTCT	—	C	G
				nucleolar, ?
G3050a7	WIAF-17751	HT1558	1438	?, ?	ACTTGAAAACAATTA[T/C]TATTGGGCTGCTTCA	S	T	C	Y	Y
G3057a16	WIAF-17763	HT1669	302	alpha-fetoprotein enhancer-	TGGAGCGCAGCCTGT[C/T]GGAGGACGAGTGGAA	M	C	T	S	L
				binding protein, ?
G3057a17	WIAF-17764	HT1669	1833	alpha-fetoprotein enhancer-	AGACCCCACTCTGGC[T/A]GAGGACCATACCATA	S	T	A	A	A
				binding protein, ?
G3057a18	WIAF-17765	HT1669	2316	alpha-fetoprotein enhancer-	GACTGGGAACAGCAG[C/T]AGTATTTCCTTGAGC	S	C	T	S	S
				binding protein, ?
G3057a19	WIAF-17766	HT1669	4542	alpha-fetoprotein enhancer-	ATCCTGCAGTACCCC[G/A]ATGCCCTCACAGGCT	S	G	A	P	P
				binding protein, ?
G3057a20	WIAF-17767	HT1669	5105	alpha-fetoprotein enhancer-	GGTCCCTGGATATGC[C/T]TTTCATGCTCTTTGA	M	C	T	P	L
				binding protein, ?
G3057a21	WIAF-17950	HT1669	6210	alpha-fetoprotein enhancer-	ATCTGGTGACAGCGG[G/A]GATCGGCCTGGGCAG	S	G	A	G	G
				binding protein, ?
G3057a22	WIAF-17951	HT1669	7220	alpha-fetoprotein enhancer-	CAGCCCCGCTGCCCA[C/T]CATGGAGTATGCGGT	M	C	T	T	I
				binding protein, ?
G3061a1	WIAF-17769	HT1702	766	BTEB2, basic transcription	TCACCACCAAGCTCA[G/A]AGCCTGGAAGTCCAG	M	G	A	E	K
				element binding protein 2
G3061a2	WIAF-17770	HT1702	804	BTEB2, basic transcription	AGCAGAGATGCTCCA[G/T]AATTTAACCCCACCT	M	G	T	Q	H
				element binding protein 2
G3067a1	WIAF=17771	HT2005	1029	GTF2H1, general transcription	AAAACAAGAAGCACA[A/C]AATGAACAAACTAGT	M	A	C	Q	H
				factor IIH, polypeptide 1
				(62 kD subunit)
G3067a2	WI-18138	HT2005	1728	GTF2H1, general transcription	TGCTTACAGGTTTTG[T/A]GAGATTGAGAGAACT	—	T	A
				factor IIH, polypeptide 1
				(62 kD subunit)
G3070a3	WIAF-17772	HT2085	221	pre-B-cell leukemia	CACGGCCACGAAGGG[G/C]CGGACGGCGACGGCA	M	G	C	A	P
				transcription factor 3, ?
G3081a2	WI-18139	HT2188	1000	PSMC2, proteasome (prosome,	GATGGTTTTGATCCT[C/A]GAGGCAATATTAAAG	S	C	A	R	R
				macropain) 26S subunit,
				ATPase, 2
G3088a17	WIAF-17309	HT2318	3424	HIVEP1, human	AAAAGGAGGAAAATG[A/G]AAAGTGTTGGGGATG	M	A	G	K	E
				immunodeficiency virus type I
				enhancer-binding protein 1
G3088a18	WIAF-17310	HT2318	3485	HIVEP1, human	CATCTCCAAAAAGTT[C/T]TGAAGGCCTTCAGTT	M	C	T	S	F
				immunodeficiency virus type I
				enhancer-binding protein 1
G3088a19	WIAF-17416	HT2318	1532	HIVEP1, human	AGAAGCCAAAAAAAC[A/C]AGGAAAATATATTTG	M	A	C	Q	P
				immunodeficiency virus type I
				enhancer-binding protein 1
G3088a20	WIAF-17417	HT2318	7249	HIVEP1, human	GACTACCCTGAGTCA[G/A]AAGAAATTCTGAGAA	M	G	A	E	K
				immunodeficiency virus type I
				enhancer-binding protein 1
G3088a21	WIAF-17418	HT2318	7359	HIVEP1, human	CCCCCAGACAGCAGC[G/A]GGGATGCCTTCTGTG	S	G	A	A	A
				immunodeficiency virus type I
				enhancer-binding protein 1
G3088a22	WIAF-17419	HT2318	7377	HIVEP1, human	GATGCCTTCTGTGGC[C/T]TCACCACATCCTGAC	S	C	T	A	A
				immunodeficiency virus type I
				enhancer-binding protein 1
G3088a23	WIAF-17420	HT2318	8217	HIVEP1, human	TGATGGCCTGAGTAA[A/T]ATGGACACAGAGAAG	M	A	T	K	N
				immunodeficiency virus type I
				enhancer-binding protein 1
G3090a1	WI-18140	HT2338	705	fosB, ?	TCCACCCACCGCCGC[C/G]GCCTCCCAGGAGTGC	S	C	G	A	A
G3092a1	WI-18142	HT2374	940	EGR4, early growth response 4	CGTTTTCCCGTAATA[G/A]GGACCAAGATTGAGG	M	G	A	G	R
G3092a2	WI-18143	HT2374	1028	EGR4, early growth response 4	ATCCCAGCGGGGCCT[A/G]TGACGCTTTCCCGCT	M	A	G	Y	C
G3092a3	WI-18144	HT2374	1744	EGR4, early growth response 4	CGGCGCGCACGAGTT[C/T]CGGGCCGTTCCCCTC	—	C	T
G3095a4	WIAF-16453	HT2435	784	TCF2, transcription factor 2,	ATATGACAGACAAAA[G/A]CAGTCAGGATCAGCT	M	G	A	S	N
				hepatic; LF-B3; variant
				hepatic nuclear factor
G3095a5	WIAF-16454	HT2435	1182	TCF2, transcription factor 2,	AGCCTGAACCCTCTG[C/T]TCTCCCACGGCTCCC	M	C	T	L	F
				hepatic; LF-B3; variant
				hepatic nuclear factor
G3095a6	WIAF-16455	HT2435	1967	TCF2, transcription factor 2,	GCCCAGTGACCTGAC[C/A]AGCACCTGCGAGAGG	—	C	A
				hepatic; LF-B3; variant
				hepatic nuclear factor
G309a7	WIAF-16456	HT2435	1968	TCF2, transcription factor 2,	CCCAGTGACCTGACC[A/G]GCACCTGCGAGAGGT	—	A	G
				hepatic; LF-B3; variant
				hepatic nuclear factor
G3102a2	WI-18145	HT2508	691	NRF1, nuclear respiratory	GCCTCTCACCATCGA[C/T]GGAATTCCAGTCTCT	S	C	T	D	D
				factor 1
G3103a3	WIAF-17429	HT2511	1039	E2F2, E2F transcription	AAGACCCCACCAGAC[C/T]TGGGAAGCAGCAACA	M	C	T	P	L
				factor 2
G3103a4	WIAF-17430	HT2511	1041	E2F2, E2F transcription	GACCCCACCAGACCT[G/A]GGAAGCAGCAACAGC	M	G	A	G	R
				factor 2
G311a15	WIAF-17575	HT0402	2302	A2M, alpha-2-macroglobulin	AGCAGGGGTGGCTGA[G/T]GTAGGAGTAACAGTC	M	G	T	E	D
G311a16	WIAF-17576	HT0402	2307	A2M, alpha-2-macroglobulin	GGGTGGCTGAGGTAG[G/T]AGTAACAGTCCCTGA	M	G	T	G	V
G3118a1	WI-18147	HT2652	897	ZNF35, zinc finger protein 35	TAGTCAGAGTGCAAA[C/T]CTCGTTGTGCATCAG	S	C	T	N	N
				(clone HF.10)
G3118a2	WI-18148	HT2652	913	ZNF35, zinc finger protein 35	CTCGTTGTGCATCAG[C/G]GAATCCACAACTGGAG	M	C	G	R	G
				(clone HF.10)
G3119a4	WI-18149	HT2654	610	GLI, glioma-associated	CCCTTCCCAACTTGC[C/T]AGCTGAAGTCTGAGC	N	C	T	Q	*
				oncogene homolog (zinc finger
				protein)
G3119a5	WI-18150	HT2654	945	GLI, glioma-associated	CCAGTACATGCTGGT[G/A]GTTCACATGCGCAGA	S	G	A	V	V
				oncogene homolog (zinc finger
				protein)
G3119a6	WI-18151	HT2654	1853	GLI, glioma-associated	ACCTGCTTCGGGCCA[G/A]ATATGCTTCAGCCAG	M	G	A	R	K
				oncogene homolog (zinc finger
				protein)
G3119a7	WI-18152	HT2654	3483	GLI, glicoma-associated	GGGAGCTGCAGTCCC[C/A]TGCACAAGATGCCCC		C	A
				oncogene homolog (zinc finger
				protein)
G3124a1	WI-18156	HT2673	1410	HOXB3, homeo box B3	CACCATGCAGGGCAG[T/C]CCGGTGTACGTGGGC	S	T	C	S	S
G3125a2	WI-18157	HT2674	614	GTF2F2, general transcription	ATACAATATCGAATA[T/C]GAAAGGAAAAAGAAA	S	T	C	Y	Y
				factor IIF, polypeptide 2
				(30 kD subunit)
G3129a1	WI-18159	HT2695	195	transcription factor ATF-a, ?	TTCATAAACACAAGC[A/C]TGAGATGACATTGAA	M	A	C	H	P
G3133a1	WI-18160	HT2729	768	GTFE1, general transcription	GCACCACCGGGAAGC[A/T]TGGGCCACCAAAGGT	S	A	T	A	A
				factor IIE, polypeptide 1
				(alpha subunit, 56 kD)
G1311a2	WI-18161	HT2729	1503	GTF2E1, general transcription	ATCCTTGTGCAAAGA[T/A]TGATGGTAGAGAGCT	—	T	A
				factor IIE, polypeptide 1
				(alpha, subunit, 56 kD)
G3141a5	WI-18163	HT27498	620	NFATC3, nuclear factor of	ACAGAGAAGCAGGGG[C/G]CCAGGGTGGGGGGGC	M	C	G	A	G
				activated T-cells, cytoplasmic
				3
G3141a6	WI-18164	HT27498	1293	NFATC3, nuclear factor of	AGTGCCCTCCCCACT[C/T]GCTTGGTCCAAGGCC	S	C	T	L	L
				activated T-cells, cytoplasmic
				3
G3161a1	WI-18165	HT27575	843	leucine zipper transcriptional	AGATTTTGGTGATGA[A/G]TTTTATTCTGCTTTC
				activator, basic, ?
G3169a1	WI-18166	HT27675	1535	ZNF127, zinc finger protein	GCCAGTCTGTTGTTT[A/T]AGCGGTTTCTTTCAC
				127
G3173a2	WI-18167	HT2772	1202	ZNF74, zinc finger protein 74	AGCCGTTCAAGTGCA[G/C]CGACTGCGAGAAGGC
				(Cos52)
G3173a3	WI-18168	HT2772	2007	ZNF74, zinc finger protein 74	TTGCCTTATCACCCC[A/C]ATCAGGTCTGCATGC	—	A	C
				(Cos52)
G3174a1	WIAF-17528	HT27736	1455	transcriptional repressor	GTGCAGTTATGCCAG[C/T]AGGGACACATACAAG	S	C	T	S	S
				CTCF, ?
G3176a1	WIAF-17538	HT27764	1578	TAF3C, TATA box binding	GGGGCGGCAGACTCC[G/A]GCCCTGGGGTCCCTG	S	G	A	P	P
				protein (TBP)-associated
				factor, RNA polymerase III, C,
				90 kD
G3177a1	WIAF-17539	HT27779	774	ZNF174, zinc finger protein	TGGACCCCAAGAGGC[G/T]CTCTCCCAGCTCCGA	S	G	T	A	A
				174
G3182a5	WIAF-17541	HT2783	248	MHC2TA, MHC class II	AGCGATGCTGACCCC[C/G]TGTGCCTCTACCACT	M	C	G	L	V
				transactivator
G3182a6	WIAF-17542	HT2783	340	MHC2TA, MHC class II	AGACACCATCAACTG[C/T]GACCAGTTCAGCAGG	S	C	T	C	C
				transactivator
G3182a7	WIAF-17543	HT2783	1301	MHC2TA, MHC class II	CAGCTGGCCCAAGGA[G/A]GCCTGGCTGAGGTGC	M	G	A	G	S
				transactivator
G3182a8	WIAF-17544	HT2783	2088	MHC2TA, MHC class II	CCCCCGGGGCCCTGG[C/G]AGAGCTGGCCAAGCT	M	C	G	A	G
				transactivator
G3182a9	WIAF-17545	HT2783	2187	MHC2TA, MHC class II	GGACCTGGGCGATGG[C/A]CAAAGGCTTAGTCCA	M	C	A	A	D
				transactivator
G3182a10	WIAF-17546	HT2783	2509	MHC2TA, MHC class II	GAAGCGGCTGCAGCC[G/A]GGGACACTGCGGGCG	S	G	A	P	P
				transactivator
G3182a11	WIAF-17547	HT2783	2680	MHC2TA, MHC class II	GGCCTTGGAGGCGGC[G/A]GGCCAAGACTTCTCC	S	G	A	A	A
				transactivator
G3182a12	WIAF-17548	HT2783	3286	MHC2TA, MHC class II	CAATAACTGCATCTG[C/T]GACGTGGGAGCCGAG	S	C	T	C	C
				transactivator
G3182a13	WIAF-17549	HT2783	3667	MHC2TA, MHC class II	GGTTGGCCCCTGCCC[G/A]GCTGCGGAATGAACC	—	G	A
				transactivator
G3183a2	WI-18169	HT27861	1027	zinc finger protein C2H2-150,	GCGGGAGCGGGGTGG[G/T]CTGGCCCTGGAGCCC	S	G	T	G	G
				?
G3185a1	WIAF-17554	HT2789	1128	transcription factor NOT, ?	TGTGGGGACAACGCG[G/A]CCTGCCAACACTACG	M	G	A	A	T
G319a7	WIAF-17577	HT0746	1504	PLI, alpha-2-plasmin	CCCCAAGTGAGGGGC[C/T]GTGGCTGTGGCATCC	—	C	T
				inhibitor
G319a8	WIAF-17578	HT0746	1569	PLI, alpha-2-plasmin	TGACTCTTTCCAACC[G/T]GCTTTGTGGCACTGG	—	G	T
				inhibitor
G323a14	WIAF-16782	HT0915	Homo sapiens inducible nitric	TGACCTGGGACCCGC[A/G]CCACTACAGGCTCGT	M	A	G	H	R
				oxide synthase (NOS) mRNA,
				complete cds., ?
G323a15	WIAF-16783	HT0915	2029	Homo sapiens inducible nitric	AGAAACTGAAGAAAT[C/T]GCTCTTCATGCTGAA	M	C	T	S	L
				oxide synthase (NOS) mRNA,
				complete cds., ?
G323a16	WIAF-17579	HT0915	2564	Homo sapiens inducible nitric	GGCCCTGGTCCAAGG[C/T]ATCCTGGAGCGAGTG	S	C	T	G	G
				oxide synthase (NOS) mRNA,
				complete cds., ?
G329a4	WIAF-16302	HT1141	1374	PLCG1, phospholipase C, gamma	ACTTCAAGAAGGTGC[T/G]GGGGGACACACTCCT	M	T	G	L	R
				1 (formerly subtype 148)
G329a5	WIAF-17067	HT1141	702	PLCG1, phospholipase C, gamma	GCAGCGGGGACATCA[C/A]CTACGGGCAGTTTGC	M	C	A	T	N
				1 (formerly subtype 148)
G3296a3	WIAF-17561	HT3466	2128	transcription factor TFIIIC,	AAGAAGAAGGTGGAT[C/T]TGGTGGTGCACCCGT	S	C	T	L	L
				RNA polymerase III, alpha
				subunit, ?
G3296a4	WIAF-17562	HT3466	2630	transcription factor TFIIIC,	CCTGCTCTGAAGCCC[C/T]ATCTAAAGGCAGCCA	M	C	T	P	L
				RNA polymerase III, alpha
				subunit, ?
G3296a5	WIAF-17563	HT3466	3546	transcription factor TFIIIC,	GACATTTCTGTCCAA[G/A]CGCCCAATGCCCCTC	S	G	A	K	K
				RNA polymerase III, alpha
				subunit, ?
G3296a6	WIAF-17564	HT3466	5116	transcription factor TFIIIC,	TGCACCCCTGTGCCC[G/A]CCCGGCTCAGGCCCG	M	G	A	A	T
				RNA polymerase III, alpha
				subunit, ?
G3296a7	WIAF-17565	HT3466	5215	transcription factor TFIIIC,	AACCCCCAGGAAAAC[A/C]CCTGCAGCTTGGAGG	M	A	C	T	P
				RNA polymerase III, alpha
				subunit, ?
G3296a8	WIAF-17566	HT3466	5632	transcription factor TFIIIC,	CCTTCTCACAGCCCC[C/G]GGGGCACCAAGAGGC	M	C	G	R	G
				RNA polymerase III, alpha
				subunit, ?
G3298a4	WIAF-17440	HT3504	1659	DNA-binding protein HRFX2, ?	GGTCATCCAGACCAA[G/A]GTGGGCGTCGTCAGT	S	G	A	K	K
G3298a5	WIAF-17441	HT3504	1693	DNA-binding protein HRFX2, ?	TTCGCCCAGACGCTG[C/T]GGCGCTACACGTCCC	M	C	T	R	W
G3299a1	WIAF-17442	HT3505	697	RFX3, regulatory factor X, 3	TTGGAAAATTAATAA[G/A]ATCAATTTTATGGG	M	G	A	R	K
				(influences HLA class II
				expression)
G3299a2	WIAF-17443	HT3505	1739	RFX3, regulatory factor X, 3	GCTTGACAATGAGAT[G/A]ATGCAAGCACTGAAA	M	G	A	M	I
				(influences HLA class II
				expression)
G3299a3	WIAF-17444	HT3505	2057	RFX3, regulatory factor X, 3	TCTAAATACATTATT[G/A]ATTAAAACCATGGTT	S	G	A	L	L
				(influences HLA class II
				expression)
G3304a4	WIAF-17445	HT3544	1030	SP2, Sp2 transcription factor	AAGCCCCCCAAAAAA[A/G]CTGTCTAAGACTAAC	S	A	G	P	P
G331a2	WIAF-17592	HT1184	819	AP0A1, apolipoprotein A-I	GGACCTCCGCCAAGG[C/A]CTGCTGCCCGTGCTG	S	C	A	G	G
G3311a3	WIAF-17446	HT3585	620	GATA3, GATA-binding protein 3	ACCTTCCCGCCCACC[C/T]CGCCGAAGGACGTCT	M	C	T	P	S
G3311a4	WIAF-17447	HT3585	621	GATA3, GATA-binding protein 3	CCTTCCCGCCCACCC[C/T]GCCGAAGGACGTCTC	M	C	T	P	L
G3311a5	WIAF-17448	HT3585	772	GATA3, GATA-binding protein 3	TGGCAGCATGACCGC[C/T]CTGGGTGGAGCCTCC	S	C	T	A	A
G3311a6	WIAF-17449	HT3585	1576	GATA3, GATA-binding protein 3	ATCATGAAGCCTAAA[C/T]GCCGATGGATATATGT	—	C	T
G3319a5	WIAF-17450	HT3613	1309	SMARCA3, SWI/SNF related,	AGTAAGTTTCGCATG[T/A]CAGAATTGTCTACGT	M	T	A	S	T
				matrix associated, actin
				dependent regulator of
				chromatin, subfamily a, member
				3
G3321a3	WIAF-17451	HT3641	739	STAT2, signal transducer and	GCTACTGCTGCCAAA[G/C]TTGGAGGAGTGGAAG	M	G	C	K	N
				activator of transcription 2,
				113 kD
G3321a4	WIAF-17452	HT3641	2515	STAT2, signal transducer and	ACTFTTGGCTGGCCA[G/T]AACACCGTGGATGAG	M	G	T	Q	H
				activator of transcription 2,
				113 kD
G3325a1	WIAF-17453	HT3647	557	zinc finger protein 20, ?	GTGGGAAAGCCTTTG[C/G]TACATCTTCACAACT	M	C	G	A	G
G3343a6	WIAF-17454	HT3770	727	ZNF76, zinc finger protein 76	ACCTCAGGAGACCTG[C/T]AGAAGCATGTCCGTA	N	C	T	Q	*
				(expressed in testis)
G3343a7	WIAF-17455	HT3770	882	ZNF76, zinc finger protein 76	GCCCCACTGTGGCCG[C/T]GGCTTCACCAGCGCC	S	C	T	R	R
				(expressed in testis)
G3343a8	WIAF-17456	HT3770	885	ZNF76, zinc finger protein 76	CCACTGTGGCCGCGG[C/T]TTCACCAGCGCCACC	S	C	T	G	G
				(expressed in testis)
G3343a9	WIAF-17597	HT3770	465	ZNF76, zinc finger protein 76	GATTCCCCGTAATGG[A/G]AAAGGGCAGCAAGTT	S	A	G	G	G
				(expressed in testis)
G3343a10	WIAF-17598	HT3770	470	ZNF76, zinc finger protein 76	CCCGTAATGGAAAAG[G/A]GCAGCAAGTTGGAGA	M	G	A	G	E
				(expressed in testis)
G3343a11	WI-17959	HT3770	1131	ZNF76, zinc finger protein 76	GGCCACGGAGGAGAG[C/T]GAGCAGGCCCTCTAT	S	C	T	S	S
				(expressed in testis)
G3343a12	WI-17960	HT3770	1208	ZNF76, zinc finger protein 76	CACCCAAACGACCCC[G/A]GATAGCTTACCTTTC	M	G	A	R	Q
				(expressed in testis)
G3344a2	WIAF-17457	HT3772	1345	zinc finger protein MAX, ?	GGCAGGCGCAGCGGC[G/A]GCAGCGGCAGCAGCG	S	G	A	A	A
G3344a3	WI-17961	HT3772	1015	zinc finger protein MAX, ?	GCGTCACATGACGG[C/A]GCTGTGCACAAGCCC	S	C	A	G	G
G3352a3	WIAF-17458	HT4005	1128	MITF, microphthalmia-	TCATGCAGACCTAAC[C/T]TGTACAACAACTCTC	S	C	T	T	T
				associated transcription
				factor
G3353a2	WIAF-17459	HT4010	738	GTF2H3, general transcription	AATCCTCCCACCCCC[G/A]GTTCATGTTGACTAC	S	G	A	P	P
				factor IIH, polypeptide 3
				(34 kD subunit)
G3369a2	WI-17962	HT4302	1073	zinc finger protein DB1, ?	GCAGCAGCAGCAGCA[A/G]CAACAACAACAACAA	S	A	G	Q	Q
G3373a2	WI-17963	HT4342	1021	MTF1, metal-regulatory	GTCACATGAAAGGTC[A/T]TGATAACAAAGGACA	M	A	T	H	L
				transcription factor 1
G339a2	WIAF-17591	HT1290	256	APOE, apolipoprotein E	GCAGACACTGTCTGA[G/T]CAGGTGCAGGAGGAG	M	G	T	E	D
G340a3	WIAF-16289	HT1386	545	CYP27A1, cytochrome P450,	AAGCAGCGCTCTATA[C/T]GGATGCTTTCAATGA	M	C	T	T	M
				subfamily XXVIIA (steroid 27-
				hydroxylase, cerebrotendinous
				xanthomatosis), polypeptide 1
G340a4	WIAF-16339	HT1386	757	CYP27A1, cytochrome P450,	GTCAGATCCATCGGG[T/C]TAATGTTCCAGAACT	S	T	C	L	L
				subfamily XXVIIA (steroid 27-
				hydroxylase, cerebrotendinous
				xanthomatosis), polypeptide 1
G3404a1	WIAF-17460	HT4518	213	ILF2, interleukin enhancer	CAGTGAGGCCTTGCT[G/A]AAGAGGAATCAGGAC	S	G	A	L	L
				binding factor 2, 45 kD
G341a3	WIAF-16266	HT1388	297	MUT, methylmalonyl Coenzyme A	TAAAACCCTTGTATT[C/T]CAAGAGAGATACTAT	M	C	T	S	F
				mutase
G341a4	WIAF-16267	HT1388	332	MUT, methylmalonyl Coenzyme A	TTACCTGAAGAACTT[C/T]CAGGAGTGAAGCCAT	M	C	T	P	S
				mutase
G341a5	WIAF-16268	HT1388	386	MUT, methylmalonyl Coenzyme A	ATGTATACCTTTAGG[C/G]CCTGGACCATCCGCC	M	C	G	P	A
				mutase
G341a6	WIAF-16313	HT1388	712	MUT, methylmalonyl Coenzyme A	TGTACCTAAAGAGAA[A/G]CTTACTGGTACCATC	S	A	G	K	K
				mutase
G341a7	WIAF-16314	HT1388	1571	MUT, methylmalonyl Coenzyme A	TTGGAAAAAGAAGAC[G/A]CTGTAGAAGTTCTGG	M	G	A	A	T
				mutase
G341a8	WIAF-16315	HT1388	1671	MUT, methylmalonyl Coenzyme A	AAGCTTTGGCTGAAC[A/G]TTGTCTTGCTGCACT	M	A	G	H	R
				mutase
G3410a8	WIAF-17461	HT4550	1260	zinc finger homeodomain	TGTACTTAAAGTGGC[G/A]GTAGATGGTAATGTA	S	G	A	A	A
				protein, ?
G3410a9	WIAF-17462	HT4550	2064	zinc finger homeodomain	GATGACTAACTCCCC[A/C]GTTTTACCAGTGGGA	S	A	C	P	P
				protein, ?
G3518a1	WIAF-17774	HT1301	444	VDAC1, voltage-dependent	AAATGCTAAAATCAA[G/A]ACAGGGTACAAGCGG	S	G	A	K	K
				anion channel 1
G3539a2	WI-18024	HT27607	906	?, ?	TCAAATCCAGTACAC[C/T]GAACTGTCCAATGCT	S	C	T	T	T
G3539a3	WI-18025	HT27607	944	?, ?	CCTACAAGCAAAACA[A/G]GGCCAACACAGCCCA	M	A	G	K	R
G3552a4	WIAF-17415	HT28101	2103	CLCN2, chloride channel 2	AGGAGGGTCCCCCTA[G/C]CCCTGAGGCTTCTGT	M	G	C	S	T
G362a8	WIAF-17585	Ht2638	942	ADRB2, adrenergic, beta-2-,	GGATGGGCGGACGGG[G/T]CATGGACTCCGCAGA	S	G	T	G	G
				receptor, surface
G362a9	WIAF-17586	HT2638	953	ADRB2, adrenergic, beta-2-,	CGGGGCATGGACTCC[G/T]CAGATCTTCCAAGTT	M	G	T	R	L
				receptor, surface
G362a10	WIAF-17587	HT2638	700	ADRB2, adrenergic, beta-2-,	CAGATGCACTGGTAC[C/A]GGGCCACCCACCAGG	S	C	A	R	R
				receptor, surface
G367a5	WIAF-15106	HT27685	6990	ACACA, acetyl-Coenzyme A	CATATCACCCACTCA[G/A]CGGGCAGAAGTCACA	M	G	A		M
				carboxylase alpha
G367a6	WIAF-16634	HT27685	3816	ACACA, acetyl-Coenzyme A	TGAGGCAGGTCACAC[G/A]TCTCTTTATGATGAG	S	G	A	T	T
				carboxylase alpha
G367a7	WIAF-16635	HT27685	4117	ACACA, acetyl-Coenzyme A	CGTATCTATCGTCAT[C/A]TGGAGCCTGCTCTGG	M	C	A	L	M
				carboxylase alpha
G378a4	WIAF-17588	HT3146	172	elastin, alt. transcript 5, ?	GCCCTTGGAGGAGGA[G/T]CGCTGGGGCCTGGAG	M	G	T	A	S
G378a5	WIAF-17589	HT3146	1201	elastin, alt. transcript 5, ?	GGCATTCCTACTTAC[G/T]GGGTTGGAGCTGGGG	M	G	T	G	W
G378a6	WIAF-17590	HT3146	1066	elastin, alt. transcript 5, ?	GGAGCTGGGATTCCA[G/T]TTGTCCCAGGTGCTG	M	G	T	V	F
G380a5	WIAF-16255	HT3159	936	INSR, insulin receptor	CAAATGCAAGAACTC[G/A]CGGAGGCAGGGCTGC	S	G	A	S	S
G380a6	WIAF-16256	HT3159	957	INSR, insulin receptor	GCAGGGCTGCCACCA[G/A]TACGTCATTCACAAC	S	G	A	Q	Q
G380a7	WIAF-16257	HT3159	1686	INSR, insulin receptor	TGTGACGGAGTTCGA[C/T]GGGCAGGATGCATGT	S	C	T	D	D
G380a8	WIAF-16258	HT3159	2538	INSR, insulin receptor	AGCCTACGTCAGTGC[G/C]AGGACCATGCCTGAA	S	G	C	A	A
G380a9	WIAF-16259	HT3159	2607	INSR, insulin receptor	AATCTTTGAGAACAA[C/T]GTCGTCCACTTGATG	S	C	T	N	N
G380a10	WIAF-16260	HT3159	2655	INSR, insulin receptor	GCCCAATGGTCTGAT[C/T]GTGCTGTATGAAGTG	S	C	T	I	I
G380a11	WIAF-16261	HT3159	2730	INSR, insulin receptor	CCGCAAGCACTTCGC[T/C]CTGGAACGGGGCTGC	S	T	C	A	A
G380a12	WIAF-16262	HT3159	2460	INSR, insulin receptor	CTTGCGACACTTCAC[G/A]GGCTATCGCATCGAG	S	G	A	T	T
G380a13	WIAF-16263	HT3159	3953	INSR, insulin receptor	ACAAGGCTCCCGAGA[G/C]TGAGGAGCTGGAGAT	M	G	C	S	T
G380a14	WIAF-16264	HT3159	4027	INSR, insulin receptor	CACTGTCAGAGGGAG[G/A]AGGCGGGGGGCCGGG	M	G	A	E	K
G380a15	WIAF-16510	HT3159	417	INSR, insulin receptor	CGCGCTGGTCATCTT[C/T]GAGATGGTTCACCTC	S	C	T	F	F
G380a16	WIAF-16511	HT3159	434	INSR, insulin receptor	AGATGGTTCACCTCA[A/G]GGAACTCGGCCTCTA	M	A	G	K	R
G380a17	WIAF-16512	HT3159	1146	INSR, insulin receptor	CGTCATCAACGGGAG[T/C]CTGATCATCAACATT	S	T	C	S	S
G380a18	WIAF-16513	HT3159	1468	INSR, insulin receptor	ATGGAAGAAGTTTCA[G/C]GAACCAAGGGGCGCC	M	G	C	G	R
G380a19	WIAF-16514	HT3159	2055	INSR, insulin receptor	AGACAGTGAGCTGTT[C/T]GAGCTGGATTATTGC	S	C	T	F	F
G383a2	WIAF-16277	HT33546	1483	phospholipase C, beta 3, alt.	CTTCACCATGACCAC[A/T]GAGGTGCCTCTGCGC	S	A	T	T	T
				transcript 2, ?
G383a3	WIAF-16278	HT33546	1540	phospholipase C, beta 3, alt.	TGCCTTCAAGACCTC[G/A]CCCTACCCCGTCATC	S	G	A	S	S
				transcript 2, ?
G383a4	WIAF-16321	HT33546	993	phospholipase C, beta 3, alt.	TGAACAAGCTGTGTC[T/G]GCGGCCGGACATTGA	M	T	G	L	R
				transcript 2, ?
G383a5	WIAF-16322	HT33546	1150	phospholipase C, beta 3, alt.	CTCCCAGGCCCGGCT[G/A]CTCATCGAAAAGTAT	S	G	A	L	L
				transcript 2, ?
G383a6	WIAF-16323	HT33546	1822	phospholipase C, beta 3, alt.	CCTGAGCGAGAGCTC[C/T]GCGGCCACCGAGCCC	S	C	T	S	S
				transcript 2, ?
G383a7	WIAF-16324	HT33546	3799	phospholipase C, beta 3, alt.	TGGGCAGCAGCAGGT[C/T]CTGCAACAGCTGGCA	S	C	T	V	V
				transcript 2, ?
G383a8	WIAF-16325	HT33546	3871	phospholipase C, beta 3, alt.	TCAGGAGCAGCGGGC[G/A]AGGCTCCCCCAGGAG	S	G	A	A	A
				transcript 2, ?
G383a9	WIAF-16326	HT33546	3916	phospholipase C, beta 3, alt.	GCTGGGCGAGATGCC[G/A]GAGGGGCTGGGGGAC	S	G	A	P	P
				transcript 2, ?
G390a2	WIAF-16784	HT3568	1272	NOS3, nitric oxide synthase 3	CAACGTGGCCGTGCT[G/T]CACAGTTACCAGCTA	S	G	C	L	L
				(endothelial cell)
G390a3	WIAF-16785	HT3568	1374	NOS3, nitric oxide synthase 3	GGCCAGGGGGGGCTG[C/T]CCTGCAGACTGGGCC	S	C	T	C	C
				(endothelial cell)
G390a4	WIAF-16786	HT3568	1970	NOS3, nitric oxide synthase 3	ACACAGACAGTGCAG[G/A]GGCCCTGGGCACCCT	M	G	A	G	E
				(endothelial cell)
G3941a3	WIAF-17792	HT3464	862	mannosidase, alpha, lysosomal,	TGTGTCGATCAGCCG[C/G]TGGTGGAGGACCCTC	M	C	G	L	V
				?
G3941a4	WIAF-17793	HT3464	1040	mannosidase, alpha, lysosomal,	TTGACAAGCTCATCC[G/A]GATGGTAAATGCGAC	M	G	A	R	Q
				?
G3941a5	WIAF-17794	HT3464	1603	mannosidase, alpha, lysosomal,	GAATTGGATGGTGGT[A/G]ATATTTCCCAGCTCA	M	A	G	N	D
				?
G3941a6	WIAF-17795	HT3464	2259	mannosidase, alpha, lysosomal,	GAACCAGACGGAGCC[C/T]GTGGCAGCAAACTAC	S	C	T	P	P
				?
G3941a7	WIAF-17796	HT3464	2514	mannosidase, alpha, lysosomal,	CCAGGCTGCAGCCGC[C/G]GGACACCGGCTCCTG	S	C	G	A	A
				?
G3968a6	WIAF-17681	HT1986	663	ACTN3, actinin, alpha 3	GCGAAAGGATGACCC[C/T]ATCGGAAACCTGAAC	S	C	T	P	P
G3968a7	WIAF-17682	HT1986	771	ACTN3, actinin, alpha 3	GCCGGATGAGAAGGC[C/G]ATCATGACCTATGTG	S	C	G	A	A
G3968a8	WIAF-17683	HT1986	1327	ACTN3, actinin, alpha 3	AGCCAGCGCGACTAC[G/T]ATTCGGCTTTGCTAC	M	G	T	D	Y
G3968a9	WIAF-17684	HT1986	1491	ACTN3, actinin, alpha 3	GAATAGCCGCTGCCA[G/A]GCCATCTGCGATCAG	S	G	A	Q	Q
G3968a10	WIAF-17685	HT1986	1586	ACTN3, actinin, alpha 3	TGGAGACCATTGACC[A/G]GCTGCAACTGGAGTT	M	A	G	Q	R
G3968a11	WIAF-17686	HT1986	1707	ACTN3, actinin, alpha 3	CCAGAGCCTGCTGAC[A/G]GCGCACGATCAGTTC	S	A	G	T	T
G3968a12	WIAF-17687	HT1986	1922	ACTN3, actinin, alpha 3	AGACACTGCAGGAGG[A/C]GCTGGCACGGCAGCA	M	A	C	E	A
G3968a13	WIAF-17688	HT1986	2715	ACTN3, actinin, alpha 3	CCTCTATGGGGAGAG[C/T]GACCTTTGACCCCAA	S	C	T	S	S
G3968a14	WIAF-17689	HT1986	2345	ACTN3, actinin, alpha 3	ACTTTGACAGGAAGC[G/A]GAATGGGATGATGGA	M	G	A	R	Q
G3968a15	WI-18038	HT1986	1511	ACTN3, actinin, alpha 3	TCTGCGATCAGTGGG[A/G]CAACCTGGGCACCCT	M	A	G	D	G
G3979a11	WIAF-16046	HT0623	1280	GPC1, glypican 1	CAACCCCCAGGGCCC[T/C]GGGCCTGAGGAGAAG	S	T	C	P	P
G3979a12	WIAF-16047	HT0623	1298	GPC1, glypican 1	GCCTGAGGAGAAGCG[G/A]CGCCGGGGCAAGCTG	S	G	A	R	R
G3979a13	WIAF-16048	HT0623	1687	GPC1, glypican 1	ACGGCAGCGGCTCGG[G/A]CAGCGGTGATGGCTG	M	G	A	G	D
G3979a14	WIAF-16049	HT0623	1799	GPC1, glypican 1	GTCAGAGCAGGAAGG[A/G]CAGAAGACCTCGGCT	S	A	G	G	G
G3979a15	WIAF-16952	HT0623	720	GPC1, glypican 1	ACGCTGGCCGAGTTC[T/C]GGGCCCGCCTGCTCG	M	T	C	W	R
G398a7	WIAF-17568	HT4554	202	BDKRB1, bradykinan receptor	GTCTTCCTCCTGCCC[C/A]GGCGGCAACTGAACG	S	C	A	R	R
				B1
G398a8	WIAF-17569	HT4554	338	BDKRB1, bradykinan receptor	GAGCCCTCCTCTGCC[G/A]TGTCATCAACGGGGT	M	G	A	R	H
				B1
G398a9	WIAF-17570	HT4554	129	BDKRB1, bradykinan receptor	GCACAGAGTGCTGCC[G/A]ACATTTATCATCTCC	S	G	A	P	P
				B1
G3986a1	WIAF-17804	HT0708	578	TNNC1, troponin C, slow	GAGTCCTGGGGTTGG[G/A]GAGGGGGTCGGGGTC	—	G	A
G399a4	WIAF-16503	HT48511	221	AQP3, aquaporin 3	GCCGGGGCACCCACG[G/A]TGGTTTCCTCACCAT	M	G	A	G	D
G399a5	WIAF-16504	HT48511	244	AQP3, aquaporin 3	CTCACCATCAACCTG[G/A]CCTTTGGCTTTGCTG	M	G	A	A	T
G399a6	WIAF-16505	HT48511	571	AQP3, aquaporin 3	ATAGGCACAGCCTCC[C/T]TTATCGTGTGTGTGC	M	C	T	L	F
G399a7	WIAF-16506	HT48511	174	AQP3, aquaporin 3	CATCCTCGTGATGTT[T/A]GGCTGTGGCTCCGTG	M	T	A	F	L
G3997a4	WIAF-17809	HT27682	560	MFAP2, microfibrillar-	GTGCCAATCCGTGGC[G/A]GCCTCCTGTGCCAGG	S	G	A	A	A
				associated protein 2
G4022a5	WIAF=17706	HT2426	480	TGM1, transglutaminase 1 (K	CGAGAGCACCACACA[G/A]ACGAGTATGAGTACG	M	G	A	D	N
				polypeptide epidermal type I,
				protein-glutamine-gamma-
				glutamyltransferase)
G4022a6	WIAF-17707	HT2426	2544	TGM1, transglutaminase 1 (K	GGTGGAGCTTAGCCC[T/C]GTGCCAGGAGCAATG	—	T	C
				polypeptide epidermal type I,
				protein-glutamine-gamma-
				glutamyltransferase)
G4038a12	WIAF-17715	HT4211	504	LAMB3, laminin, beta 3	CCGAGGGCCCATGCC[T/C]GCCGGCATGCTGATT	S	T	C	P	P
				(nicein (125 kD), kalinin
				(140 kD), BM600 (125 kD))
G4038a13	WIAF-17716	HT4211	1878	LAMB3, laminin, beta 3	TTGCTTCCAGACCTA[T/C]GATGCGGACCTCCGG	S	T	C	Y	Y
				(nicein (125 kD), kalinin
				(140 kD), BM600 (125 kD))
G4038a14	WUAF-17823	HT4211	2183	LAMB3, laminin, beta 3	TTGACAGAAGCTTCA[A/G]TGGTCTCCTTACTAT	M	A	G	N	S
				(nicein (125 kD), kalinin
				(140 kD), BM600 (125 kD))
G4038a15	WIAF-17824	HT2411	2238	LAMB3, laminin, beta 3	TGAAAAAATAAGCAG[T/C]GCTGATCCTTCAGGA	S	T	C	S	S
				(nicein (125 kD), kalinin
				(140 kD), BM600 (125 kD))
G4038a16	WIAF-17825	HT4211	2481	LAMB3, laminin, beta 3	CAACAAGCTCTGTGG[C/T]AACTCCAGGCAGATG	S	C	T	G	G
				(nicein (125 kD), kalinin
				(140 kD), BM600 (125 kD))
G4038a17	WIAF-17826	HT4211	3076	LAMB3, laminin, beta 3	GTGGTTGGGAACCTG[C/T]GGCAGGGGACAGTGG	M	C	T	R	W
				(nicein (125 kD), kalinin
				(140 kD), BM600 (125 kD))
G4045a2	WIAF-17832	HT0652	2454	adducin, beta subunit, ?	CTGATTCATGACACC[C/T]TTGGGCTCCCTCCTG		C	T
G4049a1	WIAF-17718	HT3167	1305	THM2, transglutaminase 2 (C	CACCAAGTACGATGC[G/A]CCCTTTGTCTTTGCG	S	G	A	A	A
				polypeptide, protein-glutamine-
				gamma-glutamyltransferase)
G4049a2	WIAF-17719	HT3167	1113	THM2, transglutaminase 2 (C	GGAGATCCAGGGTGA[C/T]AAGAGCGAGATGATC	S	C	T	D	D
				polypeptide, protein-glutamine-
				gamma-glutamyltransferase)
G4049a3	WIAF-17720	HT3167	2058	THM2, transglutaminase 2 (C	GGAGATCCCAGACCC[C/T]GTGGAGGCACCCCAG	S	C	T	P	P
				polypeptide, protein-glutamine-
				gamma-glutamyltransferase)
G4049a4	WIAF-17833	HT3167	1759	THM2, transglutaminase 2 (C	TTCTCTGAGAAGAGC[G/T]TTCCTCTTTGCATCC	M	G	T	V	F
				polypeptide, protein-glutamine-
				gamma-glutamyltransferase)
G4050a5	WI-18049	HT1466	1372	villin, ?	GTTTGGCAGGGCAGC[C/T]AGGCCAGCCAAGATG	N	C	T	Q	*
G4050a6	WI-18050	HT1466	1631	villin, ?	TTGAGGTCCCAGCGC[G/A]GGCCAATTTCCTCAA	M	G	A	R	Q
G4050a7	WI-18051	HT1466	1947	villin, ?	CCCTGACTTCAATCA[G/A]GATGACTTGGAAGAG	S	G	A	Q	Q
G4080a7	WIAF-17721	HT1396	5835	HSPG2, heparan sulfate	CACGGCGGCATCCTG[C/T]GCCTGCCAGCTGTCG	M	C	T	R	C
				proteoglycan 2 (perlecan)
G4080a8	WIAF-17722	HT1396	5836	HSPG2, heparan sulfate	ACGGCGGCATCCTGC[G/A]CCTGCCAGCTGTCGA	M	G	A	R	H
				proteoglycan 2 (perlecan)
G4080a9	WIAF-17723	HT1396	5979	HSPG2, heparan sulfate	CCAGAGAGGACCCAG[G/A]TCCACGCAGGCCGGA	M	G	A	V	I
				proteoglycan 2 (perlecan)
G4080a10	WIAF-17724	HT1396	9407	HSPG2, heparan sulfate	GAACCTCAGTGTGCA[C/T]GGGCCCCCTACAGTG	S	C	T	H	H
				proteoglycan 2 (perlecan)
G4080a11	WIAF-17725	HT1396	13072	HSPG2, heparan sulfate	TCAACGCCAAGGGCA[G/A]CGTCTACATCGGCGG	M	G	A	S	N
				proteoglycan 2 (perlecan)
G4080a12	WIAF-17726	HT1396	13199	HSPG2, heparan sulfate	CCGCCCCCACAGCC[C/T]CTGGACCTGCAGCAC	S	C	T	P	P
				proteoglycan 2 (perlecan)
G4080a13	WIAF-17841	HT1396	824	HSPG2, heparan sulfate	CACATTCTCTCTCCT[T/C]GTGGAGACGACATCT	S	T	C	L	L
				proteoglycan 2 (perlecan)
G4080a14	WIAF-17842	HT1396	905	HSPG2, heparan sulfate	CGCTCCTCAGCCCCT[G/A]CTTCCCGGTTCCGTC	S	G	A	L	L
				proteoglycan 2 (perlecan)
G4080a15	WIAF-17843	HT1396	1223	HSPG2, heparan sulfate	CTCTACCAACATGTG[C/T]ATCCCAGCCAGCTTC	S	C	T	C	C
				proteoglycan 2 (perlecan)
G4080a16	WIAF-17844	HT1396	2085	HSPG2, heparan sulfate	TTCTCTGAGGAGCAC[T/C]GGGTCCATGAGTCTG	M	T	C	W	R
				proteoglycan 2 (perlecan)
G4080a17	WIAF-17845	HT1396	2189	HSPG2, heparan sulfate	CAACACCAAGATGGC[A/C]AGCGTGGGACTTAGC	S	A	C	A	A
				proteoglycan 2 (perlecan)
G4080a18	WIAF-17846	HT1396	2374	HSPG2, heparan sulfate	CCTGCTCTGGTTGCA[G/A]TTGCAATGGCCATGC	M	G	A	S	N
				proteoglycan 2 (perlecan)
G4080a19	WIAF-17847	HT1396	2593	HSPG2, heparan sulfate	CGGATGGCCAAGCCA[C/T]ATGTGACGCCTGTGC	M	C	T	T	I
				proteoglycan 2 (perlecan)
G4080a20	WIAF-17848	HT1396	2634	HSPG2, heparan sulfate	ACTGGCCGCCGCTGT[G/C]AGAGCTGTGCCCCCG	M	G	C	E	Q
				proteoglycan 2 (perlecan)
G4080a21	WIAF-17849	HT1396	3637	HSPG2, heparan sulfate	ACACGGAGGGCCCTC[G/A]GTGTGAGCAGTGCCA	M	G	A	R	Q
				proteoglycan 2 (perlecan)
G4080a22	WIAF-17850	HT1396	3885	HSPG2, heparan sulfate	CAGAGAGACAGCCAG[G/C]TGCCAGGGCCCATAG	M	G	C	V	L
				proteoglycan 2 (perlecan)
G4080a23	WIAF-17851	HT1396	3918	HSPG2, heparan sulfate	TGCAACTGTGACCCC[C/T]AAGGCAGCGTCAGCA	N	C	T	Q	*
				proteoglycan 2 (perlecan)
G4080a24	WIAF-17852	HT1396	3977	HSPG2, heparan sulfate	GTGCAAGGCCCAGGT[A/G]GAAGGCCTCACTTGC	S	A	G	V	V
				proteoglycan 2 (perlecan)
G4080a25	WIAF-17853	HT1396	4128	HSPG2, heparan sulfate	TCCACCCACTTTGCC[C/T]CTGGGGACTTCCAAG	M	C	T	P	S
				proteoglycan 2 (perlecan)
G4080a26	WI-17967	HT1396	4489	HSPG2, heparan sulfate	AGGAATTCTGGCGCC[G/A]GCCCGATGGGCAGCC	M	G	A	R	Q
				proteoglycan 2 (perlecan)
G4080a27	WI-17968	HT1396	5353	HSPG2, heparan sulfate	AATCCAATACCAGCC[G/A]GGCAGAGCTGCTGGT	M	G	A	R	Q
				proteoglycan 2 (perlecan)
G4080a28	WI-17969	HT1396	5364	HSPG2, heparan sulfate	AGCCGGGCAGAGCTG[C/T]TGGTCACTGAGGCTC	S	C	T	L	L
				proteoglycan 2 (perlecan)
G4080a29	WI-17970	HT1396	5530	HSPG2, heparan sulfate	GGAAACTGCCCACCC[G/T]AGCCATGGATTTCAA	M	G	T	R	L
				proteoglycan 2 (perlecan)
G4080a30	WI-17971	HT1396	7115	HSPG2, heparan sulfate	CCAGCCCATCCGCAT[C/T]GAGCCCTCCTCCTCG	S	C	T	I	I
				proteoglycan 2 (perlecan)
G4080a31	WI-17972	HT1396	7376	HSPG2, heparan sulfate	GGGCTCAGTGCCTGC[A/T]CTTGGGGTCACCCCC	S	A	T	A	A
				proteoglycan 2 (perlecan)
G4080a32	WI-17973	HT1396	11162	HSPG2, heparan sulfate	GATCACCTTCCGGCC[C/T]GACTCAGCCGATGGG	S	C	T	P	P
				proteoglycan 2 (perlecan)
G4080a33	WI-17974	HT1396	11267	HSPG2, heparan sulfate	CTCCTTCGGCCTCGT[G/T]GGGGGAAGGCCCGAG	S	G	T	V	V
				proteoglycan 2 (perlecan)
G4080a34	WI-17975	HT1396	11420	HSPG2, heparan sulfate	CCTGGCCCCGGTCAA[T/C]GGGACCTCCCAGGGC	S	T	C	N	N
				proteoglycan 2 (perlecan)
G4080a35	WI-18052	HT1396	5822	HSPG2, heparan sulfate	GAAGGCACAAATCCA[C/T]GGCGGCATCCTGCGC	S	C	T	H	H
				proteoglycan 2 (perlecan)
G4080a36	WI-18053	HT1396	9019	HSPG2, heparan sulfate	AGCTGCGGCTCCACC[T/A]CGTCTCCCCTGCCGA	M	T	A	L	H
				proteoglycan 2 (perlecan)
G4080a37	WI-18054	HT1396	9021	HSPG2, heparan sulfate	CTGCGGCTCCACCTC[G/A]TCTCCCCTGCCGACT	M	G	A	V	I
				proteoglycan 2 (perlecan)
G4080a38	WI-18055	HT1396	9063	HSPG2, heparan sulfate	GTGTGTCGTGCAGCC[A/G]GCGGCCCAGGCCCTG	M	A	G	S	G
				proteoglycan 2 (perlecan)
G4080a39	WI-18056	HT1396	10697	HSPG2, heparan sulfate	GCAGAGCGGAGGTGT[C/T]GTCAGGATCGCCCAC	S	C	T	V	V
				proteoglycan 2 (perlecan)
G4080a40	WI-18057	HT1396	10713	HSPG2, heparan sulfate	GTCAGGATCGCCCAC[G/T]TAGAGCTGGCTGATG	M	G	T	V	L
				proteoglycan 2 (perlecan)
G4080a41	WI-18058	HT1396	10975	HSPG2, heparan sulfate	TGCTGCCCTCAGTCC[G/A]ACCCCAGGACGCAGG	M	G	A	R	Q
				proteoglycan 2 (perlecan)
G4080a42	WI-18059	HT1396	10998	HSPG2, heparan sulfate	GACGCAGGTACCTAC[G/A]TCTGCACCGCCACTA	M	G	A	V	I
				proteoglycan 2 (perlecan)
G4087a1	WI-18060	HT27961	1922	?, ?	GGACCATCCCATTGA[C/T]CTTCTCTTAAGGGAC	S	C	T	D	D
G4093a1	WIAF-17854	HT3182	155	CRYZ, crystallin, zeta	TTTTGAATTTGGTGG[G/A]CCAGAAGTCCTGAAA	S	G	A	G	G
				(quinone reductase)
G4106a1	WI-18066	HT2379	1867	IVL, involucrin	ACTTATTTCGGGTCC[G/A]CTAGGTGGCCCCGTCT	—	G	A
G4126a3	WI-17980	HT2465	1322	myosin binding protein H, ?	GAGCAAGGCGTCTGC[A/G]CCCTAGAGATCCGGA	M	A	G	T	A
G4126a4	WI-17981	HT2465	1344	myosin binding protein H, ?	AGATCCGGAAACCCA[G/C]CCCCTTTGATTCTGG	M	G	C	S	T
G4126a5	WI-17982	HT2465	1373	myosin binding protein H, ?	GGGGTCTACACCTGC[A/T]AGGCCATAAATGTGC	N	A	T	K	*
G4138a4	WI-17983	HT33664	343	?, ?	CTGGTGAATGATCCC[G/A]CTACAGATGAAACAG	M	G	A	A	T
G4178a4	WIAF-17311	HT0224	2783	ACTN2, actinin, alpha 2	GATGCCCGCCTACTC[G/A]GGCCCAGGCAGTGTG	S	G	A	S	S
G418a10	WIAF-16657	L07594	2918	TGFBR3, transforming growth	ACCCAGGCCCAACCC[G/A]GCCCAACCCAGCCCA	—	G	A
				factor, beta receptor III
				(betaglycan, 300 kD)
G418a11	WIAF-17410	L07594	1683	TGFBR3, transforming growth	AGAGGTGCAAGGGAG[C/T]GTGGATATTGCCCTG	S	C	T	S	S
				factor, beta receptor III
				(betaglycan, 300 kD)
G418a12	WIAF-17411	L07594	1548	TGFBR3, transforming growth	AAATGGAGGCCTTCC[G/A]TTTCCTTTCCCAGAT	S	G	A	P	P
				factor, beta receptor III
				(betaglycan, 300 kD)
G418a13	WIAF-17412	L07594	2589	TGFBR3, transforming growth	TAAGAAGACGTTCAC[C/T]AAGCCCCTTGCTGTG	S	C	T	T	T
				factor, beta receptor III
				(betaglycan, 300 kD)
G418a13	WIAF-17412	L07594	2589	TGFBR3, transforming growth	TAAGAAGACGTTCAC[C/T]AAGCCCCTTGCTGTG	S	C	T	T	T
				factor, beta receptor III
				(betaglycan, 300 kD)
G4181a16	WIAF-17312	HT2008	6402	SPTBN1, spectrin, beta, non-	CCAGTGTGGCCGAGG[C/A]CTGGCTGCTTGGACA	M	C	A	A	D
				erythrocytic 1
G422a1	WIAF-17675	M29039	894	JUNB, jun B proto-oncogene	ACCCCCCAACGTGTC[C/A]CTGGGCGCTACCGGG	S	C	A	S	S
G4229a2	WIAF-17125	HT1689	631	SDC4, sydecan 4	CACCAATGAGTTCTA[C/T]GCGTGAAGCTTGCTT	S	C	T	Y	Y
				amphiglycan, ryudocan)
G4229a3	WIAF-17126	HT1689	671	SDC4, sydecan 4	GGCTTGGACTTTAGC[G/C]GGGAGGGAAGCCAGG	—	G	C
				amphiglycan, ryudocan)
G4230a2	WIAF-17127	HT4995	714	TRAM protein, ?	TTCCTCGTCAGCTTG[T/C]CTACATTGGTCTTTA	M	T	C	V	A
G4243a7	WIAF-17128	HT2901	556	KRT17, keratin 17	TGACAATGCCCGTCT[G/C]GCTGCTGATGACTTC	S	G	C	L	L
G4264a13	WIAF-17129	HT0968	1880	TJP1, tight junction protein	AGGTGATGTTGTATT[G/C]AAGATAAATGGTACT	M	G	C	L	F
				1 (zona occludens 1)
G4264a14	WIAF-17130	HT0968	1985	TJP1, tight junction protein	TCAAAGAGATGAACG[G/A]GCTACGCTATTGAAT	S	G	A	R	R
				1 (zona occludens 1)
G4246a15	WIAF-17131	HT0968	2602	TJP1, tight junction protein	AAATTCTCAGGGTAA[A/G]CAACGTAGATTTTAC	M	A	G	N	S
				1 (zona occludens 1)
G4264a16	WIAF-17132	HT0968	2652	TJP1, tight junction protein	GCCGTCCTTTTCCTG[C/T]TTGACCTCCCTAAAG	M	C	T	L	F
				1 (zona occludens 1)
G4264a17	WIAF-17133	HT0968	5075	TJP1, tight junction protein	TTTTAAGCCTCCAGA[A/G]GTAGCATCTAAACCT	S	A	G	E	E
				1 (zona occludens 1)
G4264a18	WIAF-17134	HT0968	5318	TJP1, tight junction protein	TCCTGCACACATTGC[T/C]GCCAGCCATCTCTCC	S	T	C	A	A
				1 (zona occludens 1)
G4264a19	WIAF-17135	HT0968	5876	TJP1, tight junction protein	TGCACATAAACCTGA[C/T]TTGTCTTCAAAAACT	S	C	T	D	D
				1 (zona occludens 1)
G4264a20	WIAF-17136	HT0968	5913	TJP1, tight junction protein	TCTCCAAAAACTCTT[G/A]TGAAATCGCACAGTT	M	G	A	V	M
				1 (zona occludens 1)
G4264a21	WIAF-17137	HT0968	6090	TJP1, tight junction protein	GGTCATACTGTGGTG[G/A]CCACAGCCCGAGGCA	M	G	A	A	T
				1 (zona occludens 1)
G435a4	WIAF-17497	M31933	329	FCGR2B, Fc fragment of IgG,	CCACAATGGGAATCT[C/T]ATTCCCACCCACACG	S	C	T	L	L
				low affinity IIb, receptor for
				(CD32)
G435a5	WIAF-17515	M31933	671	FCGR2B, Fc fragment of IgG,	CATAGGCTACACGCT[G/A]TTCTCATCCAAGCCT	S	G	A	L	L
				low affinity IIb, receptor for
				(CD32)
G4369a4	WIAF-17787	HT0900	658	GBE1, glucan (1,4-alpha-),	GAGTTTAAGCATTCC[A/G]GACCAAAGAAGCCAC	M	A	G	R	G
				branching enzyme 1 (glycogen
				branching enzyme, Andersen
				disease, glycogen storage
				disease type IV)
G4369a5	WIAF-17788	HT0900	1806	GBE1, glucan (1,4-alpha-),	TCATTTAACTGACGA[C/T]GACCTTCTTCGCTAC	S	C	T	D	D
				branching enzyme 1 (glycogen
				branching enzyme, Andersen
				disease, glycogen storage
				disease type IV)
G4373a3	WIAF-16010	HT0940	1154	HSD17B2, hydroxysteroid (17-	CATCCAGCATGCTAT[C/T]TTGGCGAAGAGCCCT	S	C	T	I	I
				beat) dehydrogenase 2
G4373a4	WIAF-16011	HT0940	1250	HSD17B2, hydroxysteroid (17-	TGGCATATATGATTA[C/T]TTTGCTAAAAGACAT	S	C	T	Y	Y
				beat) dehydrogenase 2
G440a11	WIAF-17503	M74447	318	TAP2, transporter 2, ABC (ATP	CTGTCTGGCCACCCC[C/A]CTGACTGTCTCCCTG	S	C	A	P	P
				binding cassette)
G440a12	WIAF-17511	M74447	2319	TAP2, transporter 2, ABC (ATP	TGTTCCTGAGTTGCA[A/G]GCACGATGGAGATTT	—	A	G
				binding cassette)
G440a13	WIAF-17525	M74447	1896	TAP2, transporter 2, ABC (ATP	AATATACACAGATGT[A/C]GGGGAGAAGGGAAGC	S	A	C	V	V
				binding cassette)
G4412a3	WIAF-17677	HT1882	1276	ACADS, acyl-Coenzyme A	ACCGGAGCTGAGCCC[G/A]CGGCGGACTGCCCCA	—	G	A
				dehydrogenase, C-2 to C-3
				short chain
G4412a4	WIAF-17678	HT1882	1292	ACADS, acyl-Coenzyme A	CGGCGGACTGCCCCA[G/C]GACTGCGGGAAGGCG	—	G	C
				dehydrogenase, C-2 to C-3
				short chain
G4412a5	WIAF-17679	HT1882	1386	ACADS, acyl-Coenzyme A	TGGGGACCCCAGATG[G/A]GCTCAGTGCTGCCAC	—	G	A
				dehydrogenase, C-2 to C-3
				short chain
G4415a5	WIAF-17680	HT2503	2821	acyl-Coenzyme A:cholesterol	TTTCTATCCCGTGCT[G/C]TTCGTGCTCTTCATG	S	G	C	L	L
				acyltransferase, ?
G4417a11	WIAF-17690	HT0542	1071	AOAH, acyloxyacyl hydrolase	GAGACTCAGCTGGGG[C/G]TCATTTTCACATCTC	M	C	G	A	G
				(neutrophil)
G4417a12	WIAF-17691	HT0542	1185	AOAH, acyloxyacyl hydrolase	CCCAACTCTCTGGTG[C/T]TACAGGATTTCTGGA	M	C	T	A	V
				(neutrophil)
G4417a13	WIAF-17692	HT0542	1261	AOAH, acyloxyacyl hydrolase	GAAAAGAAACCACTG[T/C]AATCACAGGGACTAC	S	T	C	C	C
				(neutrophil)
G4417a14	WIAF-17693	HT0542	1519	AOAH, acyloxyacyl hydrolase	CAGCCATGTTATTTT[G/T]TATGGCTTACCAGAT	M	G	T	L	F
				(neutrophil)
G4417a15	WIAF-17694	HT0542	1814	AOAH, acyloxyacyl hydrolase	ATACAGGAGTGGCAG[A/G]AGAGAGGCGGACAGC	M	A	G	K	E
				(neutrophil)
G4417a16	WIAF-17695	HT0542	1559	AOAH, acyloxyacyl hydrolase	CTCTGGGATAATTTG[C/T]ACAACAGATATCATC	M	C	T	H	Y
				(neutrophil)
G4428a2	WI-18040	HT97524	751	ADFP, adipose differentiation-	AGCCAACAGACCATT[T/C]CTCAGCTCCATTCTA	M	T	C	S	P
				related protein; adipophilin
G4440a2	WIAF-16039	HT1392	633	ADRBK1, adrenergic, beta,	TGCATCGCATCATTG[G/T]GCGCGGGGGCTTTGG	M	G	T	G	V
				receptor kinase 1
G4440a3	WIAF-16040	HT1392	2109	ADRBK1, adrenergic, beta,	GTGCCAACGGCCTCT[G/A]ACCCGCCCACCCGCC	N	G	A	*	*
				receptor kinase 1
G4442a1	WIAF-17700	HT2326	2632	ALD,	CCACCTGACACAACC[G/C]TCCCCGGCCCCTGCC	—	G	C
				adrenoleukodystrophy/adrenomye
				loneuropathy
G4442a2	WIAF-17701	HT2326	2649	ALD,	CCCCGGCCCCTGCCC[C/T]GCCCCCAAGCTCGGA	—	C	T
				adrenoleukodystrophy/adrenomye
				loneuropathy
G4442a3	WIAF-17801	HT2326	1060	ALD,	TGGACGTGGCTGTGA[C/G]TTCCTACACCCTGCT	M	C	G	T	S
				adrenoleukodystrophy/adrenomye
				loneuropathy
G4457a1	WIAF-16050	HT1481	270	ALDR1, aldehyde reductase 1	TGAGGAGCTCTTCAT[C/A]GTCAGCAAGCTGTGG	S	C	A	I	I
				(low Km aldose reductase)
G4457a2	WIAF-16051	HT1481	313	ALDR1, aldehyde reductase 1	GAGAAGGGCCTGGTG[A/G]AAGGAGCCTGCCAGA	M	A	G	K	E
				(low Km aldose reductase)
G4457a3	WIAF-16052	HT1481	1121	ALDR1, aldehyde reductase 1	CTGTAGAGTGGCCAG[C/A]GAGGGCGTGTCTAGC	—	C	A
				(low Km aldose reductase)
G4468a1	WIAF-17806	HT4305	1083	FUT7, fucosyltransferase 7	CGTTTCTGTGCCATC[T/A]GTGACCGCTACCCAC	M	T	A	C	S
				(alpha (1,3)
				fucosyltransferase)
G447a5	WIAF-17498	X03663	1385	CSF1R, colony stimulating	AGGACACATACAGGC[A/G]CACCTTCACCCTCTC	M	A	G	H	R
				factor 1 receptor, formerly
				McDonough feline sarcoma viral
				(v-fms)oncogene homolog
G447a6	WIAF-17499	X03663	1548	CSF1R, colony stimulating	CAACGGCTCTGGCVAC[C/T]CTTTTGTGTGCTGCC	S	C	T	T	T
				factor 1 receptor, formerly
				McDonough feline sarcoma viral
				(v-fms) oncogene homolog
G447a7	WIAF-17516	X03663	1033	CSF1R, colony stimulating	AACAACACTAAGCTC[G/T]CAATCCCTCAACAAT	M	G	T	A	S
				factor 1 receptor, formerly
				McDonough feline sarcoma viral
				(v-fms) oncogene homolog
G447a8	WIAF-17517	X03663	1917	CSF1R, colony stimulating	GCTGCTATTGTACAA[G/A]TATAAGCAGAAGCCC	S	G	A	K	K
				factor 1 receptor, formerly
				McDonough feline sarcoma viral
				(v-fms) oncogene homolog
G4473a3	WIAF-17810	HT1352	1246	FUCA1, fucosidase, alpha-L-	CTTGAATCCCCCATA[A/T]CTACCTCAACTACAA	M	A	T	T	S
				1, tissue
G4477a1	WIAF-17811	HT1368	1717	NAGA, N-	GTGAGGAGCTGGGAC[A/C]TGTGACAGGCTGTGG	—	A	C
				acetylgalactosaminidase, alpha-
G4488a1	WIAF-17813	HT1559	694	SLC4A2, solute carrier family	GGCGGAGGCGGTGGC[G/C]GTGGCCAGTGGCACA	S	G	C	A	A
				4, anion exchanger, member 2
				(erythrocyte membrane protein
				band 3-like 1)
G4488a2	WIAF-17814	HT1559	709	SLC4A2, solute carrier family	GGTGGCCAGTGGCAC[A/T]GCAGGGGGTGACGAC	S	A	T	T	T
				4, anion exchanger, member 2
				(erythrocyte membrane protein
				band 3-like 1)
G4488a3	WI-18044	HT1559	1150	SLC4A2, solute carrier family	CGTGGAGGAGGAGAC[C/T]GAGCGCTGGGGGAAG	S	C	T	T	T
				4, anion exchanger, member 2
				(erythrocyte membrane protein
				band 3-like 1)
G4488a4	WI-18045	HT1559	3048	SLC4A2, solute carrier family	AGAGCCCCTTCCCTG[T/C]GTGGATGATGGTTGC	M	T	C	V	A
				4, anion exchanger, member 2
				(erythrocyte membrane protein
				band 3-like 1)
G4492a3	WIAF-17819	750	ANX11, annexin XI (56 kD)	CCCAGTTTGGAAGCC[G/A]AGGCACCATCACTGA	M	G	A	R	Q
				autoantigen)
G4492a4	WIAF-17820	HT3390	1821	ANX11, annexin XI (56 kD)	GTCCTAGAGCTTAGG[C/T]CTGTCTTCCACCCCT
				autoantigen)
G4502a12	WIAF-17708	HT4840	808	ASS, argininosuccinate	GATGGCACCACCCAC[C/T]AGACCTCCTTGGAGC	N	C	T	Q	*
				synthetase
G4502a13	WIAF-17709	HT4840	951	ASS, argininosuccinate	CACCATCCTTTACCA[T/C]GCTCATTTAGACATC	S	T	C	H	H
				synthetase
G451a1	WIAF-17512	Z49270	249	SCYA14, small inducible	CAAGCCCGGAATTGT[C/G]TTCATCACCAAAAGG	S	C	G	V	V
				cytokine subfamily A (Cys-
				Cys), member 14
G4526a2	WIAF-17829	HT4994	643	ATP5D, ATP synthase, H+	CTGGGCAGGGATGCC[A/G]GGTGGGCCCAGCCAG	—	A	G
				transporting, mitochondrial F1
				complex, delta subunit
G453a8	WIAF-16280	HT0768	700	PDGFRB, platelet-derived	CCGATGAGCGGAAAC[G/A]GCTCTACATCTTTGT	M	G	A	R	Q
				growth factor receptor, beta
				polypeptide
G453a9	WIAF-16281	HT0768	1355	PDGFRB, platelet-derived	TGAGCTGCATCGGAG[C/T]CGGACACTGCAGGTA	S	C	T	S	S
				growth factor receptor, beta
				polypeptide
G453a10	WIAF-16282	HT0768	1389	PDGFRB, platelet-derived	TTCGAGGCCTACCCA[C/T]CGCCCACTGTCCTGT	M	C	T	P	S
				growth factor receptor, beta
				polypeptide
G453a11	WIAF-16283	HT0768	3374	PDGFRB, platelet-derived	CCTGGACACCAGCTC[C/T]GTCCTCTATACTGCC	S	C	T	S	S
				growth factor receptor, beta
				polypeptide
G453a12	WIAF-16329	HT0768	937	PDGFRB, platelet-derived	TCTGCAAAACCACCA[T/C]TGGGGACAGGGAGGT	M	T	C	I	T
				growth factor receptor, beta
				polypeptide
G453a13	WIAF-16330	HT0768	958	PDGFRB, platelet-derived	ACAGGGAGGTGGATT[C/T]TGATGCCTACTATGT	M	C	T	S	F
				growth factor receptor, beta
				polypeptide
G453a14	WIAF-16331	HT0768	1155	PDGFRB, platelet-derived	ACTGACTTCCTCTTG[G/A]ATATGCCTTACCACA	M	G	A	D	N
				growth factor receptor, beta
				polypeptide
G453a15	WIAF-16332	HT0768	1895	PDGFRB, platelet-derived	CACGCTGCGCAACGC[T/C]GTGGGCCAGGACACG	S	T	C	A	A
				growth factor receptor, beta
				polypeptide
G453a16	WIAF-16333	HT0768	3716	PDGFRB, platelet-derived	GCCTGAAGCTCCCCC[C/G]CTGCCAGCACCCAGC	—	C	G
				growth factor receptor, beta
				polypeptide
G453a17	WIAF-16334	HT0768	3750	PDGFRB, platelet-derived	TCCTGGCCTGGCCTG[A/G]CCGGGCTTCCTGTCA	—	A	G
				growth factor receptor, beta
				polypeptide
G4533a2	WIAF-17830	HT1618	970	?, ?	CCACTTTGGTGTTTT[C/T]TATGTTCCCGTGAAG	S	C	T	F	F
G4534a2	WIAF-17831	HT3556	779	ATP6E, ATPase, H+	GGAGGTGGAGTTCGT[C/T]GTCAGCTCTCCTGCT	—	C	T
				transporting, lysosomal
				(vacuolar proton pump) 31 kD
G4535a4	WIAF-17717	HT27972	125	ATP50, ATP synthase, H+	CCAAGCTTGTGAGGC[C/T]TCCTGTTCAGGTATA	M	C	T	P	L
				transporting, mitochondrial F1
				complex, 0 subunit (oligomycin
				sensitivity conferring
				protein)
G4552a2	WIAF-17837	HT0867	2444	ATP7A, ATPase, CU++	TTGATTATTCTTCTA[G/C]TTGCAATGTATGAGA	M	G	C	V	L
				transporting, alpha
				polypeptide (Menkes syndrome)
G4565a5	WIAF-17838	HT28561	431	ATP1G1, ATPase, Na+/K+	GTCCAGCGAAGATCA[G/T]GCCCCCATTGCGAAC	M	G	T	Q	H
				transporting, gamma 1
				polypeptide
G4566a1	WIAF-17839	HT5047	1204	ATP6A1, ATPase, H+	GTGAAATGTCTTGGA[A/G]ATCCTGAAAGAGAAG	M	A	G	N	D
				transporting, lysosomal
				(vacuolar proton pump), alpha
				polypeptide, 70 kD, isoform 1
G4574a5	WI-17976	HT0198	610	beta-1,4 N-	AACCTGACTGCCTCC[C/T]TAGGCACCTGGGACG	S	C	T	L	L
				acetylgalactosaminyltransferas
				e, ?
G4574a6	WI-17977	HT0198	713	beta-1,4 N-	TGGACCAACTCAACA[G/A]GCAACTACAACTGGT	M	G	A	R	K
				acetylgalactosaminyltransferas
				e, ?
G4578a1	WI-17978	HT33747	929	beta-galactoside alpha-2,3-	GAACCTGCCCGCCAA[C/T]GTCAGCTTCGTGCTG	S	C	T	N	N
				sialyltransferase, ?
G4592a2	WI-18061	HT2128	1122	branched-chain keto acid	GGCACTATCTGCTGA[G/C]CCAAGGCTGGTGGGA	M	G	C	S	T
				dehydrogenase E1, alpha
				polypeptide, ?
G4592a3	WI-18062	HT2128	1234	branched-chain keto acid	ACCCAACCCCAACCT[G/A]CTCTTCTCAGACGTG	S	G	A	L	L
				dehydrogenase E1, alpha
				polypeptide, ?
G4597a1	WIAF-17699	HT4270	864	CDH11, cadherin 11 (OB-	TACCACGTGGTGATC[C/T]AGGCCAAGGACATGG	N	C	T	Q	*
				cadherin, osteoblast)
G4614a4	WIAF-17704	HT4835	147	S100A3, S100 calcium-binding	CAGGAATACGCAGGG[C/T]GCTGTGGGGACAAAT	M	C	T	R	C
				protein A3
G4614a5	WIAF-17705	HT4835	345	S100A3	S100 calcium-binding	TGTCTCTACTGCCAC[G/A]AGTACTTCAAGGACT	M	G	A	E	K
				protein A3
G462a2	WIAF-16279	HT4753	538	PDGFA, platelet-derived	CTCCAGCGACTCCTG[G/T]AGATAGACTCCGTAG	N	G	T	E	*
				growth factor alpha
				polypeptide
G4628a1	WI-18041	HT4892	224	S100A11, S100 calcium-binding	ATAACTACACTCTCT[C/G]CAAGACAGAGTTCCT	M	C	G	S	C
				protein A11 (calgizzarin)
G4631a1	WI-18043	HT1798	569	CALM3, calmodulin 3	CCCCGGGCAGCTGGC[G/C]ATGCCCGTTCTCTTG	—	G	C
				(phosphorylase kinase, delta)
G464a1	WIAF-17307	J05262	677	FDPS, farnesyl diphosphate	TTGATGGCGAGAAGG[A/C]GCACGCCAATGCCAA	M	A	C	E	A
				synthase (farnesyl
				pyrophosphate synthetase,
				dimethylallyltranstransferase,
				geranyltranstransferase)
G4642a1	WIAF-17812	HT0630	301	CNR1, cannabinoid receptor 1	GAAATTCCCTTTAAC[T/C]TCCTTTAGGGGAAGT	S	T	C	T	T
				(brain)
G4644a8	WIAF-17855	HT1736	2152	CPS1, carbamoyl-phosphate	CAATGCCGAGTTTCA[G/A]ATGTTGAGACGTACT	S	G	A	Q	Q
				synthetase 1, mitochondrial
G4644a9	WI-18063	HT1736	4335	CPS1, carbamoyl-phosphate	ACAATGTCCCTGCCA[A/C]CCCAGTGGCATGGCC	M	A	C	N	T
				synthetase 1, mitochondrial
G465a1	WIAF-16636	M14162	5762	APOB, apolipoprotein B	AACTCGCTCTCTGGG[G/A]AGAACATACTGGGCA	M	G	A	G	E
				(including Ag(x) antigen)
G4655a1	WI-18064	HT4642	772	CSNK1A1, casein kinase 1,	TGATGTATTTTAATA[G/A]AACCAGCCTGCCATG	M	G	A	R	K
				alpha 1
G4655a2	WI-18065	HT4642	720	CSNK1A1, casein kinase 1,	CAACAAAGAAACAAA[A/G]ATATGAAAAGATTAG	M	A	G	K	R
				alpha 1
G4659a2	WI-18046	ET1183	2123	catenin, alpha, ?	AGAAAAGCAAGCTGG[A/G]TGCAGAAGTGGCCAA	M	A	G	D	G
G4662a2	WIAF-17815	HT2142	809	CTNNB1, catenin (cadherin-	TGTACGTACCATGCA[G/C]AATACAAATGATGTA	M	G	C	Q	H
				associated protein), beta 1
				(88 kD)
G4662a3	WIAF-17816	HT2142	1733	CTNNB1, catenin (cadherin-	GATAAAGGCTACTGT[T/G]GGATTGATTCGAAAT	S	T	G	V	V
				associated protein), beta 1
				(88 kD)
G4691a10	WIAF-17712	HT97602	618	CMKBR9, chemokine (C-C motif)	AGATTTCGGCGGGCA[T/C]GGGACCATTTGGAAG	S	T	C	H	H
				receptor 9
G4691a11	WIAF-17713	HT97602	918	CMKBR9, chemokine (C-C motif)	AGAGAGCATCGCCTT[C/T]CTTCACTGCTGCTTT	S	C	T	F	F
				receptor 9
g4691a12	WIAF-17714	HT97602	947	CMKBR9, chemokine (C-C motif)	TTTCCCCCATCCTGT[A/G]TGCCTTCTCCAGTCA	M	A	G	Y	C
				receptor 9
G4751a2	WI-18067	HT1285	1334	WQCRC2, ubiquinol-cytochrome	TGCTATCATAAATGC[G/A]GCAAAGAAGTTTGTT	S	G	A	A	A
				c reductase core protein II
G5143a19	WIAF-17366	1157	ITPR3, inositol 1,4,5-	TGGACCCCACCACCT[T/G]GCAGAAAACCGACTC	M	T	G	L	W
				triphosphate receptor, type 3
G53a5	WIAF-17666	HT0508	685	DNA repair protein XRCC1, ?	GCTCTCTTCTTCAGC[C/T]GGATCAACAAGACAT	M	C	T	R	W
G53a6	WIAF-17667	HT0508	944	DNA repair protein XRCC1, ?	TGCCAGCTCCAACTC[G/A]TACCCCAGCCACAGC	M	G	A	R	H
G5515a1	WIAF-16555	HT4948	464	PRKM9, protein kinase mitogen-	CTTCTTTACCAGATG[C/G]TTTGTGGTATTAAAC	M	C	G	L	V
				activated 9 (MAP kinase)
G5836a1	WIAF-17890	HT1549	427	CSD, c-src tyrosine kinase	GCGGCTTCTGTACCC[G/A]CCGGAGACAGGCCTG	S	G	A	P	P
G5393a1	WIAF-17896	HT1557	1239	PTPN6, protein tyrosine	CATCGCCAGCCAGGG[C/T]TGTCTGGAGGCCACG	S	C	T	G	G
				phosphatase, non-receptor type
				6
G5893a2	WIAF-17897	HT1557	1360	PTPN6, protein tyrosine	GTCCCATACTGGCCC[G/A]AGGTGGGCATGCAGC[M	G	A	E	K
				phosphatase, non-receptor type
				6
G62a15	WIAF-17650	HT0855	2830	ERCC6, excision repair cross-	GACCACGCGGGTGGG[C/T]GGCTTAGGTGTCAAC	S	C	T	G	G
				complementing rodent repair
				deficiency, complementation
				group 6
G62a16	WIAF-17668	HT0855	4001	ERCC6, excision repair cross-	CGGTGTCTGGGAGCA[G/C]TGTCTGGTGTTCCCA	M	G	C	V	L
				complementing rodent repair
				deficiency, complementation
				group 6
G683a1	WIAF-17893	Y08725	1202	BMP1, bone morphogenetic	GCCGCTTCTGCGGGT[C/T]CAAACTCCCTGAGCC	M	C	T	S	F
				protein 1
G683a2	WI-17988	Y08725	1722	BMP1, bone morphogenetic	GGGCAGCTACAAGTG[C/T]AGCTGTGACCCCGGG	S	C	T	C	C
				protein 1
G683a3	WI-17989	Y08725	1776	BMP1, bone morphogenetic	CCGCTGTGAGGCTGC[T/C]TGTGGCGGATTCCTC	S	T	C	A	A
				protein 1
G798a11	WIAF-16113	X77748	1078	GRM3, glutamate receptor,	GTCGTGGTCCTCTTC[A/C]TGCGCAGCGACGACT	M	A	C	M	L
				metabotropic 3
G798a12	WIAF-16114	X77748	1846	GRM3, glutamate receptor,	TGCTGCTGGATTTGC[A/C]TCCCCTGTGAACCCT	M	A	C	I	L
				metabotropic 3
G798a13	WIAF-16115	X77748	1891	GRM3, glutamate receptor,	GATGAGTTTACCTGT[A/C]TGGATTGTGGGTCTG	M	A	C	M	L
				metabotropic 3
G798a14	WIAF-16116	X77748	2431	GRM3, glutamate receptor,	AAGCGGGAAACAGTC[A/C]TCCTAAAATGCAATG	M	A	C	I	L
				metabotropic 3
G798a15	WIAF=16117	X77748	2444	GRM3, glutamate receptor,	TCATCCTAAAATGCA[A/C]TGTCAAAGATTCCAG	M	A	C	N	T
				metabotropic 3
G798a16	WIAF-16118	X77748	2461	GRM3, glutamate receptor,	GTCAAAGATTCCAGC[A/C]TGTTGATCTCTCTTA	M	A	C	M	L
				metabotropic 3
G798a17	WIAF-16119	X77748	2566	GRM3, glutamate receptor,	GAAGCTAAGTTCATA[G/A]GTTTTACCATGTACA	M	G	A	G	S
				metabotropic 3
G798a18	WIAF-16120	X77748	2402	GRM3, glutamate receptor,	CAGGCACCAGGAGGT[A/C]TACCCTTGCAGAGAA	M	A	C	Y	S
				metabotropic 3
G86a4	WIAF-17669	HT1701	1007	RAD51, RAD51 (S. cerevisiae)	CGACTCGCTGATGAG[T/A]TTGGTGTAGCAGTGG	M	T	A	F	I
				homolog (E coli RecA homolog)
G91a3	WIAF-17670	HT1848	1045	ERCC1, excision repair cross	ACCCTGATGACCCCA[G/C]CTGCCAAGGAAACCC	—	G	C
				complementing rodent repair
				deficiency, complementation
				group 1 (includes overlapping
				antisense sequence)
G961a6	WIAF-17595	U95019	1324	CACNB2, calcium channel,	ATCTCGCTTGCCAAA[C/T]GCTCGGTATTAAACA	M	C	T	R	C
				voltage-dependent, beta 2
				subunit
G962a5	WIAF-17595	U95020	930	CACNB2, calcium channel,	GTTTGATGGGAGGAT[T/A]TCAATAACGAGAGTG	S	T	A	I	I
				voltage-dependent, beta 2
				subunit

[0107] From the foregoing, it is apparent that the invention includes a number of general uses that can be expressed concisely as follows. The invention provides for the use of any of the nucleic acid segments described above in the diagnosis or monitoring of diseases, such as cancer, inflammation, heart disease, diseases of the cardiovascular system, and infection by microorganisms. The invention further provides for the use of any of the nucleic acid segments in the manufacture of a medicament for the treatment or prophylaxis of such diseases. The invention further provides for the use of any of the DNA segments as a pharmaceutical.

[0108] While this invention has been particularly shown and described with references to preferred embodiments thereof it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

Claims

1. A nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of the nucleic acid sequences listed in the Table, wherein said nucleic acid sequence is at least 10 nucleotides in length and comprises a polymorphic site identified in the Table, and wherein the nucleotide at the polymorphic site is different from a nucleotide at the polymorphic site in a corresponding reference allele.

2. A nucleic acid molecule according to claim 1, wherein said nucleic acid sequence is at least 15 nucleotides in length.

3. A nucleic acid molecule according to claim 1, wherein said nucleic acid sequence is at least 20 nucleotides in length.

4. A nucleic acid molecule according to claim 1, wherein the nucleotide at the polymorphic site is the variant nucleotide for the nucleic acid sequence listed in the Table.

5. An allele-specific oligonucleotide that hybridizes to a portion of a nucleic acid sequence selected from the group consisting of the nucleic acid sequences listed in the Table, wherein said portion is at least 10 nucleotides in length and comprises a polymorphic site identified in the Table, and wherein the nucleotide at the polymorphic site is different from a nucleotide at the polymorphic site in a corresponding reference allele.

6. An allele-specific oligonucleotide according to claim 5 that is a probe.

7. An allele-specific oligonucleotide according to claim 5, wherein a central position of the probe aligns with the polymorphic site of the portion.

8. An allele-specific oligonucleotide according to claim 5 that is a primer.

9. An allele-specific oligonucleotide according to claim 8, wherein the 3′ end of the primer aligns with the polymorphic site of the portion.

10. An isolated gene product encoded by a nucleic acid molecule according to claim 1.

11. A method of analyzing a nucleic acid sample, comprising obtaining the nucleic acid sample from an individual; and determining a base occupying any one of the polymorphic sites shown in the Table.

12. A method according to claim 11, wherein the nucleic acid sample is obtained from a plurality of individuals, and a base occupying one of the polymorphic positions is determined in each of the individuals, and wherein the method further comprising testing each individual for the presence of a disease phenotype, and correlating the presence of the disease phenotype with the base.